---
document_datetime: 2023-09-21 22:26:04
document_pages: 136
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/aquipta-epar-public-assessment-report_en.pdf
document_name: aquipta-epar-public-assessment-report_en.pdf
version: success
processing_time: 211.7062397
conversion_datetime: 2025-12-28 20:08:16.688201
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 June 2023 EMA/CHMP/326142/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Aquipta

International non-proprietary name: atogepant

Procedure No. EMEA/H/C/005871/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                   | ..............................................7                                                          |
|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................7        |                                                                                                          |
| 1.2. Legal basis, dossier content...................................................................................7        |                                                                                                          |
| 1.3. Information on Paediatric requirements...................................................................7              |                                                                                                          |
| 1.4. Information relating to orphan market exclusivity.....................................................7                 |                                                                                                          |
| 1.4.1. Similarity..........................................................................................................7 |                                                                                                          |
| 1.5. Applicant's request(s) for consideration...................................................................8            |                                                                                                          |
| 1.5.1. New active Substance status...............................................................................8           |                                                                                                          |
| 1.6. Scientific advice                                                                                                       | ...................................................................................................8     |
| 1.7. Steps taken for the assessment of the product.........................................................8                 |                                                                                                          |
| 2. Scientific discussion                                                                                                     | ................................................................................9                        |
| 2.1. Problem statement                                                                                                       | ...............................................................................................9         |
| 2.1.1. Disease or condition...........................................................................................9      |                                                                                                          |
| 2.1.2. Epidemiology                                                                                                          | ....................................................................................................9    |
| 2.1.3. Aetiology and pathogenesis                                                                                            | ................................................................................9                        |
| 2.1.4. Clinical presentation, diagnosis..........................................................................10          |                                                                                                          |
| 2.1.5. Management...................................................................................................10       |                                                                                                          |
| 2.2. About the product                                                                                                       | ..............................................................................................11         |
| 2.3. Type of application and aspects on development                                                                          | ....................................................11                                                   |
| 2.4. Quality aspects                                                                                                         | ..................................................................................................11     |
| 2.5. Non-clinical aspects                                                                                                    | ............................................................................................18           |
| 2.5.1. Introduction....................................................................................................18    |                                                                                                          |
| 2.5.2. Pharmacology                                                                                                          | .................................................................................................19      |
| 2.5.3. Pharmacokinetics.............................................................................................21       |                                                                                                          |
| 2.5.4. Toxicology                                                                                                            | ......................................................................................................23 |
| 2.5.5. Ecotoxicity/environmental risk assessment                                                                             | .........................................................27                                              |
| 2.5.6. Discussion on non-clinical aspects......................................................................29            |                                                                                                          |
| 2.5.7. Conclusion on the non-clinical aspects................................................................33              |                                                                                                          |
| 2.6. Clinical aspects                                                                                                        | ..................................................................................................33     |
| 2.6.1. Introduction....................................................................................................33    |                                                                                                          |
| 2.6.2. Clinical pharmacology                                                                                                 | ......................................................................................37                 |
| 2.6.3. Discussion on clinical pharmacology...................................................................54              |                                                                                                          |
| 2.6.4. Conclusions on clinical pharmacology.................................................................59               |                                                                                                          |
| 2.6.5. Clinical efficacy                                                                                                     | ...............................................................................................60        |
| 2.6.6. Discussion on clinical efficacy............................................................................86         |                                                                                                          |
| 2.6.7. Conclusions on the clinical efficacy.....................................................................93           |                                                                                                          |
| 2.6.8. Clinical safety..................................................................................................94   |                                                                                                          |
| 2.7. Discussion on clinical safety...............................................................................            | 112                                                                                                      |
| 2.7.1. Conclusions on the clinical safety.....................................................................               | 117                                                                                                      |
| 2.8. Risk Management Plan ......................................................................................             | 117                                                                                                      |
| 2.8.1. Safety concerns.............................................................................................          | 117                                                                                                      |
| 2.8.2. Pharmacovigilance plan ..................................................................................             | 117                                                                                                      |

<div style=\"page-break-after: always\"></div>

2.8.4. Conclusion  ....................................................................................................  119

2.9. Pharmacovigilance  ............................................................................................  119

2.9.1. Pharmacovigilance system  ..............................................................................  119

2.9.2. Periodic Safety Update Reports submission requirements ................................... 119

2.10. Product information ........................................................................................  120

2.10.1. User consultation  .........................................................................................  120

2.10.2. Additional monitoring ...................................................................................  120

3. Benefit-Risk Balance............................................................................  120

3.1. Therapeutic Context .........................................................................................  120

3.2. Disease or condition .........................................................................................  120

3.2.1. Available therapies and unmet medical need  ..................................................... 120

3.2.2. Main clinical studies .......................................................................................  121

3.3. Favourable effects ............................................................................................  122

3.4. Uncertainties and limitations about favourable effects  ........................................... 123

3.5. Unfavourable effects  .........................................................................................  124

3.6. Uncertainties and limitations about unfavourable effects ....................................... 127

3.7. Effects Table  ....................................................................................................  128

3.8. Benefit-risk assessment and discussion  ............................................................... 134

3.9. Importance of favourable and unfavourable effects  ............................................... 134

3.9.1. Balance of benefits and risks  ...........................................................................  135

3.9.2. Additional considerations on the benefit-risk balance ......................................... 135

3.10. Conclusions ...................................................................................................  135

4. Recommendations ...............................................................................  136

<div style=\"page-break-after: always\"></div>

## List of abbreviations

5-HT

5-Hydroxytryptamin, serotonin

ABs

Antibodies

ADR

Adverse drug reaction

AE

Adverse event

AESI

Adverse event of special interest

AGP

Atogepant

AI

Accumulation index

AL

Abuse liability

ALP

Alkaline phosphatase

ALT

Alanine aminotransferase

ANOVA

Analysis of variance

AST

Aspartate aminotransferase

AUC

Area under the concentration-time curve

AUC0-inf

Area under the concentration-time curve from time 0 to infinity

AUC0-t

Area under the concentration-time curve from time 0 to time of last quantifiable concentration

AUCtau

Area under the concentration-time curve during one dosing interval at steady state

BCRP

Breast cancer resistance protein

BCS

Biopharmaceutics Classification System

BID

Bis in die (twice daily)

BP

Blood pressure

bpm

Beats per minute

CAD

Coronary artery disease

CGIc

Clinical Global Impression of Change

CGIs

Clinical Global Impression of Severity

CGRP

Calcitonin gene-related peptide

CHMP

Committee for Medicinal Products for Human Use

CI

Confidence interval

CIDV

Capsaicin-induced dermal vasodilation

CIOMS

Council for International Organizations of Medical Sciences

CL/F

Apparent oral clearance

CLR

Renal clearance

CM

Chronic migraine

Cmax

Maximum plasma concentration

CNS

Central nervous system

CrCl

Creatinine clearance

CSR

Clinical study report

C-SSRS

Columbia-Suicide Severity Rating Scale

CV

Coefficient of variation

CVWR

Within-subject Coefficient of variation

CVA

Cerebrovascular accident

CVD

Cardiovascular Disease

CYP

Cytochrome P450

DBP

Diastolic blood pressure

DBS

Dried blood spot

DDI

Drug-Drug interaction

DILI

Drug-induced liver injury

EC50

Maximal drug effect

ECG

Electrocardiogram

EE

Ethinylestradiol

EM

Episodic migraine

Emax

Maximum effectiveness

Emin

Minimum effectiveness

EOT

End of treatment

FDA

Food and Drug Administration

GCP

Good Clinical Practice

GFR

Glomerular filtration rate

GLMEM

Generalised linear mixed effect model

GMR

Geometric mean ratio

HA

Headache

HD

Headache day

HLT

High Level Term

HME-OCT

Hot melt extrudate oral compressed tablet

HR

Heart rate

HRQoL

Health-related quality of life

HV

Healthy volunteer

ICH

International Council for Harmonisation

ICHD-3

International Classification of Headache Disorders, 3 rd  ed.

IHS

International Headache Society

IND

Investigational New Drug

ITT

Intent-to-treat

Iv

Intravenous

Ki

Inhibitory constant

LFT

Liver function test

LNG

Levonorgestrel

LS mean

Least squares mean

LTS

Long-term safety Set

MAA

Marketing Authorisation Application

MAO

Monoamine oxidase

MD

Migraine day

MedDRA

Medicinal Dictionary for Regulatory Activities

MI

Multiple imputation

MIDAS

Migraine Disability Assessment Test

mITT

Modified intent-to-treat

MQoLQ

Migraine Quality of life Questionnaire

MP

Medicinal product

MS

Member state

NDA

New drug application

NEAE

Newly emergent adverse event

NSAID

Nonsteroidal anti-inflammatory drug

OAT

Organic anion transporter

OC

Oral contraceptive

OCT

Organic cation transporter

OLE

Open-label extension (phase)

PBO

Placebo

PBPK

Physiologically based pharmacokinetics

PCS

Placebo-controlled Safety Set

PD

Pharmacodynamic

PGIc

Patient Global Impression of Change

P-gp

P-glycoprotein

PK

Pharmacokinetic(s)

PMF

Pre-market formulation

popPK

Population pharmacokinetics

PPI

Proton pump inhibitor

PRN

Pro re nata (when needed)

PT

Preferred term

QTc

Corrected QT interval

QTcF

QT interval corrected using Fridericia's formula

Rdnm

Dose normalised ratio

RMP

Risk management plan

SAD

Single ascending dose

SAE

Serious adverse event

SBP

Systolic blood pressure

SCS

Summary of Clinical Safety

SD-OCT

Spray dried oral compressed tablet

SGF

Simulated gastric fluid

SIF

Simulated intestinal fluid

SL

Sublingual

SmPC

Summary of product characteristics

SMQ

Standardised MedDRA Query

SoC

Standard of care

SOC

System organ class

S-STS

Sheehan Suicidality Tracking Scale

TBL

Total bilirubin

TBM

To be marketed

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

TEAE Treatment emergent adverse event TESAE Treatment emergent serious adverse event TIA Transient ischaemic attack t½ Elimination Half-life tmax Time to maximum concentration ULN Upper limit of normal US United States VAS Visual analogue scale

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant AbbVie Deutschland GmbH &amp; Co. KG submitted on 24 June 2022 an application for marketing authorisation to the European Medicines Agency (EMA) for Aquipta, through the centralised procedure under Article 3(2)(a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 25 February 2021.

The applicant applied for the following indication:

Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on Paediatric requirements

Pursuant  to  Article  7  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision (P/0046/2020)

- on  the  agreement  of  a  paediatric  investigation  plan  (PIP)  for  the  use  of  atogepant  in  the prevention of migraine headaches in the subset of the paediatric population from 6 to less than 18 years of age, and
- on the granting of a waiver in the paediatric population from birth to less than 6 years of age.

At the time of submission of the application, the PIP was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## 1.5. Applicant's request(s) for consideration

## 1.5.1. New active Substance status

The applicant requested the active substance atogepant contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## 1.6. Scientific advice

The applicant received HTA/EMA Scientific Advice (EMA/H/SA/3835/1/2018/HTA/II) in June 2018.

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Janet Koenig

Co-Rapporteur:  Ewa Balkowiec Iskra

| The application was received by the EMA on                                                                                                                      | 24 June 2022      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                        | 14 July 2022      |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                    | 30 September 2022 |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                    | 17 October 2022   |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                 | 17 October 2022   |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                         | 10 November 2022  |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                             | 26 January 2023   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on | 6 March 2023      |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                        | 16 March 2023     |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                         | 30 March 2023     |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                 | 22 May 2023       |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues                        | 7 June 2023       |

<div style=\"page-break-after: always\"></div>

| to all CHMP and PRAC members on                                                                                                                                                         |              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Aquipta on | 22 June 2023 |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product (see Appendix on NAS)                            | 22 June 2023 |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Migraine is a serious, chronic, disabling neurological disease characterised by attacks of moderate to severe headache (HA) pain associated with other symptoms such as nausea, vomiting, photophobia, and phonophobia. Migraine attacks typically last from 4 to 72 hours if untreated or unsuccessfully treated. People with migraine may experience an aura prior to the onset of their headache.

## 2.1.2. Epidemiology

Migraine is a highly prevalent disease, occurring in 11% to 12% of people in Europe, with higher rates among women (16% to 18%) than men (6% to 7%) (Goadsby et al. 2002). The disease is particularly common among individuals between the ages of 25 and 55 years. Migraine has been reported to be the second highest cause of years lived with disability, interfering significantly with occupational, educational, household, family, and social responsibilities (GBD 2017). Because of intense pain and other burdensome symptoms including photophobia, phonophobia, nausea, and vomiting (Linde and Dahlöf 2004; Ford et al. 2017), patients with migraine report extensive limitations in life activities (Leonardi et al. 2010).

People with migraine have higher lifetime rates of comorbid depression, anxiety, panic disorder, sleep disturbances, chronic pain syndromes, and suicide attempts (Buse et al. 2009; MRF 2017). They are also at higher risk for ischaemic stroke and other cardiovascular diseases (Blumenfeld et al. 2011; Sacco and Kurth 2014).

## 2.1.3. Aetiology and pathogenesis

It is currently thought that migraine has a neurologic aetiology (Goadsby et al. 2002; Goadsby 2009; Amin et al. 2013). The brains of patients with migraine are characterised by a generalised neuronal hyperexcitability, evidenced by increased response to visual, sensory, auditory, and nociceptive stimuli, and migraine attacks involve release of neurotransmitters and activation of pain pathways, including the trigeminal nerve (Xavier et al. 2017; Dodick 2018). Migraine pain appears to involve nociceptive neurons in the dura mater being stimulated and releasing vasoactive neuropeptides such as CGRP. The trigeminal nerve pathway transmits nociception from the meninges via intermediate pathways to the cortex.

<div style=\"page-break-after: always\"></div>

The calcitonin gene-related peptide (CGRP) is a neuropeptide that modulates nociceptive signalling and causes vasodilation that has been associated with migraine pathophysiology.

## 2.1.4. Clinical presentation, diagnosis

Standard diagnostic criteria are based the International Classification of Headache Disorders (ICHD-3 beta version). They have been developed by the Headache Classification Committee of the International Headache Society (IHS).

Migraine without aura (1.1) is described as recurrent headache disorder manifesting in attacks lasting 4-72 hours. Typical characteristics of the HA are unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity and association with nausea and/or photophobia and phonophobia. For a firm diagnosis to be established, the patient has to present with at least five attacks, that fulfil a list of respective criteria. As opposed to episodic forms of migraine, chronic migraine (Code 1.3) requires headache to occur on 15 or more days per month for more than 3 months, which has the features of migraine headache on at least 8 days per month.

## 2.1.5. Management

A Guideline on Clinical Investigation of Medicinal Products for the Treatment of Migraine was released by the EMA in 2007. Further guidance is obtained from the International Headache Society that issued two guidance documents for preventive treatment of migraine attacks: The first one for preventive treatment in CM patients (Tassorelli et al, 2018) and the second one for preventive treatment in EM patients (Diener HC et al. 2020).

Currently approved preventive treatment options include anticonvulsant topiramate (e.g., Topamax), ßblockers like metoprolol or propranolol, Botox, CGRP antagonist biologics (Aimovig, Ajovy, and Emgality), and most recently, another orally administered CGRP antagonist (rimegepant, Vydura), which has been approved for preventive treatment of EM in adults. Botox (botulinum toxin type A from Clostridium botulinum) is indicated in the EU for prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). Preventive treatment of CM with Botox requires multiple bilateral intramuscular injections divided across 7 specific head and neck muscle areas, with a recommended retreatment schedule of every 12 weeks. All three antibodies (ABs) are indicated in the EU for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Although forming the mainstay of current preventive migraine therapy, these options are not optimal for many patients due to limited effectiveness, poor tolerability, contraindications, and the need for dose titration over multiple visits for some medications.

Several epidemiological surveys indicate that available migraine preventive treatments are significantly underutilised in clinical practice (D'Amico et al. 2006), which supports the need for greater dialogue concerning migraine prevention between patients and physicians. Given the pharmacological profile of available per oral preventive medications (topiramate, ß-blockers), the choice of treatment should be based on the presence of comorbid and coexisting illness in order to improve compliance and minimise side effects (Silberstein 2015). However, compliance with preventive treatment remains a challenge. Low adherence to migraine prophylaxis treatment with antidepressants, antiepileptics, or beta blockers at 6 month follow-up was reported (Berger et al. 2012).

<div style=\"page-break-after: always\"></div>

## 2.2. About the product

Atogepant (AGN-241689, MK-8031, L-004880174, AGP) is presented as a selective, high-affinity, orally administered, small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.

Calcitonin gene-related peptide is an endogenous 37 amino acid peptide contained within pain-signalling nociceptive afferents, and is thought to play a causal role in migraine (Edvinsson 2018, Moreno-Ajona 2020). Multiple lines of clinical evidence point to a role for CGRP in migraine pathophysiology: 1) serum levels of CGRP are elevated during migraine; 2) treatment with anti-migraine drugs returns CGRP levels to normal coincident with pain relief; and 3) intravenous (IV) CGRP infusion produces lasting pain in non-migraineurs and migraineurs.

Treatment with a CGRP receptor antagonist is thought to relieve migraine by: 1) blocking CGRP-induced neurogenic vasodilation (returning dilated intracranial  arteries  to normal);  2)  halting the  cascade  of CGRP-induced neurogenic inflammation (which leads to peripheral and central sensitisation); and/or 3) inhibiting the central relay of pain signals from the trigeminal nerve to the caudal trigeminal nucleus (Durham 2004).

## 2.3. Type of application and aspects on development

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application.

## 2.4. Quality aspects

## Introduction

The  finished  product  is  presented  as  tablets  containing  10  mg  and  60  mg  of  atogepant  as  active substance.

Other  ingredients  are:  polyvinylpyrrolidone/  vinyl  acetate  copolymer,  vitamin  E  polyethylene  glycol succinate, mannitol, microcrystalline cellulose, sodium chloride, croscarmellose sodium, colloidal silicon dioxide, sodium stearyl fumarate.

The product is available in aluminium foil and PVC/PE/PCTFE blisters.

## Active substance

## General information

The  chemical  name  of  atogepant  is  (3' S )-N -[(3 S ,5 S ,6 R )-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5(2,3,6-trifluorophenyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta [ b ]pyridine-6,3'pyrrolo[2,3b ]pyridine]-3-carboxamide hydrate  corresponding  to  the  molecular  formula  C29H23F6N5O3 ●H 2O. It has a molecular weight of 621.544 g/mol as monohydrate form and the following structure:

<div style=\"page-break-after: always\"></div>

Figure 1: Active substance structure

<!-- image -->

The chemical structure of atogepant was elucidated by a combination of spectroscopic methods, including UV-VIS, Infrared spectroscopy (FT-IR), Nuclear Magnetic Resonance Spectroscopy (1H-NMR, 13C-NMR, 19F-NMR) and Mass Spectrometry (LC-MS).

The active substance appears as a white to off-white non-hygroscopic powder. Atogepant is freely soluble in Ethanol, soluble in methanol, sparingly soluble in acetone, slightly soluble in acetonitrile and insoluble in water. Its partition coefficient (LogP) was determined to be 2.4 and two pKa values were determined to be pKa1= 2.2 (pyridinium group) and pKa2= 10.2 (lactam group).

Atogepant has four chiral centres and is manufactured as a single stereoisomer. Enantiomeric purity is controlled routinely by chiral HPLC and achiral HPCL methods at intermediate stage and at release.

The solid-state properties of the active substance were determined by X-Ray Powder Diffraction (XRPD), Differential Scanning Calorimetry (DSC), and Thermogravimetric Analysis (TGA). XRPD results confirmed that atogepant is present in crystalline monohydrate form.

Comprehensive screening studies for polymorphs, salts, co-crystals were conducted for Atogepant. In free-base  form,  a  monohydrate,  a  trihydrate,  and  a  few  solvates  (ethyl  acetate,  chloroform,  and methanol solvates) were obtained. No salt form was isolated for atogepant. The free-base monohydrate form was the more thermodynamically stable form of the two hydrates.

## Manufacture, characterisation and process controls

A single manufacturer for atogepant active substance is proposed. Atogepant is synthesised in  multiple steps process using two well-defined starting materials and with acceptable specifications.

The starting materials initially proposed by the applicant were re-defined as intermediates following a MO raised to achieve appropriate control of the synthesis steps . As crucial part of the synthesis, these steps  were  placed  under  GMP  control.  Sufficient  information  regarding  their  synthesis  and  relevant impurities has been provided for all of them and they are considered acceptable and are controlled by suitable specifications as requested by the CHMP.

Critical steps of the synthesis have been described and sufficient in process controls are applied. Control of  critical  steps  comprises  an  updated  critical  process  parameter  study,  based  on  which  specific operational parameters are defined. The manufacturing process and the control strategy is described in sufficient detail. Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances.

<div style=\"page-break-after: always\"></div>

Impurity limits are justified based on spike/purge studies. Absence of controls on individual impurities has been justified by results of spike/purge studies. The control strategy for residual solvents is justified; validated analytical methods are described.

Potential impurities were discussed and characterised, including organic impurities from both starting materials  as  well  as  formed  during  synthesis,  degradation  products,  inorganic  impurities  (elemental impurities), residual solvents, and nitrosamine impurities. Information on origin/formation of impurities, their fate and control strategies was included, supported by historical ranges, and control strategies. Most  of  potential  process-related  impurities  are  purged  during  synthesis  as  supported  by  results  of spike/purge studies; only the Epimer impurity is included for routine control at NMT 0.20 %, which is accepted.

The manufacturing process has evolved during the process development. The proposed manufacturing process is based on modifications of the original process. These modifications regard mainly the synthetic route for the spiroacid intermediate. As for the lactam salt intermediate and the final step, the overall synthetic  steps  have  remained  consistent.  During  development,  minor  changes  have  been  made  to reagents, solvents, and manufacturing conditions.

The commercial manufacturing process for the active substance was developed in parallel with the clinical development programme.

Changes introduced have been presented in sufficient detail and have been justified.

The active substance is packaged in in double lined low-density polyethylene (LDPE) which complies with the EC directive 2002/72/EC and EC 10/2011 as amended.

## Specification

The  active  substance  specification  includes  appropriate  tests  and  limits  for  appearance  (visual), identification (IR spectroscopy), water content (Ph. Eur.), assay (HPLC-UV), related substances (HPLCUV), residual solvents (GC-FID), specific rotation (Ph. Eur), sulfated ash (Ph. Eur).

The active substance specification is considered acceptable and has been set based on relevant guidelines and batch data. Impurities present at higher than the qualification threshold according to ICH Q3A were qualified by toxicological and clinical studies and appropriate specifications have been set.

A second method for identification of the active substance was requested to be included to the applicant along with single-crystal XRD for confirmation of absolute stereochemistry for identification of the chiral form, in line with ICH Q6A requirements. The applicant did not include a second method for identification and the justification provided was that identity is tested by infrared (IR) spectroscopy, and since the IR test is specific, a second identification test is not needed per ICH Q6A. With respect to addition of singlecrystal XRD for confirmation of absolute stereochemistry for identification of the chiral form, the control of all the chiral centres by HPLC methods either at the intermediate stage or at the final active substance stage ensures the stereochemistry of atogepant molecule. In addition, the chiral identity of the active substance is confirmed by the routine specific rotation test during release testing. Therefore, it was considered  not  necessary  to  implement  a  single-crystal  XRD  test  as  a  routine  test  to  confirm  the stereochemistry.

A detailed risk assessment on the potential presence and formation of nitrosamines during synthesis is provided  following  the  recommendations  of  EMA/CHMP/428592/2019  Rev.1.  The  risk  assessment includes the syntheses of re-defined starting material, all raw materials, equipment, process water and packaging materials, as well as potential cross-contamination. Though secondary and/or tertiary amines are  present  several  synthesis  stages,  the  risk  of  formation  of  nitrosamines  is  concluded  low  as  no

<div style=\"page-break-after: always\"></div>

nitrosating/oxidating  reagents  are  present  at  any  stage.  An  updated  genotoxic  risk  assessment  is provided for impurities introduced by the re-defined starting materials, other raw materials, synthesis intermediates, and synthesis by-products. The evaluation was performed according to ICH M7 using two complementary statistical models. As for ICH M7 Class 1-3 impurities, the proposed Option 4 quality control strategy has been completed by new data on the required purge considering the TTC for lifetime use, and the calculated purge ratio. This approach is acceptable for impurities for which purge ratios with sufficient reliability were obtained. For several compounds with borderline purge ratio values, analytical results generated with commercial batches are provided, which confirmed the theoretical calculations. All values were found below 30 % of the PDE resp. acceptable limit based on the TTC. The Option 4 approach for these borderline compounds has been justified.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data from 17 batches of varying batch size, including toxicological, clinical and stability batches, was provided. The results are within the specifications and consistent from batch to batch.

## Stability

Stability  data  from  three  primary  commercial  scale  batches  of  active  substance  from  the  proposed manufacturer stored in the intended commercial package in a container closure system representative of that intended for the market for up to 48 months under long term conditions (25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided.

A supportive batch was monitored on stability for 36 months at long term conditions (25ºC / 60% RH) and 6 months at accelerated conditions (40ºC / 75% RH). Three additional supportive batches using the proposed commercial manufacturing process were monitored on stability for up to 60 months at 25ºC / 60% RH and 6 months at 40ºC / 75% RH.

The following parameters were tested : appearance, assay, related substances, water content, specific rotation, x-ray powder diffraction, water activity, microbial enumeration test. The analytical methods used were the same as for release and were stability indicating.

All tested parameters were within the specifications. A post-approval stability protocol was provided to continue on-going stability studies for the primary batches through the re-test period. Any confirmed out-of-specification result, or significant negative trend, should be reported to the Rapporteur and EMA.

Photostability testing following the ICH guideline Q1B was performed on a primary stability batch. No significant degradation was observed; the results support the conclusion that the active substance does not need protection from light.

The  stability  results  indicate  that  the  active  substance  manufactured  by  the  proposed  supplier  is sufficiently stable. The stability results justify the proposed retest period of 48 months in the proposed container without specific storage conditions.

<div style=\"page-break-after: always\"></div>

## Finished medicinal product

## Description of the product and pharmaceutical development

The finished medicinal product is an immediate release oral tablet, presented in two strengths, containing 10 mg atogepant and 60 mg atogepant, respectively. The 10 mg strength is presented as a white to offwhite, round biconvex tablet with 'A' and '10' debossed on one side. The 60 mg strength is presented as white to off-white, oval biconvex tablet with 'A60' debossed on one side.

## Formulation development

The formulation development for Atogepant IR oral tablets has been systematically and extensively addressed.

The choice  and  function  of  each  excipient  has  been  presented.  Compatibility  with  the  AS  has  been investigated and drove the selection of excipients. The formulation was amenable to manufacture via hot melt extrusion and direct compression. The finished product quality attributes were consistently met.

Atogepant  is  categorised  as  a  Biopharmaceutics  Classification  System  (BCS)  II  molecule.  The  poor aqueous solubility of atogepant presented a great challenge for the development of conventional solid oral  tablet  formulations  with  desired  immediate  release  attributes.  Several  oral  formulations  (both solution and tablet formulations) were explored. Formulation development studies were conducted to select the appropriate excipients. The focus was to achieve immediate release tablets with excellent physical-chemical stability. Several experiments were conducted to understand the effect of polymers, surfactant levels, extrudate particle size distribution and disintegrants on finished product dissolution.

The objective of the pharmaceutical development of the finished product was to produce a stable dosage form of atogepant of consistent quality containing 10mg or 60mg of atogepant.

All  excipients  are  well  known  pharmaceutical ingredients and their quality is compliant with Ph. Eur standards,  with  exception  of  vitamin  E  polyethylene  glycol  succinate  which  meets  USP/NF  quality standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

The formulation used during clinical studies is the same as that intended for marketing.

The history of formulations used for clinical studies and the compositions of the various formulations used during development were presented and found acceptable. PK studies and in vitro studies informed formulation optimisation. Based on these studies the commercial formulation was determined

## Dissolution method development

The development of the QC dissolution method has been sufficiently described. The proposed method is a compendial method (Ph. Eur. 2.9.3) using Apparatus 2 (Paddle) at 75 rpm rotation speed in 0.1 HCl. Specificity,  accuracy,  linearity,  range,  precision,  robustness  and  sample  solution  stability  were demonstrated.

The discriminatory power of the dissolution method has been demonstrated.

Information was requested through a raised MO for the dissolution limit set in the specifications. The specification limits for the dissolution testing was revised following the MO. The acceptance criterion for in-vitro  dissolution  at  release  was  set  to  NLT  Q  85  %  after  15  minutes  to  suitably  reflect  the

<div style=\"page-break-after: always\"></div>

discriminatory  power  of  the  in-vitro  dissolution  method,  in  compliance  with  the  dissolution  method development report supplied.

## Manufacturing process development

The  finished  product  manufacturing  process  was  designed  to  consistently  produce  finished  product meeting the criteria of the target product profile and finished product quality attributes of appearance, content  uniformity,  assay,  impurities/degradation  products,  active  substance  polymorphic  form, intermediate and finished product physical and chemical stability, identity and dissolution.

The manufacture of the proposed finished product consists of four main steps: pre-blending, hot melt extrusion (HME) and milling, final blending and tablet compression.

The manufacturing process development studies were conducted to identify the key process parameter set points for unit operations including pre-blending, hot melt extrusion, milling, blending with extragranular excipients and tablet compression. The focus was to achieve intermediates with acceptable blend  uniformity,  content  uniformity,  extrudate  particle  size  distribution  and  finished  tablets  with immediate release properties, acceptable physical appearance and mechanical strength.

A control strategy with the aim to mitigate risks during finished product manufacture was established, investigating e.g. the impact of raw materials and different machine settings in every single process step on the finished product CQAs, resulting in stipulating process parameter ranges for the commercial drug manufacture.  Risk  categorisation  along  with  respective  justification  are  provided  for  the  drug manufacturing steps extrusion, extrudate milling and tablet compression.

In  summary,  the  pharmaceutical  development  is  sufficiently  discussed.  The  primary  packaging  is aluminium foil and PVC/PE/PCTFE blisters. The material complies with Ph.Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

Critical steps of the manufacturing process have been defined and are appropriately controlled. The inprocess controls are adequate for this type of manufacturing process and pharmaceutical form.

Due to the hot-melt extrusion step, the manufacturing process was considered non-standard during assessment. Thus, process validation data of production scale batches were requested and a validation report has been submitted.

Based  on  validation  data  provided,  the  overall  conclusion  was  that  the  manufacturing  process implemented at the intended finished product manufacturing site is regarded as capable of consistently producing the proposed finished product meeting the predefined specifications.

## Product specification

The finished product release and shelf-life specifications include appropriate tests and limits for physical appearance  (visual),  identification  (HPLC-UV),  assay  (HPLC-UV),  content  uniformity  (HPLC-UV), degradation products (HPLC-UV), dissolution (Ph. Eur.), water content (Ph. Eur.), microbial enumeration test (Ph. Eur.), test for specified microorganisms (Ph. Eur.).

<div style=\"page-break-after: always\"></div>

The specifications  are  in  accordance  with  ICH  Q6A.  Sufficient  information  on  control  of  the  finished product has been provided. The parameter specification for the dissolution testing has been revised appropriately during the procedure.

Possible  degradation products  have  been  discussed  with  regard  to  the  impurity  profile  of  the  active substance. The possible degradation pathway of the finished product as well as on the test performed on elemental impurities have been sufficiently described. The mutagenicity of impurities with reference to the finished product has been sufficiently addressed.

The applicant  has  provided  a  risk  assessment  for  elemental  impurities.  Batch  analysis  data  on  four representative batches of atogepant bulk tablets and six primary stability samples using a validated ICPMS method was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective  PDE.  Based  on  the  risk  assessment  and  the  presented  batch  data  it  can  be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed (as requested) considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article  5(3)  of  Regulation  (EC)  No  726/2004  referral  on  nitrosamine  impurities  in  human  medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on the information provided, it  is  accepted that  there  is  no  risk  of  nitrosamine  impurities  in  the  active substance or the related finished product. Therefore, no specific control measures are deemed necessary. The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used in the routine analysis of the finished product has been presented.

The finished product is released on the market a) based on the above release specifications, through traditional final product release testing.

Batch analysis results are provided for three primary stability batches, three phase 3 clinical batches and two  supportive  batches  confirming  the  consistency  of  the  manufacturing  process  and  its  ability  to manufacture to the intended product specification.

## Stability of the product

Stability data from three pilot scale batches for the 10 mg strength and from three commercial scale batches for the 60 mg strength of finished product stored for up to 36 months under long term conditions (25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. Also supportive stability data of Phase 3 clinical batches packaged in bottles have been presented.  The batches of the medicinal product are representative of those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples  were  tested  for  physical  appearance,  assay,  degradation  products,  dissolution,  microbial enumeration tests, water content, water activity, photostability study. The analytical procedures used are stability indicating. No significant changes have been observed. The observed physical and chemical changes were small, and not likely to have a significant effect on efficacy and safety of the product when used according to the directions in the SmPC.

In addition, 1 batch per strength (10 mg and 60mg) was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Productsto determine the effect of light exposure on  the  product  and  to  demonstrate  that  adequate  packaging  has  been  implemented  to  protect  the

<div style=\"page-break-after: always\"></div>

product  from  photo  damage.  Results  for  appearance,  assay,  degradation  products  and  dissolution remained practically unchanged. Based on the results, atogepant tablets are considered inherently photo stable in the proposed packaging under normal use conditions.

Thermal cycling study was performed for the finished product. The packaged tablets were exposed to three complete cycles of low and high temperature conditions. All test results are comparable to those of the controls and were within specifications. No adverse effects on the product quality were observed as  a  result  of  the  exposure  to  the  low  and  high  temperature  cycling  conditions.  Based  on  available stability data, the proposed shelf-life of 36 months without any special storage conditions as stated in the SmPC (section 6.3 and 6.4) is acceptable.

## Adventitious agents

No excipients derived from animal or human origin have been used.

## Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been  presented  in  a  satisfactory  manner.  The  major  objection  (MO)  raised  during  the  procedure regarding the selection of the starting materials for the active substance synthesis and the nitrosamine impurities risk assessment have been resolved by provision of the requested data and information.

The  results  of  tests  carried  out  indicate  consistency  and  uniformity  of  important  product  quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## Recommendations for future quality development

None.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

The non-clinical testing strategy was developed to support the proposed indication. In support of the atogepant investigation in human subjects, a series of non-clinical pharmacology, pharmacokinetic, and toxicology studies have been conducted.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

## In vitro

In in vitro binding experiments, atogepant shows high affinity to the native and recombinant human CGRP receptor (Ki 16 - 26 pM). However, there are marked interspecies differences. Whereas atogepant shows also high affinity to the rhesus monkey CGRP receptor (Ki 9 pM), affinity to the mice, rat and rabbit CGRP receptor is considerably lower (Ki values of 130, 700 and 2100 pM, respectively).

In in vitro functional studies, it could be shown that atogepant is an i nhibitor of αCGRP -induced cAMP response in HEK293 cells, expressing the human or rhesus monkey CGRP receptor, with an IC50 of 30 and 50 pM, respectively.

In isolated coronary, meningeal and cerebral artery segments, atogepant inhibited the vasodilatory effect of  αCGRP.  In  contrary  to  the  triptan  zolmitriptan,  atogepant  had  no  own  vasoconstrictive  effects. However, whereas in distal coronary artery segments the inhibitory effect of atogepant was apparently competitive in nature (right shift of the αCGRP dos e response curve, no decrease in maximal effect) with a pKb of 9.4 to 8.4, in middle meningeal and cerebral artery segments, atogepant antagonise d the αCGRP effect  apparently  in  a  noncompetitive  manner  (reduction  of  αCGRP´s  E max,  without  affecting  its potency).

These results suggest that the vasodilatory effects of CGRP in distal coronary artery segments on one and on middle meningeal and cerebral artery segments on the other hand are mediated by different receptors and that more than one receptor type is involved in the antagonistic effects of atogepant (see 'Discussion on non-clinical aspects').

## In vivo

A specific animal model for the evaluation of prophylactic effects of atogepant on migraine was not provided by the applicant. As a surrogate pharmacological parameter for clinical efficacy of atogepant in the  prophylaxis  of  migraine,  inhibition  of  capsaicin-induced  dermal  vasodilatation  (CIDV),  an  effect considered to be mediated largely by release of CGRP, was used by the applicant.

Species-differences are obvious for functional activity of atogepant in vivo . CIDV in the forearm of rhesus monkeys was inhibited by atogepant in a concentration-dependent manner with an IC50 of about 1 nM. In a CIDV assay in rats, a plasma concentration of 3.7 µM resulted in 47% inhibition of dermal blood flow (Report PD003). In a rabbit CIDV assay, a plasma concentration of 41 µM was associated with a 43% inhibition of dermal blood flow (Report PD003). For humans, an IC50 for inhibition of CIDV of 1.5 nM was reported (Study CGP-PK-04).

Overall, these in vivo studies confirm the existence of large (for the CIDV response more than 1000 fold) interspecies differences.

## 2.5.2.2. Secondary pharmacodynamic studies

In an in vitro screening assay, atogepant showed no appreciable affinity (IC50 &gt; 10 µM) to a broad panel of human drug receptors and drug transporters.

However, atogepant showed antagonistic activity at the human amylin 1 and adrenomedullin 2 receptor, members of the calcitonin/CGRP receptor family, in the low (IC50 2.4 nM) respectively high (IC50 400 nM) nanomolar range. Since total atogepant plasma concentrations for the 60 mg clinical dose amount to

<div style=\"page-break-after: always\"></div>

about 1.2 µM, with free (unbound) atogepant plasma concentrations of about 60 nM, affinity to these additional receptors could be of clinical relevance (see 'Discussion on non-clinical aspects').

Atogepant attenuated CGRP-induced decreases in blood pressure and increases in heart rate in rhesus monkeys (IC50 about 1.1 nM).

In an in vivo PET assay with [ 11 C]atogepant in rhesus monkeys, atogepant (in plasma levels up to 229 nM)  showed low  (about  25%)  brain  CGRP  receptor  occupancy,  suggesting  that  atogepant  does  not penetrate the blood brain barrier well (see also 'Distribution').

## 2.5.2.3. Safety pharmacology programme

## Cardiovascular / respiratory function

## In vitro

In an electrophysiological evaluation on hERG channels, stably expressed in CHO-K1 cells, using standard whole-cell voltage-clamp techniques, atogepant exhibited weak hERG current inhibition (23.9% inhibition at 28 µM), which suggests that atogepant is unlikely to alter ventricular repolarisation in humans at clinically effective doses.

## In vivo

Atogepant had no prominent in vivo effects on cardiovascular parameters in guinea pigs, rats and rhesus monkeys:

- In a rat telemetry study, there were no effects on any haemodynamic parameter after single-dose treatment with doses of 2 and 10 mg/kg.

- In an exploratory cardiovascular study in anaesthetised guinea pigs, there were no test-article related effects  on  HR,  PR  interval,  QRS  interval,  or  QT/QTcB  intervals  up  to  a  cumulative  dose  of  6  mg/kg atogepant (plasma level 7.7 ± 1.1 µM).

- Effects of atogepant on cardiovascular and respiratory function and on body temperature were also evaluated in conscious telemetered rhesus monkeys. There were no relevant atogepant-related effects on  blood  pressure  parameters  (SBP,  DBP,  and  MBP),  HR,  ECG  parameters  (PR,  QRS,  RR,  and  QT intervals),  heart  rate-corrected  QT  interval  (QTci  interval)  or  QT:RR  interval  relationship,  respiratory parameters (rate and depth of respiration) and body temperature after single oral doses of 5 and 30 mg/kg or after daily oral doses of 75 mg/kg atogepant for 3 consecutive days.

## Neurological function

Atogepant did not show relevant neurobehavioral effects in mice and rats:

- There were no significant effects on neurological function in conscious mice after a single oral dose of 100 mg/kg.

- There were no effects on nervous system function in rats at single doses of up to 20 mg/kg.  Test article-related effects in rats treated with the high dose of 250 mg/kg were limited to decreases in mean body temperature (-1.1 °C) and a decrease in the number of line crosses and rearing activity in the open field test (1 out of 6 rats).

## Abuse liability

In studies evaluating the risk for physical dependence and the reinforcing potential in rats, atogepant did not show a relevant signal for abuse liability.

## Summary

Plasma levels of the high dose atogepant groups in the safety pharmacology studies usually exceeded the atogepant plasma levels observed for the 60 mg QD clinical atogepant dose. Overall, the findings of

<div style=\"page-break-after: always\"></div>

the safety pharmacology studies with atogepant do not provide a critical safety signal for the use of atogepant for the prophylaxis of migraine in humans.

## 2.5.2.4. Pharmacodynamic drug interactions

Non-clinical pharmacodynamic drug interaction studies have not been included in this application.

## 2.5.3. Pharmacokinetics

## Methods of analysis

Liquid  chromatography  tandem  mass  spectrometry  (LC-MS/MS)  methods  were  established  for measurement of atogepant plasma levels in different species. [ 14 C]atogepant derived radioactivity was determined by liquid scintillation counting. Metabolite structures were determined by MS.

All analytical methods were appropriately described in full detail, no discrepancies have been spotted between  the  studies.  The  validation  of  the  bioanalytical  methods  included  the  linearity,  sensitivity, accuracy, precision, dilution, selectivity, recovery, matrix effect, carryover and reanalysis of incurred samples (ISR). The bioanalytical methods for mouse, rat, rabbit, and monkey plasma samples were successfully validated for atogepant according to testing site standard operating procedures (SOPs) and Food and Drug Administration (FDA)/ICH guidance on method validation in support of Good Laboratory Practice (GLP) studies.

## Absorption

Atogepant demonstrated low  clearance  in  rats,  moderate  clearance  in  rhesus  monkeys  and  a  short plasma half-life (about 1 to 4 hours) in both species. The oral bioavailability was about 27% in both species. The volume of distribution Vdss amounted to 0.9 L/kg in rats and 3.2 L/kg in rhesus monkeys.

## Distribution

## Tissue distribution

Following  oral  dosing  in  rats,  [ 14 C]atogepant  was  widely  distributed  to  tissues.  Most  tissues  had concentrations similar to those in blood, except for central nervous system tissues, eye and bone, which had negligible concentrations.  Radioactivity levels in pigmented tissues (e.g., eye uvea and skin) were similar between pigmented and albino rats, suggesting no specific association of [ 14 C]atogepant-derived radioactivity with melanin.

## Plasma protein binding / Distribution in blood cells

The  unbound  fraction  of  atogepant  was  4.3,  11.3,  and  4.7%  in  rat,  monkey,  and  human  plasma, respectively. Atogepant does not show a preferential partition into red blood cells; the blood to plasma concentration ratios were 0.6, 0.9, and 0.8 in rat, monkey, and humans, respectively.

## Metabolism

Following incubation with human liver microsomes and hepatocytes, two oxidative metabolites, M1 and M2 (N-oxide formation respectively 5-hydroxylation on the azaoxindole moiety) were observed. These metabolites were also observed following incubation with mouse, rat, and monkey hepatocytes.

In rat, atogepant is mainly metabolised to M1 and M2. Secondary metabolites including double and triple oxidations and several glucuronide conjugates were also detected.

In monkey, atogepant is also mainly metabolised to M1 and M2. The major circulating component was atogepant  with  low,  but  detectable  levels  of  M1  and  metabolite  M23  (dioxygenated  methylated glucuronide of atogepant).

<div style=\"page-break-after: always\"></div>

In vitro reaction phenotyping experiments indicated that oxidative metabolism of atogepant in human liver preparations is predominantly CYP3A4-mediated, with a minor involvement of CYP2D6.

In humans, atogepant is susceptible to drug-drug interactions with compounds such as ketoconazole that  are  known  to  inhibit  CYP3A4.  Results  from  clinical  (drug-drug  interaction)  DDI  studies  with itraconazole (CGP-PK-02) and rifampin (CGP-PK-12) confirm that atogepant is a target of DDIs with strong CYP3A4 inhibitors and inducers.

## Excretion

Following IV or oral administration to bile-duct cannulated rats and monkeys, atogepant was eliminated predominately in the form of metabolites into bile. Most of the dose was recovered in excreta within 72 hours.

Table 1: Excretion of atogepant into urine, bile and feces

| Species and Route, (n)   | Dose (mg/kg)   | Percent of Total Dose Recovered (0-72 hr)   | Percent of Total Dose Recovered (0-72 hr)   | Percent of Total Dose Recovered (0-72 hr)   |            |
|--------------------------|----------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|------------|
|                          |                | Urine                                       | Bile                                        | Feces                                       | Total %    |
| Rat P.O., (n = 4)        | 5 mg/kg        | 12.6 ± 5.1                                  | 49.4 ± 4.3                                  | 27.0 ± 1.3                                  | 92.6 ± 2.5 |
| Monkey P.O., (n = 3)     | 10 mg/kg       | 4.4 ± 1.2                                   | 45.1 ± 10                                   | 24.2 ± 1.8                                  | 73.7 ± 8.3 |
| Rat IV, (n = 3)          | 2 mg/kg        | 9.2 ±3.3                                    | 54.8 ± 4.1                                  | 18.4 ± 4.5                                  | 83.0 ± 1.3 |
| Monkey IV, (n = 3)       | 2 mg/kg        | 8.4 ± 1.5                                   | 66.5                                        | 7.3                                         | 80.8 ± 3.8 |

P.O. = Oral; IV = Intravenous

Data presented as mean ± standard deviation

Atogepant was transferred into the milk of lactating rats at concentrations that were approximately 2-to 2.5-fold of those achieved in the maternal plasma.

## Pharmacokinetic drug interactions

Inhibition of liver enzymes: Atogepant is not an inhibitor of CYP 1A2 or 3A4. Atogepant displayed weak inhibition of CYP 2B6, CYP 2C8, CYP 2C9, CYP 2D6 and CYP 2C19. Atogepant is not a potent inhibitor of MAO-A or UGT1A1.

Induction of liver enzymes: Atogepant is an inducer of CYP3A4 in vitro ; however, 'relative induction score'  modeling  indicated  no  clinically-relevant  induction  potential.  Atogepant  is  not  an  inducer  of CYP1A2 or CYP2B6.

## Interaction with drug transporters

Atogepant is a substrate but not an inhibitor of P-gp and BCRP at clinically-relevant concentrations. Atogepant is not a substrate of OAT3, OCT2 or MATE1. Atogepant is a mild inhibitor of OCT1 and MATE1 but  not  MATE-2K  at  clinically-relevant  concentrations.  Atogepant  is  a  substrate  of  hepatic  uptake transporters OATP1B1, OATP1B3 and renal uptake transporter OAT1. At clinically-relevant concentrations, atogepant is not an inhibitor of OATP1B1, OATP1B3, OCT2, OAT1 and OAT3. Atogepant is unlikely to disrupt bile acid homeostasis since it showed mild inhibition of BSEP and no inhibition of MRP3, MRP4 and NTCP.

<div style=\"page-break-after: always\"></div>

Based on in  vitro studies  and  reported  clinically  efficacious  plasma  concentrations,  atogepant  is  not anticipated  to  cause  drug-drug  interactions  through  CYP  inhibition  or  induction  or  through  drug transporter inhibition at therapeutic doses.

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

Dedicated single dose toxicity studies have not been included in this application.

## 2.5.4.2. Repeat dose toxicity

The applicant conducted a robust repeat-dose toxicity programme in 3 species (mice, rats and monkeys). All pivotal studies were GLP compliant. Duration of repeat dose toxicity studies is in line with ICH M3(R2) recommendations. There was no atogepant related mortality in repeat dose toxicity studies in mice (up to  100 mg/kg/day  for  3 months),  rats  (up  to  100 mg/kg/day  for  6 months,  200 mg/kg/day  for 3 months), and rhesus monkeys (up to 300 mg/kg/day for 9 months).

Main observations in the rodent (mouse, rat) studies were post-dose salivation, decreased body weight gain, reversible epithelial vacuolation in the small intestine or parathyroid gland and a slight elevation of liver ALT transaminase.

In a 3-month rat study, decreases in body weight gain (16 %, in males only) and increased vacuolation in the parathyroid gland were observed at 200 mg/kg/day. The vacuolation of epithelium of the small intestine,  primarily  in  the  jejunum  at  20 and  200 mg/kg/day,  was  limited  to  the  villous  tip  and  not associated with degeneration or necrosis of the epithelial cells. There was no increase in the severity of this change in the 6-month study (with a 1-month recovery period) as compared to the findings from the 2-week study. This is consistent with the observation that the vacuolation was seen only in highly differentiated surface epithelium, which is replaced within 3 to 5 days as a result of cellular turnover in the small intestine of rats. Absence of crypt hyperplasia after 6 months of dosing further supports the assumption that the turnover is unaffected in rats with vacuolation. In addition, no neoplastic changes were observed in the intestines in the carcinogenicity studies in rats or mice. In the 6-month study. the described change was shown to be reversible after a 1-month recovery period and therefore considered by the applicant to be of minimal toxicologic significance and not adverse. Additionally, these findings were not observed in rhesus monkeys. The applicant considers that the NOAEL for atogepant in rats was 100 mg/kg/day  in  the  6-month  study  with  an  AUC0-24hr of  192.5 µM·hr,  which  represents  an approximately 33-fold margin over the clinical exposure of about 5.75 µM·hr following 60 mg QD dosing.

There were no atogepant-related antemortem changes, gross or histomorphologic findings in the first 3month monkey study at doses of 4, 15, and 150 mg/kg/day. In the second 3-month monkey study, at a  dose  of  300 mg/kg/day,  designed  to  achieve  a  50-fold  margin  to  the  clinical  target  dose  for  the migraine prophylaxis indication, very slight, focal arterial inflammation and arterial medial hypertrophy was observed in the artery of the tunica albuginea of the testes and epididymis in 1 out of 3 male monkeys. The nature of the finding in this single male monkey is considered to be incidental by the applicant. This male monkey with the findings of vascular injury had the highest exposure at the end of Week 13. The mean exposure (AUC) in this study (300 mg/kg/day) on Day 1 was higher (336 μM·hr) than the exposure at 150 mg/kg/day (206 μM·hr); howev er, the average exposures at the end of the study  were  similar  between  300 mg/kg/day  (110 μM·hr  with  vascular  injury)  and  150 mg/kg/day (109 μM·hr, without vascular injury). The vascular finding was not reproduced in a later 9 -month monkey study with doses up to 300 mg/kg/day with 4/sex/group. In this study, there were no test article-related

<div style=\"page-break-after: always\"></div>

antemortem  changes,  gross  or  histomorphologic  findings  and  the  mean  exposure  (AUC)  at  the 300 mg/kg/day NOAEL was 70.7 μM·hr (Week 39) which represents an approximate 12-fold margin of safety over the reported clinical exposure of about 5.75 μM·hr following 60 mg QD dosing.

In  the  9-month  study,  systemic  exposure  to  atogepant  was  independent  of  sex  and  increased  with increasing dose. Mean AUC0-24 hr and Cmax values of atogepant were approximately dose proportional from 15 to 40 mg/kg/day and less than dose proportional from 40 to 300 mg/kg/day on Study Day 1 and in Study Weeks 5 and 39. In Study Week 13, mean AUC0-24 hr and Cmax values of atogepant were less than dose proportional across all dose groups.

## 2.5.4.3. Genotoxicity

Atogepant was negative in in vitro Ames tests and in vitro chromosome aberration assays in CHO cells. An oral in vivo micronucleus test was performed as part of a 2-week repeat-dose toxicity study in rats. No signs of micronucleated PCEs were observed. AUC-based safety margins for the 60 mg QD human dose were 22-fold as derived from the 250 mg/kg/day dose in the micronucleus test (AUC0-24h 5.75 μM·hr vs. 124 μM·hr, respectively). Taken together, atogepant is not considered to be genotoxic in vitro and in vivo .

## 2.5.4.4. Carcinogenicity

Atogepant was assessed for its carcinogenic potential in mice and rat 104-week carcinogenicity studies. There were no indications of carcinogenic effects nor were any preneoplastic lesions observed in either species. AUC-based safety margins in the mouse study for the 60 mg QD human dose at the high dose (M + F combined) were approximately 9-fold (AUC0-t 5.75 μM·hr vs. 52 μM·hr, respectively). AUC -based safety margins in the rat study for the 60 mg QD human dose as derived from the high dose at day 28 were approximately 24-fold in males (AUC0-t 5.75 μM·hr vs. 135 μM·hr, respectively) and 37 -fold  in females (AUC0-t 5.75 μM·hr vs. 214 μM·hr, respectively).

In the 2-year oral carcinogenicity study in mice, non-neoplastic findings attributed to atogepant were limited to minimal epithelial vacuolation in the duodenum observed in preterminally euthanised males at 75 mg/kg/day and females at 160 mg/kg/day.

Overall, based on these data, no carcinogenic risk is expected for patients.

## 2.5.4.5. Reproductive and developmental toxicity

A complete programme of reproductive and developmental toxicity studies has been performed with atogepant,  including  studies  on  fertility  and  early  embryonic  development  in  rats,  on  embryo-fetal development in rats and rabbits and on pre- and postnatal development in rats. The studies have been performed in accordance with the ICH S5 (R3) guideline, except for a lack of statistical analysis of the fertility and early embryonic development study and the definitive embryo-fetal developmental studies. All pivotal studies were conducted under GLP regulation. In all studies atogepant was administered orally as the free base hydrate form in 100% PEG 400. Control animals received vehicle only. Toxicokinetics of atogepant were investigated in rats and rabbits in the embryo-fetal developmental toxicity studies.

Species-specific differences in in vitro affinity for the CGRP-receptor have been observed, with lower affinity for the rat (Ki 0.7 nM) and rabbit (Ki 2.1 nM) compared to human (Ki 0.026 nM) and monkey (Ki 0.009 nM), which could potentially compromise the relevance of these species to human. However,

<div style=\"page-break-after: always\"></div>

considering the lowest mean free Cmax levels from the definitive EFD studies in rats and rabbits, the exposure is  approximately  66-fold  and  119-fold,  respectively,  above  the  Ki-value  for  CGRP-receptor affinity. Regarding the CIDV-data, the plasma concentration for 47 % inhibition of dermal blood flow in rats is similar to the mean Cmax value obtained at the NOAEL of 15 mg/kg/day (lower mid-dose) in the EFD-study. For the rabbit, the plasma concentration to achieve 43 % inhibition in the CIDV assay (41 µM) is approximately 5-fold above the highest mean Cmax-value from the definitive EFD study in rabbits. These data suggest that the reproduction and developmental toxicity studies in rats and rabbits are adequate to evaluate both on-target and off-target effects of atogepant, possibly with some limitations in case of the rabbit for the on-target effects based on the data of the CIDV assay.

Data from the literature suggest that CGRP and related neuropeptides may have essential roles in fetal development  and  control  of  fetoplacental/uteroplacental  vascular  tone  as  potent  vasodilators  and inhibition of CGRP receptor activity may be associated with impairment of uteroplacental blood flow, resulting  in  fetal  growth  retardation.  The  relevance  of  these  data  for  the  findings  observed  in  the reproduction and developmental toxicity studies with atogepant is not known.

In the male and female fertility and early embryonic developmental toxicity study, rats were treated with atogepant at doses of 0 (vehicle), 5, 10, or 125 mg/kg/day. There was no test articlerelated reproductive toxicity at any dose level as assessed by mating performance, fertility, embryonicfetal survival, testicular weights, and sperm number and motility. The only test article-related effect was a decrease in mean body weight gain and mean food consumption in males in the 20 and 125 mg/kg/day dose groups and in females in the 125 mg/kg/day dose group. The NOAEL for female and male fertility parameters in rats was 125 mg/kg/day. The NOAELs for general toxicity parameters were 20 mg/kg/day (females)  and  5  mg/kg/day  (males).  Based  on  limited  toxicokinetic  data  from  the  embryo-fetal developmental toxicity study in rats, the estimated AUC-based safety margin at the NOAEL of the male and female fertility to the maximum human exposure at the therapeutic dose of 60 mg QD (AUC: 5.75 µM*hr) is approximately 17-fold.

There were no effects of atogepant on reproductive organs in male and female animals in repeated dose toxicity studies in rats and monkeys.

In the preliminary embryo-fetal developmental toxicity study in rats and rabbits, atogepantrelated maternal effects were limited to a decrease in maternal body weight gain and maternal food consumption in the two highest dose groups (250 and 750 mg/kg/day) in rats and in rabbits in the highest dose group (325 mg/kg/day). Also at these dose levels, developmental toxicity as evidenced by decreases in mean live fetal weight were observed in rats and rabbits.

In  the definitive  GLP  embryo-fetal  developmental  toxicity  study  in  rats ,  atogepant  was administered at dose levels of 0 (vehicle), 5, 15, 125, or 750 mg/kg/day. There were atogepant-related transient  decreases  in  maternal  food  consumption  at  ≥ 125  mg/kg/day.  At  these  dose  levels, developmental toxicity was also evident in the fetuses, including a slight decrease in mean fetal weights, a slight decrease in the mean number of ossified sacrocaudal vertebrae, and a slight increase in the incidence of fetuses with incompletely ossified skull bones, respectively. Furthermore, a dose-dependent increase in fetuses and litters with azygos vein variation at ≥ 15 mg/kg/day were observed. The NOAEL for both maternal and developmental toxicity were 15 mg/kg/day. Based on toxicokinetic data in rats, the  estimated  AUC-based  safety  margin  at  the  NOAEL  to  the  maximum  human  exposure  at  the therapeutic dose of 60 mg QD (AUC: 5.75 µM*hr) is approximately 4-fold.

In  the definitive  GLP  embryo  fetal  developmental  toxicity  study  in  rabbits, atogepant  was administered at dose levels of 0 (vehicle), 30, 90 or 130 mg/kg/day. There were atogepant-related decreases in maternal body weight gain and food consumption at 130 mg/kg/day. At this dose, increased incidences of litters and fetuses with visceral variations of absent caudate lobe of the lung and of skeletal sternebral  variations  (misaligned,  misshapen  or  extra  ossification  sites  above  first  sternebra)  were

<div style=\"page-break-after: always\"></div>

observed. The NOAEL for maternal toxicity (F0 females) and developmental toxicity (F1 litters) were 90 mg/kg/day Based on toxicokinetic data in rabbits, the estimated AUC-based safety margin at a NOAEL of 90 mg/kg/day to the maximum human exposure at the therapeutic dose of 60 mg QD (AUC: 5.75 µM*hr) is approximately 3-fold.

In the GLP pre- and postnatal developmental toxicity study in rats, atogepant was administered at dose levels of 0 (vehicle), 15, 45 or 125 mg/kg/day. In addition, the maternal milk and plasma (dams) concentrations of atogepant were determined. However, no toxicokinetic analysis was performed. There was  no  atogepant-related  mortality  and  no  evidence  of  maternal  toxicity  or  effects  on  maternal performance in the F0 generation dams at ≤ 125 mg/kg/day, except for a slight non-significant decrease in gestation body weight gain and gestation and lactation food consumption. In the F1 generation, preweaning pup- and post-weaning male body weights were statistically significant lower at 125 mg/kg/day. Partly significant lower body weight gain and food consumption were also observed in post-weaning males. Analysis of atogepant milk concentrations showed that atogepant is excreted in a substantial amount into rat milk with a milk:plasma concentration ratio of 2- to 2.5-fold. The NOEL for maternal toxicity  and  maternal  performance  and  the  NOAEL  for  development  of  the  F1  generation  was 45 mg/kg/day Based on toxicokinetic data from the embryo-fetal developmental toxicity study in rats, the estimated AUC-based safety margin at the NOAEL for maternal toxicity is approximately 17-fold and at  the  NOEL  for  development  of  the  F1 generation  is  approximately  5-fold  to  the  maximum  human exposure at the therapeutic dose of 60 mg QD (AUC: 5.75 µM*hr) is.

## Toxicity to juvenile animals

No paediatric indication is currently proposed for atogepant. Nevertheless, potential adverse effects of atogepant on juvenile animals were investigated in rats in two oral studies, a non-GLP DRF study and a pivotal GLP study. In the DRF study, juvenile rats were treated for 2-weeks from PND 28 through PND 42 (corresponding to a child age of approximately 2-12 years) with dose levels of 0 (vehicle), 10, 30 or 150  mg/kg/day  and  in  the  pivotal  6-week  study,  juvenile  animals  received  atogepant  doses  of  0 (vehicle), 10, 30, or 300 mg/kg/day from PND 28 through PND 71 (corresponding to a child age of approximately 2-18 years) followed by a treatment-free recovery period through PND 99 (4-weeks). Both  studies  included  toxicokinetic  investigations.  Also  bone  assessment  and  neurohistopathology investigations  were  performed  in  the  main  study.  The  toxicity  profile  in  juvenile  rats  was  generally comparable to that in adult rats (increase in ALT, vacuolation of epithelium in small intestine, decrease in thymus weight) with the exception of bone findings in males. The findings in bone (decrease in distal femur total area, total BMX and cortical/subcortical BMC) were not considered adverse by the applicant and were associated with minimal effects on male terminal body weights.

## 2.5.4.6. Toxicokinetic data

Toxicokinetic data are listed alongside with the respective associated toxicity studies.

## 2.5.4.7. Tolerance

Not applicable.

## 2.5.4.8. Other toxicity studies

## Immunotoxicity

The applicant has provided a weight of evidence review in accordance with ICH S8 which did not reveal any concerns.

<div style=\"page-break-after: always\"></div>

## Dependence

In studies evaluating the risk for physical dependence and the reinforcing potential in rats, atogepant did not show a relevant signal for abuse liability.

## Impurities

In  total  about  130  starting  materials,  raw  materials,  intermediates  and  potential  manufacturing impurities  were  subjected  to in  silico analysis  for  potential  mutagenicity  concerns.  Overall,  the toxicological assessment  of potential mutagenic  impurities is comprehensive  and  the applied methodology is in line with ICH M7(R1).

Epimer  (AGN-242245)  is  a  process-related  impurity,  which  was  present  above  the  toxicological qualification limit of NMT 0.15%. In silico analyses revealed no mutagenic potential of this impurity. It was present in batches used in toxicology studies (e.g. 9-month monkey study, NOAEL 300 mg/kg/day) at levels up to 0.64%. The proposed specification limit of NMT 0.2% is thus justified from a toxicological point of view.

Several impurities with structural alerts were considered as non-mutagenic (Class 5) based on provided negative and GLP-conform Ames tests or by referencing to publicly available mutagenicity data (e.g. ECHA registration dossiers, OECD, or publications). Impurities with specific structural alerts (e.g. also present in the drug substance or known Ames negative impurities), were overruled by expert statements and classified as non-mutagenic (Class 4). These approaches are agreed. On request the in silico reports (DEREK, Sarah, Case Ultra) were provided.

## Other studies - Phototoxicity

A 3-day phototoxicity study of atogepant in female pigmented rats with doses up to 40 mg/kg/day followed by a single ultraviolet ray exposure did not result in any skin reactions or ocular observations indicative of phototoxicity.

## Other studies - Mechanistic studies: Prediction of hepatotoxic potential of atogepant

In vitro assays related to known hepatotoxicity mechanisms (bile acid transporter inhibition, oxidative stress, and mitochondrial dysfunction) were conducted with atogepant and 2 predecessor CGRP receptor antagonists  that  were  discontinued  because  of  clinical  hepatotoxicity,  telcagepant  and  MK-3207. Subsequently, those results were parameterised into the 'DILIsym' model along with proposed clinical dose and PBPK models for each compound. Results of the 'DILIsym' modeling suggest that atogepant has a reduced risk of causing clinically relevant elevations of ALT in excess of 3-fold the upper limit of normal (≥ 3X ULN) compared to telcagepant and MK-3207.

## 2.5.5. Ecotoxicity/environmental risk assessment

The ERA Phase II Tier A and B provided for API atogepant monohydrate is considered acceptable.

The calculation of the predicted environmental concentration (PEC) in Phase I for atogepant has been based on default values. The PECsurface water value exceeds the action limit of 10 ng/l. Consequently, a respective Phase II environmental risk assessment was partially performed by the applicant.

As the Koc values are less than 10000 kg/L and the Kd values are less than 3700 kg/L, Tier B terrestrial studies were not required for atogepant. The log Kow for atogepant was determined to be 3.33. Valid data  on  a  resulting  OECD  305  fish  bioconcentration  study  were  delivered.  On  the  study  on  Aerobic Transformation in Aquatic Systems (OECD 308) atogepant is classified as vP as DT50 total system was 2561 d (at 12°C).

Aquatic tests on algae (OECD 201), daphnia (OECD 211), and fish (OECD 210) were acceptable. The OECD 209 Activated Sludge Respiration Inhibition Test can be accepted as now the solubility limit at pH

<div style=\"page-break-after: always\"></div>

7 is used as NOEC. The PEC/PNEC ratios for surface water and groundwater were substantially less than one and the PEC/PNEC ratio for microorganisms was substantially less than 0.1. Thus, atogepant is unlikely to represent a risk to the aquatic compartment.

According to the study on Aerobic Transformation in Aquatic Systems (OECD 308) a strong shift of test substance to the sediment was determined. Therefore, a Phase II Tier B Sediment-Water Chironomid Toxicity Test (OECD 218) study was conducted to assess the potential impact of atogepant on sediment dwelling midges. The PEC/PNEC ratio for sediment was substantially less than one. Thus, atogepant is unlikely to represent a risk to sediment dwelling organisms and no further testing is required.

As a result of the above considerations, the API Atogepant monohydrate does not pose a risk to the environment when used according to the SmPC.

Table 2: Summary of main study results

| Substance (INN/Invented Name): Atogepant CAS-number (if available): 1374248-81-3   | Substance (INN/Invented Name): Atogepant CAS-number (if available): 1374248-81-3   | Substance (INN/Invented Name): Atogepant CAS-number (if available): 1374248-81-3                                                            | Substance (INN/Invented Name): Atogepant CAS-number (if available): 1374248-81-3                                                            | Substance (INN/Invented Name): Atogepant CAS-number (if available): 1374248-81-3                                                            | Substance (INN/Invented Name): Atogepant CAS-number (if available): 1374248-81-3   |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| PBT screening                                                                      |                                                                                    | Result                                                                                                                                      |                                                                                                                                             |                                                                                                                                             | Conclusion                                                                         |
| Bioaccumulation potential- log K ow                                                | OECD 107                                                                           | 3.33 (pH 7)                                                                                                                                 | 3.33 (pH 7)                                                                                                                                 | 3.33 (pH 7)                                                                                                                                 | Potential PBT (N)                                                                  |
| PBT-assessment                                                                     |                                                                                    |                                                                                                                                             |                                                                                                                                             |                                                                                                                                             |                                                                                    |
| Parameter                                                                          | Result relevant for conclusion                                                     |                                                                                                                                             |                                                                                                                                             |                                                                                                                                             | Conclusion                                                                         |
| Bioaccumulation                                                                    | log K ow                                                                           | 3.33                                                                                                                                        | 3.33                                                                                                                                        | 3.33                                                                                                                                        | Pot B                                                                              |
| Bioaccumulation                                                                    | BCF (kinetic, lipid and growth corrected)                                          | 0.806 L/kg -1                                                                                                                               | 0.806 L/kg -1                                                                                                                               | 0.806 L/kg -1                                                                                                                               | not B                                                                              |
| Persistence                                                                        | DT 50total system                                                                  | 2561 d (12°C)                                                                                                                               | 2561 d (12°C)                                                                                                                               | 2561 d (12°C)                                                                                                                               | vP                                                                                 |
| Toxicity                                                                           | NOEC                                                                               | 550 µg/L                                                                                                                                    | 550 µg/L                                                                                                                                    | 550 µg/L                                                                                                                                    | not T                                                                              |
| PBT-statement:                                                                     | The compound is not considered as PBT nor vPvB                                     | The compound is not considered as PBT nor vPvB                                                                                              | The compound is not considered as PBT nor vPvB                                                                                              | The compound is not considered as PBT nor vPvB                                                                                              | The compound is not considered as PBT nor vPvB                                     |
| Phase I                                                                            |                                                                                    |                                                                                                                                             |                                                                                                                                             |                                                                                                                                             |                                                                                    |
| Calculation                                                                        | Value                                                                              | Unit                                                                                                                                        | Unit                                                                                                                                        | Unit                                                                                                                                        | Conclusion                                                                         |
| PEC surfacewater , default                                                         | 0.3                                                                                | µ g/L                                                                                                                                       | µ g/L                                                                                                                                       | µ g/L                                                                                                                                       | > 0.01 threshold (Y)                                                               |
| Phase II Physical-chemical properties and fate                                     | Phase II Physical-chemical properties and fate                                     | Phase II Physical-chemical properties and fate                                                                                              | Phase II Physical-chemical properties and fate                                                                                              | Phase II Physical-chemical properties and fate                                                                                              | Phase II Physical-chemical properties and fate                                     |
| Study type                                                                         | Test protocol                                                                      | Results                                                                                                                                     | Results                                                                                                                                     | Results                                                                                                                                     | Remarks                                                                            |
| Adsorption-Desorption                                                              | OECD 106                                                                           | K foc soil = 270, 424, 769 K sludge = 555, 434                                                                                              | K foc soil = 270, 424, 769 K sludge = 555, 434                                                                                              | K foc soil = 270, 424, 769 K sludge = 555, 434                                                                                              | List all values                                                                    |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems                   | OECD 308                                                                           | Calwich Abbey Lake: DT 50, water = 20 d DT 50, whole system = 1200 d %shifting to sediment = 49.4 (day 14) Emperor Lake DT 50, water = 21 d | Calwich Abbey Lake: DT 50, water = 20 d DT 50, whole system = 1200 d %shifting to sediment = 49.4 (day 14) Emperor Lake DT 50, water = 21 d | Calwich Abbey Lake: DT 50, water = 20 d DT 50, whole system = 1200 d %shifting to sediment = 49.4 (day 14) Emperor Lake DT 50, water = 21 d | at 20°C                                                                            |
| (day 14) Phase IIa Effect studies                                                  | (day 14) Phase IIa Effect studies                                                  | (day 14) Phase IIa Effect studies                                                                                                           | (day 14) Phase IIa Effect studies                                                                                                           | (day 14) Phase IIa Effect studies                                                                                                           | (day 14) Phase IIa Effect studies                                                  |
| Study type                                                                         | Test protocol                                                                      | Endpoint                                                                                                                                    | value                                                                                                                                       | Unit                                                                                                                                        | Remarks                                                                            |
| Algae, Growth Inhibition Test, Raphidocelissubcapitata                             | OECD 201                                                                           | NOEC                                                                                                                                        | 1700                                                                                                                                        | µg/L                                                                                                                                        | Inhibition of growth rate and yield                                                |
| Daphnia sp . Reproduction Test, Daphnia magna                                      | OECD 211                                                                           | NOEC                                                                                                                                        | 550                                                                                                                                         | µg/L                                                                                                                                        | Reproduction                                                                       |

<div style=\"page-break-after: always\"></div>

| Fish, Early Life Stage Toxicity Test, Pimephalespromelas   | OECD 210   | NOEC   | 1600          | µg/L   | Survival, egg hatch, weight, length                              |
|------------------------------------------------------------|------------|--------|---------------|--------|------------------------------------------------------------------|
| Activated Sludge, Respiration Inhibition Test              | OECD 209   | NOEC   | 5190          | µg/L   | Respiration                                                      |
| Phase IIb Studies                                          |            |        |               |        |                                                                  |
| Bioaccumulation                                            | OECD 305   | BCF    | 0.806 L/kg -1 | L/kg   | %lipids:                                                         |
| Sediment dwelling organism Chironomus riparius             | OECD 218   | NOEC   | 4322          | mg/kg  | emergence and development rate, correction to 10% organic carbon |

## 2.5.6. Discussion on non-clinical aspects

## Pharmacology

## Primary and secondary pharmacodynamics

A specific animal model for the evaluation of prophylactic effects of atogepant on migraine was not provided by the applicant. As a surrogate pharmacological parameter for clinical efficacy of atogepant, inhibition of capsaicin-induced dermal vasodilatation (CIDV), an effect considered to be mediated largely by release of CGRP, was used by the applicant.

In isolated coronary, meningeal and cerebral artery segments, atogepant inhibited the vasodilatory effect of  αCGRP. However, while in distal coronary artery segments the inhibitory effect of atogepant was apparently  competitive  in  nature,  in  middle  meningeal  and  cerebral  artery  segments,  atogepant antagonise d the αCGRP effect apparently in a non -competitive manner.

These results suggest that more than one receptor type is involved in the observed antagonistic effects of atogepant and that the vasodilatory effects of CGRP on distal coronary artery segments and on middle meningeal and cerebral artery segments are mediated via different receptors.

In conclusion, non-clinical receptor binding studies and in vitro functional studies point to an involvement of more than one receptor type in the pharmacological effects of atogepant. Atogepant shows affinity to several receptors of the calcitonin/CGRP-receptor family. In view of the clinically relevant free plasma concentrations of atogepant (≥ 20 nM for a 60 mg dose) and the fact that CGRP and amylin -1 receptors are considered to be involved in the pathophysiology of migraine, inhibitory effects of atogepant at these receptors  (Ki-value  26  pM  respectively  2.4  nM)  could  be  of  clinical  relevance.  However,  the  precise mechanism of atogepant in the prophylaxis of migraine remains to be established.

## Safety pharmacology

Plasma levels of the high dose atogepant groups in the safety pharmacology studies usually exceeded atogepant plasma levels observed for the 60 mg QD clinical atogepant dose. Overall, the findings of the safety  pharmacology  studies  with  atogepant  do  not  provide  a  critical  safety  signal  for  the  use  of atogepant for the prophylaxis of migraine in humans.

## Pharmacodynamic drug interactions

Non-clinical pharmacodynamic drug interaction studies have not been included in this application. This is considered acceptable, since a non-clinical pharmacodynamic model for evaluation of prevention of migraine is not available. Potential pharmacodynamic interactions from concomitant use of atogepant with other gepants or with CGRP antibodies, used for acute treatment of migraine, were discussed on the clinical level (see Clinical Aspects).

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics

The ADME data submitted for rat and rhesus monkey provide supporting evidence for the use of these species in the atogepant toxicity studies.

Based on in vitro studies and clinically efficacious plasma concentrations, atogepant is not anticipated to cause drug-drug interactions through CYP inhibition or induction or through drug transporter inhibition at therapeutic doses.

## Toxicity

Overall, the non-clinical toxicology programme is largely in line with the recommendations of the ICH M3(R2) guideline. However, the following points are specifically addressed:

## Single dose toxicity

Dedicated single dose toxicity studies have not been performed with atogepant. However, in accordance with the 'Questions and answers on the withdrawal of the Note for guidance on single dose toxicity' (EMA/CHMP/SWP/81714/2010) this is considered acceptable, since relevant information on acute toxicity of atogepant can be obtained from the available repeat dose toxicity studies.

## Repeat dose toxicity

In accordance with ICH M3(R2) recommendations, the applicant conducted oral repeat-toxicity studies for up to 3 months in mice, up to 6 months (with a 1-month recovery period) in rats and up to 9 months in rhesus monkeys. In addition, information on chronic toxicity of atogepant is available from the 2-year carcinogenicity studies in mice and rats (see below).

In the pivotal repeat dose toxicity studies, at the NOAEL, AUC-based exposure multiples of &gt;1 compared with the clinical exposure at the 60 mg QD dose were observed (see 'Estimation of safety margins for atogepant', below).

Main observations in the rodent (mouse, rat) studies were post-dose salivation, decreased body weight gain, reversible epithelial vacuolation in the small intestine or parathyroid gland and a slight elevation of liver ALT transaminase.

In the 9-month rhesus monkey study, no relevant atogepant-related toxicity was observed up to the highest tested dose of 300 mg/kg/day.

Overall, the repeat dose toxicity studies do not indicate a critical safety signal for the use of atogepant for the prophylaxis of migraine in humans.

## Genotoxicity

Based on the submitted data, atogepant is not considered to be genotoxic in vitro and in vivo .

## Carcinogenicity

Based on the data from the 2-year oral carcinogenicity studies with atogepant in mice and rats, no carcinogenic risk is expected for patients.

In the mouse study, non-neoplastic findings attributed to atogepant were limited to minimal epithelial vacuolation in the duodenum observed in preterminally euthanised males at 75 mg/kg/day and females at 160 mg/kg/day.

<div style=\"page-break-after: always\"></div>

## Reproductive and developmental toxicity

A complete programme of reproductive and developmental toxicity studies has been performed with atogepant,  including  studies  on  fertility  and  early  embryonic  development  in  rats,  on  embryo-fetal development in rats and rabbits and on pre- and postnatal development in rats. The studies have been performed in accordance with the ICH S5 (R3) guideline, except for a lack of statistical analysis of the fertility and early embryonic development study and the definitive embryo-fetal developmental studies.

Species-specific differences in in vitro affinity for the CGRP-receptor have been observed, with lower affinity for the rat (Ki, 0.7 nM) and rabbit (Ki, 2.1 nM) compared to human (Ki, 0.026 nM) and monkey (Ki, 0.009 nM), which could potentially compromise the relevance of these species to human. However, plasma Cmax-levels in the rat and rabbit reproduction and developmental toxicity studies are well above the respective Ki-value for CGRP-receptor affinity, suggesting adequacy for evaluation of on- and offtarget effects in these species.

Data from the literature, discussed by the applicant, suggest that CGRP and related neuropeptides may have essential roles in fetal development and control of fetoplacental/uteroplacental vascular tone as potent vasodilators and antagonism of CGRP receptor activity may be associated with impairment of uteroplacental  blood  low,  resulting  in  fetal  growth  retardation.  The  relevance  of  these  data  for  the findings observed in the reproduction and developmental toxicity studies with atogepant is unknown.

In the definitive embryo-fetal developmental toxicity studies in rats and rabbits some findings were observed with an unclear relation to treatment. In rats, a dose-dependent increase in resorptions and postimplantation loss at ≥ 125 mg/kg/day and of fetuses and litters with azygos vein var iation at ≥ 15 mg/kg/day were observed. In rabbits, increased incidences of litters and fetuses with visceral variations of absent caudate lobe of the lung and of skeletal sternebral variations (misaligned, misshapen or extra ossification sites above first sternebra) were observed at 130 mg/kg/day. Whereas in rats the increase in resorptions and postimplantation losses are likely incidental, for the azygos vein variation a relation to treatment cannot be excluded for the highest dose group, since the incidence was above the historical control. Nevertheless, this has no great impact on the overall risk assessment and on the NOAEL, which is already set at a dose level of 15 mg/kg/day for developmental toxicity of the F1 litters. However, it was included in section 5.3 of the SmPC.

Also, for the increased incidences of litters and fetuses with visceral variations of absent caudate lobe of the lung and of skeletal sternebral variations (misaligned, misshapen or extra ossification sites above first sternebra) observed in rabbits an association with atogepant treatment cannot be excluded since the incidences were above the historical control. The NOAEL for developmental toxicity of the F1 litters should be lowered to 90 mg/kg/day.

For the pre-postnatal study in rats, in the F1 generation pre-weaning pup- and post-weaning male- body weights were statistically significantly lower at 125 mg/kg/day as well as a partly significant lower body weight gain and food consumption were also observed in post-weaning males. Analysis of atogepant milk concentrations  showed  that  atogepant  is  excreted  in  a  substantial  amount  into  rat  milk  with  a milk:plasma concentration ratio of 2- to 2.5-fold. Also, in the juvenile toxicity studies with atogepant in rats, an atogepant-related body weight loss, associated with further findings was observed in males. Therefore,  the  relevance  to  humans  is  currently  not  known Although  the  body  weight  loss  was  not considered as adverse it is mentioned in section 5.3 of the SmPC, together with the approximately 5fold safety margin to human exposure at the MRHD based on the TK data extrapolated from the rat EFD study at the NOEL of 45 mg/kg/day,

Although no paediatric indication is currently proposed for atogepant, two juvenile animal toxicity studies in rats have been performed. The toxicity profile in juvenile rats was generally comparable to that in adult rats (increase in ALT, vacuolation of epithelium in small intestine, decrease in thymus weight) with the exception of bone findings in males.

<div style=\"page-break-after: always\"></div>

## Phototoxicity

A 3-day phototoxicity study of atogepant in female pigmented rats with doses up to 40 mg/kg/day followed by a single ultraviolet ray exposure did not result in any skin reactions or ocular observations indicative of phototoxicity.

According to the ICH S10 'Guideline on phototoxicity testing', for new active substances, in the EU a validated in vitro alternative method should generally be used before considering animal testing. A tiered approach could include (i) an evaluation whether a compound absorbs wavelengths between 290 and 700  nm.  Absorption  with  a  molar  extinction  coefficient  (MEC)  less  than  1000  L  mol -1   cm -1  is  not considered to result in a photosafety concern (ii) For compounds with a MEC greater than 1000 L mol -1 cm -1 , an in vitro phototoxicity assay should be considered. The currently most widely used in vitro assay for phototoxicity is the ' In vitro 3T3 Neutral Red Uptake Phototoxicity Test' (3T3 NRU-PT) for which a guideline is available (OECD Test No. 432).

However,  the  ICH  S10  guideline  also  clearly  spells  out,  that  in  cases,  where  an in  vivo animal phototoxicity study has already been conducted, there is no reason to subsequently conduct an in vitro phototoxicity assay. In conclusion, for atogepant no additional non-clinical in vitro phototoxicty testing is requested.

## Estimation of safety margins for atogepant

Marked interspecies difference in the in vitro affinity for the CGRP receptor exist with the rat (Ki, 0.7 nM), mouse (Ki, 0.13 nM), and rabbit (Ki, 2.1 nM) having lower affinity for the CGRP receptor than monkey (Ki, 0.009 nM) and human (Ki, 0.026 nM). Despite this, pharmacologically relevant plasma levels were likely achieved in the rat and rabbit studies as supported by the CIDV assay (a biomarker for peripheral target activity of CGRP) and the fact that plasma levels measured in safety pharmacology and toxicology studies were significantly greater than respective Ki values in these species. Although CIDV data in the mouse are not available, a pharmacologically relevant exposure was likely achieved in mouse safety assessment studies, as the affinity of atogepant for the mouse CGRP receptor is higher than for the rat one. The high-dose (i.e., 300 mg/kg/day) exposure achieved in the monkey 9-month study resulted in a Cmax (on Day 1) that exceeded the EC50 in the monkey CIDV assay (1 nM) by more than 10,000-fold. Thus, the rat, mouse, rabbit, and monkey studies are considered to provide an appropriate toxicity evaluation for both on- and off-target related toxicity.

The exposure multiples achieved in the pivotal toxicology studies are shown below.

Table 3: Margins of safety for atogepant

| Study                          | Doses (mg/kg)              | NOAEL               | Margin (AUC) a   |
|--------------------------------|----------------------------|---------------------|------------------|
| 6 Month Rat                    | 10, 30, 100                | 100                 | 33x              |
| 9 Month Monkey                 | 15, 40, 300                | 300                 | 12x              |
| Embryofetal Development Rat    | 5, 15, 125, 750            | 15 (developmental)  | 4x               |
| Embryofetal Development Rabbit | 30, 90, 130                | 130 (developmental) | 8x               |
| Fertility Rat                  | 5, 20, 125                 | 125                 | 17x b            |
| Pre/postnatal Development Rat  | 15, 45, 125                | 125                 | 17x b            |
| Carcinogenicity Mouse          | M: 5, 20, 75 F: 5, 30, 160 | 75 160              | 9x               |

<div style=\"page-break-after: always\"></div>

| Carcinogenicity Rat   | M: 10, 20, 100 F: 25, 65, 200   | 100 200   | 24x/37x   |
|-----------------------|---------------------------------|-----------|-----------|

## 2.5.7. Conclusion on the non-clinical aspects

The submitted non-clinical data are considered sufficient to support the marketing approval of atogepant for the prophylaxis of migraine.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

## Table 4: Phase 1 PK studies in healthy subjects

| Study ID     |                                                                                                                                                                                                                                                                                                                |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MK-8031 P001 | Single ascending dose study in healthy young male subjects investigating (Part I) safety and PK of atogepant 1, 2.5, 5, 10, 20, 40, and 50 mg; and (Part II) PD of atogepant 0.4, 2.5 or 30 mg (provided as AIB, for on-site oral solution formulation)                                                        |
| MK-8031 P002 | Single and multiple ascending dose study in healthy young males investigating safety, PK and PD of atogepant Part I: Single doses of 40 mg, 100 mg, 170 mg, or 200 mg spray dried OCT, or placebo. Part II: Multiple doses of atogepant 50, 100, or 170 mg once daily or 30 mg twice daily (SD-OCT) or placebo |
| MK-8031 P004 | A 28-day multiple dose PK study with repeated once daily doses of 170 mg atogepant to evaluate safety, tolerability, and PK                                                                                                                                                                                    |
| CGP-PK-03    | Mass balance study with single oral dose of 50 mg [14C]- atogepant (~200 μCi) to determine the absorption, distribution, metabolism and excretion profile of atogepant in healthy male subjects                                                                                                                |

Table 5: Phase 1 PK studies investigating intrinsic factors

| Study ID     |                                                                                                         |
|--------------|---------------------------------------------------------------------------------------------------------|
| MK-8031 P003 | A single dose study to evaluate the safety, tolerability, and PK of 40 mg atogepant in elderly subjects |

<div style=\"page-break-after: always\"></div>

| 3101-101-002   | A randomized, double-blind, placebo-controlled study to evaluate the PK, safety, and tolerability of 10 mg, 30 mg, and 60 mg once daily, and 60 mg twice daily atogepant in healthy Japanese and Caucasian subjects   |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3101-104-002   | A single-centre, open-label, pharmacokinetic study of atogepant in adult healthy Chinese participants                                                                                                                 |
| CGP-PK-01      | An open-label, single dose study to evaluate safety and PK of 60 mg atogepant in patients with impaired hepatic function and subjects with normal hepatic function                                                    |

Table 6: Phase 1 studies investigating extrinsic factors and PD

| Study ID     |                                                                                                                                                                                                                                                                                                                                                                                      |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CGP-PK-02    | Phase 1, drug-drug interaction study to assess the effect of co-administration of strong CYP3A4 inhibitor itraconazole on the PK of 60 mg atogepant                                                                                                                                                                                                                                  |
| CGP-PK-12    | Phase 1, drug-drug interaction study to assess the effect of strong OATP inhibitor (single dose rifampin) and CYP3A4 inducer (600 mg rifampin once daily for 5 days) on the PK of 60 mg atogepant                                                                                                                                                                                    |
| CGP-PK-14    | An open-label, multiple-dose, 2-cohort, drug-drug interaction study between atogepantand topiramate in healthy participants                                                                                                                                                                                                                                                          |
| 3101-103-002 | A study to evaluate the effects of quinidine gluconate, a P-gp inhibitor, on single dose pharmacokinetics of 60 mg atogepant in healthy adult subjects                                                                                                                                                                                                                               |
| MK-8031 P005 | A Phase 1 drug-drug interaction study to assess the potential interaction between 60 mg atogepant and oral contraceptives. A majority of migraine patients are young women, who are likely to be taking oral contraceptives. Therefore, this study was conducted to determine whether concomitant administration of atogepant and oral contraceptives could lead to a PK interaction |
| MK-8031 P008 | An explorative biocomparison study to evaluate the bioavailability of different PMF formulations of 60 mg atogepant in healthy volunteers (Included famotidine DDI)                                                                                                                                                                                                                  |
| 3101-102-002 | A Phase 1, drug-drug interaction study to evaluate the effect of the co-administration of the proton pump inhibitor esomeprazole on the oral bioavailability and PK parameters of 60 mg atogepant                                                                                                                                                                                    |
| CGP-PK-13    | A Phase 1, drug-drug interaction study to evaluate the effect of concomitant use of sumatriptan, the most commonly used triptan for the treatment of headaches and migraines, and 60 mg atogepant                                                                                                                                                                                    |
| CGP-PK-06    | A Phase 1, drug-drug interaction study to evaluate the effect of concomitant use of the NSAID naproxen, and acetaminophen, both commonly used for the treatment of headaches and migraines, and 60 mg atogepant                                                                                                                                                                      |
| 3101-106-002 | A Phase 1b, open-label, fixed-sequence, safety, tolerability and drug-drug interaction study between atogepant and ubrogepant in participants with a history of migraine                                                                                                                                                                                                             |
| 3101-105-002 | A single dose study investigating the effects of a high fat meal on the oral bioavailability of atogepant 60 mg IR tablet formulation                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

CGP-PK-04

A single dose study to evaluate the effects of a supratherapeutic dose of 300 mg atogepant on cardiac repolarisation (QTcF)

Table 7: Description of phase II/III clinical efficacy and safety study - dose-finding, supportive

| Study ID/ No.of Centers\"/ Locations/ Duration         | Study Status FPFV LPLV Randomized Actual/ Planned   | Design Control Type                                                       | Study& Control Drugs Dose, Route & Regimen                                                                           | Study Objectives                                                                                                                                                                                                                                                                                                                                                               | No. of Subjects by Arm Randomized/ Completedb                                                                                                           | Sex M/F Median Age (Min, Max)c   | Diagnosis Inclusion Criteria                                                                                                            | Primary Endpoints                                                                      |
|-------------------------------------------------------|-----------------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| CGP-MD-01/ 80/ US/ 12 weeks of double-blind treatment | Completed 06 Sep 2016d 23 April 2018e 834/810       | Phase 2/3, randomized, double- blind, placebo controlled, parallel- group | Atogepant 10 mg QD, Atogepant 30 mg QD, Atogepant 60 mg QD, Atogepant 30 mg BID, Atogepant 60 mg BID, Placebo Orally | To evaluate the safety and tolerability of the following doses and dose regimens of atogepant (10 mg QD,30 mgQD, 30 mg BID, 60 mg QD, and 60 mg BID) for the preventive treatmentofmigraine in participants with EM. To characterize the dose/response relationship across the following doses and dose regimens (10 mg QD,30 mg QD, 30 mg BID, 60 mg QD, and 60 mg BID)forthe | Atogepant 10 mg QD: 94/80 Atogepant 30 mg QD: 185/149 Atogepant 60 mg QD: 187/164 Atogepant 30 mg BID: 89/70 Atogepant 60 mg BID:93/73 Placebo: 186/148 | 111/714 39 years (18, 74)        | EM Adults with a history of migraine with or without aura for ≥ 1 year and who had 4-14 migraine days during the 28-day baseline period | Change from baseline in mean monthly migraine days across the 12-week treatment period |
|                                                       |                                                     |                                                                           |                                                                                                                      | of migraine in participants with EM. To prospectively test for superiority of the following doses and dose regimens of atogepant (10 mg QD, 30 mg QD, 30 mg BID, 60 mg QD, and 60 mg BID) versus placebo for the preventive treatment of migraine in participants with EM.                                                                                                     |                                                                                                                                                         |                                  |                                                                                                                                         |                                                                                        |

BID = twice daily; CM = chronic migraine; EM = episodic migraine; FPFV = first participant first visit; LPLV = last participant last visit; max = maximum; min = minimum; QD=once daily; US =United States

a. Number ofsitesthatscreenedparticipants.

b. Reflects thenumberofparticipantswhocompleted the12-week double-blind treatment periodof thestudy.

C. Demography is based on data from the safety population (all participants who took at least 1 dose of study drug).

d. Reflects the date the first participant enrolled.

e. Reflects the date the last participant completed.

<div style=\"page-break-after: always\"></div>

Table 8: Description of phase III clinical efficacy and safety studies - primary

| Study ID/ No.of Centersa/ Locations/ Duration                                                                                                                                                              | Study Status FPFV LPLV Randomized Actual/ Planned   | Design Control Type                                                    | Apms Control Drugs Dose, Route & Regimen                            | Study Objectives                                                                                                                                                                                                                                                                                                                                      | No. of Subjects by Arm Randomized/ Completedb                                                      | Ser M/F Median Age (Min, Max)*   | Diagnosis Inclusion Criteria                                                                                                                                                          | Primary Endpoints                                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| 3101-301-002/ 136/ US/ 12 weeks of double-blind treatment                                                                                                                                                  | Completed 14 Dec 2018 19 June 2020 910/872          | Phase 3, randomized, double-blind, placebo controlled, parallel-group  | Atogepant 10 mg. Atogepant 30 mg, Atogepant 60 mg, Placebo orallyQD | To evaluate the safety and tolerability of atogepant 10 mg, atogepant 30 mg, and atogepant 60 mg QD for thepreventivetreatment of migraine in participants with EM. To prospectively test for superiority of atogepant 10 mg, atogepant 30 mg. and atogepant 60 mg QD versus placebofor the preventive treatment of migraine in participants with EM. | Atogepant 10 mg QD: 222/193 Atogepant30mg QD: 230/207 Atogepant 60 mg QD: 235/204 Placebo: 223/201 | 101/801 41 years (18, 73)        | EM Adults with a history of migraine with or without aura for ≥ 1 year and who had 4-14 migraine days during the  28-day baseline period                                              | Change from baseline in mean monthly migraine days across the 12-week treatment period |
| 3101-303-002/ 142/ US, Canada, China, Czech Republic, Denmark, France, Germany, Italy, Japan, Republic of Korea, Poland, Russian Federation, Spain, Sweden, Taiwan, UK/ 12 weeks of double-blind treatment | Completed 11 March 2019 20 Jan 2022 778/750         | Phase 3, randomized, double-blind, placebo- controlled, parallel-group | Atogepant 30 mg BID, Atogepant 60 mg QD, Placebo orally             | To evaluate the safety and tolerability of atogepant 30 mg BID and60mgQDforthe preventivetreatmentof migraine in participants with CM. To prospectively test for superiority of atogepant 30 mg BID and 60 mg QD versus placebo for the preventive treatment of migraine in participants with CM.                                                     | Atogepant 30 mg BID: 257/231 Atogepant 60mg QD: 262/233 Placebo:259/230                            | 96/677 43 years (18, 74)         | CM Adults with a history of CM for ≥1 year and who had ≥15 headache days during the 4-week baseline period AND ≥8 days during thebaseline period that qualify as being a migraine day | Change from baseline in mean monthly migraine days across the 12-week treatment period |

BID = twice daily; CM = chronic migraine; EM = episodic migraine; FPFV = first participant first visit; LPLV = last participant last visit; max = maximum; min = minimum;

QD=once daily;US=UnitedStates a. Numberofsitesthatscreenedparticipants.

b. Reflects the number of participants who completed the 12-week double-blind treatment period of the study.

Demography is based on data from the safety population (all participants who took at least 1 dose of study drug).

Table 9: Completed phase III long-term studies

| 3101-302-002   | Long-term safety and tolerability   | Open-label,long-temmsafety Adultswithahistoryofmigrainewithorwithoutaurafor≥1yearand whohad4-14migrainedaysduringthe28-daybaselineperiod Denovoparticipantswhodidnotparticipateinanypreviousatogepant studyandparticipantswhocompletedStudyCGP-MD-01   | 52weeksof open-label treatment   | SoCpreventivemigraine medication (196) Atogepant60mgQD(543) Total:739   |
|----------------|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------------------------------------------------------|
| 3101-309-002   | Long-term safety and tolerability   | Open-label,long-termsafety Adultswith ahistoryofmigrainewithorwithout aurafor≥1yearand whohad 4-14 migraine days duringthe28-daybaselineperiod RolloverparticipantswhocompletedStudy3101-301-002                                                       | 40weeksof open-label treatment   | Atogepant60mgQD(685) Total:685                                          |

<div style=\"page-break-after: always\"></div>

Table 10: Ongoing phase III studies

| 3101-304-002b   | Efficacy and safety               | Multicenter,randomized,double-blind,placebo-controlled parallel-group Adultswithahistoryofmigrainewithorwithout aurafor≥1yearand whohad4-14migrainedaysduringthe28-daybaselineperiodwhohave failed2to4classesoforalprophylactictreatment   | 12weeksof double-blind treatment   | Placebo (150) Atogepant60mgQD(150) Total: 300 ISS cutoff:207   |
|-----------------|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|----------------------------------------------------------------|
| 3101-306-002    | Long-term safety and tolerability | Multicenter,open-label,long-temmsafetyextension,conductedinJapan JapaneseadultswhoeithercompleteStudy3101-303-002orwho are de novo                                                                                                         | 52weeks of open-label treatment    | Atogepant60mgQD(140) Total:atleast 140 ISScutoff:155           |
| 3101-311-002    | Safety and tolerability           | Multicenter, open-label, safety extension conducted in China Chinese adultswhocompleteStudy3101-303-002                                                                                                                                    | 12 weeks of open-label treatment   | Atogepant 60 mg QD (120) Total:120 ISScutoff:3                 |
| 3101-312-002    | Long-term safety and tolerability | Multicenter, open-label, long-term safety extension Adults who complete either Study 3101-303-002 or Study 3101-304-002                                                                                                                    | 104 weeks of open-label treatment  | Atogepant 60 mg QD (670) Total: 670 ISScutoff:286              |

BID=twicedaily;CM=chronicmigraine;QD=once daily;SoC=standard-of-care

a. Atogepant60mgBIDwas studiedinonly91participantsinStudyCGP-MD-01.

b. Study 3101-304-002 is ongoing and blinded; therefore, data from this study are not included in the analysis sets (see Section 2.7.4.1.1.2)

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

## Absorption

Atogepant drug substance is categorised as a BCS II molecule. The poor aqueous solubility of atogepant drug  substance  presented  a  great  challenge  for  the  development  of  conventional  solid  oral  tablet formulations  with  desired  immediate  release  attributes.  The  formulation  evolution  through  different clinical stages was as follows.

Initially,  to  support  the  first-in-human  SAD  Phase  1  study  (Study  MK-8031  P001),  an  oral  solution formulation with atogepant was developed.

Later, solid oral dosage formulations were explored in Phase 1 clinical studies.

The HME-OCT formulation was used for all Phase 2 and Phase 3 clinical studies and is the to-be-marketed tablet formulation.

## Early SAD using an oral solution

## A Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8031 (Study MK-8031 P001)

In Part I of early SAD study P001 single doses of 1, 2.5, 5, 10, 20, 40, and 50 mg (on-site solution formulation) and placebo were administered in healthy, young male subjects. Subjects were assigned to 1 of 2 alternating panels (A or B) consisting of 8 subjects each (n = 6 active, n = 2 placebo per dose level). Subjects received alternating single rising oral doses of AGP or placebo in up to 5 treatment periods (Periods 1 through 5). There was a minimum 7-day washout between treatment periods for any given subject. All doses were administered after an overnight fast.

Following oral administration of single doses of atogepant (solution; 1 to 50 mg dose), atogepant was absorbed rapidly with median Tmax values ranging from 1 to 2 hours post-dose. The plasma profile declined generally bi-exponentially post-Cmax. Approximately 90% of the total AUC was contained in the first 24 hours.

An exploratory analysis of dose proportionality over the dose range 1-mg to 50-mg was conducted. Estimates and 95% CIs [1 represents exact dose proportionality] for the slope from the power model were 1.01 (0.96, 1.05) for AUC0∞, 0.96 (0 .91, 1.01) for Cmax, 1.02 (0.97, 1.07) for C2hr, and 0.97

<div style=\"page-break-after: always\"></div>

(0.90, 1.04) for C24hr, suggesting approximately dose proportional increases for these PK parameters over the 1-mg to 50-mg dose range.

## Early tablet SD-OCT formulation

## A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Atogepant (Study MK-8031 P002)

Study P002 was a 2-part study in which a SD-OCT formulation of atogepant was administered to healthy young subjects in a single-dose extension study (Part I) and a multiple rising-dose study (Part II). In Part I, single doses of 40 mg (with and without food), 100 mg (fasted), 170 mg (fasted), and 200 mg (fasted) atogepant or placebo were administered in 5 periods to a single panel of 8 subjects (n = 6 active, n = 2 placebo at each dose level).

In Part II, multiple doses of 50 mg, 100 mg, and 170 mg atogepant or placebo were administered fasted daily for 10 days in sequential panels of 8 subjects (n = 6 active, n = 2 placebo at each dose level). One additional  panel  received  30  mg  atogepant  or  placebo  twice  daily  for  10  days.  Blood  samples  for assessment of plasma concentrations of atogepant were taken on Days 1 and 10 at pre-dose and 20 minutes, 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post-dose. On Days 3, 4, 5, and 8, blood was collected pre-dose. Additionally, on Day 10, samples were taken at 48 and 72 hours post-dose.

Similar to the on-site solution formulation in Study P001, atogepant was absorbed rapidly after oral administration of single doses of the SD-OCT formulation from 40 to 200 mg to healthy subjects in Part I of study P002. The median Tmax values ranged from 1.0 to 1.5 hours post-dose. The plasma profile declined generally bi-exponentially post-Cmax, and the apparent terminal t1/2 appeared to be about 11 hours. The AUC0∞ and Cmax of single doses of 40 mg atogepant OCT appeared to be about 2 -fold and 3-fold higher, respectively, given as the tablet formulation compared to those observed for oral solution at 40 mg in Study MK-8031 P001. The difference appeared to be due to a higher bioavailability and a potentially faster rate of absorption for the tablet formulation compared to solution formulation.

In Part II, multiple doses of atogepant (SD-OCT) were administered once daily for 10 days in a total of 4 panels of 8 subjects each (6 active, 2 placebo). Upon review of individual concentration-time profiles at different dose levels, it appeared that most subjects reached steady state by Day 3. The AUC0-24h and Cmax geometric mean accumulation ratios (Day 10/Day 1) ranged from 1.16 to 0.77, demonstrating minimal accumulation, which is generally consistent with expectation based on the single-dose PK profile (bi-exponential decay with 11-hour terminal t1/2).

<div style=\"page-break-after: always\"></div>

Figure 2: Arithmetic Mean Plasma Concentration of Atogepant vs. Time Following Administration of Multiple Oral Doses to Healthy Fasted Young Male Subjects (PK Population; MK-8031 P002 [Part II])

<!-- image -->

Top panel = linear; bottom panel = log-linear

Source: Derived from Module 5.3.3.1, MK-8031 P002 CSR, Figures 11-3 and 11-4

Comparative BA between the TBM and the early tablet formulation

An Explorative Biocomparison Study to Evaluate the Bioavailability of Different PMF Formulations (SD-OCT and HME-OCT) of Atogepant in Healthy Volunteers (Study MK-8031 P008)

Study P008 was a single-site, open-label, single-dose, randomised, 5-way crossover trial of atogepant in healthy adult subjects (N = 15, males and females). The purpose of this study was to evaluate the relative bioavailability of different premarket formulations (PMF) of atogepant, namely SD-OCT and HMEOCT, and to evaluate the effect of famotidine on the PK of atogepant. Each subject received Treatments

<div style=\"page-break-after: always\"></div>

A to E in a randomised crossover fashion in Periods 1 to 5, with famotidine administered as described below:

- Treatment A: Single oral dose of 60 mg atogepant as one 10 mg and one 50 mg SD-OCT
- Treatment B: Single oral dose of 60 mg atogepant as 1 HME-OCT (low-compression force)
- Treatment C: Single oral dose of 60 mg atogepant as 1 HME-OCT (high-compression force)
- Treatment D: Single oral dose of 60 mg atogepant as 1 HME-OCT (low-compression force) in the presence of famotidine pre-treatment, and in the fasting state. (Famotidine treatment consisted of one dose of famotidine 20 mg in the evening on Day -1 and one dose of famotidine 20 mg in the morning of Day 1. Two hours after the morning dose on Day 1, the atogepant dose was given)
- Treatment E: Single oral dose of 10 mg atogepant as 1 HME-OCT (one compression force)

All treatments were administered in the fasting state.

Table 11: Arithmetic mean (SD) PK parameter values of atogepant following single oral dose administration of 60 mg atogepant (Phase I SD-OCT tablets) and in two test formulations (PMF low compression HME-OCT and PMF high compression HME-OCT) to healthy subjects under fasting conditions (PK population; MK-8031 P008)

| Dose (mg)                                     | AUCo-14h (ng*h/mL)   | AUCo... (ng*lh/mL)   | Cmr (ng/mL)       | C24h (ng/mL)      | Tmu (h) a        | Apparent Terminal tin (h)   |
|-----------------------------------------------|----------------------|----------------------|-------------------|-------------------|------------------|-----------------------------|
| 60 (SD-0CT) (A)                               | 4616.8 (4713.3)      | 4906.5 (5153.9)      | 1038.0 (917.3)    | 20.9 (39.0)       | 1.50 (1.00-2.00) | 10.2 (9.22)                 |
| 60 (Low compression, HME-OCT) (B)             | 4327.1 (3796.0)      | 4568.5 (4140.0)      | 1019.9 (736.3)    | 16.4 (24.9)       | 1.50 (0.67-2.00) | 8.02 (3.72)                 |
| 60 (High compression, HME-0CT) (C)            | 4266.7 (3258.9)      | 4502.1 (3542.5)      | 959.6 (580.0)     | 16.1 (20.5)       | 1.50 (0.67-2.00) | 8.98 (8.02)                 |
| GMR (90% CI) Low compression HME- OCT/SD-OCT  | 1.00 (0.86, 1.17)    | 0.99 (0.85, 1.16)    | 1.07 (0.85, 1.34) | 0.92 (0.78, 1.09) | NA               | NA.                         |
| GMR (90% CI) High compression HME. OCT/SD-OCT | 1.03 (0.88, 1.21)    | 1.03 (0.88, 1.20)    | 1.05 (0.83, 1.33) | 1.01 (0.85, 1.21) | NA               | NA                          |

NA = Not applicable

Source: Module 5.3.1.2, MK-8031 P008 CSR, Table 11-1

Study P008 is important to the overall PK development, since it is intended to deliver comparative BA data between the SD-OCT and the HME-OCT tablet formulation, and thereby to build the bridge to previous PK study P002. At the same time, a low-compression force version of the tablet is tested vs a high-compression force version.

The extent and rate of absorption were similar between the SD-OCT tablet and the HME-OCT tablet formulation.  Indeed,  GMRs  were  close  to  1.  Formally,  however,  study  P008  did  not  demonstrate bioequivalence  between  the  formulations,  since  the  upper  limit  of  general  80-125%  criteria  for  the 90%CIs was exceeded for Cmax (GMR Cmax high compression: 1.05 [0.83, 1.33], GMR Cmax low compression:1.07 [0.85, 1.34]).

<div style=\"page-break-after: always\"></div>

Median Tmax was 1.5 hours after Phase 1 SD-OCT tablets and HME-OCT low- and high-compression tablet formulations.

## Effect of food -HME-OCT formulation

Single-Centre, Randomised, Open-Label, Single-Dose, Two-Period Crossover Study to Evaluate the Effect of a High-Fat Meal on the Pharmacokinetics of an Immediate-Release Tablet Formulation of Atogepant (Study 3101-105-002)

In food study 105, subjects were randomly assigned to receive interventions A and B in 1 of 2 sequences, with a washout of at least 7 days between each study intervention. The 2 study interventions were: (A) single dose of 60 mg atogepant under fed conditions; (B) single dose of 60 mg atogepant under fasted conditions. Blood samples for assessment of plasma concentrations of atogepant were taken at pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

Table 12: Arithmetic mean (SD) plasma atogepant concentration-time profiles following single dose oral administration of 60 mg atogepant under fed or fasted conditions to healthy subjects (PK population; 3101-105-002)

<!-- image -->

Inset: Mean profile, semilogarithmic scale

<div style=\"page-break-after: always\"></div>

Table 13: Statistical comparisons of plasma atogepant PK parameters following single dose oral administration of 60 mg atogepant under fed or fasted conditions in healthy adult subjects (PK population; 3101-105-002)

|                    |            |            |              |              | Ratios of   |               | Intra-CV%   | Intra-CV%   |        |
|--------------------|------------|------------|--------------|--------------|-------------|---------------|-------------|-------------|--------|
|                    | Fed (Iest) | Fed (Iest) | Fasted (Ref) | Fasted (Ref) | GLSMs (%6)  |               | A           | 8           | Inter- |
| Paraineter (units) | N          | GLSM       | N            | GLSM         | Test/Ref    | 90% CIs       | (Iest)      | (Ref)       | CV%    |
| AUCo-t (h*ng/mL)   | 19         | 2558.05    | 20           | 3130.99      | 81.70       | 71.57 - 93.26 | 23.80*      | 23.80*      | 50.29  |
| AUCg-=(h*ng/mL)    | 18         | 2606.55    | 20           | 3158.38      | 82.53       | 71.77 - 94.89 | 34.50       | 3.62        | 49.89  |
| Cmx (ng/mL)        | 19         | 527.40     | 20           | 677.01       | 77.90       | 64.14 - 94.62 | 40.75       | 29.73       | 30.32  |

Mixed-effects model with natural logarithm-transformed values of AUCo+, AUCo--, and Cmx, as the dependent variable, terms for study intervention, sequence, and period as fixed independent variables and subject nested in Sequence as a random effect.

Study intervention was a single dose of 60 mg atogepant immediate-release formulation (1 x 60 mg tablet), under fed and fasted conditions.

Source: Module 5.3.1.1, 3101-105-002 CSR,Table 14.2.3 and Table 14.2.2

Since the 90% CI of the GLSM ratio was not contained within the default equivalence limits of 80.00% to 125.00% for AUC0-t, AUC0∞, or Cmax, the high -fat meal was demonstrated to have a statistically significant effect on atogepant exposure for the IR tablet (HME-OCT) formulation. Administration under fed  conditions  reduced  AUCs  by  approximately  18%,  reduced  Cmax  by  approximately  22%,  and  no change in median Tmax.

## Distribution

## Mass balance

## A Study of the Mass Balance and Metabolism of [14C]-Atogepant in Healthy Male Subjects (Study CGP-PK-03)

Mass balance study PK-03 was a single-centre, open-label, single-dose study in which 6 healthy male subjects aged 19 through 55 years were enrolled.

Following a single oral dose of 50 mg (~ 200 μCi) [14C] -atogepant in healthy male subjects, the median Tmax values were 1 hour and 1.5 hours post-dose with mean terminal elimination t1/2 values of 18.46 hours  and  11.64  hours  for  atogepant  and  total  radioactivity,  respectively.  Atogepant  contributed  to approximately 75% of the total radioactivity systemic exposure (AUC).

<div style=\"page-break-after: always\"></div>

Table 14: Arithmetic mean (SD) of atogepant and total radioactivity following a single oral 50 mg (~200 μCi) Dose of [14C] -atogepant in healthy male subjects (PK population; CGPPK-03)

| PK Parameter                   | Atogepant        | Total Radioactivity   | Ratio of Atogepant/Total Radioactivity   |
|--------------------------------|------------------|-----------------------|------------------------------------------|
| Cmax (ng/mL or ng-Eq/mL)       | 367.33 (189.44)  | 349.31 (82.6)         | 1.00 (0.29)                              |
| Tm.x (h)*                      | 1 (0.98 -2.98)   | 1.5 (1 -2.98)         | NC                                       |
| AUCo-t (ng.h/mL or h*ng-Eq/mL) | 2176.33 (959.97) | 2711.72 (758.86)      | 0.78 (0.17)                              |
| AUCo- (ng.h/mL or h*ng-Eq/mL)  | 2222.97 (965.55) | 2967.43 (779.02)      | 0.73 (0.17)                              |
| tun (h)                        | 18.46 (11.88)    | 11.64 (6.84)          | NC                                       |
| % dose excreted in urine       | 4.84 (1.63)      | 7.86 (1.83)           | 0.61 (0.11)                              |

Source: Module 5.3.3.1, CGP-PK-03 CSR,Table 11-1

Approximately 8% and 81% of the radioactive dose of 14C-atogepant was recovered in urine and faeces, respectively through the last collection interval. Thereof, approximately 5% of the administered dose was recovered as parent drug (atogepant) in urine. Atogepant was the only peak detected over 1% of the  radioactive  dose  in  urine.  In  faeces,  42%  of  the  dose  was  recovered  as  parent  drug  due  to unabsorbed drug, biliary  excretion,  intestinal  secretion,  or  a  combination.  Most  of  the  administered radioactivity was recovered in the first 24 hours (~ 90%).

Table 15: Arithmetic Mean (SD) urinary and faecal recovery of radioactivity following a single oral 50 mg (~200 μCi) dose of [14C]-atogepant in healthy male subjects (PK population; CGP-PK-03)

| Percentof Dose   | Percentof Dose   | Percentof Dose   |
|------------------|------------------|------------------|
| Urine            | Feces            | Total            |
| 7.86± 1.83       | 80.64±3.35       | 88.50±2.40       |

Source: Module 5.3.3.1, CGP-PK-03 CSR,Table 11-2

## Special populations

## Impaired renal function

In  the  human  ADME  study  with  14 C-atogepant  (Study  CGP-PK-03),  approximately  8%  of  the  total administered radioactivity was recovered in urine, most radioactivity (approximately 81%) was found in the  faecal  samples.  Thus,  biliary/hepatic  route  of  elimination  is  the  major  route  of  elimination  of atogepant, while the renal route plays a minor role. A clinical pharmacology study to evaluate the impact of  renal  impairment  on  the  PK  of  atogepant  was  not  conducted,  and  instead,  physiologically  based pharmacokinetic (PBPK) modelling based on the atogepant 60 mg QD dose along the population PK approach was used to assess the impact of renal impairment.

In the covariate screening (Report CGP-MS-03), renal function (as measured by creatinine clearance in mild and moderately impaired patients) did not have a statistically significant effect on any structural PK parameter. The atogepant 10 mg QD dose is recommended in patients with severe renal impairment or end-stage renal disease (ESRD).

## Impaired hepatic function

An Open-Label, Single Dose, Pharmacokinetic Study of Atogepant in Patients with Impaired Hepatic Function and Subjects with Normal Hepatic Function (Study CGP-PK-01)

<div style=\"page-break-after: always\"></div>

Study PK-01 was a multi-centre, open-label, PK study of atogepant in 32 subjects with impaired hepatic function (8 mild, 8 moderate, 8 severe) and 8 subjects with normal hepatic function. The objective of the study was to assess the PK, safety, and tolerability profiles of atogepant in subjects with impaired hepatic  function  and  matched  healthy  subjects  with  normal  hepatic  function  after  a  single  dose administration. Subjects received a single 60 mg dose of atogepant on Day 1.

Table 16: Summary of statistical analysis of plasma atogepant PK parameters following single dose oral administration of 60 mg atogepant in participants with mild, moderate, or severe hepatic impairment (test) as compared with participants with normal hepatic function (reference), PK population

<!-- image -->

|                     |                    | Geometric Least Squares Mean   | Geometric Least Squares Mean   | Ratio of Geometric Meals   | 90% Lower CI   | 90% Upper CI   |
|---------------------|--------------------|--------------------------------|--------------------------------|----------------------------|----------------|----------------|
| Hepatic Group       | PK Parameter       |                                | Reference                      | Test/Reference             |                |                |
| Mild impairment     | C.x (ng/mL)        | 586.89                         | 538.55                         | 108.97                     | 72.72          | 163.31         |
|                     | AUCo-t (ng-h/mL)   | 3249.63                        | 2612.14                        | 124.40                     | 89.78          | 172.38         |
|                     | AUCo-inf (ng-h/mL) | 3273.58                        | 2633.43                        | 124.31                     | 89.93          | 171.83         |
|                     | Cx (ng/mL)         | 474.85                         | 538.55                         | 88.17                      | 58.83          | 132.14         |
| Moderate impairment | AUCo-t (ngh/mL)    | 2976.87                        | 2612.14                        | 113.96                     | 82.25          | 157.91         |
|                     | AUCo-nf (ng-h/mL)  | 3028.57                        | 2633.43                        | 115.00                     | 83.20          | 158.97         |
|                     | Cm (ng/mL)         | 515.45                         | 538.55                         | 95.71                      | 63.86          | 143.44         |
| Severe impaiment    | AUCo-t (ng-h/mL)   | 3601.63                        | 2612.14                        | 137.88                     | 99.51          | 191.05         |
| Severe impaiment    | AUCo-nf (ng-h/mL)  | 3633.22                        | 2633.43                        | 137.97                     | 99.81          | 190.71         |

Compared with subjects with normal hepatic function, the maximum plasma concentrations of atogepant were generally unchanged in subjects with mild, moderate, or severe hepatic impairment (+9%, -12%, -4% respectively). The overall extent of atogepant systemic exposures (AUC) were slightly higher (14% to  38% higher) in subjects with hepatic impairment as compared with subjects with normal hepatic function; but these changes are unlikely to be clinically relevant.

In participants with mild, moderate, or severe hepatic impairment administered a single oral dose of 60 mg  atogepant,  percentage  of  plasma  protein-bound  atogepant  was  97.4%,  97.1%,  and  95.3%, respectively, as compared with 98.2% in participants with normal hepatic function. The unbound fraction of plasma atogepant was 2.6-fold higher in severe hepatic impairment group compared to participants with normal hepatic function.

<div style=\"page-break-after: always\"></div>

Table 17: Summary of atogepant plasma protein-binding (expressed as percent bound) in participants with mild, moderate, or severe hepatic impairment and in participants with normal hepatic function following single dose oral administration of 60 mg atogepant (PK population, CGP-PK-01)

| Hepatic Group                 | 0 hr (Predose)   | 2 hr         |
|-------------------------------|------------------|--------------|
| Mild-impaired (N=8)           | 97.03 ±0.75      | 97.36±0.70   |
| Moderate-impaired 1(N=8)      | 96.60 ±0.94      | 97.05±0.62   |
| Severe-impaired (N=8)         | 94.48±1.21       | 95.34±0.85   |
| Normal Hepatic Function (N=8) | 97.89 ±0.54      | 98.21 ± 0.46 |

PK in elderly female vs elderly male

## A Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-8031 in Elderly Subjects (Study MK-8031 P003)

Study P003 was a double-blind, randomised, placebo-controlled, parallel, single-dose study in healthy elderly male and elderly female subjects. Subjects were divided in 2 panels of 8 subjects each: Panel A: 8 healthy elderly female subjects (n = 6 active and 2 placebo); and Panel B: 8 healthy elderly male subjects (n = 6 active and 2 placebo). Subjects received a single oral dose of 40 mg atogepant or matching placebo in a randomised fashion.

Table 18: Arithmetic mean (SD) and statistical comparisons of plasma PK for atogepant following the administration of a single oral dose of 40 mg atogepant in healthy elderly females and males (PK population; MK-8031 P003)

|                           | Elderly Females        | Elderly Females     | Elderly Males            | (ElderlyFemales/ Elderly Males)   | (ElderlyFemales/ Elderly Males)   | (ElderlyFemales/ Elderly Males)   |
|---------------------------|------------------------|---------------------|--------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Pharmacolinetic Parameter | Arithmetic Mean N (SD) | N                   | Arithmetic Mean (SD) GMR | I0%06                             | rMSE*                             | P-value                           |
| AUCo-(ng-h/mL)            | 6 3246.8 (1967.4)      | 6                   | 2456.2 (694.0) 1.10      | (0.59, 2.05)                      | 0.60                              | 0.796                             |
| Cm.x (ng/mL)              | 6 736.3 (396.5)        | 6 457.5 (131.6)     | 1.38                     | (0.73, 2.60)                      | 0.60                              | 0.375                             |
| Tmax(h)b                  | 6 1.26 (0.67 - 2.00)   | 6 2.00 (1.00- 4.00) | NC                       | NC                                | NC                                | NC                                |
| Apparent terminal tin (h) | 6 9.97 (5.07)          | 6 8.31 (3.74)       | NC                       | NC                                | NC                                | NC                                |

P-value: P-value for the comparison elderly females vs. elderly males.

a. rMSE: Square root of the residual variance component from the ANOVA model. rMSE *100% approximates the between-subject percent coefficient of variation (%CV) on the raw scale.

b. Median (range)

Souuce: Module 5.3.3.3, MK-8031 P003 CSR, Table 11-1, Table 11-3

Following a single dose of 40 mg of atogepant, AUC0∞ was 10% greater (GMR [90% CI] of 1.10 [0.59, 2.05]) and Cmax was 38% greater in elderly females than in elderly males. The median Tmax occurred earlier in elderly females (1.26 hours) than in elderly males (2.00 hours).

## Pharmacokinetic interaction studies

In vivo interaction with CYP and transporter inhibitors and inducers

The following drug-drug interactions have been investigated in clinical studies:

<div style=\"page-break-after: always\"></div>

- itraconazole (CYP3A4 and P-gp inhibitor; Study CGP-PK-02
- rifampin (potent CYP3A4 and P-gp inducer and OATP inhibitor; Study CGP-PK-12
- topiramate (mild inducer of CYP3A4)
- quinidine gluconate (P-gp inhibitor; Study 3101-103-002)

Table 19: PK parameters of atogepant following single doses of atogepant alone, and following concomitant administration of CYP3A4, P-gp or OATP inhibitors/inducers

<!-- image -->

|               |                        | CYP/P-gp/ OATP Inhibitor or   |                     |    |         |               | GM Ratio (90% CIs)   | GM Ratio (90% CIs)                        |
|---------------|------------------------|-------------------------------|---------------------|----|---------|---------------|----------------------|-------------------------------------------|
| Study         | Atogepant              | Inducer                       | Daily Dose (timing) | N  | (ng/mL) | AUC (ng-h/mL) |                      | AUC                                       |
| CGP-PK-02     | 60 mg single dose      |                               |                     | 40 | 740     | 3470          | NC                   | NC                                        |
| CGP-PK-02     |                        | Itraconazole                  | 200 mg,QD (7 days)  | 40 | 1580    | 18900         |                      | 2.15 (1.95, 2.37) 5.51 (5.09, 5.96)       |
| CGP-PK-12     | 60 mg single dose      |                               |                     | 31 | 711     | 3000          | NC                   | NC                                        |
|               |                        | Rifampin                      | 600 mg single dose  | 31 | 1550    | 8130b         |                      | 2.23 (1.99, 2.50) 2.85 (2.60,3.12)        |
|               |                        | Rifampin                      | 600 mg QD (5 days)  | 31 | 487     | 1130c         |                      | 0.70 (0.60, 0.81) 0.39 (0.35, 0.44)       |
| CGP-PK-14     | Atogepant              | 60 mg                         | Atogepant           | 25 | 626.06  | 3015.38d      | NC                   | NC                                        |
| CGP-PK-14     | Atogepant + Topiramate | 60 mg + 25 through 100 mg     | Atogepant           | 21 | 491.38  |               |                      | 2298.75d75.8 (67.5, 85.1)74.6 (68.7,80.9) |
| CGP-PK-14     | Topiramate             | 25 through 100 mg             | Topiramate          | 24 | 7.71    | 76.51d        | NC                   | NC                                        |
| CGP-PK-14     | Atogepant + Topiramate | 60 mg + 200 mg                | Topiramate          | 22 | 7.28    | 72.57d        |                      | 93.8 (87.0, 101)94.5 (88.1, 101)          |
| 3101-103- 002 | 60 mg single dose      |                               |                     | 24 | 660     | 2902          | NC                   | NC                                        |
| 3101-103- 002 |                        | Quinidine gluconate           | 648 mg BID (3 days) | 24 | 644     | 3527          |                      | 1.04 (0.89, 1.22) 1.26 (1.11, 1.43)       |

C.

N=28

NC = Not calculated

Source: Module 5.3.3.4, CGP-PK-02 CSR, Table 11-1; Module 5.3.3.4, CGP-PK-12 CSR Table 11-1, Table 11-2, Table 11-3;

Co-administration of atogepant with itraconazole increased atogepant Cmax by 2.15-fold and AUC by 5.5-fold.  Thus,  CYP3A4  inhibition  by  itraconazole  or  other  strong  CYP3A4  inhibitors  will  result  in  a clinically significant increase in the exposure of atogepant. The lowest dose of atogepant (10 mg) should be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin).

A statistically significant increase in atogepant systemic exposure (2.85-fold for AUC0-24h and 2.23-fold for Cmax) was observed following co-administration of single-dose atogepant 60 mg and single-dose rifampin 600 mg compared with administration of single-dose atogepant 60 mg alone. The increases in atogepant Cmax and AUC when co-administered with OATP inhibitors could be clinically significant and

<div style=\"page-break-after: always\"></div>

atogepant  dose  adjustment  is  recommended.  A  lower  dose  of  atogepant  (10  or  30  mg)  should  be considered with concomitant OATP inhibitors (e.g., cyclosporine).

In vivo interaction with commonly used concomitant medications

Table 20: PK parameters following single doses of atogepant alone, and following concomitant administration of other medications commonly used in the migraine patient population

|              | Treatment                 | Daily Dose                     | Analyte           |    |         | AUC,,     | GM Ratio                       | GM Ratio          |
|--------------|---------------------------|--------------------------------|-------------------|----|---------|-----------|--------------------------------|-------------------|
| Study        |                           | (timing)                       |                   | n  | (mg/mL) | (ng-h/mL) | Cm                             | AUC               |
| MK-8031 P005 | Nordette-28               | 0.03 mg EE/0.15 mg LNG         | Ethinyl estradiol | 26 | 75.92b  | 846.45b   | NC                             | NC                |
| MK-8031 P005 | Atogepant + Nordette-28   | 60 mg + 0.03 mg EE/0.15 mg LNG | Ethinyl estradiol | 26 | 68.34b  | 848.36b   | 0.90 (0.84, 0.96)(0.96, 1.05)  | 1.00              |
| MK-8031 P005 | Nordette-28               | 0.03 mg EE/0.15 mg LNG 60 mg + | Levonorgestrel    | 26 | 2.95b   | 40.09b    | NC                             | NC                |
| MK-8031 P005 | Atogepant + Nordette-28   | 0.03 mg EE/0.15 mg LNG         | Levonorgestrel    | 26 | 3.22b   | 47.89b    | 1.09 (1.03, 1.17) (1.13, 1.26) | 1.19              |
| MK-8031 P005 | Atogepant                 | 60 mg                          | Atogepant         | 23 | 1164.8  | NC        | NC                             | NC                |
| CGP-PK-- 06  | Atogepant                 | 60 mg                          | Atogepant         | 37 | 788.10  | 3673.44   | NC                             | NC                |
| CGP-PK-- 06  | Atogepant + Acetaminophen | 60 mg + 1000 mg                | Atogepant         | 37 | 761.56  | 4161.84   | 1.00 (0.90, 1.11)(1.04, 1.22)  | 1.13              |
| CGP-PK-- 06  | Atogepant + naproxen      | 60 mg + 500 mg                 | Atogepant         | 38 | 765.26  | 3577.09   | 1.00 (0.91, 1.11)              | 0.99 (0.92,1.06)  |
| CGP-PK-- 06  | Acetaminophen             | 1000 mg                        | Acetaminophen     | 39 | 15.82c  | 62.30e    | NC                             | NC                |
| CGP-PK-- 06  | Atogepant + acetaminophen | 60 mg + 1000 mg                | Acetaminophen     | 38 | 15.04c  | 60.97c    | 0.89 (0.81, 0.97)(0.89, 0.99)  | 0.94              |
| CGP-PK-- 06  | Naproxen                  | 500 mg                         | Naproxen          | 36 | 79.86   | 1292.47e  | NC                             | NC                |
| CGP-PK-- 06  | Atogepant + naproxen      | 60 mg + 500 mg                 | Naproxen          | 38 | 74.52   | 1268.05   | 0.94 (0.90, 0.97)              | 0.98 (0.96, 1.00) |
| CGP-PK- 13   | Atogepant                 | 60 mg                          | Atogepant         | 27 | 840.78  | 3899.30   | NC                             | NC                |
| CGP-PK- 13   | Atogepant +               | 60 mg +                        | Atogepant         | 27 | 667.72  | 3729.28   | 0.79                           | 0.95              |
| CGP-PK- 13   | Sumatriptan Sumatriptan   | 100 mg 100 mg                  | Sumatriptan       | 27 | 74.14   | 306.86    | (0.69,0.89)(0.86, 1.05) NC     | NC                |
| CGP-PK- 13   | Atogepant + Sumatriptan   | 60 mg + 100 mg                 | Sumatriptan       | 27 | 71.27   | 316.64    | 0.95 (0.85, 1.07)              | 1.02 (0.97, 1.08) |
| CGP-PK- 14   | Atogepant                 | 60 mg                          | Atogepant         | 25 | 626.06  | 3015.38d  | NC                             | NC                |
| CGP-PK- 14   | Atogepant + Topiramate    | 60 mg + 25 through 100 mg      | Atogepant         | 21 | 491.38  | 2298.75d  | 75.8 (67.5, 85.1) (68.7, 80.9) | 74.6              |
| CGP-PK- 14   | Topiramate                | 25 through 100 mg              | Topiramate        | 24 | 7.71    | 76.51d    | NC                             | NC                |
| CGP-PK- 14   | Topiramate + Atogepant    | 60 mg + 200 mg                 | Topiramate        | 22 | 7.28    | 72.57d    | 93.8 (87.0, 101)               | 94.5 (88.1, 101)  |

In vivo interaction with gastric acid reducing agents (proton pump inhibitors, H2-receptor blockers) DDI Famotidine (Study MK-8031 P008)

<div style=\"page-break-after: always\"></div>

Table 21: Arithmetic mean (SD) and statistical comparison of plasma PK for atogepant following a single oral dose of 60 mg atogepant PMF low compression tablet with and without famotidine pretreatment to healthy subjects under fasting conditions (PK population; MK-8031 P008)

| PK                | Atogepant +Famotidine   | Atogepant +Famotidine   | Atogepant Alone   | Atogepant Alone    | Atogepant +Famotidine/ Atogepant   |
|-------------------|-------------------------|-------------------------|-------------------|--------------------|------------------------------------|
| Parameter         | N                       | Mean (SD)               | N                 | Mean (SD)          | GMR (90% C1)                       |
| AUCo24 (ng-lh/mL) | 15                      | 3796.0 (4218.5)         | 15                | 4327.1 (3796.0)    | 0.78 (0.66, 0.92)                  |
| AUCq-(ng-h/mL)    | 15                      | 4043.5 (4520.2)         | 15                | 4568.5 (4140.0)    | 0.79 (0.67, 0.93)                  |
| C.. (ng/mL)       | 15                      | 568.5 (523.8)           | 15                | 1019.9 (736.3)     | 0.51 (0.41,0.63)                   |
| C (ng/mL)         | 15                      | 18.4 (24.7)             | 15                | 16.4 (24.9)        | 1.18 (1.02,1.36)                   |
| T(h)              | 15                      | 1.50 (0.67 - 4.00)      | 15                | 1.50 (1.00 - 2.00) | NC                                 |
| tn*(h)            | 15                      | 9.15 (3.49)             | 15                | 8.02 (3.72)        | NC                                 |

a. Median (range)

Sowce:Module5.3.12,MK-8031P008 CSR,Table11-2

A possible interaction of atogepant with H2 receptor blocker famotidine was examined to explore the effect of gastric pH change on atogepant's PK. Concomitant use of 60 mg atogepant (single dose) with famotidine  (20  mg  in  the  evening  of  Day  -1  and  the  morning  of  Day  1)  appeared  to  reduce  the bioavailability of atogepant, with Cmax reduced by approximately 50%, AUC reduced by approximately 20%, and Tmax unchanged in the presence of famotidine.

DDI Esomeprazole (proton pump inhibitor, Study 3101-102-002)

Table 22: Arithmetic mean (SD) of atogepant following a single oral dose of 60 mg atogepant when administered alone or in combination with esomeprazole 40 mg in healthy subjects (atogepant PK population; 3101-102-002)

| PK Parameter,Unit   | Atogepant Alone   | Atogepant + Esomeprazole   | GMR (%o) of Atogepant + Esoineprazole/Atogepant Alone (90% C1)   |
|---------------------|-------------------|----------------------------|------------------------------------------------------------------|
| C., ng/mL           | 792 (368)         | 594 (230)                  | 76.63 (68.19-86.11)                                              |
| AUCo-, ng-h/mL      | 3810 (1590)       | 3410 (1200)                | 91.61 (83.67-100.29)                                             |
| AUCon,ng-h/mL       | 3830 (1600)       | 3450 (1220)                | 92.04 (84.12-100.71)                                             |
| T.. h               | 1.51 (1.00,4.03)  | 3.00 (1.01, 6.03)          | NC                                                               |
| tin, h              | 8.48 (2.45)       | 9.80 (3.51)                | NC                                                               |
| VF, L               | 218 (101)         | 270 (132)                  | NC                                                               |
| CL/F, L/h           | 18.4 (7.8)        | 19.6 (7.1)                 | NC                                                               |

N=29

a. Median (range)

Souce: Module 5.3.3.4, Study 3101-102-002 CSR,Table 11-1,Table 11-2

Concomitant use of 60 mg atogepant (single dose) with esomeprazole (multiple doses of 40 mg once daily for 5 days) appeared to reduce the rate of absorption (23% reduced Cmax, increased Tmax), but not the extent of absorption (AUC).

<div style=\"page-break-after: always\"></div>

## Modelling and Simulation

Three different PopPK models were developed using nonlinear mixed effects modelling during clinical development.

Firstly, a popPK (2016) was used to describe data from five phase 1 studies (n=99) through a twocompartment-model with first order absorption and linear elimination. As covariates, formulation on ka and Freal was used as well as dose on ka, famotidine treatment on Frel and gender on CL. This analysis has limited value due to the small sample size.

Secondly, (2019) more data was available for model development from nine phase 1 studies and one phase  2/3  study  CGP-MD-01  (n=631).  The  final  model  describing  these  data  best  was  a  threecompartment model with linear elimination. Typical CL and V were estimated to be 18.2 L/h and 73 L, respectively. IIV was included on CL, ka, and intercompartmental CL. Dose had a significant influence on ka (lower with increasing dose level) and on Frel (higher with increasing dose level). Furthermore, the different drug formulations added complexity to model the absorption phase.

This model was evaluated using GOF checks and VPCs and this evaluation showed an appropriate fit of the model. This model was further used to test different efficacy models (see Dose-Response Modelling 2.2.3) and was used to simulate exposure in children aged six to less than 18 years of age.

Thirdly, in 2020 phase 3 data from study 3101-301-002 was added to the dataset (n=1287 in total) resulting in 11766 observations combining HV data and patient data. Typical apparent clearance was 23.7% lower in patients (17.4 L/h) compared to healthy volunteers (22.9 L/h). Typical apparent volume of distribution was estimated as 86.1 L. IPREDs in GOF plots revealed a tendency to underprediction. Parameter estimates for the final PopPK model are listed below. GOF plots and VPCs are shown in Figure 3.

<div style=\"page-break-after: always\"></div>

Table 23: Parameter estimates final PopPK model (Run 61) - all studies

| Alias                                                                |   Estimate |   Relative SE (%) | 95% CI             |
|----------------------------------------------------------------------|------------|-------------------|--------------------|
| Apparent clearance healthy volunteers [CL/F (L.h-1)]                 |    22.9    |               2.4 | (21.8 - 23.9)      |
| Duration zero-order absorption [Tko (h)]                             |     0.908  |               4.7 | (0.824 - 0.992)    |
| Apparent central volume of distribution [V1/F (L)]                   |    86.1    |               2.3 | (82.2 - 89.9)      |
| Intercompartmental rapid clearance [Q/F (L.h-1)]                     |     1.43   |              10   | (1.15 - 1.71)      |
| Apparent rapid peripheral volume of distribution [V2/F (L)]          |    40.5    |               7.3 | (34.7 - 46.3)      |
| Intercompartmental slow clearance [Q2/F (L·h-1)]                     |     1.68   |               7.4 | (1.44 - 1.93)      |
| Apparent slow peripheral volume of distribution [V3/F (L)]           |    13      |              11.9 | (9.96 - 16.0)      |
| Zero-order lag time [ALAGo (h)]                                      |     0.276  |               0.5 | (0.273 - 0.279)    |
| Fraction zero-order absorption (Fk0)                                 |     0.693  |               2.9 | (0.654 - 0.732)    |
| Blood-plasma ratio                                                   |     0.573  |               2   | (0.550 - 0.596)    |
| Itraconazole effect on apparent clearance                            |    -0.662  |               0.6 | (-0.669 - -0.654)  |
| Rifampin effect on apparent clearance after first dose               |    -0.128  |              14.2 | (-0.164 - -0.0924) |
| Rifampin effect on apparent clearance following multiple doses       |     0.818  |               3.9 | (0.756 - 0.881)    |
| Quinidine effect on apparent clearance                               |    -0.285  |               3.4 | (-0.305 - -0.266)  |
| Itraconazole effect on relative bioavailability                      |     0.949  |              11.4 | (0.737 - 1.16)     |
| Rifampin effect on relative bioavailability following multiple doses |    -0.248  |              15.7 | (-0.325 - -0.172)  |
| Rifampin effect on relative bioavailability after first dose         |     1.42   |              11   | (1.12 - 1.73)      |
| Effect of severe hepatic impairment on apparent clearance            |    -0.366  |              19   | (-0.503 - -0.230)  |
| Food effect on lag-time                                              |     0.672  |               2.1 | (0.644 - 0.699)    |
| Exponential dose effect onrelativebioavailability                    |     0.119  |              11.2 | (0.0928 - 0.145)   |
| Formulation effect on zero-order absorption                          |    -0.353  |              22.3 | (-0.507 - -0.198)  |
| Exponential weight effect on apparent central volume of distribution |     0.411  |              11.7 | (0.317 - 0.505)    |
| Exponential dose effect on zero-order absorption                     |     0.199  |               9   | (0.164 - 0.234)    |
| Apparent clearance patients [CLpat/F (L.h-1)]                        |    17.4    |               2   | (16.8 - 18.1)      |
| WCL/F                                                                |     0.0243 |               9.9 | (0.0196 - 0.0290)  |
| tk0                                                                  |     0.163  |               5.8 | (0.144 - 0.182)    |
|                                                                      |     0.234  |               5   | (0.211 - 0.257)    |
| IOVFrel                                                              |     0.0373 |               3.5 | (0.0347 - 0.0399)  |
| WQ2/F                                                                |     0.471  |              17.1 | (0.313 - 0.629)    |
| CovQ2,V3                                                             |     0.422  |              14.6 | (0.301 - 0.543)    |
| Wv3/F                                                                |     0.601  |              14.5 | (0.430 - 0.772)    |
| Oprop                                                                |     0.307  |               0.5 | (0.304 - 0.310)    |
| Oprop (Study CGP-PK-02)                                              |     0.228  |               1.4 | (0.222 - 0.235)    |
| Oprop (Study CGP-MD-01)                                              |     0.585  |               3.1 | (0.550 - 0.620)    |
| Oprop (Study 3101-301-002)                                           |     0.491  |               2   | (0.472 - 0.510)    |

<div style=\"page-break-after: always\"></div>

Figure 3: Observations (DV) versus Population and Individual Predictions

<!-- image -->

Predicted Flasma Concentration (nM)

PRED: Population Predictions.IPRED: Individual Predictions. Magenta line: Loess smooth (95% CI) Black line: line of identity. Upper panel depicts observed and predicted concentrations on the normal scale whereas the lower plots showlog-log concentrations

<div style=\"page-break-after: always\"></div>

Figure 4: Visual Predictive Checks by Dosing Regimen

<!-- image -->

Circles: Observations, Solid black line: Median of the observed atogepant concentrations, Solid green line: Median of the simulated atogepant concentrations Dashed Lines: 2.5th and 97.5th percentiles of the observed atogepant concentrations, Shaded Area: The shaded areas indicate the 95% CI around the median (green area), and 2.5th and 97.5th percentiles of the simulated concentrations (gray areas).

This model was further used to develop a dose-response model as an exposure response model showed no clear relationship between exposure and response. The effect of two migraine days less per month compared  to  placebo  was  supported  through  efficacy  simulation,  but  no  clear  atogepant  dose-  or exposure-response relationship was observed.

A combined PBPK model analysis for CYP3A4, P-gp, and BCRP was conducted using clinical data from study CGP-PK-12 (rifampicin DDI study) for development and studies 3101-101-002 (Japanese/Caucasian bridging study) and CGP-PK-02 (itraconazole DDI study) for verification. The aim was to predict plasma concentrations of atogepant after a single dose of 60 mg atogepant after dosing of a moderate CYP3A4 inhibitor, mild CYP3A4 inhibitor as well as the prediction of atogepant plasma concentrations following complete P-gp or BCRP inhibition. A first Addendum regarding PBPK modelling was submitted to predict the impact of OATP1B1/OATP1B3 and renal impairment. A second Addendum was submitted for atogepant impact as a perpetrator for OCT1, OCT2, and MATE1.

This modelling analysis was not accepted, as the platform is not qualified for the intended purpose.

<div style=\"page-break-after: always\"></div>

In addition to that, a simplified PBPK model was presented suggesting that the AUC of atogepant is predicted to be 2.75-fold higher when co-administered with a moderate CYP3A4 inhibitor. This increase would be larger than predicted using the combined PBPK model. The applicant discussed whether dose adjustments are needed based on the generally expected increase in the AUC as atogepant appears to be a sensitive CYP3A4 substrate.

The platform for the combined PBPK model approach is not qualified, simulation results are not accepted. Therefore, results derived by PBPK modelling were removed from the SmPC. No additional analyses for BCRP were submitted. PBPK modelling is regarded as not sufficiently qualified to predict BCRP transporter interactions. As mentioned BRCP inhibitors were not prohibited in pivotal studies, the applicant provided the available clinical data and compare atogepant exposure in patients treated with and without BRCP inhibitor.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Atogepant is a potent antagonist of the human CGRP receptor. In the ligand-binding assays, atogepant exhibited very high affinity for human CGRP receptors (Ki = 15-26 pM) as well as monkey CGRP receptors (Ki = 9 pM).

## Primary and Secondary pharmacology

## Pharmacodynamics: Inhibition of CGRP-induced vasodilation

## A Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Atogepant (Study MK-8031 P001)

This was a 2-Part study. Part II of Study P001 was a 4-period crossover study in 16 healthy male subjects who each received single oral doses of 0.4, 2.5, and 30 mg of atogepant (on-site formulation) and placebo, with PD assessments of the inhibition of Capsaicin-induced Dermal Vasodilation (CIDV).

Concomitant with dosing of atogepant or placebo, subj ects received 2 single topical doses (300 μg/20 μL and 1000 μg/20 μL) of capsaicin solution (in ethanol/polysorbate 20/water [3:3:4]) at 2 time points via 10-mm rubber 'O' rings on the volar surface of each forearm (a total of 4 capsaicin applications). Capsaicin applications on each arm were timed so that the maximal blood flow response coincided with appropriate timepoints relative to the PK profile of atogepant (i.e., 0.5 and 4.5 hours). Laser Doppler scans of the subjects' forearms were conducted at baseline, 1 hour, and 5 hours as a measure of blood flow. Blood samples were also drawn at 1 hour and 5 hours to obtain plasma PK of atogepant.

Mean  perfusion  decreased  in  dose-dependent  fashion  compared  with  placebo  following  single  dose administration of atogepant, both at 1 and 5 hours post-dose, regardless for the capsaicin concentration applied.

## Evaluation of the Effects of a Single Supra-Therapeutic Dose of Atogepant on Cardiac Repolarisation in Healthy Participants (Study CGP-PK-04)

Part A of this study was designed to establish the safety, tolerability, and PK profile of a supra-therapeutic dose (300 mg) of atogepant, in order to determine whether this supra-therapeutic dose could be safely evaluated in Part B. The study design for Part B was designed to assess the effects of a supra-therapeutic dose of atogepant (300mg) on cardiac repolarisation.

<div style=\"page-break-after: always\"></div>

Mean change-frombaseline QTcF (ΔQTcF) on atogepant followed closely the placebo pattern and did not suggest an effect on cardiac repolarisation. After a single, oral dose of 300 mg atogepant, the LS mean point estimate and upper 2-sided 90% CIs for the LS mean difference between atogepant and placebo QTcF intervals were lower than the 10-msec threshold at all timepoints. A maximum change in mean ΔΔQTcF of +0.6 msec was noted after 300 mg atogepant treatment at 24 hours postdose.

## 2.6.3. Discussion on clinical pharmacology

## Pharmacokinetics

A comprehensive PK study programme was provided to delineate the PK profile of atogepant (AGP) 10 and 60 mg tablets subject of the present MAA. During the clinical pharmacology programme, validated HPLC-MS/MS methods were used to determine the concentrations of atogepant and co-administered drugs in human plasma, whole blood (as measured using dry blood spot assay), and urine (as applicable in individual studies). In general, the bioanalytical methods are acceptable. The poor aqueous solubility of atogepant drug substance presented a great challenge for the development of conventional solid oral tablet  formulations  with  desired  immediate  release  (IR)  attributes.  Therefore,  an  oral  solution formulation with atogepant dissolved in PEG 400, and/or water was developed for the initial first-inhuman SAD study P001. Two bioavailability enhancing formulations were developed: an intermediate SD-OCT formulation and the HME-OCT proposed for commercialisation.

First-in-human study P001 demonstrated rapid absorption of AGP following single ascending doses of AGP, administered as on site solution, across the 1 mg to 50 mg dose range. Repetitive dosing of 5 mg in Periods 2 and 5 yielded reasonably similar blood levels pointing to a rather low intra-subject variability. Both the rate and extent of absorption increased in a dose dependent way. Exploratory data point to approximate dose proportionality, although the dataset is too limited for definite conclusion.

Early PK study P002 examined the bioavailability of single ascending doses of AGP using the intermediate spray-dried OCT tablet formulation (Part I). Higher doses between 40 mg and 200 mg were applied as compared to previous PK study P001. Inter-study comparison with study P001 (testing the oral solution) points to increased availability for the newly developed tablet. After SD administration of 40 mg AGP about 3-fold higher AUC values were observed with the spray-dried tablet formulation. Absorption was rapid with Tmax values of 1 -1.5 hrs and elimination was similar (elimination half-life of 9-11 hrs) across the  40-200  mg  high  dose  range.  About  linear  increases  in  the  rate  and  extent  of  absorption  were observed across the 40 mg to 170 mg range, while AUC and Cmax appeared to reach a plateau when the dose was further increased to 200 mg. Absolute bioavailability of atogepant was not determined.

Although (only) the intermediate SD-OCT tablet formulation was used in the multiple dose Part II of study P002, it is considered to contribute valuable information for the once-daily dose regimen pursued during the subsequent clinical development. Compatible with the elimination half-life of about 9-11 hrs found after single dose administration, no clinically relevant accumulation was observed after once daily doses of 50 mg, 100 mg, and 170 mg over 10 days. This is reflected by GMR comparison of AUC and Cmax  between  Day  1  and  Day  10,  and  also  by  trough  concentration  levels  observed  pre-dose  on intermediate Days 3, 4, 5, and 8. Pre-dose blood concentrations reach about plateau values after about third once-daily dosing. Apart from testing once daily dosing, study P002 also contained a dose arm with 30 mg twice daily dosing over 10 days. C24 hrs trough values after 30 mg BID dosing were remarkably high, higher than after 100 mg once daily dosing and almost reaching the level of the 170 mg once daily regime. The clinical significance of this overall less fluctuating plasma concentration profile following a twice daily dosing regimen was not clear at this stage. The 30 mg BID dose arm was taken over into phase II/III dose finding study CGP-MD-01.

<div style=\"page-break-after: always\"></div>

Study P008 is important to the overall PK development, since it is intended to deliver comparative BA data between the SD-OCT and the HME-OCT tablet formulation, and thereby to build the bridge to previous PK study P002. The extent and rate of absorption were similar between the SD-OCT tablet and the HME-OCT tablet formulation. Indeed, GMRs were close to 1. Formally, however, study P008 did not demonstrate bioequivalence between the formulations, since the upper limit of general 80-125% criteria for the 90%CIs was exceeded for Cmax (GMR Cmax high compression: 1.05 [0.83, 1.33], GMR Cmax low compression 1.07 [0.85, 1.34]). It is reminded that comparative BA study P008 was exploratory and was not powered to demonstrate BE. Failure to formally conclude BE does not invalidate the transfer of data  obtained  for  the  intermediate  SD-OCT  formulation  from  study  P002.  Multiple  dose  study  P002 yielded baseline information on AGP's PK profile after multiple once daily dosing over 10 days in terms of  accumulation  and  elimination  half-life.  These  data  are  considered  meaningful  to  inform  dosing regimens tested in subsequent dose finding study CGP-MD-01.

Food study 105 was conducted after finalisation  of  phase  II/III  dose  finding  study  CGP-MD-01  and examined the 60 mg single dose of atogepant, ultimately proposed as regular daily dose in the SmPC. Ingestion  of  a  standardised  high-fat,  high-calorie  meal  reduced  AUC  by  about  18%  and  Cmax  of atogepant by about 22%. Hence, a statistically significant food effect was observed. However, the time to Cmax (2 hrs) and elimination half-life (9-10 hrs) remained unaffected by the fed vs fasted condition. Section 4.2 of the SmPC specifies that /../ is to be taken once daily orally with or without food . This is acceptable given the fact that in pivotal trials 301 and 303, expanding over a 12-week outpatient DBT period, no restrictions were specified with regard to AGP administration in the fed resp. fasted state. Participants were merely instructed to take their study intervention at approximately the same time each day.

Mass balance study PK-03 showed that urinary excretion plays  a  minor  role  only  as  an  elimination pathway. After oral administration of 50 mg radiolabelled atogepant, approximately 8% of the radioactive dose was recovered in urine. About 5% of atogepant was recovered in the urine as non-metabolised parent drug. The majority of the radioactivity (about 81%) was recovered in the faeces. A considerable portion of the 50 mg oral dose appears not to have been absorbed. About 42% of the administered dose was recovered in the faeces as parent compound. This finding may go along with the classification of atogepant as low soluble BCS class II drug. Data on expected absolute bioavailability in the relevant clinical dose range were not provided, however, respective data are requested. The metabolites of 14Catogepant in plasma, urine, and faeces were profiled and characterised. At least 11 metabolites were detected in faeces and each represented &lt; 10% of the radioactive dose. Metabolite M23 (dioxygenated methylated glucuronide of atogepant) represented approximately 15% of radioactivity exposure (AUC) in plasma and was not a long-lasting metabolite. No other metabolite represented more than 1% of the circulating radioactivity.

The focus of multiple dose study P004 was set on tolerability, in particular, any potential influence of 28day once daily administration of 170 mg supra-therapeutic doses of AGP on hepatic enzymes, and vital signs were monitored. As regards PK, preliminary data obtained from MD of atogepant over 10 days in study P002 are largely confirmed. Comparison of AUC and Cmax GMRs between Day 28 and Day 1 does not reveal relevant accumulation.

Taken together, it is concluded that the PK profile of atogepant was adequately characterised. Rapid absorption was observed after administration of the HME-OCT tablet formulation with median Tmax values  ranging  from  1  to  2  hrs.  Compatible  with  the  elimination  half-life  of  about  10-11  hrs,  no accumulation occurred upon multiple once daily dosing. About dose-proportional increases in plasma levels were observed across the therapeutic dose range. With regular once daily administration, predose trough levels reach about plateau values on the third day of dosing.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics in special populations

Dedicated studies were conducted in hepatically impaired subjects, in the elderly (incl. gender-related effects), and in Japanese resp. Chinese subjects as part of AGP's global development.

The hepatic impairment study PK-01 examined the impact of various degrees of hepatic impairment after administration  of  a  therapeutic  60  mg  single  dose.  Compared  with  participants  with  normal  hepatic function, the maximum plasma concentrations of atogepant were generally unchanged in participants with mild, moderate, or severe hepatic impairment (+9%, -12%, -4% respectively). The overall extent of atogepant systemic exposures (AUC) were slightly higher (14% to 38% higher) in participants with hepatic impairment as compared with subjects with normal hepatic function. The results of study PK-01 are adequately reflected in the SmPC, which states in section 4.2 that no dose adjustment is required in patients with mild or moderate hepatic impairment. However, the use of atogepant should be avoided in patients with severe hepatic impairment. This is to be seen in the context that the fraction of unbound atogepant is about 3-fold higher in severely impaired subjects as compared to matched controls. SmPC section 5.2 adequately informs about the increase in unbound atogepant in line with the EMA Guideline on hepatic impairment.

No  dedicated  study  in  subjects  with  renal  impairment  was  conducted.  Mass  balance  study  PK-03 demonstrated that the renal route of elimination plays a minor role in the clearance of atogepant. Only 8% of the total administered radioactivity was recovered in the urine. Posology recommendations in renally impaired subjects were derived from PBPK modelling. As patients with severe renal impairment or ESRD (CLcr&lt; 30 mL/min) have not been studied, the use of the lowest effective dose of atogepant (10 mg) is recommended in those patients, which appears plausible. Dose modifications, recommended for special populations (strong CYP3A4 inhibitors, strong OATP inhibitors, severe renal impairment), were adequately justified.

Study P003 compared the PK profile of a 40 mg single dose (fasting condition) of atogepant in a group of elderly female vs elderly male subjects. The dataset of study P003 was limited consisting of 8 subjects per group only (2 of these received placebo). Therefore, data should be interpreted with caution. However, exposure of atogepant was considerably higher in elderly women as compared to elderly men (GMRs: AUC0∞ 1.10 [0.59, 2.05], Cmax 1.38 [0.73, 2.60]).

As concerns between-age comparisons, study P003 does not allow for direct comparison of atogepant's PK profile between non-elderly and elderly subjects, because only elderly subjects were recruited. Instead, reference was made to historical data obtained from preceding study P002. Data are compared between young and elderly male subjects after administration of a single 40 mg dose of atogepant. The dataset is very limited, the young vs elderly population is represented by only N=6 subjects, respectively. The historical data comparison points to an increased AUC in the elderly by about 40% as compared to younger male subjects. Larger size population PK analyses, however, based on &gt; 1900 subjects per comparison, show only marginal differences in the extent and rate of atogepant absorption in relation to gender or age. The PK of atogepant in children was not studied as the product is intended for adult subjects.

## Pharmacokinetic Interactions

The pharmacokinetic interaction potential of atogepant was thoroughly characterised by a number of in vivo DDI studies.

In vitro testing revealed that atogepant is metabolised primarily via CYP3A4 with a minor contribution of CYP2D6. Co-administration of atogepant with prototype strong CYP3A4 inhibitor itraconazole (DDI Study PK-02)  increased  atogepantCmax  by  2.15-fold  and  AUC  by  5.5-fold.  Thus,  CYP3A4  inhibition  by itraconazole or other strong CYP3A4 inhibitors will result in a clinically significant increase in the exposure of atogepant. The posology section of the SmPC specifies that the lowest dose of atogepant (10 mg QD)

<div style=\"page-break-after: always\"></div>

should be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin). The proposed 10 mg dose corresponds to 1/6 of the regular 60 mg once daily dose. Given the 5.5-fold increase  in  atogepant's  AUC,  if  co-administered  itraconazole,  the  proposed  dose  adaptation  for concomitant use with strong CYP3A4 inhibitors appears plausible.

Transporter assays have shown in vitro that atogepant is a substrate of P-gp, BCRP, OATP1B1, OATP1B3, and OAT1. Inhibition of the AOTP1B1 transporter, which is located basolateral on hepatocyte membranes, through rifampin (DDI Study PK-12) inhibits atogepant metabolism by inhibition of its influx into the hepatocyte. As a result, atogepant blood levels increase to a clinically relevant degree (2.85-fold for AUC0-24 and 2.23-fold for Cmax). Like in the case of co-administration with strong CYP3A4 inhibitors, the  recommended daily dose of atogepant is limited to 10 mg if co-administered with strong OATP inhibitors. SmCP section 5.2 adequately reflects the data obtained from study PK-12.

In DDI Study 103, an increase in atogepantCmax and AUC by approximately 4% and 25%, respectively, was observed upon co-administration with the P-gp inhibitor quinidine gluconate. Based on these results, a clinically significant PK interaction between atogepant, a P-gp substrate, and P-pg inhibitors is not expected.  It  appears  therefore  justified  not  to  specify  any  dose  modification  for  atogepant  when concomitantly administered with P-pg inhibitors.

Pre-clinical in vitro dissolution testing revealed that dissolution was most rapid and complete under acid conditions (0.1 N HCl). The impact of gastric pH and the potential interaction with a pH modifying agent (famotidine) was explored within comparative BA Study P008. Indeed, a notable decrease in Cmax (GMR 0.51) and in AUC (GMR 0.78) was observed after co-administration with the antacid agent famotidine as compared to atogepant given alone.

More  specific  insight  into  pH  dependency  of  atogepant  absorption  was  obtained  from  Study  102 examining the DDI between atogepant and PPI esomeprazole. A similar decreasing effect on atogepant's plasma level was observed for esomeprazole (Cmax [GMR 0.77], AUC [GMR 0.92]). Furthermore, the observed decrease in atogepant's rate and extent of absorption is compatible with in vitro data showing pH dependency for atogepant dissolution. Nonetheless, the applicant's conclusion that the observed effect is not considered clinically relevant and does not warrant particular posology recommendations is still endorsed. Throughout the phase II/III clinical study programme evaluating 12-week DBT with once daily atogepant dosing, concomitant antacid treatment was not prohibited. More than 10% of patients participating in pivotal trials actually reported concomitant PPI use (PPI use during DBT: pivotal EM study 301: 10.8%, pivotal CM study 303: 10.1%). A subgroup analysis for the primary efficacy endpoint was provided for those subjects receiving a PPI throughout studies 301 / 303. The numerical mean reduction of MDs per month in subjects taking antacid medication and the total study population was about similar.

Migraine prevalence peaks in women during childbearing ages. A DDI study examining the potential IA between atogepant (as a potential perpetrator of drug IA) and oral contraceptives is therefore of critical importance.  In  DDI  Study  P005,  Nordette-28™  was  adequately  chosen  as  a  two-component  OC containing a standard oestrogen (EE) and gestagen (LNG) component. As compared to a SD of the OC given alone, multiple therapeutic doses of atogeoant did not relevantly interact with either the oestrogen or gestagen component. AUC levels for LNG were slightly increased (LNG: GMR AUC: 1.19), however, this is not considered clinically relevant from a safety perspective. Continuous atogepant administration did not compromise the contraceptive effect of a standard OC.

A total of four studies was conducted to examine potential DDI when atogepant is co-administered with other  commonly  used  migraine  medications.  Atogepant  is  proposed  for  migraine  prevention.  It  is common  to  use  acute  migraine  medication  like  e.g.  acetaminophen  or  NSAIDs,  or  triptans  during migraine prophylactic treatment in case of an acute migraine attack. Accordingly, throughout pivotal trials 301 (EM) and 303 (CM), concomitant use of any triptan and / or any NSAID agent was permissible.

<div style=\"page-break-after: always\"></div>

Three of these 'migraine DDI' studies concerned the use of acute migraine medications on top of regular once daily atogepant use.

In DDI Study PK-06, no clinically relevant PK interaction between acute medication like acetaminophen (1000 mg) or naproxen (500 mg) and atogepant (60 mg) was observed in either direction. Equally, DDI Study PK-13 revealed no clinically relevant PK interaction with regular once daily atogepant 60 mg doses and intermittent sumatriptan 100 mg doses.

Ubrogepant is approved for the acute treatment of migraine (labelled as 50 mg or 100 mg dose, as needed). Both atogepant and ubrogepant share the same CGRP antagonist mode of action. In case of acute migraine attacks in patients already receiving CGRP-antagonist atogepant for prevention, it may be considered intuitive to choose an acute migraine medication with a different mechanism of action, e.g.  a  triptan  or  NSAIDs.  However,  there  is  a  certain  likelihood  that  physicians  could  prescribe ubrogepant  for  the  acute  treatment  of  breakthrough  migraines  in  patients  already  taking  migraine preventives. In DDI study 106, plasma levels under steady state conditions of atogepant alone were compared with steady state atogepant plus intermittent additional single doses of 100 mg ubrogepant doses. Intermittent single doses of ubrogepant did not have an impact on steady state atogepant plasma levels. However, the rate and extent of absorption after single dose administration of ubrogepant were significantly increased if administered on top of regular atogepant dosing as compared to ubrogepant given alone (Cmax GMR 125.6 [105.6, 149.5], AUC GMR 118.8 [108.7, 129.8]). Given the common molecular mode of action between both agents, increased exposure of ubrogepant single doses is to be seen in the context safety in healthy subjects resp. patients after administration of supra-therapeutic doses.

In clinical practice, it might occur in severe cases that patients receive two different migraine preventive agents at the same time. Throughout pivotal study 301 (EM) the concomitant use of any medication with demonstrated  efficacy  in  migraine  prevention  (incl.  e.g.  amitriptyline,  topiramate,  propranolol)  was prohibited. This is necessary in order not to confound the net effect of study medication (atogepant / placebo). DDI Study PK-14 examined the combined use of atogepant and topiramate. Topiramate is an approved treatment for adults for prophylaxis of migraine headache and is a mild inducer of CYP3A4 activity. The included Cohort 1 and Cohort 2 cover both scenarios that topiramate is added to ongoing atogepant therapy (Cohort 1), and Cohort 2 reflects the inverse scenario.

Additional  60  mg  once  daily  atogepant  administration  in  patients  already  receiving  maintenance topiramate (100 mg BID) for migraine prevention has no clinically relevant impact on topiramate's rate and extent of absorption under steady state conditions (Cmax,ss, AUCss). However, atogepant exposure under steady state conditions (AUCss) was considerably decreased when regular topiramate (100 mg BID) was concomitantly administered (GMR AUCss: 74.55 [68.72, 80.87]). The information provided in SmPC section 5.2 that no significant interaction between atogepant and topiramate was observed, it was not felt to fully reflect the outcome of study PK-12. It is not considered that the concomitant use of both preventive agents should be avoided. However, the change in atogepant exposure (incl. the potential mechanism, i.e. CYP3A4 induction through topiramate) was more closely reflected in the SmPC.

Taken together, a number of clinically relevant IAs were explored. These mainly relate to changes in atogepant exposure if co-administered with strong CYP3A4 inhibitors or strong inhibitors of the OATP transporter (e.g. rifampin). Both IAs are adequately labelled. No clinically relevant IA was observed between atogepant and a standard two-component (EE, LNG) oral contraceptive.

## Pharmacodynamics

The  Thorough  QTc  study  CGP-PK-04  appears  well  conducted.  Moxifloxacin  was  included  as  positive control  and  yielded  the  expected  results  (QTc  prolongation  by  5  to  10  ms).  This  demonstrates  an appropriate sensitivity of the study. Neither visual inspection of the results nor formal statistical analysis

<div style=\"page-break-after: always\"></div>

gave any hint that atogepant could prolong the QT interval in a relevant way. As most of the migraine patients are females, subgroup analysis by gender (ΔQTcF and ΔΔQTcF estimates incl. 90% CI per timepoint) was presented.

## PK Modelling

Population PK (PopPK) modelling and simulation studies were conducted at four stages in the late-stage development  of  atogepant  for  the  preventive  treatment  of  migraine.  CGP-MS-01  established  a preliminary PopPK model based on a pooled dataset from 5 Phase 1 studies. CGP-MS-02, CGP-MS-03 and 3101-S02-000 each consisted of a reiteration of the PopPK modelling as well as exposure-response evaluation of efficacy endpoints in the pivotal clinical studies. In addition to the four PopPK modelling studies, a PBPK modelling study (3101-S04-000) was conducted to predict the exposure of atogepant following co-administration of weak and moderate CYP3A4 inhibitors and inhibitors of P-gp and BCRP.

Modelling revealed that formulation, dose, food status, liver function, concomitant medication and body weight were each found to have a statistically significant influence on the atogepant PK. Apparent central volume of distribution was found to increase exponentially with body weight. Duration of zero-order absorption increased at higher doses and the spray dried compression tablet formulation had a 35% shorter duration compared to the hot melt extrusion oral compressed tablet (HMEOCT) formulation; relative bioavailability was estimated to increase with increasing dose level and was approximately 1.24fold higher at the 60 mg dose compared to the 10 mg dose. In addition, administration of atogepant following a high fat meal lengthened absorption lag time from 0.28 hours to 0.46 hours. Subjects with severe hepatic impairment had a 36.6% lower apparent systemic clearance. In the exposure-response modelling,  there  is  no  clear  relationship  between  the  assessed  covariates  of  age,  baseline  monthly migraine days, gender, length of migraine history, previous use of migraine preventive medication, and use of acute medication and the treatment effect. Only baseline monthly migraine days affected the reduction  in  monthly  migraine  days,  resulting  in  a  lower  overall  treatment  effect  at  higher  baseline values.

## 2.6.4. Conclusions on clinical pharmacology

A comprehensive PK study programme was provided to delineate the PK profile of atogepant (AGP) 10 and 60 mg tablets subject of the present MAA. This includes PK characterisation in heathy subjects (including exploration of a suitable tablet formulation, and mass balance), special populations (hepatic impairment and others), and a number of relevant DDI studies.

Taken together, the pharmacokinetics of atogepant were adequately characterised to substantiate the proposed once daily dosing scheme. Rapid absorption was observed after administration of the HMEOCT tablet formulation with median Tmax values ranging from 1 to 2 hrs. Compatible with the elimination half-life  of  about  10-11  hrs,  no  accumulation  occurred  upon  multiple  once  daily  dosing.  About dose-proportional increases in plasma levels were observed across the therapeutic dose range. With regular once daily administration, pre-dose trough levels reach about plateau values on the third day of dosing.

In terms of primary pharmacology, atogepant was characterised using the standard inhibition of CGRPinduced  vasodilation  model.  Plausible  results  were  obtained  for  inhibition  of  capsaicin-induced vasodilation through atogepant. The Thorough QTc study did not give any hint that a supra-therapeutic dose (300 mg) of atogepant could prolong the QT interval in a relevant way.

Overall, the characterisation of atogepant's clinical pharmacology profile is adequate.

<div style=\"page-break-after: always\"></div>

## 2.6.5. Clinical efficacy

Primary evidence for efficacy is derived from 2 pivotal studies, Study 3101-301-002 ('Advance' study, conducted in the US) for the preventive treatment of migraine in participants with EM and Study 3101303-002 ('Progress' study, conducted at 142 sites in the US, Europe, Russia, Japan, Korea and others) for the preventive treatment of migraine in participants with chronic migraine (CM).Additional supportive data  is  provided  by  dose-finding  Study  CGP-MD-01  for  the  preventive  treatment  of  migraine  in  EM patients.

## 2.6.5.1. Dose response study(ies)

## Dose finding study in EM patients

## A Phase 2/3, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention (Study CGP-MD-01)

Does finding study CGP-MD-01 was conducted at 78 clinical centres in the US from Sep 2016 to April 2018.  It  was  a  Phase  2/3,  multicentre,  randomised,  double-blind,  placebo-controlled,  parallel-group study comparing atogepant with placebo for the preventive treatment of migraine in participants with EM. A total of 834 eligible participants were randomised (1:2:1:2:1:2 ratio) to 12 weeks of double-blind treatment with either atogepant 10 mg QD, atogepant 30 mg QD, atogepant 30 mg BID, atogepant 60 mg  QD,  atogepant  60  mg  BID,  or  placebo.  To  maintain  the  blind,  investigational  product  will  be administered orally twice daily for 12 weeks to all patients.

## Efficacy endpoints

## Primary

- Change from baseline in mean monthly migraine days (MD) across the 12-week DBT.

## Secondary

- Change from baseline in mean monthly headache days (HD) across the 12-week DBT;
- Proportion of patients with at least a 50% reduction in mean monthly migraine days across the 12-week DBT;
- Change from baseline in mean monthly acute medication use days across the 12-week DBT.

Efficacy assessments were based on information recorded by the patient. An eDiary was used daily at home to collect data on headache duration, headache characteristics, symptoms, and acute medication use, which were collectively applied to define migraine, probable migraine, and headache days.

Efficacy evaluations will be based on the modified intention-to-treat (mITT) population which excludes patients never receiving treatment or not having baseline or any post-baseline diary data. Although bias may  have  been  introduced,  as  the  number  of  patients  excluded  from  the  mITT  population  due  to potentially treatment-related reasons is quite high for MD-01, this issue is not further pursued given the supportive character of the study.

The primary endpoint will be analysed using a mixed model for repeated measurements (MMRM) similar to the primary analysis for main studies (see below).  As no estimand is defined for Study MD-01 and data are not collected following treatment discontinuation, the MMRM targets a hypothetical estimand (effect if all had adhered). Although this is of less relevance for pivotal studies, it can be acceptable for this supportive dose finding study. Furthermore, a sensitivity analysis (pattern-mixture model approach

<div style=\"page-break-after: always\"></div>

based on the copy-reference method (Carpenter et al, 2013)) is conducted and yields similar results as the primary analysis.

The overall type I error rate for multiple comparisons across active treatment doses and the primary and secondary efficacy parameters will be adequately controlled at the 0.05 level using a graphical approach by Bretz et al (2011).

## Demographics

Mean age was 40.1 years. Most patients were female (86.5%). White and Black or African American patients accounted for 76.1% and 20.4% of the safety population, respectively. Mean BMI was 30.1 kg/m 2 .

Overall, 99.6% of patients in the safety population took concomitant medications during the treatment period. The most frequently used concomitant medications (≥ 20% of patients) were ibuprofen (50.8%), Thomapyrin  N  (also known  as  Excedrin  Migraine: aspirin, acetaminophen,  caffeine)  (40.7%), paracetamol (also known as acetaminophen; 26.7%), and sumatriptan (20.5%, [triptans as a class: 35.4%]).

As regards migraine history, 50.4% of patients reported history of migraine without aura, 22.3% of patients reported migraine with aura, and 27.3% reported migraine both with and without aura. The mean duration of migraine disorder was 19.37 years. Patients reported an average of 7.4 migraine days per month and 9.5 headache days per month in the 3 months prior to screening. At screening, nearly all patients  (97.6%)  reported  current  treatment  for  acute  migraine,  the  most  common  of  which  were NSAIDs (67.5%) and triptans (36.2%). Only 28.1% of patients reported previous migraine prophylactic treatment.

## Disposition of subjects

A total of 834 patients were randomised into the study and 825 (98.9%) received study treatment. Overall, 82% of patients completed the 12-week treatment period, and completion rates were similar across  the  6  treatment  groups  (range  78.5%  to  87.7%).  The  most  common  reason  for  premature discontinuation during the treatment phase was withdrawal of consent (6.7% overall).

## Efficacy results

Statistically  significant  higher  response  rates  were  observed  for  all  treatment  arms  of  atogepant compared with placebo for the primary endpoint (P1) of mean monthly migraine days across the 12week treatment period after  multiplicity  adjustment.  No  clear  dose  response  was  evident  in  the  P1 results.

<div style=\"page-break-after: always\"></div>

Table 24: Change from baseline in mean monthly migraine days across the 12-week treatment period (mITT Population), Study CGP-MD-01

|                           |              |                 | Atogepant       | Atogepant        | Atogepant    | Atogepant         | Atogepant      |
|---------------------------|--------------|-----------------|-----------------|------------------|--------------|-------------------|----------------|
|                           | Statisties   | Placebo (N=178) | 10 mg QD (N=92) | 30 mg QD (N-182) | 60mg (N=177) | 30 mg BID (6L=ND) | 60mg BD (N-S7) |
| Baseline                  | Mean         | 7.81            | 7.63            | 7.64             | 7.74         | 7.38              | 7.62           |
|                           | SD           | 2.51            | 2.51            | 2.37             | 2.59         | 2.43              | 2.56           |
|                           | SEM          | 0.19            | 0.26            | 0.18             | 0.19         | 0.27              | 0.27           |
|                           | Median       | 8.00            | 7.00            | 7.54             | 7.26         | 7.00              | 7.00           |
|                           | Min, Mnx     | 4.0.14.0        | 4.0. 13.5       | 4.0. 13.4        | 4.0.162      | 40.12.8           | 3.2.14.0       |
|                           |              | 178             | 92              | 182              | 177          | 6L                | 87             |
| Post-baseline             | Mean         | 4.97            | 3.71            | 3.91             | 4.17         | 3.37              | 3.61           |
| (Month 1-3)               | SD           | 3.36            | 3.05            | 3.36             | 3.68         | 2.66              | 3.72           |
|                           | SEM          | 0.25            | 0.32            | 0.25             | 0.28         | OEO               | 0.40           |
|                           | Medim        | 4.54            | 3.04            | 3.10             | 3.35         | 3.12              | 2.67           |
|                           | Min, Mnx.    | 0.0,18.2        | 0.0, 14.0       | 0.0, 14.3        | 0.0, 17.0    | 0.0,11.6          | 0.0,17.8       |
|                           | n            | 178             | 92              | 182              | 177          | 79                | 87             |
| Change from baseline Mean |              | -2.85           | -3.93           | -3.73            | -3.56        | -4.00             | -4.01          |
|                           | SD           | 3.42            | 3.16            | 3.44             | 3.43         | 2.75              | 3.77           |
|                           | SEM          | 0.26            | EE'0            | 0.26             | 0.26         | 0.31              | 0.40           |
|                           | Medin        | -2.72           | -3.85           | -3.73            | -3.55        | 4.00              | -4.28          |
|                           | Min, Max     | -13.4, 9.2      | -10.7, 5.1      | -12.0, 6.6       | -12.0, 7.8   | -10.0, 3.1        | -13.0,6.6      |
|                           |              | 178             | 92              | 182              | 177          | 79                | 87             |
| MMRM*                     | LS Mean (SE) | -2.85 (0.23)    | -4.00 (0.32)    | -3.76 (0.23)     | -3.55 (0.23) | 4.23 (0.35)       | -4.14 (0.33)   |
|                           | 95%6 C1      | 607- '00'6      | -4.63, -3.36    | -421. -3.31      | -4.01, -3.10 | -4.92. -3.55      | 4.79, -3.48    |
| CGP vs. Placebo           | LSMD (SE)    |                 | -1.15 (0.40)    | -0.91 (0.33)     | -0.70 (0.33) | -1.39 (0.42)      | -1.29 (0.41)   |
|                           | 95% CI       |                 | -1.93, -0.37    | -1.55, -0.27     | -1.35, -0.06 | -2.21.-0.56       | -2.09,-0.49    |
|                           | p-walue      |                 | 0.0039          | 0.0056           | 0.0325       | 0.0010            | 0.0016         |

Statistically  significant  higher  response  rates  were  observed  for  all  treatment  arms  of  atogepant compared with placebo for the 1st secondary endpoint (S1) of change from baseline in mean monthly headache days across the 12-week treatment period, with a similar magnitude of change in headache days across the treatment arms.

Table 25: Change from baseline in mean monthly headache days across the 12-week treatment period (mITT Population), Study CGP-MD-01

|                              |                 | Atogepant       | Atogepant        | Atogepant        | Atogepant        | Atogepant         |
|------------------------------|-----------------|-----------------|------------------|------------------|------------------|-------------------|
|                              | Placebo (N=178) | 10 mg QD (N=92) | 30 mg QD (N=182) | 60 mg QD (N=177) | 30 mg BID (N=79) | 60 mg BID ((N=87) |
| Baseline                     |                 |                 |                  |                  |                  |                   |
| Mean                         | 9.07            | 8.89            | 8.74             | 8.86             | 8.71             | 8.80              |
| (SD)                         | 2.70            | 2.70            | 2.51             | 2.76             | 2.73             | 3.12              |
| Post baseline (Month 1 to 3) |                 |                 |                  |                  |                  |                   |
| Mean                         | 6.18            | 4.65            | 4.68             | 5.05             | 4.64             | 4.65              |
| (SD)                         | 3.82            | 3.20            | 3.56             | 4.04             | 3.15             | 4.36              |
| ChangefromBaseline           |                 |                 |                  |                  |                  |                   |
| Mean                         | -2.89           | -4.24           | -4.06            | -3.81            | -4.08            | -4.15             |
| (SD)                         | 3.78            | 3.37            | 3.66             | 3.65             | 3.01             | 4.02              |
| MMRM                         |                 |                 |                  |                  |                  |                   |
| LS Mean (SE)                 | -2.93 (0.25)    | -4.31 (0.35)    | -4.17 (0.25)     | -3.86 (0.25)     | -4.23 (0.38)     | -4.32 (0.36)      |
| 95%6 CI                      | -3.42,-2.43     | -4.99.-3.62     | -4.66,-3.68      | -4.36.-3.37      | -4.97.-3.48      | -5.03.-3.61       |
| CGP vs.Placebo               |                 | -1.38 (0.43)    | -1.24 (0.36)     | -0.94 (0.36)     | -1.30 (0.46)     | -1.39 (0.44)      |
| LSMD (SE) I0 9656            |                 | -2.23, -0.54    | -1.94,-0.55      | -1.64, -0.24     | -2.20,-0.41      | -2.26,-0.53       |
| p-value                      |                 | 0.0014          | 0.0005           | 0.0087           | 0.0044           | 0.0017            |

The mixed-effect model for repeated measuues (MMRM) included treatment group and visit as fixed effects, the baseline value as a covaniate, and treatment group by visit and baseline by visit as interaction terms, with an wmstruchued covariamce matix. P-values Were from the test between the atogepant dose group and placebo.

Post-baseline (Month 1-3) = average of monthly headache days across the 12-week treatment period.

<div style=\"page-break-after: always\"></div>

The proportion of patients with at least a 50% reduction in mean monthly migraine days (S2) was higher in all atogepant treatment arms than in the placebo group (odds ratios ranging from 1.42 to 2.03), and the  comparison  with  placebo  was  statistically  significant  after  multiplicity  adjustment  for  both  BID treatment arms.

Table 26: Proportion of patients with at least 50% reduction in mean monthly migraine days across the 12-week treatment period (mITT population), Study CGP-MD-01

|                        |                 | Atogepant       | Atogepant        | Atogepant        | Atogepant        | Atogepant        |
|------------------------|-----------------|-----------------|------------------|------------------|------------------|------------------|
|                        | Placebo (N=178) | 10 mg QD (N=92) | 30 mg QD (N=182) | 60 mg QD (N=177) | 30 mg BID (N=79) | 60 mg BID (N=87) |
| Responders, n (%6)     | 72 (40.4)       | 53 (57.6)       | 97 (53.3)        | 92 (52.0)        | 46 (58.2)        | 54 (62.1)        |
| Non-responders, n (%6) | 106 (59.6)      | 39 (42.4)       | 85 (46.7)        | 85 (48.0)        | 33 (41.8)        | 33 (37.9)        |
| Odds Ratio Vs.Placebo  |                 | 1.50            | 1.46             | 1.42             | 1.83             | 2.03             |
| (95% CI)               |                 | (0.98, 2.31)    | (1.02, 2.08)     | (1.00, 2.03)     | (1.15, 2.91)     | (1.30, 3.18)     |
| p-value                |                 | 0.0617          | 0.0369           | 0.0512           | 0.0113           | 0.0019           |

Analyses were based on generalized linear mixed model for repeated measures. The model included treatment group and visit as fixed effect, the baseline value as a covariate, and treatment group by visit and baseline by visit as interaction terms, with an umstuctured covariance matrix. P-values were from the test between the atogepant dose group and placebo.

A greater reduction from baseline in mean monthly acute medication use days (S3) was observed for all atogepant treatment arms compared with placebo (LSMD range -1.11 to -1.44 compared with placebo).

Table 27: Change from baseline in mean monthly acute medication use days across the 12week treatment period (mITT population), Study CGP-MD-01

|                              |                 | Atogepant       | Atogepant        | Atogepant        | Atogepant        | Atogepant       |
|------------------------------|-----------------|-----------------|------------------|------------------|------------------|-----------------|
|                              | Placebo (N=178) | 10 mg QD (N=92) | 30 mg QD (N=182) | 60 mg QD (N=177) | 30 mg BID (N=79) | 60 mgBID (N=87) |
| Baseline                     |                 |                 |                  |                  |                  |                 |
| Mean                         | 6.57            | 6.16            | 6.62             | 6.79             | 6.20             | 6.37            |
| (SD)                         | 3.21            | 3.31            | 3.04             | 3.27             | 3.26             | 3.41            |
| Post baseline (Month 1 to 3) |                 |                 |                  |                  |                  |                 |
| Mean                         | 4.18            | 2.65            | 2.73             | 3.16             | 2.61             | 2.88            |
| (SD)                         | 3.57            | 2.71            | 2.85             | 3.48             | 2.43             | 3.30            |
| ChangefiromBaseline          |                 |                 |                  |                  |                  |                 |
| Mean                         | -2.39           | -3.51           | -3.89            | -3.63            | -3.59            | -3.49           |
| (SD)                         | 3.35            | 3.09            | 2.94             | 3.38             | 2.98             | 3.41            |
| MMRM                         |                 |                 |                  |                  |                  |                 |
| LS Mean (SE)                 | -2.42 (0.21)    | -3.71 (0.29)    | -3.86 (0.20)     | -3.53 (0.21)     | -3.77 (0.31)     | -3.64 (0.29)    |
| 95% CI                       | -2.82,-2.01     | -4.27,-3.15     | -4.26,-3.46      | -3.93.-3.13      | -4.38,-3.16      | -4.22,-3.06     |
| CGP vs.Placebo LSMD (SE)     |                 | -1.30 (0.35)    | -1.44 (0.29)     | -1.11 (0.29)     | -1.35 (0.37)     | -1.22 (0.36)    |
| 95% CI                       |                 | -1.99,-0.60     | -2.01,-0.87      | -1.68,-0.54      | -2.08,-0.62      | -1.93,-0.52     |
| p-value                      |                 | 0.0002          | .0001            | 0.0001           | 0.0003           | 0.0007          |

The mixed-effect model for repeated measuues (MMRM) included treahment group and visit as fixed effects, the baseline value values were firom the test between the atogepant dose group and placebo.

Post-baseline (Month 1-3) = average of monthly acute medication use days across the 12-week treatment period

<div style=\"page-break-after: always\"></div>

In terms of acute medication reduction, treatment differences were statistically significant for the BID treatment arms of at ogepant compared with placebo after multiplicity adjustment (p ≤ 0.0339). However, the treatment differences in the QD arms did not achieve statistical significance after multiplicity adjustment because the results for the 50% responder endpoint (S2), which were placed higher in the testing hierarchy, did not achieve statistically significant separation from placebo for the corresponding doses.

Table 28: Summary of primary and secondary efficacy analyses with multiplicity adjustment (mITT population)

|                                                                                                                                                                                                 | Atogepant                  | Atogepant                   | Atogepant                  | Atogepant                   | Atogepant                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------|----------------------------|-----------------------------|----------------------------|
| Decision Sequence                                                                                                                                                                               | 10 mg QD (N-92)            | 30 mg QD (N-182)            | 60 mg QD (N-177)           | 30 mg BID (N-79)            | 60 mg B1D (N-87)           |
| Pl: Chunge from baseline in mean monthly migraine days aeross the 12-week ireatment period LSMD (95%% CI), alogepant vs. Placebo                                                                | -1.15 (-1.93, -0.37)       | -0.91 (-1.55, -0.27) 9500'0 | -0.70 (-1.35.-0.06) 0.0325 | -1.39 (-2.21,-0.56) 0.0010  | -1.29 (-2.09,-0.49) 0.0016 |
| Model p-value                                                                                                                                                                                   | 60000                      |                             |                            |                             |                            |
| Adjusted p-value                                                                                                                                                                                | 0.0236                     | 0.0390                      | 0.0390                     | 0.0034                      | 0.0031                     |
| Sl: Change from baseline in mean monthly headache days across the 12-week treatment peniod LSMD (95% CI), atogepant vs. Placebo                                                                 | -1.38                      | -1.24                       | -0.94                      | -1.30                       | -1.39                      |
| Model p-value                                                                                                                                                                                   | (-2.23,-0.54)              | (-1.94,-0.55) 5000'0        | (-1.64,-0.24) 0.0087       | (-2.20,-0.41) 0.0044 0.0131 | (-2.26, -0.53) 0.0017      |
| Adjusted p-value                                                                                                                                                                                | 0.0014                     |                             | 0.0390                     |                             | E8000                      |
| S2: Proportion of patients with at least a 50% reduction in mean monthly migraine/probable migraine headache days aeross the 12-week treatment period Odds ntio (95% C1). atogepant vs. Placebo | 0.0236 1.50                | 0.0390 1.46                 | 1.42                       | 1.83                        | 2.03 (1.30,3.18)           |
| Model p-value Adjusted p-value                                                                                                                                                                  | (0.98, 2.31) 0.0617 0.1107 | (1.02.2.08) 0.0369 0.1107   | (1.00.2.03) 0.0512 0.1537  | (1.15. 2.91) 0.0113 0.0339  | 61000 0.0097               |
| S3: Change fiom baseline in mean monthly acute medieation use days across the 12-week treatment period                                                                                          | -1.30                      | -1.44                       | -1.11                      | -1.35                       | -1.22                      |
| LSMD (95% CI). atogepant vs. Plncebo Model p-value                                                                                                                                              | (-1.99, -0.60)             | (-2.01,-0.87) 0001          | (-1.68.-0.54) 0.0001       | (-2.08,-0.62) EO00O         | (-1.93, -0.52) 2000'0      |
| Adjusted p-value                                                                                                                                                                                | 0,0002 0.1107              | 0.1107                      | 0.1537                     | 0.0339                      | 0.0097                     |

Pl model results are fiom Table 14.2.1.2; S1 model results are from Table 14.2 2.1; S2 model results are firom Table 14.2.2.2; S3 model results are from Table 14.2.2.3.

Adjusted p-values: using graphice approach to control the overall type I enor rale for multiple comparisons. Refer to statistieal analysis plan for details.

## 2.6.5.2. Main study(ies)

Studies  301  and  303  were  12-week,  Phase  3,  multi-centre,  randomised,  double-blind,  placebocontrolled,  parallel-group studies  comparing  atogepant  with  placebo  for  the  preventive  treatment  of migraine in participants with EM (Study 301; atogepant 10 mg, 30 mg, and 60 mg QD) and in participants with CM (Study 303; atogepant 30 mg BID and 60 mg QD). The primary efficacy endpoint in both studies was the change from baseline in mean monthly migraine days across the 12-week treatment period.

## Pivotal Study 301 in EM

A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE) (Study 3101-301-002)

This study was conducted in the US.

The study consisted of a 4-week screening and baseline period, a 12-week double-blind treatment period, and a 4-week safety follow-up period.

<div style=\"page-break-after: always\"></div>

Figure 5: Study 3101-301-002 schema

<!-- image -->

n = mumber of participants anticipated to be randomized to each treatment group (as descnbed in the protocol)

Pivotal Study 303 in CM

A Phase 3, Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (PROGRESS) (Study 3101-303-002)

142  sites  in  the  United  States,  United  Kingdom,  Canada,  China,  Czech  Republic,  Denmark,  France, Germany,  Italy,  Japan,  Republic  of  Korea,  Poland,  Russian  Federation,  Spain,  Sweden,  and  Taiwan screened subjects for study eligibility.

Figure 6: Study design schematic, study 3101-303-002

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Methods

## Study Participants

## Study 3101-301-002 (Episodic Migraine)

The participants in Study 301 were generally representative of patients with EM in the general population with respect to demographics and baseline disease characteristics (Katsarava 2012).

The study enrolled participants 18 to 80 years of age who had a history of migraine with onset before age 50 years, with or without aura for at least 1 year consistent with a diagnosis according to the ICHD3  criteria  (ICHD-3  2018).  Participants  must  have  experienced  4  to  14  migraine  days  per  month  on average in the 3 months before screening (Visit 1) in the investigator's judgement. During the 28-day baseline period, participants had to experience 4 to 14 migraine days per electronic diary (eDiary).

Randomisation  was  stratified  by  prior  exposure  (yes,  no)  to  a  migraine  prevention  medication  with proven efficacy.

## Study 3101-303-002 (Chronic Migraine)

The study enrolled participants 18 to 80 years of age who had at least a 1-year history of CM consistent with  a  diagnosis  according  to  the  ICHD-3  criteria  (ICHD-3  2018)  with  onset  before  age  50  years. Participants must have experienced, on average, ≥ 15 headache days per month in the 3 months prior to Visit 1 in the opinion of the investigator, ≥ 15 headache days during the 4 -week screening/baseline period per the eDiary, and≥ 8 da ys during the 4-week screening/baseline period that qualify as being a migraine day per the eDiary.

## Treatments

The HME-OCT tablet formulation (as described in section 3.3.1.1) at dose strengths of 10 mg, 30 mg, and 60 mg was used in phase II/III trials. Atogepant treatment arms examined once daily QD 10 mg, 30 mg, and 60 mg doses in EM study 301, and the highest 60 mg dose in CM study 303, administered either as QD 60 mg or 30 mg BID.

There were virtually no restrictions with regard to medication to be taken for acute migraine attacks throughout studies 301/303. Patients were allowed to take any triptan, ergot derivative, opioid, any other form of analgesic (incl. acetaminophen), any NSAID, or any antiemetic agent.

However, there were differences between EM study 301 and CM study 303 in terms of concomitant migraine  preventive  medication.  In  EM  study  301,  medications  with  demonstrated  efficacy  for  the prevention of migraine (e.g., amitriptyline, topiramate, propranolol) were prohibited within 30 days prior to Visit 1 and throughout the study period. Injectable monoclonal antibodies blocking the CGRP pathway (e.g., Aimovig, Emgality, Ajovy) within 6 months prior to Visit 1 and through the study period, were prohibited.

In CM study 303, participants taking one medication with demonstrated efficacy for the prevention of migraine may be randomised provided that in the opinion of the investigator:

- Dose has been stable and the medication has been well-tolerated for at least 12 weeks prior to Visit 1 AND
- Participant is willing and able to maintain at a stable dose and dosage regimen during the study, which should be assessed to ensure compliance at each study visit

Enrolment of participants with current use of a migraine prevention medication will be capped at ~15%

<div style=\"page-break-after: always\"></div>

Like in study 301, injectable monoclonal antibodies blocking the CGRP pathway (e.g., Aimovig, Emgality, Ajovy) within 6 months prior to Visit 1 and throughout the study period were prohibited.

## Objectives

## EM Study 301

- To evaluate the safety and tolerability of atogepant 10 mg, atogepant 30 mg, and atogepant 60 mg for the prevention of migraine in participants with EM.
- To prospectively test for superiority of atogepant 10 mg, atogepant 30 mg, and atogepant 60 mg versus placebo for the prevention of migraine in participants with EM.

## Clinical Hypothesis

In individuals with EM, at least one of the atogepant doses, 10 mg, 30 mg, and 60 mg, is superior to placebo as measured by the change from baseline in mean monthly migraine days across the 12-week treatment period.

## CM Study 303

- To evaluate the safety and tolerability of atogepant 30 mg BID and atogepant 60 mg once daily for the prevention of CM.
- To prospectively test for superiority of atogepant (30 mg BID and atogepant 60 mg once daily) versus placebo for the prevention of CM.

## Clinical Hypothesis

In participants with CM, at least one dose of atogepant (30 mg BID and atogepant 60 mg once daily) is superior to placebo as measured by the change from baseline in mean monthly migraine days across the 12-week treatment period.

For EU filing, studies 301 and 303 target an estimand addressing the effect regardless of treatment discontinuation  and  acute  migraine  treatment  (treatment  policy  strategy)  and  had  other  preventive migraine treatment not been available (hypothetical strategy). Although it can be argued whether it is reasonable  to  apply  a  hypothetical  strategy  for  'starting  new  preventive  migraine  treatment',  the targeted estimand is agreed, as in both studies the number of patients that have started new preventive migraine treatment is very limited and use of alternative strategies to handle this intercurrent event is unlikely  to  relevantly  change  conclusions.  Furthermore,  the  Copy-Reference  analysis  (pre-planned sensitivity  analysis)  as  well  as  the  requested  and  provided  additional  analysis  (Jump-to-Reference analysis) can be interpreted to target estimands that use alternative strategies to handle the intercurrent event 'starting new preventive migraine treatment'. Labelling the targeted estimand as 'Off-treatment Hypothetical Estimand' is unusual and somewhat confusing, as the terms off-treatment and hypothetical relate to different concepts and it is unclear from the name to which intercurrent events these refer.

## Outcomes/endpoints

<div style=\"page-break-after: always\"></div>

Table 29: Summary of primary and secondary efficacy endpoints

<!-- image -->

| Primary Analysis                                 | Study3101-301-002 (ADVANCE)                                                                                                                                                                                                                                                                                                                                 | Study3101-303-002 (PROGRESS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Study CGP-MD-01                                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Population:                                      | Europe: OTHE Other Regions:mITT                                                                                                                                                                                                                                                                                                                             | Europe: OTHE Other Regions:mITT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | mITT                                                                                                                                                                                                                                                                                                                              |
| Prinary (P) and Secondary (S) Efficacy Endpoints | Prinary (P) and Secondary (S) Efficacy Endpoints                                                                                                                                                                                                                                                                                                            | Prinary (P) and Secondary (S) Efficacy Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Prinary (P) and Secondary (S) Efficacy Endpoints                                                                                                                                                                                                                                                                                  |
| Primary efficacy endpoint:                       | Change from baseline in mean monthly migraine days across the 12-week treatment period [P1]                                                                                                                                                                                                                                                                 | Change from baseline in mean monthly migraine days across the 12-week treatment period [P1]                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Change from baseline in mean monthly migraine days across the 12-week treatment period [P1]                                                                                                                                                                                                                                       |
| Clinical secondary efficacy endpoints:           | Changefrom baselinein mean monthly headache days across the 12-week treatment period [S1] Change from baseline in mean monthly acute medication use days across the 12-week treatment period [S2] At least a 50% reduction in 3-month average of monthly migraine days [S3]                                                                                 | Changefrom baselinein mean monthly headache days across the 12-week treatment period [S1] Change from baseline in mean monthly acute medication use days across the 12-week treatment period [S2] At least a 50% reduction in 3-month average of monthly migraine days [S3]                                                                                                                                                                                                                                                                                     | Change from baseline in mean monthly headache days across the 12-week treatment period [S1] Proportion of participants with at least a50%reduction in mean monthly migraine days across the 12-week treatment period [S2] Change from baseline in mean monthiy acute medication use days across the 12-week treatment period [S3] |
| Health outcomes secondary efficacy endpoints:    | Change from baseline in MSQ v2.1 Role Function- Restrictive domain score at Week 12 [S4] Change from baseline in mean monthly Perfomance of Daily Activities domain score of the AIM-D across the 12-week treatment period [S5] Change from baseline in mean monthly Physical Impairment domain score of the AIM-D across the 12-week treatment period [S6] | Europe: Change from baseline in the HIT-6 total score at Week 12 [S4] Change from baseline in MSQ v2.1 Role Function-Restrictive domain score at Week 12 [S5] All Regions Except Europe and Canada: Change from baseline in MSQ v2.1 Role Function-Restrictive domain score at Week 12 [S4] Change from baseline in mean monthly Performance of Daily Activities domain score of the AIM-D across the 12-week treatment period [S5] Change from baseline in mean monthly Physical Impairment domain score of the AIM-D across the 12-week treatment period [S6] | NA                                                                                                                                                                                                                                                                                                                                |

AIM-D = Activity Impaiment in Migraine - Diary; HIT-6 = Headache Impact Test; mITT = modified intent-to-treat; MSQ = Migraine Specific Quality of Life Questiomaire; NA = not applicable; OTHE = off-treatment hypothetical estimand

Note:

Baseline for endpoints derived from eDiary data was from 28 days prior to the randomization date (Day 1). Baseline for MSQ and HIT-6 endpoints was from Day 1.

<div style=\"page-break-after: always\"></div>

## Migraine Day

A migraine day is defined as any calendar day on which a headache occurs which meets criteria A, B, and C OR meets criteria D and E, as listed below, as per participant eDiary.  Calendar days begin at midnight and last until 11:59 PM (23:59).

- A.Headache has at least two of the following four characteristics:
- i Unilateral location
- ii. Pulsating quality
- ili. Moderate orseverepain intensity
- iv. Aggravated by orcausing avoidance ofroutinephysical activity(eg,walking or climbing stairs)
- B. At least one of the following:
- i. Nausea and/or vomiting
- ii. Photophobia andphonophobia
- ili. Typical aura (ie, visual, sensory, or speech/language) accompanying or within 60 minutes before headachebegins
- C.Duration ofheadachelasting 2 hours or longer on a calendar day unless an acute, migraine-specific medication (ie, triptan or ergot derivative) was used after the start of theheadache,inwhichcasenominimumdurationwill bespecified
- D.Any headache which fulfills 1 criterion from (1) and at least 1 criterion from (2) OR fulfills at least 2 criteria from (1) and no criteria from (2).
- 1)Headache characteristics:
- i.Unilateral location
- ii. Pulsating quality
- ili. Moderate or severe pain intensity
- iv.Aggravated by or causing avoidance of routine physical activity (eg, walking or climbing stairs)
- 2) Symptoms:
- i.Nausea and/or vomiting
- ii.Photophobia and phonophobia
- ili. Typical aura (ie, visual, sensory, or speech/language) accompanying or within 60 minutes before headache begins
- E.Duration of headache lasting 2 hours or longer on a calendar day unless an acute, migraine-specific medication (ie, triptan or ergot derivative) was used after the start of the headache, in which case no minimum duration will be specified.

## Headache Day

A headache day is defined as any calendar day on which headache pain lasting 2 hours or longer occurs unless an acute headache medication (e.g., ibuprofen, triptan) was used after the start of the headache, in which case no minimum duration will be specified.

## Sample size

For Study 301/302, a total sample size of 218/250 per treatment group will provide at least 98%/96% power to detect the treatment difference between each of the 3/2 doses (assumed equally effective) and placebo for the primary efficacy endpoint (assumptions based on results from other prevention studies). This sample size was selected to provide sufficient power for the first 3 secondary endpoints as well and takes multiplicity control into account.

## OR

<div style=\"page-break-after: always\"></div>

## Randomisation and blinding (masking)

Participants will be randomised to the different treatment arms in an equal ratio using a centralised IWRS. Approximately 70% of randomised participants will have taken at least 1 prior migraine prevention medication with proven efficacy. Randomisation is stratified by prior exposure to a migraine prevention medication for study 301 (EM) and region, acute headache medication overuse, and migraine prevention medication  exposure  (further  stratified  based  on  the  number  of  medications  failed  with  unique mechanisms of action for study 303 (CM)).

A double-dummy design will be used to maintain study blind. Atogepant tablets and matching placebo will be provided in identical blister cards to maintain masking of the study.

## Statistical methods

In line with the estimand, for EU filing, the Off-treatment Hypothetical Estimand (OTHE) population is used for analysis. It excludes randomised participants never receiving treatment or not having baseline or any post-baseline diary data (regardless of whether on or off study treatment). Data collected after treatment discontinuation is included in evaluations and data collected after new preventive migraine treatment  was  started  is  excluded.  While  inclusion  of  off-treatment  data  is  supported,  exclusion  of randomised patients from the analysis population is generally not. However, although around 1 to 4 % of rand. patients were excluded from the OTHE population in both studies (majority due to missing postbaseline assessments), given the clear efficacy results of studies 301 and 303, it is highly unlikely that including all randomised patients will relevantly change conclusions. Hence, use of the OTHE population is supported.  For US filling, the mITT population excluding all randomised patients never receiving study treatment or not having baseline or any post-baseline data (on study treatment) will be used.

The  primary  endpoint  will  be  analysed  using  a  mixed  model  for  repeated  measures  (MMRM).  The response variable is the change from baseline to each post-baseline month in monthly migraine days. The  model  will  include  treatment,  visit,  stratification  factors,  and  treatment  by  visit  interaction  as categorical fixed effects as well as baseline and baseline-by visit interaction as covariates. Within-patient correlation will be modelled using an unstructured covariance matrix. Contrasts will be constructed to obtain the average treatment effects across the 12-week treatment period to compare each treatment group vs placebo. Although this analysis with its underlying missing-at-random (MAR) assumption is less aligned to the targeted estimand (unless no data are missing) as compared to imputation approaches based on placebo data (CR or J2R analysis), there are minimal to none differences in results for the CR and J2R analysis as compared to the primary analysis supporting overall robustness of results. Hence it is agreed to report results of the primary analysis in the SmPC.

Only few daily eDiary data are missing and impact of these on availability of primary/secondary endpoints as well as on results is negligible. Continuous secondary endpoints will be analysed similar to the primary endpoint. The 50% responder endpoint, defined as a participant with at least a 50% reduction from baseline in the 3-month average of monthly migraine days, will be assessed for each individual. A logistic regression model will be used to analyse the 50% responders across the 12-week treatment period.

The overall familywise error rate (FWER) will be controlled at α = 0.05 for the primary and secondary endpoints between each dose level of atogepant vs placebo using a graphical approach with weightedBonferroni  test  procedure  (Bretz  2009).  For  the  primary  and  first  three  secondary  endpoints  this approach essentially corresponds to sequential testing vs placebo within each atogepant dose group with splitted alpha.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

## Study 301 in EM population

A total of 910 participants were randomised and included in the intent-to-treat population of Study 301. Overall, 805 participants completed the 12-week double-blind treatment period, and completion rates were similar across the 4 treatment groups (range 86.8% to 90.1% for all randomised patients).

A  total  of  88.5%  of  all  randomised  participants  completed  the  study  and  11.5%  of  participants discontinued the study in the double-blind treatment period.  The  most  common  reason  for discontinuation, based on the total number of participants, was withdrawal by subject (3.8%), adverse events (2.7%), and protocol deviations (2.6%).

Figure 7: Participant disposition - study 301

<!-- image -->

## Study 303 in CM population

Overall, 1489 subjects were screened for eligibility at 142 sites in the US, UK, Canada, China, CZ, DK, FR, DE, IT, Japan, Republic of Korea, PL, Russian Federation, ES, SE, and Taiwan. Of these, N=778 subjects were randomised.

The majority of randomised subjects (89.2%) completed the double-blind treatment period. The main reasons for discontinuation reported during DBT were AE and withdrawal by subject.

<div style=\"page-break-after: always\"></div>

Table 30: Subject disposition - ITT population, study 303 (DBT extract)

| Phase Disposition                   | Placebo (N=259)   | Atogepant 30 mg BID (N=257)   | Atogepant 60mg QD (N=262)   | Total (N=778)   |
|-------------------------------------|-------------------|-------------------------------|-----------------------------|-----------------|
|                                     | n (&)             | n (&)                         | n (%)                       | n (&)           |
| Number of Participants Randomized   | 259 (100.0)       | 257 (100.0)                   | 262 (100.0)                 | 778 (100.0)     |
| Number of Participants Treated      | 255 (98.5)        | 257 (100.0)                   | 261 (99.6)                  | 773(99.4)       |
| Double-Blind Treatment Period       |                   |                               |                             |                 |
| Number of Participants Entered      | 259 (100.0)       | 257 (100.0)                   | 262 (100.0)                 | 778 (100.0)     |
| Number of Participants Completed    | 230(88.8)         | 231 (89.9)                    | 233(88.9)                   | 694(89.2)       |
| Number of Participants Discontinued | 29 (11.2)         | 26 (10.1)                     | 29 (11.1)                   | 84(10.8)        |
| Reason for Discontinuation          |                   |                               |                             |                 |
| Adverse Event                       | 10 3.9)           | 13 5.1)                       | 9 （ 3.4)                    | 32 4.1)         |
| Lack of efficacy                    | 5 1.9)            | 2 0.8)                        | 1 （ 0.4)                    | 8 1.0)          |
| Withdrawal by subject               | 8 3.1)            | 7 2.7)                        | 14 （ 5.3)                   | 29 3.7)         |
| Lost to Follow-Up                   | 0 0.0)            | 1 0.4)                        | 3 1.1)                      | 4 ( 0.5)        |
| Pregnancy                           | 0 0.0)            | 0 0.0)                        | 0 0.0)                      | 0 0.0)          |
| Protocol Deviation                  | 5 1.9)            | 3 ( 1.2)                      | 2 0.8)                      | 10 1.3)         |
| Non=compliance with study drug      | 1 0.4)            | 0 0.0)                        | 0 （ 0.0)                    | 1 （ 0.1)        |
| Study Terminated by Sponsor         | 0 0.0)            | 0 ( 0.0)                      | 0 0.0)                      | 0 0.0)          |
| Site Terminated by Sponsor          | 0 0.0)            | 0 0.0)                        | 0 ( 0.0)                    | 0 0.0)          |
| other                               | 0 0.0)            | 0 0.0)                        | 0 0.0)                      | 0 0.0)          |

## Baseline data

Study populations between Studies 301 and 303 were similar in terms of mean age (41-42 years) and gender partition (87-89% female) with differences as regards mean weight (US study 301: 83.9 kg, multiregional study 303: 69.5 kg), and BMI (301: 30.46 kg/m 2 , 303: 25.52 kg/m 2 ) of participants.

<div style=\"page-break-after: always\"></div>

Table 31: Migraine history - individual studies 3101-301-002 and 3101-303-002 (safety population)

|                                                            | Study 3101-301-002 (EM) Total   | Study3101-303-002 (CM) Total   |
|------------------------------------------------------------|---------------------------------|--------------------------------|
| N                                                          | 902                             | 773                            |
| Migraine Diagnosis, n (%)                                  |                                 |                                |
| With Aura                                                  | 146 (16.2)                      | 103 (13.3)                     |
| Without Aura                                               | 406 (45.0)                      | 462 (59.8)                     |
| Both                                                       | 350 (38.8)                      | 208 (26.9)                     |
| Migraine Disorder Duration in Years                        |                                 |                                |
| Mean (SD)                                                  | 21.2 (12.63)                    | 21.4 (12.18)                   |
| Migraine Prevention Medication in the Past, n (%)          |                                 |                                |
| Yes                                                        | 634 (70.3)                      | 641 (82.9)                     |
| No                                                         | 268 (29.7)                      | 132 (17.1)                     |
| Average Number of Migraine Days per Month in Last 3 Months |                                 |                                |
| Mean (SD)                                                  | 7.4 (2.47)                      | 16.0 (5.91)                    |
| Average Number of Headache Days per Month in Last 3 Months |                                 |                                |
| Mean (SD)                                                  | 9.3 (2.71)                      | 21.1 (5.36)                    |
| Acute Medication Treatment,\"n (%)                          |                                 |                                |
| Yes                                                        | 896 (99.3)                      | 760 (98.3)                     |
| Triptan                                                    | 440 (48.8)                      | 558 (72.2)                     |
| Ergot or Ergot Combinations                                | 3 (0.3)                         | 17 (2.2)                       |
| NSAID                                                      | 569 (63.1)                      | 540 (69.9)                     |
| Opiate or Opiate Combination                               | 35 (3.9)                        | 28 (3.6)                       |
| Antiemetie Agent                                           | 73 (8.1)                        | 116 (15.0)                     |
| Barbihurates                                               | 6 (0.7)                         | 2 (0.3)                        |
| Other                                                      | 570 (63.2)                      | 250 (32.3)                     |

CM = chronice migraine, EM = episodic migaine; NSAID = nonsteroidal anti-imflammatory dnugs, OTHE = off-treahment hypothetical estimand; SD = standard deviation

Medication(s) that the participant usually takes to treat migraine headaches.

Note. The safety population was defined as all participants who took at least I dose of shudy dnug. Souce: Shudy 3101-301-002 CSR, Table 14.1-32.2 and Shudy 3101-303-002 CSR, Table 14.1-5.1.2

## Numbers analysed

The number of participants included in each analysis population, overall and by treatment group, is summarised in on the following tables for studies 301 and 303.

Table 32: Analysis populations - all screened subjects (301)

| Population                                                  | Placebo   | Atogepant 10mg QD   | Atogepant 30mg QD   | Atogepant 60mg QD   |   Total |
|-------------------------------------------------------------|-----------|---------------------|---------------------|---------------------|---------|
| Screened                                                    |           |                     |                     |                     |    2270 |
| Intent-to-Treat                                             | 223       | 222                 | 230                 | 235                 |     910 |
| Safety                                                      | 222       | 221                 | 228                 | 231                 |     902 |
| ModlifiedIntent-to-Treat                                    | 214       | 214                 | 223                 | 222                 |     873 |
| Analysis Population for Off-Treatment Hypothetical Estimand | 216       | 216                 | 224                 | 226                 |     882 |

<div style=\"page-break-after: always\"></div>

Table 33: Analysis populations - all screened subjects (303)

<!-- image -->

| Country Population                           | Placebo   | Atogepant30mgBID   | Atogepant60mgQD   | Total   |
|----------------------------------------------|-----------|--------------------|-------------------|---------|
| Overall                                      |           |                    |                   |         |
| Intent-to-Treat                              | 259       | 257                | 262               | 778     |
| Safety                                       | 255       | 257                | 261               | 773     |
| ModifiedIntent-to-Treat                      | 246       | 253                | 256               | 755     |
| Off-treatmentHypotheticalEstimand Population | 249       | 254                | 257               | 760     |

BID=twice daily;ITT=intent-to-treat;eDiary=electronic diary,mITT=modified intent-to-treat;QD=once daily

The primary efficacy analysis population for EU filing is the Off-treatment Hypothetical Estimand (OTHE) population, while the mITT population used primarily for US filing.

## Outcomes and estimation

## Primary Efficacy Endpoint

Change from Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period

In both studies 301 303, greater reductions from baseline in mean monthly migraine days across the 12-week treatment period were observed for each of the atogepant doses (10 mg, 30 mg, and 60 mg QD in  Study  301  and  30  mg  BID  and  60  mg  QD  in  Study  303)  compared  with  placebo  and  were statistically significant after multiplicity adjustment.

Table 34: Change from baseline in mean monthly migraine days across the 12-week treatment period: individual studies 3101-301-002 and 3101-303-002 (OTHE population)

|                      |                 | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-303-002 (CM)   | Study3101-303-002 (CM)   | Study3101-303-002 (CM)   |
|----------------------|-----------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                      | Statistic       | Placebo                  | Atogepant 10 mg QD       | Atogepant 30 mg QD       | Atogepant 60 mgQD        | Placebo                  | Atogepant 30 mgBID       | Atogepant 60 mgQD        |
| Baselinenumberofdays | N               | 216                      | 216                      | 224                      | 226                      | 249                      | 254                      | 257                      |
|                      | Mean (SD)       | 7.53 (2.394)             | 7.46 (2.466)             | 7.86 (2.311)             | 7.75 (2.334)             | 18.95 (4.795)            | 18.60 (5.090)            | 19.19 (5.291)            |
| Changefrombaseline   | LS mean (SE)    | -2.47 (0.210)            | -3.69 (0.209)            | -3.85 (0.206)            | 4.14 (0.205)             | -5.09 (0.409)            | -7.33 (0.406)            | -6.75 (0.406)            |
| Atogepantvs.placebo  | LSMD            |                          | -1.22                    | -1.38                    | -1.66                    |                          | -2.24                    | -1.66                    |
| Atogepantvs.placebo  | ID%S6           |                          | -1.79,-0.65              | -1.94, -0.81             | -2.23,-1.10              |                          | -3.31,-1.16              | -2.72,-0.59              |
| Atogepantvs.placebo  | Nominalp-value  |                          | <0.0001                  | <0.0001                  | <0.0001                  |                          | <0.0001                  | 0.0024                   |
| Atogepantvs.placebo  | Adjustedp-value |                          | ≤0.0001                  | <0.0001                  | ≤0.0001                  |                          | 0.0001                   | 0.0024                   |

BID=twice daily;CI=confidenceinterval;CM=chronicmigraine;EM=episodicmigraine;LS=least squares;LSMD=least squares meandifference;OTHE=off-treatment hypotheticalestimand;QD=oncedaily;SD=standarddeviation;SE=standarderror

Source:Study3101-301-002CSR,Table14.2-1.6andTable14.2-1.1.BandStudy3101-303-002CSR,Table14.2-2.1.2andTable14.2-1.2

## Secondary Efficacy Endpoint [S1]

Change from Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period

In both studies, greater reductions from baseline in mean monthly headache days across the 12-week treatment period were observed for each of the atogepant doses (10 mg, 30 mg, and 60 mg QD in Study 301 and 30 mg BID and 60 mg QD in Study 303) compared with placebo and were statistically significant after multiplicity adjustment.

<div style=\"page-break-after: always\"></div>

Table 35: Change from baseline in mean monthly headache days across the 12-week treatment period: individual studies 3101-301-002 and 3101-303-002 (OTHE population)

|                      |                 | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-303-002 (CM)   | Study3101-303-002 (CM)   | Study3101-303-002 (CM)   |
|----------------------|-----------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                      | Statistic       | Placebo                  | Atogepant 10 mgQD        | Atogepant 30 mgQD        | Atogepant 60 mgQD        | Placebo                  | Atogepant 30mgBID        | Atogepant 60 mgQD        |
| Baselinenumberofdays | N               | 216                      | 216                      | 224                      | 226                      | 249                      | 254                      | 257                      |
|                      | Mean (SD)       | 8.45 (2.550)             | 8.43 (2.754)             | 8.78 (2.615)             | 8.99 (2.577)             | 21.42 (4.111)            | 21.17 (4.145)            | 21.54 (4.323)            |
| Changefrombaseline   | LS mean (SE)    | -2.52 (0.225)            | -3.94 (0.224) -1.42      | -4.03 (0.220) -1.51      | -4.17 (0.219)            | -5.17 (0.403)            | -7.32 (0.399)            | -6.90 (0.399)            |
| Atogepant vs.placebo | LSMD            |                          |                          |                          | -1.65                    |                          | -2.14                    | -1.72                    |
| Atogepant vs.placebo | ID%S6           |                          | -2.03,-0.81              | -2.11,-0.91              | -2.25,-1.04              |                          | -3.20,-1.09              | -2.78,-0.67              |
| Atogepant vs.placebo | Nominalp-value  |                          | <0.0001                  | <0.0001                  | <0.0001                  |                          | <0.0001                  | 0.0014                   |
| Atogepant vs.placebo | Adjustedp-value |                          | <0.0001                  | <0.0001                  | <0.0001                  |                          | 0.0002                   | 0.0024                   |

BID=twice daily,CI=confidenceinterval;CM=chronicmigraine;EM=episodicmigraine;LS=least squares;LSMD=least squares mean difference;OTHE=off-treatment hypothetical estimand;QD=oncedaily;SD=standarddeviation;SE=standarderror

Source:Study3101-301-002CSR,Table14.2-2.2andTable14.2-1.1.BandStudy3101-303-002CSR,Table14.2-3.1.2andTable14.2-1.2

## Secondary Efficacy Endpoint [S2]

Change from Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week DBT Period

In both studies, greater reductions from baseline in mean monthly acute medication use days across the 12-week treatment period were observed for each of the atogepant doses (10 mg, 30 mg, and 60 mg QD in  Study  301  and  30  mg  BID  and  60  mg  QD  in  Study  303)  compared  with  placebo  and  were statistically significant after multiplicity adjustment.

Table 36: change from baseline in mean monthly acute medication use days across the 12week treatment period: individual studies 3101-301-002 and 3101-303-002 (OTHE population)

|                       |                 | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-303-002 (CM)   | Study3101-303-002 (CM)   | Study3101-303-002 (CM)   |
|-----------------------|-----------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                       | Statistic       | Placebo                  | Atogepant 10 mg QD       | Atogepant 30 mg QD       | Atogepant 60 mg QD       | Placebo                  | Atogepant 30mgBID        | Atogepant 60 mg QD       |
| Baselinenumberof days | N               | 216                      | 216                      | 224                      | 226                      | 249 15.31                | 254                      | 257 15.45                |
|                       | Mean (SD)       | 6.50 (3.152)             | 6.58 (2.989)             | 6.66 (3.050)             | 6.88 (3.151)             | (7.048)                  | 14.53 (7.223)            | (7.363)                  |
| Changefrombaseline    | LS mean (SE)    | -2.34 (0.184)            | -3.68 (0.183) -1.34      | -3.65 (0.181) -1.31      | -3.78 (0.180) -1.44      | -4.09 (0.389)            | -6.61 (0.388)            | -6.19 (0.383) -2.09      |
| Atogepantvs.placebo   | LSMD            |                          |                          |                          |                          |                          | -2.52                    |                          |
| Atogepantvs.placebo   | ID%S6           |                          | -1.84, -0.84             | -1.81,-0.82              | -1.93,-0.94              |                          | -3.52,-1.53              | -3.09,-1.10              |
| Atogepantvs.placebo   | Nominalp-value  |                          | <0.0001                  | <0.0001                  | <0.0001                  |                          | <0.0001                  | <0.0001                  |
| Atogepantvs.placebo   | Adjustedp-value |                          | <0.0001                  | <0.0001                  | <0.0001                  |                          | 0.0002                   | 0.0024                   |

BID=twice daily;CI=confidence interval;CM=chronicmigraine;EM=episodicmigraine;LS=least squares;LSMD=least squares mean difference;OTHE=off-treatment hypothetical estimand;QD=oncedaily,SD=standarddeviation;SE=standard error

Source:Study3101-301-002CSR,Table14.2-2.5andTable14.2-1.1.BandStudy3101-303-002CSR,Table14.2-3.2.2andTable14.2-1.2

## Secondary Efficacy Endpoint [S3]

## At Least a 50% Reduction in 3-Month Average of Monthly Migraine Days

In both studies, the proportion of participants with at least a 50% reduction from baseline in mean monthly migraine days across the 12-week treatment period was greater for each of the atogepant doses (10 mg, 30 mg, and 60 mg QD in Study 301 and 30 mg BID and 60 mg QD in Study 303) compared with placebo, and was statistically significant after multiplicity adjustment.

<div style=\"page-break-after: always\"></div>

Table 37 : Reduction of ≥ 50% in 3-month average of monthly migraine days: individual studies 3101-301-002 and 3101-303-002 (OTHE population)

|                     |                 | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-301-002 (EM)   | Study3101-303-002 (CM)   | Study3101-303-002 (CM)   | Study3101-303-002 (CM)   |
|---------------------|-----------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                     | Statistic       | Placebo                  | Atogepant 10 mgQD        | Atogepant 30 mgQD        | Atogepant 60 mgQD        | Placebo                  | Atogepant 30 mg BID      | Atogepant 60 mgQD        |
|                     | N               | 216                      | 216                      | 224                      | 226                      | 249                      | 254                      | 257                      |
| Responders          | (%) u           | 63 (29.2)                | 118 (54.6)               | 131 (58.5)               | 134 (59.3)               | 66 (26.5)                | 107 (42.1)               | 103 (40.1)               |
| Atogepantvs.placebo | Oddsratio       |                          | 2.91                     | 3.46                     | 3.55                     |                          | 2.03                     | 1.90                     |
| Atogepantvs.placebo | ID%56           |                          | 1.95,4.33                | 2.32,5.14                | 2.39,5.28                |                          | 1.38,2.98                | 1.29,2.79                |
| Atogepantvs.placebo | Nominal p-value |                          | <0.0001                  | <0.0001                  | <0.0001                  |                          | 0.0003                   | 0.0011                   |
| Atogepantvs.placebo | Adjustedp-value |                          | <0.0001                  | ≤0.0001                  | <0.0001                  |                          | 0.0006                   | 0.0024                   |

BID=twice daily;CI=confidence interval;CM=chronicmigraine;EM=episodicmigraine;LS=least squares;LSMD=least squares mean difference;OTHE=off-treatment hypothetical estimand;QD=oncedaily,SD=standarddeviation;SE=standard error

Source:Study3101-301-002Table14.2-2.8andTable14.2-1.1.BandStudy3101-303-002CSR,Table14.2-3.3.2andTable14.2-1.2

## Time Course of Efficacy

## Efficacy Across the 12-Week Treatment Period by 4-Week Interval

The time course of efficacy based on the least square mean change from baseline in the number of MDs during  DBT  in  Studies  301  and  303  is  presented  in  the  figure  below.  In  both  studies,  each  of  the atogepant doses (10 mg, 30 mg, and 60 mg QD in EM Study 301 and 30 mg BID and 60 mg QD in CM Study  303)  separate  from  placebo,  starting  with  the  first  month  of  treatment  (Weeks  1  to  4),  and provided similar reductions in the number of monthly migraine days during the 12-week BDT. In Study 301, a dose-response relationship was evident, particularly during the first month, with the atogepant 60 mg QD dose providing a numerically greater reduction in the number of monthly migraine days than the 10 mg and 30 mg QD doses.

<div style=\"page-break-after: always\"></div>

Figure 8: Least square mean (± SE) of change from baseline in number of monthly migraine days (MMRM) during the double-blind treatment period - individual studies 3101-301-002 and 3101-303-002 (OTHE population)

Study 3101-301-002 (EM)

<!-- image -->

Study 3101-303-002 (CM)

<!-- image -->

BID = twice daily; CM = chronic migraine; EM = episodic migraine; MMRM = mixed-effects model for repeated measures; OTHE = off-reatment hypothetical estimand; QD = once daily; SE = Standard Eror

Source: Shudy 3101-301-002 CSR, Figuue 14.2-1.1B and Study 3101-303-002 CSR, Figue 14.2-2.1.2

## Additional Health Outcomes Measures

A number of additional health outcomes measures were common to both Studies 301 and 303, including the Patient Global Impression of Change (PGIC), Patient Satisfaction with Study Medication (PSSM), Work Productivity and Activity Impairment Questionnaire: Migraine v2.0 (WPAI:MIGRAINE), Migraine Disability Assessment (MIDAS), Patient Global Impression of Severity (PGI-S), and Activity Level and Limitation. In addition, the MSQ v2.1, AIM-D, and HIT-6 were also administered at multiple time points in the study to construct additional endpoints.

Overall, results for these additional health outcomes measures were consistent with the results of the primary and secondary efficacy endpoints for both studies, with numerically greater improvements or greater  reductions  (i.e.,  improvement)  from  baseline  observed  for  each  of  the  atogepant  treatment groups compared with placebo for the majority of measures.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup Analyses

Subgroup analyses were conducted by age, sex, race, baseline BMI, baseline monthly MDs, exposure to migraine prevention medication with proven efficacy, and migraine prevention medication failures for the EM and CM studies. Specifically for Study 303, further subgroup analyses were conducted by region, acute  medication  overuse,  current  use  of  migraine  prevention  medication  for  the  primary  efficacy endpoint and each of the 3 clinical secondary efficacy endpoints.

## Subgroup Analysis per Baseline Monthly MDs

In the total pooled population across Studies 301 and MD-01 (atogepant QD and placebo treatment groups), baseline monthly migraine days was &lt; 8 days for 54.2% of participants and ≥ 8 days for 45.8% of participants.

Figure 9: Forest plot of subgroup analysis for change from baseline in mean monthly migraine days across the 12-week treatment period by baseline monthly migraine days pooled studies 301 and md-01 (efficacy analysis population)

## Pooled Studies 3101-301-002 and CGP-MID-01 (EM)

<!-- image -->

Estimate of LS Mean Differelce (95% CI) of Change from baseline in mean monthly migrnine days across the 12-week treatment period

In Study 303 (atogepant 30 mg BID, atogepant 60 mg QD, and placebo treatment groups), the mean baseline number of migraine days was 18.9 days. For CM Study 303, although a numerically greater treatment effect was observed for participants with baseline monthly migraine days &lt; 18 days compared with participants with baseline monthly migraine days ≥ 18 days, the 95% CIs overlapped.

<div style=\"page-break-after: always\"></div>

Figure 10: Forest plot of subgroup analysis for change from baseline in mean monthly migraine days across the 12-week treatment period by baseline monthly migraine days study 303 (efficacy analysis population)

## Study 3101-303-002 (CM)

<!-- image -->

Estimate of LS Mean Difference (95% Cl) of Change from baseline in mean monthly migraine days across the 12-week treatment period

CI = confidence interval; CM = chronic migraine; EM = episodic migraine; LS = least squares; mITT = modified intent-ot-treat; N1 = treatment, N2 = placebo; OTHE = off-treatment hypothetical estimand The efficacy amalysis population is defined as the 0THE population for Studies 3101-301-002 and 3101-303-002 and the mITT population for Shudy CGP-MD-01.

## Study 303 - Subgroup Analysis per Acute Medication Overuse

Both atogepant doses showed numerical improvement compared with placebo for the primary efficacy endpoint in participants with acute medication overuse and those without.

Figure 11: Forest plot of subgroup analysis for change from baseline in mean monthly migraine days across the 12-week treatment period by acute medication overuse status study 303 (OTHE population)

<!-- image -->

Estimate of LS Mean Difference (95% Cl) of Change from baseline in mean monthly migraine days across the 12-week treatment period

BID = twice daily; CI = confidence interval; LS = least squares; N1 = treatment; N2 = placebo; OTHE =off-treatment hypothetical estimand; QD = once daily

Study 303 - Subgroup Analysis per Current Preventive Medication Use

<div style=\"page-break-after: always\"></div>

Both atogepant doses showed numerical improvement compared with placebo for the primary efficacy endpoint in participants with preventive medication current use and those without. A numerically greater treatment effect was observed for current users of preventive medications in the atogepant 30 mg BID treatment  group  compared  with  the  atogepant  60  mg  QD  treatment  group,  however  the  95%  CIs overlapped for the 2 treatment groups.

Figure 12: Forest plot of subgroup analysis for change from baseline in mean monthly migraine days across the 12-week treatment period by preventive medication current use status - study 303 (OTHE population)

<!-- image -->

Estimate of LS MeanDifferenoe(95%CIj of Change from baselint inmean monthly migraine days across the 12-week Ireatmenl period

BID = twice daily; CI= confidence interval; LS = least squares; N1 = treatment; N2 = placebo; OTHE = off-treatment hypothetical estimand; QD = once daily

## · Summary of main efficacy results

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 38: Summary of efficacy for trial 3101-301-002

| Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)   | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)                                                                                                                                               | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)                                                                                                                                               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                         | 3101-301-002, NCT03777059                                                                                                                                                                                                                                                                                                                                                                            | 3101-301-002, NCT03777059                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                   | Phase 3, US multicentre, randomised, placebo-controlled, parallel group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (EM). Participants were randomised to 1 of 4 treatment groups (placebo, atogepant 10 mg, atogepant 30 mg, and atogepant 60 mg, administered once daily) in a 1:1:1:1 ratio. | Phase 3, US multicentre, randomised, placebo-controlled, parallel group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (EM). Participants were randomised to 1 of 4 treatment groups (placebo, atogepant 10 mg, atogepant 30 mg, and atogepant 60 mg, administered once daily) in a 1:1:1:1 ratio. |
|                                                                                                                                                                                                                                                          | Durationofmainphase:Durati onofRun- inphase:DurationofExtension phase:                                                                                                                                                                                                                                                                                                                               | 12-week double-blind treatment (DBT) 4-week screening and baseline period 4-week safety follow-up                                                                                                                                                                                                                                                                                                    |
| Hypothesis                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                                                                                                                          | Superiority                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)   | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)                                                                                                                                                                                                                                                                       | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)                                                                                                                                                                                                                                                                       | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)                                                                                                                                                                                                                                                                       | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)                                                                                                                                                                                                                                                                       | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)                                                                                                                                                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                         | 3101-301-002, NCT03777059                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3101-301-002, NCT03777059                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3101-301-002, NCT03777059                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3101-301-002, NCT03777059                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3101-301-002, NCT03777059                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Treatments groups                                                                                                                                                                                                                                        | Placebo (PBO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Placebo (PBO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| (Total N=910                                                                                                                                                                                                                                             | Atogepant (AGP) 10 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Atogepant (AGP) 10 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| randomised (ITT);                                                                                                                                                                                                                                        | Atogepant (AGP) 30 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Atogepant (AGP) 30 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 224                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 224                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 224                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| OTHE Population                                                                                                                                                                                                                                          | Atogepant (AGP) 60 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Atogepant (AGP) 60 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 226                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 226                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 226                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| N=882) Endpoints and definitions, with Multiplicity Adjustment                                                                                                                                                                                           | Primary endpoint (P1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | MD reduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Change from baseline in mean monthly migraine days (MD) across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                  | Change from baseline in mean monthly migraine days (MD) across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                  | Change from baseline in mean monthly migraine days (MD) across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                          | Secondary endpoint (S1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | HD reduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Change from baseline in mean monthly headache days                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | (HD) across the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12-week                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                          | Secondary endpoint (S2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Acute medication use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | treatment period Change from baseline in mean monthly acute medication use days across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                          | treatment period Change from baseline in mean monthly acute medication use days across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                          | treatment period Change from baseline in mean monthly acute medication use days across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                          | Secondary endpoint (S3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Responder, > 50% MD reduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | > 50% reduction in 3-month average of monthly migraine days                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | > 50% reduction in 3-month average of monthly migraine days                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | > 50% reduction in 3-month average of monthly migraine days                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Database lock                                                                                                                                                                                                                                            | 06 July 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 06 July 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 06 July 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 06 July 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 06 July 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Results and Analysis Analysis description Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT                                                                                                                              | Results and Analysis Analysis description Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                  | Results and Analysis Analysis description Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                  | Results and Analysis Analysis description Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                  | Results and Analysis Analysis description Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                  | Results and Analysis Analysis description Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                  |
| Analysis population and timepoint description                                                                                                                                                                                                            | OTHE population: all randomised participants who received at least 1 dose of study intervention, had an evaluable baseline period of eDiary data, and had at least 1 evaluable post-baseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to 12) of eDiary data during the study, regardless of whether on study treatment or off study treatment. The primary and key secondary endpoints are the same for the US and the EU. The primary estimand in support of the EU filing is the off-treatment hypothetical estimand (OTHE). | OTHE population: all randomised participants who received at least 1 dose of study intervention, had an evaluable baseline period of eDiary data, and had at least 1 evaluable post-baseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to 12) of eDiary data during the study, regardless of whether on study treatment or off study treatment. The primary and key secondary endpoints are the same for the US and the EU. The primary estimand in support of the EU filing is the off-treatment hypothetical estimand (OTHE). | OTHE population: all randomised participants who received at least 1 dose of study intervention, had an evaluable baseline period of eDiary data, and had at least 1 evaluable post-baseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to 12) of eDiary data during the study, regardless of whether on study treatment or off study treatment. The primary and key secondary endpoints are the same for the US and the EU. The primary estimand in support of the EU filing is the off-treatment hypothetical estimand (OTHE). | OTHE population: all randomised participants who received at least 1 dose of study intervention, had an evaluable baseline period of eDiary data, and had at least 1 evaluable post-baseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to 12) of eDiary data during the study, regardless of whether on study treatment or off study treatment. The primary and key secondary endpoints are the same for the US and the EU. The primary estimand in support of the EU filing is the off-treatment hypothetical estimand (OTHE). | OTHE population: all randomised participants who received at least 1 dose of study intervention, had an evaluable baseline period of eDiary data, and had at least 1 evaluable post-baseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to 12) of eDiary data during the study, regardless of whether on study treatment or off study treatment. The primary and key secondary endpoints are the same for the US and the EU. The primary estimand in support of the EU filing is the off-treatment hypothetical estimand (OTHE). |
| Descriptive statistics and estimate variability                                                                                                                                                                                                          | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | PBO, N=216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Atogepant 10 mg QD, N=216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Atogepant 30 mg QD, N=224                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Atogepant 60 mg QD, N=226                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                          | Baseline number of monthly MDs, Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 7.53 (2.394)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 7.46 (2.466)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 7.86 (2.311)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 7.75 (2.334)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                          | LS Mean (SE) change from baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | -2.47 (0.210)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -3.69 (0.209)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -3.85 (0.206)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -4.14 (0.205)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                          | LSMD (95% CI) Atogepant vs. Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -1.22 (-1.79, -0.65)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -1.38 (-1.94, -0.81)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -1.66 (-2.23, -1.10)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                          | Adjusted p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | <.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | <.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Analysis description Secondary endpoint (S1): Change from baseline in mean monthly headache days (HD) across the 12-week DBT                                                                                                                             | Analysis description Secondary endpoint (S1): Change from baseline in mean monthly headache days (HD) across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                 | Analysis description Secondary endpoint (S1): Change from baseline in mean monthly headache days (HD) across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                 | Analysis description Secondary endpoint (S1): Change from baseline in mean monthly headache days (HD) across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                 | Analysis description Secondary endpoint (S1): Change from baseline in mean monthly headache days (HD) across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                 | Analysis description Secondary endpoint (S1): Change from baseline in mean monthly headache days (HD) across the 12-week DBT                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability                                                                                                                                                                                                          | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | PBO N=216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Atogepant 10 mg QD N=216                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Atogepant 30 mg QD N=224                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Atogepant 60 mg QD N=226                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                          | Baseline number of monthly HDs, Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 8.45 (2.550)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 8.43 (2.754)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 8.78 (2.615)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 8.99 (2.577)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                          | LS Mean (SE) change from baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | -2.52 (0.225)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -3.94 (0.224)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -4.03 (0.220)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -4.17 (0.219)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Study identifier                                                                                                                                 | Episodic Migraine (ADVANCE) 3101-301-002, NCT03777059                                                                                            | Episodic Migraine (ADVANCE) 3101-301-002, NCT03777059                                                                                            | Episodic Migraine (ADVANCE) 3101-301-002, NCT03777059                                                                                            | Episodic Migraine (ADVANCE) 3101-301-002, NCT03777059                                                                                            | Episodic Migraine (ADVANCE) 3101-301-002, NCT03777059                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                 | LSMD (95% CI) Atogepant vs. Placebo Adjusted                                                                                                     |                                                                                                                                                  | -1.42 (-2.03, -0.81) <.0001                                                                                                                      | -1.51 (-2.11, -0.91) <.0001                                                                                                                      | -1.65 (-2.25, -1.04) <.0001                                                                                                                      |
| p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly Acute Medication (Mx) Use Days across the 12-week DBT | p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly Acute Medication (Mx) Use Days across the 12-week DBT | p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly Acute Medication (Mx) Use Days across the 12-week DBT | p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly Acute Medication (Mx) Use Days across the 12-week DBT | p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly Acute Medication (Mx) Use Days across the 12-week DBT | p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly Acute Medication (Mx) Use Days across the 12-week DBT |
| Descriptive statistics and estimate variability                                                                                                  | Treatment group                                                                                                                                  | PBO N=216                                                                                                                                        | Atogepant 10 mg QD N=216                                                                                                                         | Atogepant 30 mg QD N=224                                                                                                                         | Atogepant 60 mg QD N=226                                                                                                                         |
| Descriptive statistics and estimate variability                                                                                                  | Baseline No. of monthly Acute Mx Use Days, Mean (SD)                                                                                             | 6.50 (3.152)                                                                                                                                     | 6.58 (2.989)                                                                                                                                     | 6.66 (3.050)                                                                                                                                     | 6.88 (3.151)                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                  | LS Mean (SE) change from baseline                                                                                                                | -2.34 (0.184)                                                                                                                                    | -3.68 (0.183)                                                                                                                                    | -3.65 (0.181)                                                                                                                                    | -3.78 (0.180)                                                                                                                                    |
| Descriptive statistics and estimate variability                                                                                                  | LSMD (95% CI) Atogepant vs. Placebo                                                                                                              |                                                                                                                                                  | -1.34 (-1.84, -0.84)                                                                                                                             | -1.31 (-1.81, -0.82)                                                                                                                             | -1.44 (-1.93, -0.94)                                                                                                                             |
| Descriptive statistics and estimate variability                                                                                                  | Adjusted p-value                                                                                                                                 |                                                                                                                                                  | <.0001                                                                                                                                           | <.0001                                                                                                                                           | <.0001                                                                                                                                           |
| Analysis description Secondary endpoint (S3): > 50% reduction in 3-month average of monthly MDs                                                  | Analysis description Secondary endpoint (S3): > 50% reduction in 3-month average of monthly MDs                                                  | Analysis description Secondary endpoint (S3): > 50% reduction in 3-month average of monthly MDs                                                  | Analysis description Secondary endpoint (S3): > 50% reduction in 3-month average of monthly MDs                                                  | Analysis description Secondary endpoint (S3): > 50% reduction in 3-month average of monthly MDs                                                  | Analysis description Secondary endpoint (S3): > 50% reduction in 3-month average of monthly MDs                                                  |
| Descriptive statistics and estimate variability                                                                                                  | Treatment group                                                                                                                                  | PBO N=216                                                                                                                                        | Atogepant 10 mg QD N=216                                                                                                                         | Atogepant 30 mg QD N=224                                                                                                                         | Atogepant 60 mg QD N=226                                                                                                                         |
| Descriptive statistics and estimate variability                                                                                                  | Responders, n (%)                                                                                                                                | 63 (29.2)                                                                                                                                        | 118 (54.6)                                                                                                                                       | 131 (58.5)                                                                                                                                       | 134 (59.3)                                                                                                                                       |
| Descriptive statistics and estimate variability                                                                                                  | Odds ratio (95% CI), Atogepant vs. Placebo                                                                                                       |                                                                                                                                                  | 2.91 (1.95, 4.33)                                                                                                                                | 3.46 (2.32, 5.14)                                                                                                                                | 3.55 (2.39, 5.28)                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                  | Adjusted p-value                                                                                                                                 |                                                                                                                                                  | <.0001                                                                                                                                           | <.0001                                                                                                                                           | <.0001                                                                                                                                           |
| Notes                                                                                                                                            | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error        | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error        | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error        | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error        | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error        |

Table 39: Summary of efficacy for trial 3101-303-002

| Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine (PROGRESS)   | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine (PROGRESS)                                                                                                                                                                                 | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine (PROGRESS)                                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                           | 3101-303-002; EudraCT 2018-004337-32; NCT03855137                                                                                                                                                                                                                                                                                                                                                        | 3101-303-002; EudraCT 2018-004337-32; NCT03855137                                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                     | Phase 3, multicentre, randomised, placebo-controlled, parallel group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine (CM). Participants were randomised to 1 of 3 treatment arms (placebo, atogepant 30 mg BID, atogepant 60 mg QD) in a 1:1:1 ratio. 142 sites in US, Canada, Europe, Russia, East Asia (Korea, Japan, China, Taiwan) | Phase 3, multicentre, randomised, placebo-controlled, parallel group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine (CM). Participants were randomised to 1 of 3 treatment arms (placebo, atogepant 30 mg BID, atogepant 60 mg QD) in a 1:1:1 ratio. 142 sites in US, Canada, Europe, Russia, East Asia (Korea, Japan, China, Taiwan) |
|                                                                                                                                                                                                                            | Durationofmainphase:Durati onofRun- inphase:DurationofExtension                                                                                                                                                                                                                                                                                                                                          | 12-week double-blind treatment (DBT) 4-week screening and baseline period 4-week safety follow-up                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine   | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine                                                                                                                                                                                                                                                                                                                                                             | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine                                                                                                                                                                                                                                                                                                                                                             | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine                                                                                                                                                                                                                                                                                                                                                             | Title: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Chronic Migraine                                                                                                                                                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                | 3101-303-002; EudraCT 2018-004337-32; NCT03855137 phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3101-303-002; EudraCT 2018-004337-32; NCT03855137 phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3101-303-002; EudraCT 2018-004337-32; NCT03855137 phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3101-303-002; EudraCT 2018-004337-32; NCT03855137 phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                                                      | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Treatments groups                                                                                                                                                                                               | Placebo (PBO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Placebo (PBO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 249                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 249                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| (Total N=778 randomised (ITT); OTHE Population                                                                                                                                                                  | Atogepant (AGP) 30 mg BID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Atogepant (AGP) 30 mg BID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 254                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 254                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| (Total N=778 randomised (ITT); OTHE Population                                                                                                                                                                  | Atogepant (AGP) 60 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Atogepant (AGP) 60 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 257                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 257                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| N=760) Endpoints and definitions, with Multiplicity Adjustment                                                                                                                                                  | Primary endpoint (P1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | MD reduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Change from baseline in mean monthly migraine days (MD) across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Change from baseline in mean monthly migraine days (MD) across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| N=760) Endpoints and definitions, with Multiplicity Adjustment                                                                                                                                                  | Secondary endpoint (S1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | HD reduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Change from baseline in mean monthly headache days (HD) across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Change from baseline in mean monthly headache days (HD) across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| N=760) Endpoints and definitions, with Multiplicity Adjustment                                                                                                                                                  | Secondary endpoint (S2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Acute medication use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Change from baseline in mean monthly acute medication use days across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Change from baseline in mean monthly acute medication use days across the 12-week treatment period                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| N=760) Endpoints and definitions, with Multiplicity Adjustment                                                                                                                                                  | Secondary endpoint (S3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Responder, > 50% MD reduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | > 50% reduction in 3-month average of monthly migraine days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | > 50% reduction in 3-month average of monthly migraine days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Database lock                                                                                                                                                                                                   | 21 April 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21 April 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21 April 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21 April 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Results and Analysis                                                                                                                                                                                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Analysis description                                                                                                                                                                                            | Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT OTHE population: all randomised participants who received at least 1 dose of intervention, had an evaluable baseline period of eDiary data, and had least 1 evaluable post-baseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to of eDiary data during the study, regardless of whether on study treatment off study treatment. primary and key secondary endpoints are the same for the US and the The primary estimand in support of the EU filing is the off-treatment estimand (OTHE). | Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT OTHE population: all randomised participants who received at least 1 dose of intervention, had an evaluable baseline period of eDiary data, and had least 1 evaluable post-baseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to of eDiary data during the study, regardless of whether on study treatment off study treatment. primary and key secondary endpoints are the same for the US and the The primary estimand in support of the EU filing is the off-treatment estimand (OTHE). | Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT OTHE population: all randomised participants who received at least 1 dose of intervention, had an evaluable baseline period of eDiary data, and had least 1 evaluable post-baseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to of eDiary data during the study, regardless of whether on study treatment off study treatment. primary and key secondary endpoints are the same for the US and the The primary estimand in support of the EU filing is the off-treatment estimand (OTHE). | Primary endpoint: Change from baseline in mean monthly MDs across the 12-week DBT OTHE population: all randomised participants who received at least 1 dose of intervention, had an evaluable baseline period of eDiary data, and had least 1 evaluable post-baseline 4-week period (Weeks 1 to 4, 5 to 8, 9 to of eDiary data during the study, regardless of whether on study treatment off study treatment. primary and key secondary endpoints are the same for the US and the The primary estimand in support of the EU filing is the off-treatment estimand (OTHE). |
| Analysis population and timepoint description                                                                                                                                                                   | study at 12) or The EU. hypothetical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | study at 12) or The EU. hypothetical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | study at 12) or The EU. hypothetical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | study at 12) or The EU. hypothetical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability                                                                                                                                                                 | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | PBO N=249                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Atogepant 30 mg BID N=254                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Atogepant 60 mg QD N=257                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                                                                 | Baseline number of monthly MDs, Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 19.0 (4.80)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 18.6 (5.09)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 19.2 (5.29)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                                                                 | LS Mean (SE) change from baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -5.09 (0.409)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | -7.33 (0.406)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | -6.75 (0.406)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability                                                                                                                                                                 | LSMD (95% CI) Atogepant vs. Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | -2.24 (-3.31, -1.16)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -1.66 (-2.72, -0.59)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability                                                                                                                                                                 | Adjusted p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.0024                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Analysis description Secondary endpoint (S1): Change from baseline in mean monthly                                                                                                                              | Analysis description Secondary endpoint (S1): Change from baseline in mean monthly                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Analysis description Secondary endpoint (S1): Change from baseline in mean monthly                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Analysis description Secondary endpoint (S1): Change from baseline in mean monthly                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Analysis description Secondary endpoint (S1): Change from baseline in mean monthly                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability                                                                                                                                                                 | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | PBO N=249                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Atogepant 30 mg BID N=254                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Atogepant 60 mg QD N=257                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                                                                 | Baseline number of monthly HDs, Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 21.4 (4.11)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 21.2 (4.15)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 21.5 (4.32)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                                                                 | LS Mean (SE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -5.17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -7.32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -6.90                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Study identifier                                                                                                                                 | 3101-303-002; EudraCT 2018-004337-32; NCT03855137                                                                                                | 3101-303-002; EudraCT 2018-004337-32; NCT03855137                                                                                                | 3101-303-002; EudraCT 2018-004337-32; NCT03855137                                                                                                | 3101-303-002; EudraCT 2018-004337-32; NCT03855137                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                 | change from baseline                                                                                                                             | (0.403)                                                                                                                                          | (0.399) -2.14 (-3.20, -1.09)                                                                                                                     | (0.399)                                                                                                                                          |
| p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly acute medication (Mx) use days across the 12-week DBT | p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly acute medication (Mx) use days across the 12-week DBT | p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly acute medication (Mx) use days across the 12-week DBT | p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly acute medication (Mx) use days across the 12-week DBT | p-value Analysis description Secondary endpoint (S2): Change from baseline in mean monthly acute medication (Mx) use days across the 12-week DBT |
| Descriptive statistics and estimate variability                                                                                                  | Treatment group                                                                                                                                  | PBO N=249                                                                                                                                        | Atogepant 30 mg BID N=254                                                                                                                        | Atogepant 60 mg QD N=257                                                                                                                         |
| Descriptive statistics and estimate variability                                                                                                  | Baseline No. of monthly acute Mx use days, Mean (SD)                                                                                             | 15.3 (7.05)                                                                                                                                      | 14.5 (7.22)                                                                                                                                      | 15.5 (7.36)                                                                                                                                      |
| Descriptive statistics and estimate variability                                                                                                  | LS Mean (SE) change from baseline                                                                                                                | -4.09 (0.389)                                                                                                                                    | -6.61 (0.388)                                                                                                                                    | -6.19 (0.383)                                                                                                                                    |
| Descriptive statistics and estimate variability                                                                                                  | LSMD (95% CI) Atogepant vs. Placebo                                                                                                              |                                                                                                                                                  | -2.52 (-3.52, -1.53)                                                                                                                             | -2.09 (-3.09, -1.10)                                                                                                                             |
| Descriptive statistics and estimate variability                                                                                                  | Adjusted p-value                                                                                                                                 |                                                                                                                                                  | 0.0002                                                                                                                                           | 0.0024                                                                                                                                           |
| Analysis description Secondary endpoint (S3): > 50% Reduction in 3-month average of monthly migraine days                                        | Analysis description Secondary endpoint (S3): > 50% Reduction in 3-month average of monthly migraine days                                        | Analysis description Secondary endpoint (S3): > 50% Reduction in 3-month average of monthly migraine days                                        | Analysis description Secondary endpoint (S3): > 50% Reduction in 3-month average of monthly migraine days                                        | Analysis description Secondary endpoint (S3): > 50% Reduction in 3-month average of monthly migraine days                                        |
| Descriptive statistics and estimate variability                                                                                                  | Treatment group                                                                                                                                  | PBO N=249                                                                                                                                        | Atogepant 30 mg BID N=254                                                                                                                        | Atogepant 60 mg QD N=257                                                                                                                         |
| Descriptive statistics and estimate variability                                                                                                  | Responders, n (%)                                                                                                                                | 66 (26.5)                                                                                                                                        | 107 (42.1)                                                                                                                                       | 103 (40.1)                                                                                                                                       |
| Descriptive statistics and estimate variability                                                                                                  | Odds ratio (95% CI), Atogepant vs. Placebo                                                                                                       |                                                                                                                                                  | 2.03 (1.38, 2.98)                                                                                                                                | 1.90 (1.29, 2.79)                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                  | Adjusted p-value                                                                                                                                 |                                                                                                                                                  | 0.0006                                                                                                                                           | 0.0024                                                                                                                                           |
| Notes                                                                                                                                            | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error        | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error        | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error        | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error        |

## · Supportive study

## Persistence of Efficacy

The long-term studies of atogepant for the preventive treatment of migraine in participants with CM are ongoing. No study results are available.

The long-term efficacy of atogepant for the preventive treatment of migraine in participants with EM was evaluated in Study 3101-302-002.

<div style=\"page-break-after: always\"></div>

## Long-term Study 302 in EM

## A Phase 3, Multi-centre, Randomised, Open-Label Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants with Episodic Migraine (Study 3101-302-002)

Study 302 was a multi-centre, randomised, open-label, 52-week, long-term safety study conducted at 111 centres in the United States (111 centres screened participants and 106 centres randomised at least 1 participant). Participants were randomised in a 5:2 ratio to one of the following treatment groups:

- atogepant 60 mg once daily (n = 546) or
- oral SOC migraine preventive medication (n = 198).

All  participants  randomised  to  oral  SOC  migraine  preventive  medication  were  treated  with  an  oral medication recognised as safe and effective for the preventive treatment of migraine.

The following 2 groups of participants were eligible to participate in this study:

- De Novo Participants : participants with no previous exposure to atogepant and who met the inclusion criteria and did not meet the exclusion criteria
- Study MD-01 Completers :  participants  who  completed  Study  CGP-MD-01 (Visit  8)  without significant protocol deviations (e.g., noncompliance to protocol required procedures) and who met the inclusion criteria and did not meet the exclusion criteria

Study MD-01 Completers experienced a gap of at least 6 months from the time of completion of Study MD-01 to the start of this long-term safety study. Thus, they had to re-establish study eligibility and had their baseline migraine days re-established (completed at least 20 out of 28 days in the eDiary) during the  screening  period  (but  the  migraine  days  were  not  used  as  inclusion/exclusion  criteria  for randomisation).

Of  the  543  participants  in  the  atogepant  group  for  the  safety  population,  428  participants  and  362 participants received atogepant for at least 180 days and at least 360 days, respectively.

Efficacy  endpoints  for  long-term  efficacy  evaluation  were  not  classified  as  primary,  secondary,  or additional. Efficacy variables include frequency of migraine days, headache days, acute medication use days, and health outcomes assessments. All efficacy analyses were performed using the modified intent to treat (mITT) population, consisting of all randomised participants who received at least 1 dose of atogepant, had an evaluable baseline period of eDiary data and had at least 1 evaluable postbaseline 4week period of eDiary data. The mITT population was defined only for the atogepant arm, as no clinical efficacy measurements were collected from participants in the oral standard of care (SOC) migraine preventive medication arm. The purpose of the SOC arm is to collect comparative safety data for 52 weeks.

<div style=\"page-break-after: always\"></div>

Figure 13: Least square mean (±SE) of change from baseline in the number of monthly migraine days (MMRM) during the treatment period (mITT Population), study 302

<!-- image -->

MMRM=Mixed-effectsmodel forrepeatedmeasures,SE=Standarderror.

Themodelincludesvisit(derived asmonth)as a categorical fixedeffect,and thebaseline score,baseline-by-visit interaction ascovariates,withanunstructuredcovariancematrix.

## 2.6.6. Discussion on clinical efficacy

AbbVie Inc. has developed atogepant as an IR tablet in 2 dose strengths containing 10 mg, resp. 60 mg atogepant which is proposed to be indicated for prophylaxis of migraine in adults who have at least 4 migraine days (MD) per month. By using the broad term 'migraine' in the proposed indication wording, this is understood to comprise both episodic (EM, Episodic Migraine) and chronic (CM, Chronic migraine) forms of the disease. Another member of the gepant family (rimegepant) was recently approved for prophylactic  treatment  of  episodic  migraine.  Hence,  atogepant  is  introduced  as  the  first  orally administered CGRP antagonist for use across the full spectrum of migraine preventive treatment.

The clinical data package is comprehensive and adequate. It comprises phase II/III dose finding, pivotal efficacy/ safety studies in both the EM and CM population, and additional long-term tolerability studies, which also provide data to support maintenance of effect.

Primary evidence for efficacy is derived from 2 pivotal studies, Study 3101-301-002 ('Advance' study, conducted in the US) for EM prevention and Study 3101-303-002 ('Progress' study, conducted at 142 sites in the US, Europe, Russia, Japan, Korea and others) for the preventive treatment of CM. Additional supportive data are provided by dose-finding Study CGP-MD-01 for EM prophylaxis.

Furthermore, two long-term open-label studies in EM (Study 3101-302-002) [52-week duration] and Study  3101-309-002  [40-week  duration])  were  conducted.  Persistence  of  efficacy  data  in  EM  were obtained from long term study 302 including de novo participants and patients who completed dose finding Study CGP-MD-01. In long-term study 309, including rollover patients, who completed EM study 301, maintenance of effect was not recorded.

## Design and conduct of clinical studies

Studies 301 and 303 were 12-week, Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group studies comparing atogepant with placebo for the preventive treatment of migraine in

<div style=\"page-break-after: always\"></div>

participants with EM (Study 301; atogepant 10 mg, 30 mg, and 60 mg QD) and in participants with CM (Study 303; atogepant 30 mg BID and 60 mg QD). The primary efficacy endpoint in both studies was the change from baseline in mean monthly migraine days across the 12-week treatment period (DBT).

Essential  features  of  prevention  studies  301  and  303  are  accordant  with  EU  Guideline  provisions (CPMP/EWP/788/01  Rev.1).  The  frequency  of  migraine  attacks  is  documented  during  an  initial prospective  1-month  baseline  period.  Additionally,  eligible  subjects  had  to  present  with  pre-defined frequency of migraine attacks per month within the last 3 months prior to Screening visit. The doubleblind  treatment  period  covers  a  12  week  duration.  During  double-blind  treatment,  subjects  were randomised to receive either atogepant or placebo, an active control arm was not included. Large and highly variable placebo effects have been observed in past migraine prevention trials. Therefore, placebo control is indispensable. An active control arm would have provided added information to contextualise the  clinical  effect  of  the  test  medication,  however,  is  not  considered  essential  from  the  regulatory perspective.

The designs of studies 301 and 303 are similar. The major difference between the two studies lies in the target population (EM vs CM) and the atogepant dose range that was tested. While all once daily dose arms examined in dose finding study CGP-MD-01 (10 mg QD, 30 mg QD, 60 mg QD) were taken over into pivotal EM study 301, only the highest total daily dose of 60 mg atogepant (tested for the QD and BID dosing interval) was carried forward to the pivotal CM study 303. This may be explained by the expectation that higher dose requirements are given in the more severely affected CM population. In essence, however, the lower 10 and 30 mg daily doses were not tested in CM patients. The posology section  of  the  proposed  SmPC  does  not  differentiate  between  EM  and  CM.  The  general  dose recommendation is 60 mg atogepant per day. Only in case of concomitant use of either strong CYP3A4 inhibitors or strong OATP inhibitors and in patients with severe renal impairment the dose should be reduced to 10 mg QD.

Inclusion criteria applied throughout pivotal studies align with the standard ICHD-3 diagnostic criteria (ICHD-3, 2018). In EM study 301, a minimum number of 4 MDs per month at baseline is required for study eligibility. Subjects with medication overuse (triptans &gt; 10 days/month, or simple analgesics &gt; 15 days/month etc.) were excluded. Eligible EM patients must not have &gt; 15 headache days (HD) per month on average across the 3 month prior to Visit 1. Conversely, in CM study 303, a minimum number of &gt; 15 HDs per month during the 3-month prior to screening and during the 1-month baseline is required for study eligibility. During the baseline period, &gt; 8 of these have to qualify as a MD. Other than in EM study 301, subjects with medication overuse were not excluded in the CM population of study 303. Medication  overuse  is  prevalent  across  CM  patients.  Inclusion  of  medication  overuse  is  therefore considered to adequately reflect the target population.

Throughout pivotal studies 301 / 303 for prevention of EM resp. CM any medication to be taken for acute migraine attacks (incl. triptans, NSAIDs, acetaminophen etc.) was permissible. As concerns concomitant preventive migraine medication, there were differences between the EM and the CM study. While any medication with demonstrated efficacy for the prevention of migraine (e.g. amitriptyline, topiramate, propranolol etc.) was prohibited in EM study 301, participants of CM study 303 could take one preventive medication with demonstrated efficacy, provided that the dose has been stable for at least 12 weeks prior to Visit 1. Enrolment of participants with current use of a migraine prevention medication was capped  at  ~15%.  There  is  no  objection  against  allowing  concomitant  use  of  another  stably  dosed preventive medication on top of atogepant in study 303. This is considered to reflect clinical practice in the more severely affected CM population. At study entry, about 83% of CM subjects reported the use of preventive medication in the past.

In both studies, injectable monoclonal antibodies blocking the CGRP pathway (e.g., Aimovig, Emgality, Ajovy) within 6 months prior to Visit 1 and throughout the study period, were prohibited. It is unclear

<div style=\"page-break-after: always\"></div>

whether there is any space for further improvement in patients already receiving biological CGRP ABs. Exclusion of subjects with concomitant injectable CGRP antibodies is therefore acceptable.

Standard and clinically meaningful efficacy endpoints were tested. The change from baseline in mean monthly migraine days across the 12-week DBT was defined as primary endpoint. Further secondary endpoints were tested for superiority of atogepant over placebo while controlling for multiplicity in studies 301/303. The three most relevant was the change from baseline in mean monthly headache days across the 12-week DBT [S1], change from baseline in mean monthly acute medication use days across the 12week [S2 ], and ≥ 50% reduction in 3 -month average of monthly MDs as responder analysis [S3].

Factually, throughout dose finding study MD-01 and pivotal studies 301/303 identical efficacy endpoints were  applied  in  terms  of  migraine  resp.  headache  days.  Like  in  dose  finding  study  MD-01  (after implementation of SAP Addendum, 2019-04-11), migraine days (MD) in the narrow sense (per IHS Treatment Guideline) and probable migraine days (PMD) are grouped together and summarised into 'Migraine days' in the definition of the primary endpoint of studies 301/303.

Definition of a MD in the narrow sense combines criteria as laid down in the IHS Guidelines and diagnostic criteria ICHD-3. A minimum 2-hour headache duration was defined by the applicant for all phase II/III studies (unless acute medication was taken earlier). Therefore, it differs from IHS Guidelines of the International  Headache  Society  that  issued  two  guidance  documents  for  preventive  treatment  of migraine attacks: The first one for preventive treatment in CM patients (Tassorelli C et al. 2018), and the  second  one  for  preventive  treatment  in  EM  patients  (Diener  HC  et  al.  2020).  These  guidance documents specify different definitions of what constitutes a 'Migraine Day'. While in the EM population a MD is defined as a day with headache lasting at least 30 minutes without intake of analgesics, the guidance  for  chronic  migraine  requires  the  headache  to  last  for  at  least  4  hours  (all  other  criteria identical).  The  applicant's  defined  minimum  2-hour  duration  of  headache  is  therefore  somewhat  inbetween the two guidance documents. The advantage of defining a uniform endpoint across trials is acknowledged. Furthermore, current guidelines recommend early intervention in acute attacks, i.e. to take  acute  migraine  medication  early  after  the  onset  migraine  headache.  By  early  intervention,  the practical sequelae of differences in minimum headache duration are unclear anyway.

Combined measurement of MDs and PMDs (grouped together as primary endpoint 'MDs') is acceptable given the variable character of migraine. Symptomatology may vary from one attack to the following within one subject and from one subject to another. It can therefore be expected that on some days not all diagnostic criteria may formally be fulfilled to qualify for a MD in the narrow sense. A reduction of these probable MDs as compared to baseline is, however, still regarded as a relevant clinical benefit.

Apart  from  clinical  primary  and  secondary  endpoints  as  outlined  above,  additional  health-related secondary efficacy endpoints were measured, like the Migraine Specific Quality of Life Questionnaire (MSQ)  v2.1,  the  Activity  Impairment  in  Migraine-Diary  (AIM-D)  Performance  of  Daily  Activities  and Physical Impairment Domain Scores, and the Headache Impact Test (HIT-6).

Overall,  it  is  concluded  that  standard  endpoints  were  defined  in  pivotal  studies  301/303  that  are considered to adequately measure the efficacy of atogepant across the full spectrum of episodic and chronic migraine as compared to placebo. Specified inclusion and exclusion criteria adequately define the proposed target population in line with current ICHD-3 diagnostic criteria. Essential design features of pivotal studies 301/303 are concordant with EU Guideline provisions. There are no major objections related to the design or conduct of pivotal studies in support of the atogepant MAA.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

## Phase II/III Dose-finding Study MD-01

The  total  daily  dose  range  tested  in  dose-finding  study  MD-01  ranged  from  10  mg  to  a  maximum atogepant dose of 120 mg per day. Apart from dose variation, study MD-01 also examined two different dosing  intervals,  i.e.  once  daily  vs  twice  daily  regimens.  The  results  of  study  MD-01  demonstrated atogepant 10 mg QD, 30 mg QD, 60 mg QD, 30 mg BID, and 60 mg BID were superior to placebo (statistically significant after multiplicity adjustment), as measured by the reduction in mean monthly MDs across the 12-week DBT. Secondary endpoints like reduction of HDs, responder analyses of &gt; 50% reduction of MDs, and reduction of acute migraine medication use go along the results obtained for the primary  endpoint.  The  positive  effect  of  atogepant  in  prevention  of  EM  did  not  reveal  a  clear  dose response relationship. Therefore, the sponsor's decision to take over all three QD dose arms (10 mg, 30 mg, 60 mg) into pivotal EM study 301 appears plausible. The effect achieved with twice daily dosing of atogepant was noticeable. Across all efficacy endpoints, the results obtained with 30 mg BID atogepant were numerically more favourable as compared to the 60 mg QD dose arm. This was not further explored in EM study 301, which followed dose finding study MD-01, however, a BID dose arm was re-explored in the pivotal CM study 303, which was initiated later on.

## Pivotal Studies 301/303: Baseline

Pivotal studies 301 (US) and 303 (multiregional incl. US, UK, Canada, China, CZ, DK, FR, DE, IT, Japan, Republic of Korea, PL, Russian Federation, ES, SE, and Taiwan) were conducted in different regions. The population of study 303 was composed of 35% European, 30% North American, and 35% East Asian participants. Demographic features like age (42 years) and gender proportions (87-88% female) were essentially similar between the two studies. There are no issues raised with regard to transferability of study results across regions.

Baseline characteristics of migraine reflect the differences between the EM (study 301) and CM (study 303) population. The more severe disease burden in CM participants (Safety Population) is reflected by the higher portion of subjects with previous migraine prevention attempts (82.9% vs 70.3% in EM), the higher number of MDs per month (16.0 vs 7.4 in EM), and the higher number of monthly HDs (21.1 vs 9.3 in EM). The higher number of monthly MDs and HDs in CM subjects goes along with the higher portion of CM subjects usually taking triptans for acute attacks (72.2% in CM, 48.8% in EM).

A considerable portion of included subjects was overweight. In the total safety population, mean baseline weight was 84.20 kg and mean baseline BMI was 30.56 kg/m 2 . Overall, 25% of participants weighed ≥ 96.4 kg and 25% of participants had a BMI ≥ 34.96 kg/m 2 . Further reflection is requested to justify that the included study population reflects the target population in terms of BMI.

## Pivotal Studies 301/303: Disposition

Completion rates were high in study 301 (total completion 88.5%) and similar across treatment arms (ranging from 86.8% for atogepant 10 mg to 90.1% for the placebo arm, related to all randomised participants).  The  rates  of  subjects  discontinuing  for  adverse  events  were  about  equal  between  the highest 60 mg atogepant dose arm (2.6%) and placebo subjects (2.7%). Lack of efficacy was reported very rarely as reason for discontinuation with only one placebo subject and one participant receiving atogepant 60 mg (0.4% each). Like in study 301, the overall completion rate was high in CM study 303 (89.2%). Completion rates for DBT were almost identical across the atogepant 30 mg BID, atogepant 60 mg QD, and placebo arm (89-90%).

In studies 301 and 303, significant Protocol deviations mainly refer to 'Exclusion criteria met' (4.5 to 7.3%), 'Prohibited concomitant medication taken' (301: 9% for placebo / atogepant 30 mg QD), and

<div style=\"page-break-after: always\"></div>

'Study procedure not performed per protocol' (13.2% in study 303). Protocol deviations did not impact data integrity.

## Pivotal Studies 301/303: Primary endpoint

The difference in disease severity between the EM and CM population is documented by the number of baseline mean monthly MDs. While EM patients present with 7-8 MDs per month, about 18-19 MDs are reported for CM patients during the 28-day baseline period. Like it could be observed in previous migraine prevention trials, a considerable placebo response was observed in both populations. Both EM and CM placebo patients reduced the number of mean monthly MDs by up to one third (EM: -2.5 MD [-32.8%], CM: -5.1 MD [-26.9%]). Superiority over placebo was shown for all atogepant treatment arms across the two trials. A numerical dose-response relationship was evident for the change from baseline in mean monthly MDs across the 12-week treatment period in Study 301, with greater reductions seen with increasing atogepant dose from 10 to 60 mg QD (LSMD over placebo: 10 mg QD: -1.22, 30 mg QD: 1.38, 60 mg QD: -1.66). The placebo-corrected mean reduction from baseline in mean monthly migraine days observed with the atogepant 60 mg QD dose was the same in the EM and CM studies (LSMD of 1.66 in both Study 301 and Study 303).

Apart from testing dose response in EM study 301 across the once daily 10, 30, 60 mg dose range, the effect of changing the dosing interval from once daily to twice daily was examined for the highest 60 mg daily dose in the CM population. A noticeable difference was observed in favour of the twice daily dosing schedule in terms of the net difference over placebo for the reduction of mean monthly MDs (Study 303: LSMD over placebo: 30 mg BID: -2.24, 60 mg QD: -1.66). The favourable treatment effect of the 30 mg BID regime (as compared to 60 mg QD) was analogously observed in phase II/III dose finding study MD-01 (reduction in mean monthly MDs from baseline: 30 mg BID: -4.0, 60 mg QD: -3.56). It also translates into most relevant secondary endpoints, like reduction of HDs, reduction of acute medication use, and 50% response rates. Further plausibility for the favourable outcome in the 30 mg BID treatment arm is provided by PK study P002. In study P002, plasma levels were compared for different atogepant doses  after  repetitive  dosing  over  10  days.  C24  hrs  trough  values  after  30  mg  BID  dosing  were remarkably high, higher than after 100 mg once daily dosing and almost reaching the level of the 170 mg once daily regime.

Both in EM study 301 and CM study 303, subjects were followed up for another 4-week period after termination of the 12-week DBT or early discontinuation. According to the Schedule of Procedures of Study 301, participants' eDiary entries regarding headache were evaluated only in those patients who terminated early, but not in patients who completed the entire 12-week DBT. Hence, no data were provided on potential rebound of migraine after cessation of study medication in (all) participants of studies 301/303.

## Pivotal Studies: Secondary endpoints

A Headache Day (HD) is defined as any calendar day on which headache pain lasting 2 hours or longer occurs unless an acute headache medication (e.g. ibuprofen, triptan) was used after the start of the headache.  As  such,  a  HD  captures  days  with  headache  irrespective  of  any  other  migraine-specific symptoms. In particular in CM patients, where tension type headache and migraine headache often overlap, and who complain about highly frequent or almost continuous headache, measurement of HD is an important parameter for disease burden. Accordingly, reduction of HD from baseline during the 12week DBT was placed highest in hierarchical multiplicity testing [S1] of secondary endpoints. The results obtained for  the  S1  secondary  endpoint  are  similar  to  those  obtained  for  the  primary  MD  reduction endpoint. Statistically significant superiority over placebo after multiplicity adjustment was achieved for each of the atogepant dosages tested in studies 301 and 303. Numerically more favourable results were obtained with increasing doses across the QD (10 mg, 30 mg, 60 mg) dose arms in EM study 301. The net treatment effect over placebo was more favourable for the 30 mg BID dose arm as compared to the

<div style=\"page-break-after: always\"></div>

60 mg QD dose arm in study 303 (LSMD for HD reduction from baseline: 30 mg BID: -2.14, 60 mg QD: -1.72).

At baseline, acute medication (incl. both unspecific analgesics and triptans) was used on a mean of 6-7 days among EM patients and on about 15 days in the CM population. The change from baseline in mean monthly acute medication use days [S2] was second in hierarchical testing of secondary endpoints. For both the Acute Medication Use Day and the Triptan Use Day (which was singled out) secondary endpoint significant superiority over placebo could be demonstrated for each atogepant dose arm.

In  terms  of  the  &gt;  50%  reduction  in  3-month  average  of  monthly  MDs  [S3],  statistically  significant superiority over placebo was achieved for each atogepant dose arm tested across studies 301 / 303. In study 301, more than 50% of subjects allocated to one of the atogepant dose arms achieved a reduction by &gt; 50% in the 3-month average of monthly MDs (atogepant: 10 mg QD: 54.6%, 30 mg QD: 58.5%, 60 mg QD: 59.3%; placebo 29.2%). This underlines the clinical relevance of the improvement achieved in terms of the primary MD reduction from baseline across all atogepant dose arms. Among the more severely affected CM population of study 303, response rates were slightly lower (30 mg BID: 42.1%, 60 mg QD: 40.1%). Nonetheless, the probability of achieving a &gt; 50% reduction in the 3-month average of monthly MDs was still about twice as high for atogepant as compared to placebo (OR: 30 mg BID: 2.03, 60 mg QD: 1.90).

## Time course

The major part of the overall treatment effect is achieved within the first 4-week dosing interval of the 12-week DBT in both the EM and CM population. Thereafter, the reduction of mean monthly MDs is maintained or even slightly increases. The dose response relation across the three QD dose arms of study 301 is consistently observed across the three 28-day intervals of the 12-week DBT. In CM study 303, the more favourable effect of the 30 mg BID dosing regimen as compared to the 60 mg QD dosing scheme gets more pronounced with ongoing treatment duration.

The course of treatment effect was further analysed per week for the first 28-day period of the DBT of studies 301 and 303. In both EM and CM patients, the treatment effect starts within the first week of treatment. There was no clear tendency of increasing or decreasing effect of atogepant over the four 1week intervals of the first 28-day treatment interval. This is considered to provide valuable information to  the  prescriber  when  the  treatment  effect  of  atogepant  is  evaluated  within  the  context  of  clinical monitoring.

## Health Outcome Measures

A number of Health Outcomes Measures were recorded throughout or at the end of 12-week DBT of studies 301 and 303, e.g. Patient Global Impression of Change [PGI-C], Patient Global Impression of Severity  [PGI-S],  Headache  Impact  Test  Questionnaire  [HIT-6],  Migraine-Specific  Quality  of  Life Questionnaire  [MSQ  v2.1],  Migraine  Disability  Assessment  Questionnaire  [MIDAS],  or  the  Activity Impairment in Migraine-Diary [AIM-D]. Overall, results for these patient-reported outcomes measures were consistent with the results of the primary and secondary efficacy endpoints for both studies, with numerically greater improvements or greater reductions (i.e., improvement) from baseline observed for each of the atogepant treatment groups compared with placebo for the majority of measures.

## Subgroups

Several subgroup analyses were performed to explore the effect of baseline factors in the EM (pooled studies 301 and MD-01) and CM population. Atogepant showed consistently greater reductions from baseline in mean monthly migraine days compared with placebo across the demographic subgroups of sex, age (&lt; 40 years; ≥ 40 to &lt; 65 years), race, and BMI. In the Forest Plot presentation for MD reduction, atogepant does separate from placebo in the small subgroup of both EM and CM subjects aged

<div style=\"page-break-after: always\"></div>

&gt; 65 years. However, the sample sizes were too small per dose group to infer a clinically meaningful difference.

As concerns subgroup per baseline MD, among EM subjects, the portions of patients with &lt; or ≥ 8 migraine  days  at  baseline  were  about  comparable  (54.2%  resp.  45.8%).  In  both  subgroups,  the reduction of mean monthly MDs was significant over placebo across the three atogepant QD dose arms. In the most severely affected subgroup of CM patients with &gt; 18 MDs per month at baseline, atogepant only numerically separates from placebo for the atogepant 60 Mg QD dose arm (LSMD: -0.60 [-2.17, 0.97]), while the atogepant 30 mg BID dose arm reaches statistical significance over placebo (LSMD: 1.79 [-3.38, -0.20]). The more favourable result, obtained in study 303 for the subgroup with the highest disease burden (&gt; 18 MDs at baseline) for the atogepant 30 mg BID dose arm as compared to 60 mg QD, aligns with the generally more favourable results observed for the twice daily dosing regimen across primary and secondary efficacy endpoints.

Subgroup analyses were also conducted in EM and CM patients per prior use of migraine preventive medication use. Among EM patients, the portions of subjects with (52.4%) or without (47.6%) prior use of prophylactic treatment were about equal. The net difference over placebo in terms of monthly MD reduction was more favourable in those EM participants that reported prior use of migraine preventive Mx.  The  more  favourable  result  in  subjects  with  prior  prophylaxis  experience  may  be  explained  by differences  in  the  placebo  response  between  both  subgroups.  The  placebo  response  was  more pronounced in prevention in naïve patients (MD change from baseline: -3.17) as compared to EM subjects reporting  prior  preventive  treatment  (MD  change  from  baseline  -2.04).  Results  obtained  in  the  CM population  were  comparable  to  the  EM  population  (Study  303:  MD  change  from  baseline,  placebo response: prior use yes: -4.78, prior use no: -6.98). Again, the outcome in the 30 mg BID dose arm was more favourable as compared to the atogepant 60 mg QD dose arm.

Subgroup analyses per number of failures to previous migraine preventive treatment attempts revealed that the effect of atogepant in terms of reduction of monthly MDs was maintained regardless of the number of previous preventive treatment failures. As evidenced by the net treatment effect over placebo per atogepant dose arm, there was no tendency for a decline in atogepant's efficacy with increasing number of previous treatment failures across the EM and CM population.

The stratification factors unique to Study 303 allowed subgroup analyses by region, acute medication overuse, and preventive medication current use.

While EM Study 301 was conducted at US sites only, CM study 303 comprises different global regions (North America 29.5%, Europe 35.2%, East Asia 35.3%). The effect of atogepant was consistent across regions.

In CM Study 303, participants were stratified for acute headache medication overuse (MoH), which was prevalent in 63.8% of recruited subjects. On average, acute headache medication was taken on 15-16 days during the 28-day baseline period. Across the two atogepant dose arms, point estimates reflecting the net effect over placebo for monthly reduction of MDs were more favourable in those subjects with MoH as compared to those without. The effect of atogepant was consistent regardless of whether subjects presented with acute medication overuse or not.

Concomitant preventive migraine medication was permissible throughout study 303 and was actually taken by 10.5% of recruited CM patients. The subgroup analysis per current preventive medication use showed efficacy of atogepant to be maintained regardless of whether additional concomitant migraine preventive medication was taken or not. Due to the small sample size of participants with concomitant prophylactic treatment the CIs for the point estimates for the net effect over placebo in terms of monthly MD reduction were considerably wider in this subgroup.

## Persistence of effect

<div style=\"page-break-after: always\"></div>

In open-label, long-term study 302, the daily use of 60 mg atogepant QD (N=546) was compared to SOC (N=198) over a 52-week treatment period in EM patients, either recruited de novo (85.6%) or taken  over  from  dose  finding  study  MD-01  (14.4%).  Participants  randomised  to  oral  SOC  migraine preventive medication (topiramate: 35.7%, beta-blockers 26.0%, tricyclic antidepressants 25.5%) were included to contextualise safety results.

It was primarily designed to examine safety of long term atogepant use in EM patients. However, efficacy was  also  monitored  in  those  subjects  randomised  to  atogepant.  In  atogepant  patients,  a  clinically relevant reduction in mean monthly MDs was achieved within the 1st month and was sustained over the 1-year treatment period. Atogepant treatment led to a reduction in the LS mean number of monthly MDs in the first month (Weeks 1-4) of 3.84 days with continued improvement during the remainder of the 52-week treatment period to a LS mean reduction of -5.19 days in the last month (Weeks 49 to 52).

It has to be considered that with ongoing treatment duration the portion of likely atogepant responders is expected to accumulate. However, study completion is high. About two thirds of subjects allocated to atogepant 60 mg QD remains in treatment until week 52 (335/521 [64.3%]). Long term study 302 is concluded to provide supportive evidence of long-term efficacy (52 weeks duration) of atogepant 60 mg once daily in EM patients.

## 2.6.7. Conclusions on the clinical efficacy

Dose-finding  study  MD-01  and  pivotal  studies  301  (EM  population)  and  303  (CM  population)  were designed concordant with IHS and EMA guidance and provide a sound database demonstrating evidence for the benefit of atogepant in preventive migraine treatment across the full spectrum of episodic and chronic forms of the disease.

Atogepant in dosages of 10, 30, and 60 mg QD in EM and 60 mg QD and 30 mg BID in CM demonstrated superiority over placebo in reducing the frequency of both migraine days [primary P1], as well as the frequency of headache days [secondary S1] and the associated use of medication for the acute treatment of migraine [S2]. Higher response rates were seen with each atogepant dosage compared with placebo for participants with ≥ 50% reduction in the 3 -month average of monthly migraine days [S3].

A numerical dose-response relationship was evident for the change from baseline in mean monthly MDs across the 12-week DBT in EM Study 301, with greater reductions seen with increasing atogepant dose from 10 to 60 mg QD. Only the highest maximum daily dose of 60 mg tested in EM study 301 was taken over in CM Study 303. To explore the potential impact of the once daily vs twice daily dosing regimen, the 60 mg daily dose was examined across a 60 mg QD and a 30 mg BID treatment arm in CM Study 303. The placebo-corrected mean reduction from baseline in mean monthly migraine days observed with the atogepant 60 mg QD dose was the same in the EM and CM studies (LSMD of -1.66 in both Study 301 and 303).

The robustness of the primary and secondary endpoint results [S1-3] after multiplicity adjustment for each  of  the  atogepant  dosages  tested  in  studies  301/303  was  confirmed  across  several  subgroup analyses,  like  e.g.  prior  use  of  prevention  medication,  concomitant  use  of  another  prophylactic medication (study 303), or prevalent medication overuse (study 303).

The onset of clinical effect of atogepant is early. In both the EM and CM population, the major part of the overall treatment effect in terms of MD reduction is achieved within the first 28-day period of the 12-week DBT of studies 301 and 303.

In terms of persistence of effect, supportive efficacy data are obtained from open-label, long-term study 302 in EM patients for treatment with atogepant 60 mg QD over 52 weeks. A clinically relevant reduction

<div style=\"page-break-after: always\"></div>

in mean monthly MDs was achieved within the 1st month and was sustained over the 1-year treatment period.

Overall, there are no objections with regard to efficacy for the proposed use of atogepant in migraine prevention. The choice of the dosing interval of the 60 mg daily dose of atogepant was further elucidated. The numerically most favourable outcome across primary and secondary endpoints in studies MD-01 (EM) and pivotal study 303 (CM) was observed for the 30 mg BID dosing regimen. However, the applicant applied for the 60 mg QD once daily as regular dosing scheme only. It is established that compliance with migraine preventive treatment remains a challenge. Therefore, the potential advantage of a once daily dosing regimen is evident in terms of compliance. On the other hand, administration of the most effective treatment is equally expected to positively impact on patient compliance. A 30 mg tablet formulation was tested in Study 301, i.e. is available. Nonetheless, the proposed posology strategy is to confine to the uniform 60 mg once daily dosing schedule in order to provide a simple and convenient posology scheme, which the applicant assumes will best promote patient compliance.

## 2.6.8. Clinical safety

## 2.6.8.1. Patient exposure

Safety data from the clinical  studies  included  in  the  application  have  been organised  into  4  distinct analysis sets for the ISS based on study design and populations.

Placebo-controlled (PCS) analysis set (Group 1a) : pooled data from the 3 completed double-blind placebo-controlled studies of atogepant administered orally for 12 weeks for the prevention of migraine in participants with EM (Studies 301 and MD-01) and participants with CM (Study 303).

Long-term safety (LTS) analysis set (Group 2a) :  pooled data from 4 atogepant open-label LTS studies up to 104 weeks duration (completed Studies 302 and 309 in participants with EM, and ongoing Studies 306 and 312 in participants with CM).

Although extension Study 312 enrolled completers from Studies 303 and 304, the latter study is ongoing and still blinded. Therefore, data from participants who rolled over from Study 304 are not included in the LTS analysis set for this application. At the time of the 10 January 2022 ISS data cut-off date, Study 312 included a 52-week open-label treatment period (the protocol was subsequently amended to include a 104-week open-label treatment period).

An interim update of LTS data cut-off (11 October 2022) was provided within the course of the procedure with focus on hepatic safety. LTS studies 306 and 312 are still ongoing. The comprehensive analysis of the LTS safety dataset, as presented within this document (and Module 2.7.4) refers to the initial data cut-off (10 January 2022).

All atogepant analysis set (Group 3a) : pooled data from all atogepant-treated participants in Phase 2/3 and Phase 3 Studies MD-01, 301, 302, 303, 306, 309, 311, and 312.

Phase 1 analysis set (Group 4a) : pooled data from 20 Phase 1 clinical pharmacology studies (19 conducted in healthy participants [including participants with hepatic impairment in Study CGP-PK-01] and 1 conducted in participants with migraine [Study 3101-106-002, a drug-drug interaction study with ubrogepant]).

Across all  studies  in  the  atogepant  clinical  development  programme,  3230  unique  participants  were exposed to ≥ 1 dose of atogepan t, including 2626 participants in Phase 2/3 and Phase 3 studies and 604 participants in Phase 1 clinical pharmacology studies. The Placebo-controlled Analysis Set (PCS) included

<div style=\"page-break-after: always\"></div>

N=2500 subjects in total, N=1837 of these received atogepant and N=663 received placebo. The Longterm safety Set (LTS) included N=1858 subjects in total, 1662 received atogepant 60 mg QD and N=196 received SOC.

Table 40: Number of treated participants by clinical trial group (as of 10 january 2022)

| Clinical Trial Group                                                                                 | Atogepant   | Placebo   | Standard of Care\"   |
|------------------------------------------------------------------------------------------------------|-------------|-----------|---------------------|
| Phase 1 studiesb                                                                                     | 604         | 132       |                     |
| Placebo-controlled studies (Studies CGP-MD-01, 3101-301-002,3101-303-002)                            | 1837        | 663       |                     |
| Open-label safety studies (Studies3101-302-002,3101-306-002, 3101-309-002,3101-311-002,3101-312-002) | 1665°       |           | 196                 |

- a. Standard-of-care group was included only in Study 3101-302-002.
- b. Some participants were exposed to both atogepant and placebo due to crossover study design.
- C. Total includes 1662 participants in the long-term safety analysis set (Group 2a) and 3 participants from 12-week open-label Study 3101-311-002.

Source: ISS (R&amp;D/22/0367) Table 1-3.1.2 and Table 2-1.2.2

## · Adverse events

The percentages of participants who had AEs were generally similar across treatment groups in the analysis sets. Most individual AE preferred terms were reported at low rates in all treatment groups. The majority of AEs were mild or moderate in severity, with few severe AEs in any treatment group.

Table 41: Overview of adverse events in the placebo-controlled analysis set (safety population)

|                                |                         | Atogepant                | Atogepant               | Atogepant               | Atogepant               | Atogepant                |
|--------------------------------|-------------------------|--------------------------|-------------------------|-------------------------|-------------------------|--------------------------|
|                                | Placebo (N = 663) n (%) | 10 mg QD (N = 314) n (%) | 30 mgQD (N = 411) n (%) | 60 mg QD (N= 678) n (%) | 30 mg BID (N=343) n (%) | 60 mg BID (N = 91) n (%) |
| TEAEs                          | 344 (51.9)              | 178 (56.7)               | 234 (56.9)              | 396 (58.4)              | 197 (57.4)              | 53 (58.2)                |
| Deaths                         | 0                       | 0                        | 0                       | 0                       | 0                       | 0                        |
| TESAEs                         | 7 (1.1)                 | 3 (1.0)                  | 2 (0.5)                 | 9 (1.3)                 | 4 (1.2)                 | 0                        |
| TEAEsleadingto discontinuation | 21 (3.2)                | 13 (4.1)                 | 14 (3.4)                | 21 (3.1)                | 18 (5.2)                | 6 (6.6)                  |

BID = twice daily; QD = once daily; TEAE = treatment-emergent adverse events; TESAE = treatment-emergent serious adverse events

Souce: ISS (R&amp;D/22/0367) Table 5-1.1.1.Table 6-1.3.1,Table 5-1.5.1, Table 6-1.1.1

## Placebo-controlled Analysis Set

The most common AEs in any atogepant group (≥ 5% of participants) were nausea, constipation, fatigue, and upper respiratory tract infection.

<div style=\"page-break-after: always\"></div>

For the following AEs the majority of cases were considered by the Investigator to be related to study drug:

- Constipation was reported for 2.0% of participants in the placebo group, compared with 6.1%, 6.3%, and 7.5% in the atogepant 10, 30, and 60 mg QD groups, respectively, and 9.0% and 6.6% in the atogepant 30 and 60 mg BID groups, respectively.
- Nausea was reported for 3.3% of participants in the placebo group compared with 5.1%, 5.6%, and 9.0% in the atogepant 10, 30, and 60 mg QD groups, respectively, and 8.2% and 9.9% in the atogepant 30 and 60 mg BID groups, respectively; the incidence of nausea increased with higher doses of atogepant.
- Fatigue was reported for 2.6% of participants in the placebo group compared with 1.3%, 2.4%, and 3.2% in the atogepant 10, 30, and 60 mg QD groups, respectively, and 3.8% and 9.9% in the atogepant 30 and 60 mg BID groups.

Table 42: Number and percentage of participants with common AEs (≥ 2% of participants in any treatment group) by preferred term in the placebo-controlled analysis set

| Preferred Term                         | Placebo (N=663) n (%)   | Placebo (N=663) n (%)   | Atogepant 10 mg QD (N=314) n (%)   | Atogepant 10 mg QD (N=314) n (%)   |   Atogepant 30 mg QD (N=411) n (%) | Atogepant 30 mg QD (N=411) n (%)   | Atogepant 60 mg QD (N=678) n (%)   | Atogepant 60 mg QD (N=678) n (%)   |   Atogepant 30 mg BID (N=343) n (%) | Atogepant 30 mg BID (N=343) n (%)   | Atogepant 60 mg BID (N=91) n (%)   | Atogepant 60 mg BID (N=91) n (%)   | Atogepant Overall (N=1837) n (%)   | Atogepant Overall (N=1837) n (%)   |
|----------------------------------------|-------------------------|-------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|-------------------------------------|-------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Nausea                                 | 22 （                    | 3.3)                    | 16                                 | 5.1)                               |                                 23 | 5.6)                               | 61                                 | 9.0)                               |                                  28 | 8.2)                                | 9                                  | 9.9)                               | 137                                | 7.5)                               |
| Constipation                           | 13 (                    | 2.0)                    | 19                                 | 6.1)                               |                                 26 | 6.3)                               | 51                                 | 7.5)                               |                                  31 | 9.0)                                | 6 （                                | 6.6)                               | 133                                | 7.2)                               |
| Upper respiratory tract infection      | 31 (                    | 4.7)                    | 15                                 | 4.8)                               |                                 27 | 6.6)                               | 21                                 | 3.1)                               |                                  12 | 3.5)                                | 6                                  | 6.6)                               | 81                                 | 4.4)                               |
| Nasopharyngitis                        | 23                      | 3.5)                    | >                                  | 2.2)                               |                                 19 | 4.6)                               | 33                                 | 4.9)                               |                                  11 | 3.2)                                | 3                                  | 3.3)                               | 73                                 | 4.0)                               |
| Urinary tract infection                | 15                      | 2.3)                    | 5                                  | 1.6)                               |                                 20 | 4.9)                               | 20                                 | 2.9)                               |                                  12 | 3.5)                                | 3                                  | 3.3)                               | 60                                 | 3.3)                               |
| Fatigue                                | 17                      | 2.6)                    | 4                                  | 1.3)                               |                                 10 | 2.4)                               | 22                                 | 3.2)                               |                                  13 | 3.8)                                | 9                                  | 9.9)                               | 58                                 | 3.2)                               |
| Dizziness                              | 10                      | 1.5)                    | 5                                  | 1.6)                               |                                  8 | 1.9)                               | 18                                 | 2.7)                               |                                  12 | 3.5)                                | 3                                  | 3.3)                               | 46                                 | 2.5)                               |
| Decreased appetite                     | 1                       | 0.2)                    | 5                                  | 1.6)                               |                                  4 | 1.0)                               | 19                                 | 2.8)                               |                                   7 | 2.0)                                | 4                                  | 4.4)                               | 39                                 | 2.1)                               |
| Blood creatine phosphokinase increased | 5                       | 0.8)                    | 9                                  | 2.9)                               |                                  5 | 1.2)                               | 11                                 | 1.6)                               |                                   7 | 2.0)                                | 2                                  | 2.2)                               | 34                                 | 1.9)                               |
| Somnolence                             | 7                       | 1.1)                    | 9                                  | 2.9)                               |                                  8 | 1.9)                               | 13                                 | 1.9)                               |                                   3 | 0.9)                                | 0                                  | 0.0)                               | 33                                 | 1.8)                               |
| Sinusitis                              | 9                       | 1. 4)                   | 8                                  | 2.5)                               |                                  5 | 1.2)                               | 11                                 | 1.6)                               |                                   6 | 1.7)                                | 2                                  | 2.2)                               | 32                                 | 1.7)                               |
| Diarrhoea                              | 12                      | 1.8)                    | 3                                  | 1.0)                               |                                  6 | 1.5)                               | 14                                 | 2.1)                               |                                   4 | 1.2)                                | 3                                  | 3.3)                               | 30                                 | 1.6)                               |
| Gastroenteritis                        | 8 (                     | 1.2)                    | 3                                  | 1.0)                               |                                 10 | 2.4)                               | 10                                 | 1.5)                               |                                   5 | 1.5)                                | 0                                  | 0.0)                               | 28                                 | 1.5)                               |
| Insomnia                               | 8 (                     | 1.2)                    | 5                                  | 1.6)                               |                                  2 | 0.5)                               | 11                                 | 1.6)                               |                                   5 | 1.5)                                | 2                                  | 2.2)                               | 25                                 | 1. 4)                              |
| Arthralgia                             | 11 (                    | 1.7)                    | 3                                  | 1.0)                               |                                  7 | 1.7)                               | 7                                  | 1.0)                               |                                   7 | 2.0)                                | 0                                  | 0.0)                               | 24                                 | 1.3)                               |
| Vomiting                               | 10 (                    | 1.5)                    | 4                                  | 1.3)                               |                                  1 | 0.2)                               | 11                                 | 1.6)                               |                                   4 | 1.2)                                | 3                                  | 3.3)                               | 23                                 | 1.3)                               |
| Abdominal pain                         | 5                       | 0.8)                    | 2                                  | 0.6)                               |                                  3 | 0.7)                               | 7                                  | 1.0)                               |                                   6 | 1.7)                                | 2                                  | 2.2)                               | 20                                 | 1.1)                               |
| Abdominal pain upper                   | 6                       | 0.9)                    | 2                                  | 0.6)                               |                                  4 | 1.0)                               | 5                                  | 0.7)                               |                                   8 | 2.3)                                | 0                                  | 0.0)                               | 19                                 | 1.0)                               |
| Muscle strain                          | 2                       | 0.3)                    | 5                                  | 1.6)                               |                                  5 | 1.2)                               | 4                                  | 0.6)                               |                                   0 | 0.0)                                | 2                                  | 2.2)                               | 16                                 | 0.9)                               |
| Vertigo                                | 4                       | 0.6)                    | 3                                  | 1.0)                               |                                  3 | 0.7)                               | 4                                  | 0.6)                               |                                   4 | 1.2)                                | 2 （                                | 2.2)                               | 16                                 | 0.9)                               |
| Weight decreased                       | 3                       | 0.5)                    | 1                                  | 0.3)                               |                                  0 | 0.0)                               | 9                                  | 1.3)                               |                                   0 | 0.0)                                | 2                                  | 2.2)                               | 12                                 | 0.7)                               |
| Choking                                | 1                       | 0.2)                    | 0                                  | 0.0)                               |                                  2 | 0.5)                               | 1                                  | 0.1)                               |                                   0 | 0.0)                                | 2 (                                | 2.2)                               | 5 (                                | 0.3)                               |
| Flank pain                             | 1                       | 0.2)                    | 0                                  | 0.0)                               |                                  0 | 0.0)                               |                                    | 0.1)                               |                                   1 | 0.3)                                | 3                                  | 3.3)                               | 5 (                                | 0.3)                               |
| Bacterial vaginosis [f]                | 2                       | 0.3)                    | 0                                  | 0.0)                               |                                  1 | 0.3)                               |                                    | 0.2)                               |                                   0 | 0.0)                                | 2                                  | 2.4)                               | 4                                  | 0.2)                               |

Notes:

BID = twice daily; QD = once daily

N = number of participants in the safety population of the treatment group.

Percentages calculated as 1o0 x (n/N).

n = number of participants in the specific category.

Participants are counted only once within each preferred term.

## Long-term Safety Set

AEs were reported for 78.6% of participants in the standard-of-care group and 63.5% of participants in the atogepant 60 mg QD group (64.5% in EM Studies 302 and 309 and 60.8% in CM Studies 306 and 312) in the long-term safety analysis set.

The majority of AEs were mild or moderate in severity, with few severe AEs in either treatment group. AEs that were considered by the investigator to be related to study drug were reported for 36.2% of participants in the standard-of-care group and 13.3% of participants in the atogepant 60 mg QD group.

The most common AEs in the atogepant 60 mg QD group (≥ 5% of participants) were constipation and upper respiratory tract infection.

<div style=\"page-break-after: always\"></div>

Table 43: Number and percentage of participants with common AEs (≥ 2% o f participants in either treatment group) by preferred term in the long-term safety analysis set

| Preferred Term                       | Standard-of-Care (N=196) n (%)   | Atogepant 60 mg QD (N=1662) n (8)   |
|--------------------------------------|----------------------------------|-------------------------------------|
| Constipation                         | 6 3.1)                           | 99 6.0)                             |
| Upper respiratory tract infection    | 24 12.2)                         | 99 6.0)                             |
| Nasopharyngitis                      | 10 5.1)                          | 81 4.9)                             |
| Urinary tract infection              | 6 4.6)                           | 72 4.3)                             |
| Nausea                               | 12 6.1)                          | 71 4.3)                             |
| Pyrexia                              | 1 0.5)                           | 59 3.5)                             |
| Arthralgia                           | 6 3.1)                           | 46 2.8)                             |
| Sinusitis                            | 6 3.1)                           | 44 2.6)                             |
| Back pain                            | 5 2.6)                           | 37 2.2)                             |
| Dizziness                            | 22 11.2)                         | 37 2.2)                             |
| Weight decreased                     | 3 1.5)                           | 37 2.2)                             |
| Gastroenteritis                      | 0 0.0)                           | 36 2.2)                             |
| Influenza                            | 5 2.6)                           | 35 2.1)                             |
| Anxiety                              | 11 5.6)                          | 34 2.0)                             |
| Aspartate aminotransferase increased | 5 2.6)                           | 29 1.7)                             |
| Fatigue                              | 12 6.1)                          | 29 1.7)                             |
| Alanine aminotransferase increased   | 4 2.0)                           | 27 1.6)                             |
| Diarrhoea                            | 6 3.1)                           | 23 1. 4)                            |
| Migraine                             | 6 3.1)                           | 23 1. 4)                            |
| Depression                           | 4 2.0)                           | 22 1.3)                             |
| Headache                             | 5 2.6)                           | 20 1.2)                             |
| Gastroenteritis viral                | 4 2.0)                           | 18 1.1)                             |
| Insomnia                             | 7 3.6)                           | 15 0.9)                             |
| Weight increased                     | 11 5.6)                          | 15 0.9)                             |
| Somnolence                           | 8 4.1)                           | 13 0.8)                             |
| Contusion                            | 6 3.1)                           | 9 0.5)                              |
| Paraesthesia                         | 12 6.1)                          | 8 0.5)                              |
| Dry mouth                            | 8 4.1)                           | 7 0.4)                              |
| Hypoaesthesia                        | 4 2.0)                           | 5 0.3)                              |
| Sedation                             | 4 2.0)                           | 0 0.0)                              |

QD = once daily

Notes:

N = number of participants in the safety population of the treatment group.

n = number of participants in the specific category.

Percentages calculated as lo0 x (n/N).

Participants are counted only once within each preferred term.

Cross reference:ISS (R&amp;D/22/0367) Tab1e 5-2.4.1

## Adverse Drug Reactions

Adverse drug reactions (ADRs) were determined by evaluating TEAEs in the placebo-controlled migraine studies (Studies MD01, 301, and 303) that occurred with a ≥ 2% overall incidence rate in any of the atogepant groups and at a rate at least 2% greater than placebo.

All AEs that met either criterion above were evaluated using medical judgment to determine if there was a plausible causal relationship between the AE and atogepant, including evaluation of the extent to which the  AE  was  consistent  with  the  pharmacology  of  study  drug  and  the  consistency  of  the  pattern  of symptoms across multiple studies.

Constipation, decreased appetite, nausea, and fatigue/somnolence were identified as ADRs.

## Comparison of Adverse Events in EM versus CM Studies

## Placebo-Controlled Studies

The type and frequency of AEs were similar in the placebo-controlled EM and CM studies.

<div style=\"page-break-after: always\"></div>

Table 44: Summary of AEs in placebo-controlled EM studies and CM study

|                                           | Nunber (%)Participants                | Nunber (%)Participants                | Nunber (%)Participants                | Nunber (%)Participants                | Nunber (%)Participants                | Nunber (%)Participants                | Nunber (%)Participants   | Nunber (%)Participants   | Nunber (%)Participants   |
|-------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|--------------------------|--------------------------|--------------------------|
|                                           | Study3101-301-002andStudyCGP-MD-0l:EM | Study3101-301-002andStudyCGP-MD-0l:EM | Study3101-301-002andStudyCGP-MD-0l:EM | Study3101-301-002andStudyCGP-MD-0l:EM | Study3101-301-002andStudyCGP-MD-0l:EM | Study3101-301-002andStudyCGP-MD-0l:EM | Study3101-303-002:CM     | Study3101-303-002:CM     | Study3101-303-002:CM     |
|                                           |                                       | Atogepant                             | Atogepant                             | Atogepant                             | Atogepant                             | Atogepant                             | Placebo                  | Atogepant                | Atogepant                |
|                                           | Placebo (N =408)                      | 10 mg QD (N=314)                      | 30 mg QD (N =411)                     | 60 mgQD (N =417)                      | 30 mgBID (N =86)                      | 60mgBID (N=91)                        | (N = 255)                | 30 mgBID (N =257)        | 60 mg QD (N = 261)       |
| AEs                                       | 218 (53.4)                            | 178 (56.7)                            | 234 (56.9)                            | 231 (55.4)                            | 52 (60.5)                             | 53 (58.2)                             | 126 (49.4)               | 145 (56.4)               | 165 (63.2)               |
| Treatment-relatedAEs                      | 50 (12.3)                             | 68 (21.7)                             | 73 (17.8)                             | 87 (20.9)                             | 18 (20.9)                             | 24 (26.4)                             | 34 (13.3)                | 52 (20.2)                | 45 (17.2)                |
| Deaths                                    | 0                                     | 0                                     | 0                                     | 0                                     | 0                                     | 0                                     | 0                        | 0                        | 0                        |
| SAEs                                      | 4 (1.0)                               | 3 (1.0)                               | 2 (0.5)                               | 2 (0.5)                               | 0                                     | 0                                     | 3 (1.2)                  | 4 (1.6)                  | 7 (2.7)                  |
| AEsleading to discontinuationofstudy drug | 11 (2.7)                              | 13 (4.1)                              | 14 (3.4)                              | 12 (2.9)                              | 5 (5.8)                               | 6 (6.6)                               | 10 (3.9)                 | 13 (5.1)                 | 9 (3.4)                  |

AE=adverse event;BID=twice daily;CM=chronic migraine;EM=episodic migraine;QD=once daily;SAE=serious adverse event

Table 45: Number of participants with c ommon AEs (≥ 5 % of participants in any treatment group) by preferred term in placebo-controlled EM studies and CM study

|                                        | Number(%)Participants                     | Number(%)Participants                     | Number(%)Participants                     | Number(%)Participants                     | Number(%)Participants                     | Number(%)Participants                     | Number(%)Participants   | Number(%)Participants   | Number(%)Participants   |
|----------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------|-------------------------|-------------------------|
|                                        | Study 3101-301-002 and Study CGP-MD-0l:EM | Study 3101-301-002 and Study CGP-MD-0l:EM | Study 3101-301-002 and Study CGP-MD-0l:EM | Study 3101-301-002 and Study CGP-MD-0l:EM | Study 3101-301-002 and Study CGP-MD-0l:EM | Study 3101-301-002 and Study CGP-MD-0l:EM | Study 3101-303-002:CM   | Study 3101-303-002:CM   | Study 3101-303-002:CM   |
|                                        |                                           | Atogepant                                 | Atogepant                                 | Atogepant                                 | Atogepant                                 | Atogepant                                 | Placebo                 | Atogepant               | Atogepant               |
| PreferretlTerm                         | Placebo (N= 408)                          | 10 mg QD (N=314)                          | 30 mgQD (N =411)                          | 60 mg QD (N=417)                          | 30 mg BID (N = 86)                        | 60 mg BID (N=91)                          | (N =255)                | 30 mgBID (N =257)       | 60 mg QD (N =261)       |
| Fatigue                                | 10 (2.5)                                  | 4 (1.3)                                   | 10 (2.4)                                  | 14 (3.4)                                  | 2 (2.3)                                   | 9 (9.9)                                   | 7 (2.7)                 | 11 (4.3)                | 8 (3.1)                 |
| Nausea                                 | 13 (3.2)                                  | 16 (5.1)                                  | 23 (5.6)                                  | 36 (8.6)                                  | 8 (9.3)                                   | 9 (9.9)                                   | 9 (3.5)                 | 20 (7.8)                | 25 (9.6)                |
| Constipation                           | 5 (1.2)                                   | 19 (6.1)                                  | 26 (6.3)                                  | 25 (6.0)                                  | 3 (3.5)                                   | 6 (6.6)                                   | 8 (3.1)                 | 28 (10.9)               | 26 (10.0)               |
| Upper respiratory tract infection      | 25 (6.1)                                  | 15 (4.8)                                  | 27 (6.6)                                  | 19 (4.6)                                  | 6 (7.0)                                   | 6 (6.6)                                   | 6 (2.4)                 | 6 (2.3)                 | 2 (0.8)                 |
| Nasopharyngitis                        | 12 (2.9)                                  | 7 (2.2)                                   | 19 (4.6)                                  | 22 (5.3)                                  | 1 (1.2)                                   | 3 (3.3)                                   | 11 (4.3)                | 10 (3.9)                | 11 (4.2)                |
| Blood creatine phosphokinase increased | 5 (1.2)                                   | 9 (2.9)                                   | 5 (1.2)                                   | 9 (2.2)                                   | 6 (7.0)                                   | 2 (2.2)                                   | 0                       | 1 (0.4)                 | 2 (0.8)                 |

BID=twice daily,CM=chronicmigraine;EM=episodicmigraine;QD=oncedaily

Notes: Data are presented by decreasing frequency in the atogepant 60 mg BID group.

Participantscountedonly oncewithineachpreferred term.

MedDRA version 22.0 was used for the EM studies;MedDRA version 24.0 was used for the CM study.

## Long-Term Safety Studies

Pyrexia was reported at a higher rate in CM (11.1%) than in EM (0.9%) atogepant-treated participants in the long-term safety analysis set, which was likely related to COVID-19 vaccination in Study 306. Although  upper  respiratory  infection  was  higher  in  EM  (7.7%)  than  CM  (1.2%)  atogepant-treated participants, it is lower than in the standard-of-care group (12.2%); this was likely related to global mask-wearing and social distancing during the COVID-19 pandemic that occurred during the conduct of the CM studies. With the exception of these 2 AEs (pyrexia and upper respiratory infection), the type and frequency of AEs were similar in the long-term safety EM and CM studies.

<div style=\"page-break-after: always\"></div>

Table 46: Number of participants with common AEs (≥ 5% of participants in any treatment group) by preferred term in long-term safety EM and CM studies

|                             | Nunber (%) Participants   | Nunber (%) Participants                  | Nunber (%) Participants                  |
|-----------------------------|---------------------------|------------------------------------------|------------------------------------------|
|                             | Study 3101-302-002        | Studies 3101-302-002 and 3101-309-002:EM | Studies 3101-306-002 and 3101-312-002:CM |
|                             | Standard-of-Care          | Atogepant 60 mg QD                       | Atogepant 60 mg QD                       |
| Preferred Term              | (N =196)                  | (N =1228)                                | (N =434)                                 |
| Pyrexia                     | 1 (0.5)                   | 11 (0.9)                                 | 48 (11.1)                                |
| Constipation                | 6 (3.1)                   | 62 (5.0)                                 | 37 (8.5)                                 |
| Nausea                      | 12 (6.1)                  | 57 (4.6)                                 | 14 (3.2)                                 |
| Fatigue                     | 12 (6.1)                  | 22 (1.8)                                 | 7 (1.6)                                  |
| Upper respiratory infection | 24 (12.2)                 | 94 (7.7)                                 | 5 (1.2)                                  |
| Nasopharyngitis             | 10 (5.1)                  | 57 (4.6)                                 | 24 (5.5)                                 |
| Urinary tract infection     | 9 (4.6)                   | 64 (5.2)                                 | 8 (1.8)                                  |
| Weight increased            | 11 (5.6)                  | 15 (1.2)                                 | 0                                        |
| Dizziness                   | 22 (11.2)                 | 34 (2.8)                                 | 3 (0.7)                                  |
| Paraesthesia                | 12 (6.1)                  | 8 (0.7)                                  | 0                                        |
| Anxiety                     | 11 (5.6)                  | 30 (2.4)                                 | 4 (0.9)                                  |

CM = chronic migraine; EM = episodic migraine; QD = once daily

Cross reference: ISS (R&amp;D/22/0367)Table 5-2.1.1

## Analysis of Adverse Events of Special Interest (AESI)

Cardiovascular  events  (cardiac  arrythmias,  central  nervous  system  vascular  disorders,  embolic  and thrombotic, hypertension, and ischaemic heart disease), hepatic AEs, suicide-related events, and abuserelated AEs were identified as AESIs for the placebo-controlled, long-term safety, and Phase 1 analysis sets.

## AESI: Cardiovascular Events

Cardiovascular events were examined for reported preferred terms that could be indicative of a potential effect of atogepant on the cardiovascular system because of blockade of calcitonin gene-related peptide (CGRP) receptors (which are expressed widely throughout the vascular system), and which could inhibit vasodilation, with potential effects on vascular tone, blood pressure, and global or regional blood flow. The following 5 AEs of clinical interest categories were evaluated: cardiac arrhythmias, ischaemic heart disease, hypertension, central nervous system vascular disorders, and embolic and thrombotic events.

## Placebo-Controlled Analysis Set

A history of hypertension was reported for 10.4% of participants in the placebo group; 10.5%, 10.5%, and 9.6% in the atogepant 10, 30, and 60 mg QD groups, respectively; and 7.9% and 13.2% in the atogepant 30 and 60 mg BID groups, respectively, in the placebo-controlled analysis set.

The incidence of hypertension AEs in the atogepant groups was low and similar to that of placebo in the placebo-controlled analysis set (0.5% in the placebo group; 0.6%, 1.0%, and 0.6% in the atogepant 10, 30, and 60 mg QD groups, respectively; and 1.7% and 1.1% in the atogepant 30 and 60 mg BID groups, respectively).

<div style=\"page-break-after: always\"></div>

Table 47: Number and percentage of participants with cardiovascular events in the placebocontrolled analysis set

| Category                             | Placebo (N=663)   |      | Atogepant 30 mg QD (N=411)   | Atogepant 10 mg QD (N=314) n (&)   | n (8)   |      | Atogepant 60 mg QD (N=678)   |      | (N=343) n (名)   | Atogepant 30 mg BID   | Atogepant 60 mg BID (N=91) n (名)   | Atogepant Overall (N=1837) n (名)   |      |
|--------------------------------------|-------------------|------|------------------------------|------------------------------------|---------|------|------------------------------|------|-----------------|-----------------------|------------------------------------|------------------------------------|------|
| Preferred Term                       | n (名)             |      |                              |                                    |         |      | n (名)                        |      |                 |                       |                                    |                                    |      |
| Cardiac arrhythmias TEAE             | 1                 | 0.2) | 1                            | 0.3)                               | 1       | 0.2) | 3                            | 0.4) | 1               | 0.3)                  | 0.0)                               | 6                                  | 0.3) |
| Ventricular extrasystoles            | 0                 | 0.0) | 0                            | 0.0)                               | 0       | 0.0) | 2                            | 0.3) | 1               | 0.3)                  | 0.0)                               | 3                                  | 0.2) |
| Atrioventricular block second degree | 0                 | 0.0) | 1                            | 0.3)                               | 0       | 0.0) | 0                            | 0.0) | 0               | 0.0)                  | 0.0)                               | 1                                  | 0.1) |
| Bundlebranch block left              | 0                 | 0.0) | 0                            | 0.0)                               | 0       | 0.0) | 1                            | 0.1) | 0               | 0.0)                  | 0.0)                               | 1                                  | 0.1) |
| Supraventricular extrasystoles       | 0                 | 0.0) | 0                            | 0.0)                               | 1       | 0.2) | 0                            |      | 0.0) 0          | 0.0)                  | 0.0)                               | 1                                  | 0.1) |
| Atrioventricular block first degree  | 1                 | 0.2) | 0                            | 0.0)                               | 0       | 0.0) | 0                            |      | 0.0)            | 0 0.0)                | 0.0)                               | 0                                  | 0.0) |
| Central nervous system vascular      | 0                 | 0.0) | 0                            | 0.0)                               | 1       | 0.2) | 2                            | 0.3) | 0               | 0.0)                  | 0.0)                               | 3                                  | 0.2) |
| disorders TEAE                       |                   |      |                              |                                    |         |      |                              |      |                 |                       |                                    |                                    |      |
| Hemianaesthesia                      | 0                 | 0.0) | 0                            | 0.0)                               | 0       | 0.0) | 1                            | 0.1) | 0               | 0.0)                  | 0.0)                               | 1                                  | 0.1) |
| Hemiparaesthesia                     | 0                 | 0.0) | 0                            | 0.0)                               | 0       | 0.0) | 1                            |      | 0.1) 0          | 0.0)                  | 0.0)                               | 1                                  | 0.1) |
| Intracranial aneurysm                | 0                 | 0.0) | 0                            | 0.0)                               | 1       | 0.2) | 0                            | 0.0) | 0               | 0.0)                  | 0.0)                               | 1                                  | 0.1) |
| Embolic and thrombotic events TEAE   | 0                 | 0.0) | 0                            | 0.0)                               | 0       | 0.0) | 2                            |      | 0.3) 1          | 0.3)                  | 0.0)                               | 3                                  | 0.2) |
| Deep vein thrombosis                 | 0                 | 0.0) | 0                            | 0.0)                               | 0       | 0.0) | 1                            | 0.1) | 0               | 0.0)                  | 0.0)                               | 1                                  | 0.1) |
| Haemorrhoids thrombosed              | 0                 | 0.0) | 0                            | 0.0)                               | 0       | 0.0) | 0                            | 0.0) | 1               | 0.3)                  | 0.0)                               | 1                                  | 0.1) |
| Postoperative thrombosis             | 0                 | 0.0) | 0                            | 0.0)                               | 0       | 0.0) | 1                            | 0.1) | 0               | 0.0)                  | 0.0)                               | 1                                  | 0.1) |
| Hypertension TEAE                    | 3                 | 0.5) | 2                            | 0.6)                               | 4       | 1.0) | 4                            | 0.6) | 6               | 1.7)                  | 1.1)                               | 17                                 | 0.9) |
| Hypertension                         | 1                 | 0.2) | 1                            | 0.3)                               | 4       | 1.0) | 3                            | 0.4) | 5               | 1.5)                  | 1.1)                               | 14                                 | 0.8) |
| Blood pressure diastolic increased   | 0                 | 0.0) | 1                            | 0.3)                               | 0       | 0.0) | 1                            | 0.1) | 0               | 0.0)                  | 0.0)                               | 2                                  | 0.1) |
| Blood pressure increased             | 1                 | 0.2) | 0                            | ( 0.0)                             | 1       | 0.2) | 0                            | 0.0) | 1               | 0.3)                  | 0.0)                               | 2                                  | 0.1) |
| Blood pressure fluctuation           | 1                 | 0.2) | 0 1                          | 0.0)                               | 0       | 0.0) | 0                            | 0.0) | 0               | 0.0)                  | 0.0)                               | 0                                  | 0.0) |
| Ischaemic heart disease TEAE         | 0                 | 0.0) | 0                            | 0.0)                               | 0       | 0.0) | 0                            | 0.0) | 0               | 0.0)                  | 0.0)                               | 0                                  | 0.0) |

Participants are counted only once within each category, and preferred term.

BID= twice daily;QD= once daily;TEAE = treatment-emergent adverse event Notes:

Cross reference: ISS (R&amp;D/22/0367) Tables 7-1.1.1 through 7-1.5.1

All hypertension AEs were mild or moderate in severity and non-serious and with the exception of the 1 participant in Study 303 (atogepant 30 BID group) with an AE of blood pressure increased, none were considered  by  the  investigator  to  be  related  to  study  drug.  No  dose-dependent  relationship  in  the incidence of hypertension events was evident. One participant in the atogepant 30 mg BID group in Study CGP-MD-01 had an AE of hypertension (worsening of) that resulted in discontinuation of study drug; the event was moderate and began on Day 54 and was ongoing at last report.

New antihypertensive medication use and/or increased dose of an existing antihypertensive medication occurred infrequently (0.8% in placebo versus 0.6%, 1.0%, and 0.1% in the atogepant 10, 30, and 60 mg QD groups, respectively, and 1.5% and 2.2% in the atogepant 30 and 60 mg BID groups).

The incidence  of  other  cardiovascular  events  was  low  in  the  placebo-controlled  analysis  set  and  no clinically meaningful differences between the placebo group and the atogepant groups were observed. No safety concerns were identified.

## AESI: Hepatic Safety

The atogepant clinical development programme incorporated monitoring for any signs of hepatic injury in  participants.  Hepatic  AEs  (comprised  of  the  hepatic  disorders  SMQ  [broad]  plus  the  PT  of  liver transplant) and laboratory data were examined.

A clinical external adjudication committee (an independent panel of liver experts) was established for the blinded surveillance, monitoring, and adjudication of postbaseline elevations of ALT and/or AST ≥ 3 × ULN for participants who received either atogepant o r placebo; aminotransferase elevations ≥ 3 × ULN for participants who received standard-of-care were not adjudicated per the adjudication charter. The adjudication charter defined a standardised process for the adjudication of data associated with these events to determine whether the elevation was related to study drug. The relationship of the cases to study drug was adjudicated using a 3-category scale (probable, possible, or unlikely) based on the criteria specified in the hepatic adjudication committee charter.

Postbaseline ALT or AST elevations ≥ 3 × ULN were prospectively defined in the Phase 2/3 study and Phase 3 studies as AESIs and were systematically investigated in accordance with the drug-induced liver injury (DILI) guidance (FDA 2009).

<div style=\"page-break-after: always\"></div>

## Placebo-Controlled Analysis Set (PCS)

## Hepatic Injury Adverse Events (PCS)

The percentages of participants in the placebo-controlled analysis set who had hepatic injury AEs were 1.8% in the placebo group versus 1.5% across atogepant groups. The most common AEs were ALT increased and AST increased.

None of these AEs was serious, and the majority were mild or moderate in severity. Two participants discontinued study drug because of these AEs.

| Category Preferred Term               | Placebo (N=663) n(8)   | Placebo (N=663) n(8)   | Atogepant 10mg QD (N=314) n (%)   |   Atogepant 30mgQD (N=411) n (8) | Atogepant 30mgQD (N=411) n (8)   |   Atogepant 60mg QD (N=678) n (%) | Atogepant 60mg QD (N=678) n (%)   |   Atogepant 30mg BID (N=343) n (%) | Atogepant 30mg BID (N=343) n (%)   |   Atogepant 60mgBID (N=91) n (%) | Atogepant 60mgBID (N=91) n (%)   | Atogepant Overall (N=1837) n (%)   | Atogepant Overall (N=1837) n (%)   | Atogepant Overall (N=1837) n (%)   |
|---------------------------------------|------------------------|------------------------|-----------------------------------|----------------------------------|----------------------------------|-----------------------------------|-----------------------------------|------------------------------------|------------------------------------|----------------------------------|----------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Hepatic Injury TEAE                   | 12                     | 1.8)                   | 1.9)                              |                                6 | 1.5)                             |                                11 | 1.6)                              |                                  4 | 1.2)                               |                                1 | 1.1)                             | 28                                 |                                    | 1.5)                               |
| Alanine aminotransferase increased    | 10                     | 1.5)                   | 6 5 1.6)                          |                                4 | 1.0)                             |                                 9 | 1.3)                              |                                  2 | 0.6)                               |                                1 | 1.1)                             |                                    | 21                                 | 1.1)                               |
| Aspartate aminotransferase increased  | 9                      | 1. 4)                  | 4 1.3)                            |                                4 | 1.0)                             |                                 7 | 1.0)                              |                                  3 | 0.9)                               |                                1 | 1.1)                             | 19                                 |                                    | 1.0)                               |
| Bloodalkaline phosphatase increased   | 2                      | 0.3)                   | 0 0.0)                            |                                1 | 0.2)                             |                                 1 | 0.1)                              |                                  0 | 0.0)                               |                                0 | 0.0)                             | 2                                  |                                    | 0.1)                               |
| Internationalnormalisedratioincreased | 0                      | 0.0) 0 0.0)            | 0.0)                              |                                1 | 0.2)                             |                                 0 | 0.0)                              |                                  1 | 0.3)                               |                                0 | 0.0)                             |                                    | 2                                  | 0.1)                               |
| Hepatitis E antibodypositive          | 0                      | 0                      | 0.0)                              |                                0 | 0.0)                             |                                 0 | 0.0)                              |                                  1 | 0.3)                               |                                0 | 0.0)                             |                                    | 1                                  | 0.1)                               |
| Liver injury                          | 0                      | 0.0) 0 0.0)            | 0.0)                              |                                0 | 0.0)                             |                                 1 | 0.1)                              |                                  0 | 0.0)                               |                                0 | 0.0)                             |                                    | 1 (                                | 0.1)                               |
| Prothrombin time prolonged            | 0                      | 0                      | 0.0)                              |                                0 | 0.0)                             |                                 0 | 0.0)                              |                                  1 | 0.3)                               |                                0 | 0.0)                             | 1                                  |                                    | 0.1)                               |
| Blood bilirubin increased             | 1 (                    | 0                      | ( 0.0)                            |                                0 | 0.0)                             |                                 0 | 0.0)                              |                                  0 | 0.0)                               |                                0 | 0.0)                             | 0                                  |                                    | 0.0)                               |
| Hepatic steatosis                     | 1                      | 0.2) 0.2) 0            | 0.0)                              |                                0 | 0.0)                             |                                 0 | 0.0)                              |                                  0 | 0.0)                               |                                0 | 0.0)                             | 0                                  |                                    | 0.0)                               |

Table 48: Number and percentage of participants with hepatic disorder or liver transplant adverse events in the placebo-controlled analysis set

<!-- image -->

## Hepatic Laboratory Values of Special Interest (PCS)

Postbaseline elevations of ALT and/or AST ≥ 3 × ULN were generally similar across atogepant groups and similar to placebo. No participant had concurrent ALT or AST elevations ≥ 3 × ULN and total bilirubin ≥ 1.5 × ULN.

One participant (atogepant 60 mg QD group), with a family history of Gilbert's syndrome, had a postbaseline isolated total bilir ubin elevation ≥ 2 × ULN.

<div style=\"page-break-after: always\"></div>

Table 49: Number and percentage of participants in the placebo-controlled analysis set with post-baseline hepatic laboratory values of special interest

| Hepatic Laboratory Parameter (Unit)   | Criterion                                  | Placebo (N=663) n/N1(8)   |       | Atogepant 10 mg QD (N=314) n/N1 (8)   | Atogepant 10 mg QD (N=314) n/N1 (8)   | Atogepant 30 mg QD (N=411) n/N1 (8)   | Atogepant 30 mg QD (N=411) n/N1 (8)   | Atogepant 60 mg QD (N=678) n/N1 (8)   | Atogepant 60 mg QD (N=678) n/N1 (8)   | Atogepant 30 mg BID (N=343) n/N1 (8)   | Atogepant 30 mg BID (N=343) n/N1 (8)   | Atogepant 60 mg BID (N=91) n/N1 (8)   | Atogepant Overall (N=1837) n/N1 (8)   | Atogepant Overall (N=1837) n/N1 (8)   |       |
|---------------------------------------|--------------------------------------------|---------------------------|-------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|----------------------------------------|----------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-------|
| ALT (U/L)                             | >= 1.0 ULN                                 | 85/653                    | 13.0) | 30/312                                | 9.6)                                  | 46/405                                | 11.4)                                 | 59/666                                | 8.9)                                  | 27/339                                 |                                        | 8.0) 8/88 2.7)                        | 9.1) 170/1810 1.1)                    |                                       | 9.4)  |
| ALT (U/L)                             | >= 1.5 ULN                                 | 33/653                    | 5.1)  | 5/312                                 | 1.6)                                  | 19/405                                | 4.7)                                  | 19/666                                | 2.9)                                  | 9/339                                  |                                        | 1/88                                  |                                       | 53/1810                               | 2.9)  |
| ALT (U/L)                             | >= 2.0 ULN                                 | 15/653                    | 2.3)  | 5/312                                 | 1.6)                                  | 6/405                                 | 1.5)                                  | 9/666                                 | 1.4)                                  | 3/339                                  | 0.9)                                   | 1/88                                  | 1.1)                                  | 24/1810                               | 1.3)  |
| ALT (U/L)                             | >= 3.0 ULN                                 | 6/653                     | 0.9)  | 4/312                                 | 1.3)                                  | 2/405                                 | 0.5)                                  | 4/666                                 | 0.6)                                  | 2/339                                  | 0.6)                                   | 1/88                                  | 1.1)                                  | 13/1810                               | 0.7)  |
| ALT (U/L)                             | >= 5.0 * ULN                               | 2/653                     | 0.3)  | 1/312                                 | 0.3)                                  | 1/405                                 | 0.2)                                  | 2/666                                 | 0.3)                                  | 1/339                                  | 0.3)                                   | 0/88                                  | 0.0)                                  | 5/1810                                | 0.3)  |
| ALT (U/L)                             | >= 10.0 ULN                                | 0/653                     | 0.0)  | 1/312                                 | 0.3)                                  | 0/405                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 1/1810                                | 0.1)  |
| ALT (U/L)                             | >= 20.0 NTN                                | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/405                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 0/1810                                | 0.0)  |
| AST (U/L)                             | >= 1.0 ULN                                 | 51/653                    | 7.8)  | 16/312                                | 5.1)                                  | 21/405                                | 5.2)                                  | 34/666                                | 5.1)                                  | 14/339                                 | 4.1)                                   | 2/88                                  | 2.3)                                  | 87/1810                               | 4.8)  |
| AST (U/L)                             | >= 1.5 * ULN                               | 17/653                    | 2.6)  | 5/312                                 | 1.6)                                  | 6/405                                 | 1.5)                                  | 9/666                                 | 1.4)                                  | 6/339                                  | 1.8)                                   | 1/88                                  | 1.1)                                  | 27/1810                               | 1.5)  |
| AST (U/L)                             | >= 2.0 ULN                                 | 7/653                     | 1.1)  | 3/312                                 | 1.0)                                  | 5/405                                 | 1.2)                                  | 8/666                                 | 1.2)                                  | 4/339                                  | 1.2)                                   | 1/88                                  | 1.1)                                  | 21/1810                               | 1.2)  |
| AST (U/L)                             | >= 3.0 ULN                                 | 4/653                     | 0.6)  | 1/312                                 | 0.3)                                  | 3/405                                 | 0.7)                                  | 5/666                                 | 0.8)                                  | 2/339                                  | 0.6)                                   | 0/88                                  | 0.0)                                  | 11/1810                               | 0.6)  |
| AST (U/L)                             | >= 5.0 ULN                                 | 3/653                     | 0.5)  | 1/312                                 | 0.3)                                  | 0/405                                 | 0.0)                                  | 4/666                                 | 0.6)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 5/1810                                | 0.3)  |
| AST (U/L)                             | >= 10.0 ULN                                | 0/653                     | 0.0)  | 1/312                                 | 0.3)                                  | 0/405                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | （                                      | 0.0)                                  | 0.0)                                  | 1/1810                                | 0.1)  |
| AST (U/L)                             | >= 20.0 ULN                                | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/405                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88 0/88                             | 0.0)                                  | 0/1810                                | 0.0)  |
| ALT or AST (U/L)                      | >= 1.0 *ULN                                | 93/653                    | 14.2) | 36/312                                | 11.5)                                 | 50/405                                | 12.3)                                 | 71/666                                | 10.7)                                 | 32/339                                 |                                        | 9.4) 9/88                             | 10.2)                                 | 198/1810                              | 10.9) |
| ALT or AST (U/L)                      | >= 1.5 ULN                                 | 35/653                    | 5.4)  | 7/312                                 | 2.2)                                  | 20/405                                | 4.9)                                  | 21/666                                | 3.2)                                  | 10/339                                 | （ 2.9)                                 | 1/88                                  | 1.1)                                  | 59/1810                               | 3.3)  |
| ALT or AST (U/L)                      | >= 2.0 ULN                                 | 17/653                    | 2.6)  | 6/312                                 | 1.9)                                  | 8/405                                 | 2.0)                                  | 12/666                                | 1.8)                                  | 5/339                                  | 1.5)                                   | 1/88                                  | 1.1)                                  | 32/1810                               | 1.8)  |
| ALT or AST (U/L)                      | >= 3.0 ULN                                 | 8/653                     | 1.2)  | 4/312                                 | 1.3)                                  | 3/405                                 | 0.7)                                  | 6/666                                 | 0.9)                                  | 3/339                                  | 0.9)                                   | 1/88                                  | 1.1)                                  | 17/1810                               | 0.9)  |
| ALT or AST (U/L)                      | >= 5.0 *ULN                                | 4/653                     | 0.6)  | 1/312                                 | 0.3)                                  | 1/405                                 | 0.2)                                  | 4/666                                 | 0.6)                                  | 1/339                                  | 0.3)                                   | 0/88                                  | 0.0)                                  | 7/1810                                | 0.4)  |
| ALT or AST (U/L)                      | >= 10.0 *ULN                               | 0/653                     | 0.0)  | 1/312                                 | 0.3)                                  | 0/405                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 1/1810                                | 0.1)  |
| ALT or AST (U/L)                      | >= 20.0 ★ ULN                              | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/405                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 0/1810                                | 0.0)  |
| TBL (umol/ L)                         | >= 1.0 *ULN                                | 18/653                    | 2.8)  | 7/312                                 | 2.2)                                  | 21/404                                | 5.2)                                  | 27/666                                | 4.1)                                  | 11/339                                 | 3.2)                                   | 1/88                                  | 1.1)                                  | 67/1809                               | 3.7)  |
| TBL (umol/ L)                         | >= 1.5 ULN                                 | 4/653                     | 0.6)  | 1/312                                 | 0.3)                                  | 3/404                                 | 0.7)                                  | 6/666                                 | 0.9)                                  | 2/339                                  | 0.6)                                   | 0/88                                  | 12/1809                               |                                       | 0.7)  |
| TBL (umol/ L)                         | >= 2.0 ULN                                 | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 1/666                                 | 0.2)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0) 0.0)                             | 1/1809                                | 0.1)  |
| TBL (umol/ L)                         | >= 3.0 ULN                                 | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 0/1809                                | 0.0)  |
| TBL (umol/ L)                         | >= 5.0 ULN                                 | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | （ 0.0)                                 | 0/88                                  | 0.0)                                  | 0/1809                                | 0.0)  |
| TBL (umol/ L)                         | >= 10.0 ULN                                | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | （ 0.0)                                 | 0/88                                  | 0.0)                                  | 0/1809                                | 0.0)  |
| TBL (umol/ L)                         | >= 20.0 ULN                                | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 0/1809                                | 0.0)  |
| ALP (U/L)                             | >= 1.0 ★ ULN                               | 52/653                    | 8.0)  | 33/312                                | 10.6)                                 | 44/404                                | 10.9)                                 | 51/666                                | 7.7)                                  | 18/339                                 | 5.3)                                   | 3/88                                  | 3.4) 0.0)                             | 149/1809                              | 8.2)  |
| ALP (U/L)                             | >= 1.5 ULN                                 | 4/653                     | 0.6)  | 5/312                                 | 1.6)                                  | 2/404                                 | 0.5)                                  | 2/666                                 | 0.3)                                  | 2/339                                  | 0.6)                                   | 0/88                                  | 11/1809                               |                                       | 0.6)  |
| ALP (U/L)                             | >= 2.0 *ULN                                | 0/653                     | 0.0)  | 2/312                                 | 0.6)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 1/339                                  | 0.3)                                   | 0/88                                  |                                       | 3/1809                                | 0.2)  |
| ALP (U/L)                             | >= 3.0 *ULN                                | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 1/339                                  | 0.3)                                   | 0/88                                  | 0.0) 0.0)                             | 1/1809                                | 0.1)  |
| ALP (U/L)                             | >= ：5.0*ULN                                | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 0/1809                                | 0.0)  |
| ALP (U/L)                             | >= 10.0* ULN                               | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 0/1809                                | 0.0)  |
| ALP (U/L)                             | >=20.0*ULN                                 | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 0/1809                                | 0.0)  |
| Concurrent elevations*                | ALT or AST >=                              | 0/653                     | 0.0)  | 0/312                                 | 0.0)                                  | 0/404                                 | 0.0)                                  | 0/666                                 | 0.0)                                  | 0/339                                  | 0.0)                                   | 0/88                                  | 0.0)                                  | 0/1809                                | 0.0)  |
|                                       | 3.0 X ULN AND TBL >=1.5x ULN ALT or AST >= | 0/653（                    |       |                                       |                                       |                                       |                                       |                                       |                                       |                                        |                                        |                                       |                                       |                                       |       |
|                                       | 3.0 *ULN AND TBL >=2.0x                    |                           | 0.0)  | 0/312（                                | 0.0)                                  | 0/404（（                               | 0.0)                                  | 0/666(0.0)                            |                                       | 0/339（                                 | 0.0)                                   | 0/88（                                 | 0.0)                                  | 0/1809（                               | 0.0)  |
| Potential                             | ULN ALT or AST >= 3.0                      | 0/653（                    | 0.0)  | 0/312（                                | 0.0)                                  |                                       |                                       | 0/404(0.0）0/666(0.0)                  |                                       | 0/339（                                 | 0.0)                                   | 0/88                                  | 0.0)                                  | 0/1809 (0.0)                          |       |
| Hy's Law*                             | *ULN AND TBL >=2.0x ULNANDALP< 2.0* ULN    |                           |       |                                       |                                       |                                       |                                       |                                       |                                       |                                        |                                        |                                       |                                       |                                       |       |

bilirubin; QD = once daily; ULN = upper limit of normal

ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; BID = twice daily; TBL = total

x Concurrent elevations are from the same day.

N = number of participants in the safety population of the treatment group.

Notes:

Nl = number of participants with at least one postbaseline assessment.

Percentages are calculated as 100 x (n/Nl)

n = number of participants within a specific category.

Twenty-four participants in the placebocontrolled analysis set had ALT and/or AST elevations ≥ 3 × ULN that  were  adjudicated  by  the  clinical  adjudication  committee;  17  of  these  cases  were  in  atogepant groups. Of these 17 cases in atogepant-treated participants, 2 cases (1 in the atogepant 30 mg QD group and 1 in the atogepant 60 mg QD group) were adjudicated as probably related to study drug and 2 cases (1 in the atogepant 10 mg QD group and 1 in the atogepant 30 mg QD group) were adjudicated as possibly related. The remaining 13 atogepant cases were adjudicated as unlikely related to study drug.

All 4 atogepant-treated cases that were adjudicated as probably or possibly related to study drug were asymptomatic, non-serious, mild or moderate in severity, without concurrent bilirubin elevations, and resolved with or without atogepant discontinuation; all but one of these cases had potential confounding factors.

<div style=\"page-break-after: always\"></div>

Table 50: Number and percentage of participants in the placebo-controlled analysis set with adjudicated cases of post-baseline elevations of ALT and/or AST ≥ 3 × ULN by relationship to study drug

<!-- image -->

## Long-Term Safety Analysis Set (LTS)

## Hepatic Injury Adverse Events (LTS)

The number and percentages of participants in the standard-of-care and atogepant 60 mg QD groups who had hepatic injury AEs in the long-term safety analysis were similar (3.1% and 2.5%, respectively). The most common AEs were AST increased and ALT increased. The AE of hepatitis E antibody positive was  reported  for  6  participants  (0.4%)  in  the  atogepant  60  mg  QD  group;  per  the  protocols  all participants from the lead-in studies were to repeat hepatitis E serology tests at the time of enrolment in the long-term extension studies and participants with a positive result were to be discontinued from study drug.

The majority of AEs were mild or moderate in severity and non-serious. Fifteen participants had AEs that led to discontinuation of study drug.

Table 51: Number and percentage of participants with hepatic disorder or liver transplant adverse events in the long-term safety analysis set

| Category                             | Standard-of-Care (N=196)   | Atogepant 60mg QD (N=1662)   |
|--------------------------------------|----------------------------|------------------------------|
| Preferred Term                       | n (名)                      | n ()                         |
| Hepatic Injury TEAE                  | 6 3.1)                     | 42 2.5)                      |
| Aspartate aminotransferase increased | 5 2.6)                     | 29 1.7)                      |
| Alanine aminotransferase increased   | 4 2.0)                     | 27 1.6)                      |
| HepatitisE antibodypositive          | 0 0.0)                     | 6 0.4)                       |
| Bloodalkalinephosphataseincreased    | 0 0.0)                     | 4 0.2)                       |
| Hepatic function abnormal            | 0 0.0)                     | 1 0.1)                       |
| Hepatic steatosis                    | 0 0.0)                     | 1 0.1)                       |
| Hepatitis E                          | 0 0.0)                     | 1 0.1)                       |
| Hypertransaminasaemia                | 0 0.0)                     | 1 0.1)                       |
| Prothrombintimeprolonged             | 0 0.0)                     | 1 0.1)                       |

=treatment-emergentadverseevent

QD=once daily;TEAE

Note:

Participants are counted only once within each category，and preferred term.

## Hepatic Laboratory Values of Special Interest (LTS)

Postbaseline elevations of ALT and/or AST ≥ 3 × ULN were higher in the standard -of-care group (3.2%) than in the atogepant 60 mg group (1.5%).

One participant (atogepant 60 mg QD group) had concurrent ALT or AST elevations ≥ 3 × ULN and total bilirubin ≥ 1.5 × ULN, in the context of symptomatic cholelithiasis. This case was considered by the investigator to be not related to study drug and adjudicated as unlikely related to study drug by the external adjudication committee.

<div style=\"page-break-after: always\"></div>

One participant (atogepant 60 mg QD group), with a history of Gilbert's syndrome, had isolated postbaseline total bilirubin elevations ≥ 2 × ULN.

Table 52: Number and percentage of participants in the long-term safety analysis set with post-baseline hepatic laboratory values of special interest

| Hepatic Laboratory Parameter (Unit)   | Criterion                                                                | (N=196) n/N1 (%)   | Atogepant 60 mg QD (N=1662) n/N1 (8)   |
|---------------------------------------|--------------------------------------------------------------------------|--------------------|----------------------------------------|
| ALT (U/L)                             | >= 1.0 ULN                                                               | 47/190 24.7)       | 207/1643 12.6)                         |
| ALT (U/L)                             | >= 1.5 ULN                                                               | 14/190 7.4)        | 73/1643 4.4)                           |
| ALT (U/L)                             | >= 2.0 ULN                                                               | 8/190 4.2)         | 43/1643 2.6)                           |
| ALT (U/L)                             | >= 3.0 ULN                                                               | 3/190 1.6)         | 20/1643 1.2)                           |
| ALT (U/L)                             | >= 5.0 ULN                                                               | 1/190 0.5)         | 10/1643 0.6)                           |
| ALT (U/L)                             | >= 10.0 ULN                                                              | 0/190 0.0)         | 3/1643 0.2)                            |
| ALT (U/L)                             | >= 20.0 ULN                                                              | 0/190 0.0)         | 1/1643 0.1)                            |
| AST (U/L)                             | >= 1.0 ULN                                                               | 34/190 17.9)       | 125/1644 7.6)                          |
| AST (U/L)                             | >= 1.5 ULN                                                               | 7/190 3.7)         | 56/1644 3.4)                           |
| AST (U/L)                             | >= 2.0 ULN                                                               | 5/190 2.6)         | 29/1644 1.8)                           |
| AST (U/L)                             | >= 3.0 ULN                                                               | 4/190 2.1)         | 16/1644 1.0)                           |
| AST (U/L)                             | >= 5.0 ULN                                                               | 0/190 0.0)         | 8/1644 0.5)                            |
| AST (U/L)                             | >= 10.0 ULN                                                              | 0/190 0.0)         | 3/1644 0.2)                            |
| AST (U/L)                             | >= 20.0 ★ULN                                                             | 0/190 0.0)         | 1/1644 0.1)                            |
| ALT or AST (U/L)                      | >= 1.0 ULN                                                               | 55/190 28.9)       | 236/1644 14.4)                         |
| ALT or AST (U/L)                      | >= 1.5 ULN                                                               | 16/190 8.4)        | 90/1644 5.5)                           |
| ALT or AST (U/L)                      | >= 2.0 ULN                                                               | 11/190 5.8)        | 50/1644 3.0)                           |
| ALT or AST (U/L)                      | >= 3.0 ULN                                                               | 6/190 3.2)         | 24/1644 1.5)                           |
| ALT or AST (U/L)                      | >= 5.0 ULN                                                               | 1/190 0.5)         | 12/1644 0.7)                           |
| ALT or AST (U/L)                      | >= 10.0 ULN                                                              | 0/190 0.0)         | 4/1644 0.2)                            |
| ALT or AST (U/L)                      | >= 20.0 ULN                                                              | 0/190 0.0)         | 1/1644 0.1)                            |
| TBL (umol/L)                          | >= 1.0 ULN                                                               | 10/190 5.3)        | 72/1643 4. 4)                          |
| TBL (umol/L)                          | >= 1.5 ULN                                                               | 0/190 0.0)         | 9/1643 0.5)                            |
| TBL (umol/L)                          | >= 2.0 ULN                                                               | 0/190 0.0)         | 1/1643 0.1)                            |
| TBL (umol/L)                          | >= 3.0 ★ ULN                                                             | 0/190 0.0)         | 0/1643 0.0)                            |
| TBL (umol/L)                          | >= ：5.0 ULN                                                              | 0/190 0.0)         | 0/1643 0.0)                            |
| TBL (umol/L)                          | >= 10.0 ★ULN                                                             | 0/190 0.0)         | 0/1643 0.0)                            |
| TBL (umol/L)                          | >= 20.0 ULN                                                              | 0/190 0.0)         | 0/1643 0.0)                            |
| ALP (U/L)                             | >= 1.0 ULN                                                               | 32/190 16.8)       | 210/1643 12.8)                         |
| ALP (U/L)                             | >= 1.5 ULN                                                               | 3/190 1.6)         | 17/1643 1.0)                           |
| ALP (U/L)                             | >= 2.0 ULN                                                               | 0/190 0.0)         | 5/1643 0.3)                            |
| ALP (U/L)                             | >= 3.0 ULN                                                               | 0/190 0.0)         | 1/1643 0.1)                            |
| ALP (U/L)                             | >= 5.0 ULN                                                               | 0/190 0.0)         | 0/1643 0.0)                            |
| ALP (U/L)                             | >=10.0*ULN                                                               | 0/190 0.0)         | 0/1643 0.0)                            |
| ALP (U/L)                             | >=20.0xULN                                                               | 0/190 0.0)         | 0/1643 0.0)                            |
| Concurrent elevations*                | ALT or AST >=3.0*ULNAND                                                  | 0/190 0.0)         | 1/1643 0.1)                            |
| Concurrent elevations*                | TBL >= 1.5 ULN ALT or AST >=3.0 *ULN AND                                 | 0/190 0.0)         | 0/1643 0.0)                            |
| PotentialHy'sLaw*                     | TBL >= 2.0 *ULN ALT or AST >=3.0*ULN AND TBL >= ：2.0 *ULNANDALP< 2.0 ULN | 0/190 0.0)         | 0/1642 0.0)                            |

ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; TBL = total bilirubin; ULN = upper limit of normal Notes:

N = number of participants in the safety population of the treatment group.

n = number of participants within a specific category.

Nl= number of participants with at least one postbaseline assessment.

Percentages are calculated as lo0 x (n/Nl).

Twenty-four participants (all in the atogepant 60 mg QD group) in the long-term safety analysis set had ALT and/or AST elevations ≥ 3 × ULN. Twenty -two of these cases were adjudicated by the external clinical adjudication committee prior to the 10 January 2022 clinical cutoff date. The remaining 2 cases were adjudicated in April 2022. Three cases were adjudicated as probably related to study drug and 5 cases  were  adjudicated  as  possibly  related;  the  remaining  16  atogepant  cases  were  adjudicated  as unlikely  related  to  study  drug.  Aminotransferase  elevations  in  the  standard-of-care  group  were  not adjudicated per the adjudication charter.

Among the 8 cases that were adjudicated as probably or possibly related to study drug all were nonserious, mild to moderate in severity, without concurrent bilirubin elevation, and resolved with or without atogepant discontinuation.

<div style=\"page-break-after: always\"></div>

Table 53: Number and percentage of participants in the long-term safety analysis set with adjudicated cases of postbaseline elevations of ALT and/or AST ≥ 3 × ULN by relationship to study drug

<!-- image -->

## AESI: Suicidal Ideation and Suicidal Behaviour

The potential risk of suicidal ideation and suicidal behaviour was examined because brain-penetrant drugs can cause behavioural or psychiatric side-effects. Atogepant was not associated with an increased risk of suicidal ideation or suicidal behaviour compared with placebo in the placebo-controlled analysis set or with the  standard-of-care group in the long-term safety analysis set.

Suicidal ideation was reported via C-SSRS assessment for &lt; 1% of participants in any of the atogepant groups during the treatment period in either the placebo-controlled analysis set or the long-term safety analysis  set.  The  percentage  of  participants  with  suicidal  ideation  or  behaviour  in  the  atogepant treatment groups was similar or lower than that of the placebo or standard-of-care groups.

## AESI: Abuse

There is no evidence in the literature that CGRP signalling is linked to drug reinforcement or physical dependence and/or withdrawal. Atogepant, a potent CGRP receptor antagonist (Ki = 15-26 pM), did not exhibit significant affinity for a variety of central nervous system targets known to be associated with drugs of abuse, e.g., dopamine, cannabinoid, acetylcholine and opioid receptors, gamma-aminobutyric acid  (GABA)  or  N-methyl-D-aspartate  (NMDA)  receptor  complex,  and  transporters  for  dopamine, serotonin, and norepinephrine.

AE PTs potentially predictive of abuse potential were identified based on the FDA Guidance for Industry: Assessment of Abuse Potential of Drugs (2017). The totality of the data support a lack of abuse potential risk with atogepant based on its pharmacological class and properties and its lack of abuse signal in nonclinical and clinical studies.

- Serious adverse events, deaths, and other significant events

## Serious Adverse Events (SAEs)

## Placebo-controlled Analysis Set

The percentages of participants with SAEs in the atogepant groups in the placebo-controlled analysis set were low and similar to that of placebo with no more than 1.3% of participants in any of the atogepant groups having had SAEs compared with 1.1% of participants in the placebo group. A total of 3.6% of participants in the standard-of-care group and 3.4% of participants in the atogepant 60 mg QD group had SAEs in the long-term safety analysis set. The majority of preferred terms for SAEs were not reported for more than 1 participant. With the exception of an SAE of optic neuritis in the placebo-controlled

<div style=\"page-break-after: always\"></div>

analysis set (atogepant 10 mg QD), none of the SAEs was considered by the investigator to be related to study drug. The event of optic neuritis was considered by the sponsor to be not related to study drug as the characteristics of the event were not consistent with the diagnosis of optic neuritis.

## Long-term Safety Analysis Set

SAEs were reported for 3.6% of participants in the standard-of-care group and 3.4% of participants in the  atogepant  60  mg  group  in  the  long-term  safety  analysis  set  (2.7.4,  Table  22).  The  majority  of preferred terms were not reported for more than 1 participant. None of the SAEs was considered by the investigator to be related to study drug.

## Death

No fatal AEs were reported in the placebo-controlled analysis set or in the Phase 1 analysis set; 3 fatal AEs, all in the atogepant 60 mg QD group in the long-term safety analysis set were reported. The causes of death were beta-haemolytic streptococcal infection (toxic shock syndrome), homicide, and asphyxia (by house fire). None of the deaths was considered by the investigator to be related to study drug. Narratives for deaths are provided.

## · Laboratory findings

Analysis of laboratory parameters does not suggest any safety concerns. Mean changes from baseline to post-baseline visits were similar across treatment groups in both the placebo-controlled analysis set and the long-term safety analysis set.

## Blood Pressure Over Time

Mean and median changes from baseline to predefined visits and to the end of study for blood pressure parameters  in  the  placebo-controlled  analysis  set  were  typically  small  and  similar  across  treatment groups.

Figure 14: Mean sitting systolic blood pressure in the placebo-controlled analysis set

<!-- image -->

ATO = atogepant; BID = twice daily, CI = confidence interval; QD = once daily; SFU = safety follow-up

<div style=\"page-break-after: always\"></div>

Figure 15: Mean sitting diastolic blood pressure in the placebo-controlled analysis set

ATO = atogepant; BID = twice daily, CI= confidence interval; QD = once daily, SFU = safety follow-up

<!-- image -->

## Weight

A total of 14.1% of participants in the placebo-controlled analysis set had a history of obesity at baseline: 13.9% in the placebo group and 14.2% in the atogepant groups (8.7% to 20.1% across the atogepant groups). Mean weight at baseline for all participants was 79.3 kg, and mean BMI was 28.86 kg/m 2 , with 25% of participants weighing between 92.0 and 226 kg and 25% of participants with a BMI between 33.18 and 82.0 kg/m 2 .

The change from baseline to end of treatment in mean weight was +0.23 kg in the placebo group versus +0.07, -0.40, and -0.90 kg in the atogepant 10, 30, and 60 mg QD groups, respectively, and -0.86 in both the atogepant 30 and 60 mg BID groups; weight appeared to decrease in a dose-dependent manner across atogepant groups. Decreases in mean weight in the atogepant groups were apparent at Week 2, the first post-dose measurement, and continued to decrease over the 12-week treatment period.

Increases and decreases in weight that met potentially clinically significant (PCS) criteria (≥ 7% change from baseline) were observed in both the placebo and atogepant groups. The percentage of participants with PCS weight decrease was greater in the atogepant groups (4.6%) than in the placebo group (2.5%) and appeared to be dose-dependent. The percentage of participants with PCS weight gain was lower in the atogepant groups (1.6%) than in the placebo group (2.3%).

<div style=\"page-break-after: always\"></div>

Figure 16: Potentially clinically significant decreases or increases in weight in the placebocontrolled analysis set

<!-- image -->

In the Long-Term Safety Analysis Set, the change from baseline to end of treatment in mean weight was +0.20 kg in the standard-of-care group and -1.60 kg in the atogepant 60 mg QD group. A decrease in mean  weight  in  the  atogepant  60  mg  QD  group  was  apparent  at  Week  4,  the  first  post-dose measurement, and remained generally stable after approximately Week 20.

Increases and decreases in weight that met PCS crite ria (≥ 7% change from baseline) were observed in both the standard-of-care and atogepant 60 mg QD groups. The percentage of participants with PCS weight decrease was 23.4% than in the atogepant 60 mg QD group and 14.7% in the standard-of-care group. The percentage of participants with PCS weight gain was 7.4% in the atogepant 60 mg QD group and 12.6% in the standard-of-care group.

Figure 17: Potentially clinically significant decreases or increases in weight in the long-term safety analysis set

<!-- image -->

## Safety related to drug-drug interactions and other interactions

Drug interactions studies were conducted for concomitant administration of atogepant with ubrogepant, topiramate,  sumatriptan,  naproxen  /  acetaminophen,  oral  contraceptives,  esomeprazole,  quinidine, rifampin, and itraconazole.

Changes in atogepant exposure were observed after co-administration of strong CYP3A4 inhibitors, OATP inhibitors,  and  strong  CYP3A4  inducers.  Appropriate  guidance  for  prescribers  and  participants  was proposed in the labelling with respect to drug-drug interactions.

To examine the potential effects of drug interactions, AE data were examined in the subset of participants who took common classes of concomitant medications (i.e., World Health Organization Drug Dictionary ATC4 medication classes used by ≥ 10% of particip ants in any treatment group during the treatment period) in the placebo-controlled studies and in the long-term safety studies. Review of AE data showed no appreciable differences in the type of AEs reported in the subsets of participants who took common

<div style=\"page-break-after: always\"></div>

classes  of  concomitant  medications  for  the  placebo-controlled  and  long-term  safety  analysis  sets, respectively.

## Discontinuation due to adverse events

## Placebo-Controlled Analysis Set

AEs that led to discontinuation of study drug were reported for 3.2% of participants in the placebo group; 4.1%, 3.4%, and 3.1% of participants in the atogepant 10, 30, and 60 mg QD groups, respectively; and 5.2% and 6.6% of participants in the 30 and 60 mg BID groups, respectively, in the placebo-controlled analysis  set.  AEs  that  led  to  discontinuation  in  more  than  1  participant  in  any  treatment  group  are presented in the table below.

Table 54: Number and percentage of participants (≥ 2 participants in any treatment group) with AEs that led to discontinuation in the placebo-controlled analysis set

| Preferred Term                                  |   Placebo (N=663) n (%) | Placebo (N=663) n (%)   |   Atogepant 10 mg QD (N=314) n (8) | Atogepant 10 mg QD (N=314) n (8)   |   Atogepant 30mg QD (N=411) n (%) | Atogepant 30mg QD (N=411) n (%)   | Atogepant 60mg QD (N=678) n (%)   | Atogepant 60mg QD (N=678) n (%)   |   Atogepant 30mg BID (N=343) n (8) | Atogepant 30mg BID (N=343) n (8)   | Atogepant 60mg BID (N=91) n (8)   | Atogepant 60mg BID (N=91) n (8)   |   Atogepant Overall (N=1837) n (%) | Atogepant Overall (N=1837) n (%)   |
|-------------------------------------------------|-------------------------|-------------------------|------------------------------------|------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|------------------------------------|------------------------------------|-----------------------------------|-----------------------------------|------------------------------------|------------------------------------|
| Participants with AEsleading to discontinuation |                      21 | 3.2)                    |                                 13 | 4.1)                               |                                14 | 3.4)                              | 21                                | 3.1)                              |                                 18 | 5.2)                               | 6                                 | 6.6)                              |                                 72 | 3.9)                               |
| Palpitations                                    |                       0 | 0.0)                    |                                  0 | 0.0)                               |                                 0 | 0.0)                              | 0                                 | 0.0)                              |                                  2 | 0.6)                               | 0                                 | 0.0)                              |                                  2 | 0.1)                               |
| Nausea                                          |                       2 | 0.3)                    |                                  1 | 0.3)                               |                                 3 | 0.7)                              | 3 (                               | 0.4)                              |                                  3 | 0.9)                               | 1 一                               | 1.1)                              |                                 11 | 0.6)                               |
| Constipation                                    |                       2 | 0.3)                    |                                  1 | 0.3)                               |                                 3 | 0.7)                              | 2                                 | 0.3)                              |                                  3 | 0.9)                               | 1                                 | 1.1)                              |                                 10 | 0.5)                               |
| Abdominal distension                            |                       0 | 0.0)                    |                                  0 | 0.0)                               |                                 0 | 0.0)                              | 0                                 | 0.0)                              |                                  3 | 0.9)                               | 0                                 | 0.0)                              |                                  3 | 0.2)                               |
| Abdominal pain                                  |                       3 | 0.5)                    |                                  1 | 0.3)                               |                                 0 | 0.0)                              | 0                                 | 0.0)                              |                                  1 | 0.3)                               | 0 (                               | 0.0)                              |                                  2 | 0.1)                               |
| Fatigue                                         |                       0 | 0.0)                    |                                  1 | 0.3)                               |                                 0 | 0.0)                              | 1                                 | 0.1)                              |                                  1 | 0.3)                               | 3 (                               | 3.3)                              |                                  6 | 0.3)                               |
| Dizziness                                       |                       1 | 0.2)                    |                                  0 | 0.0)                               |                                 2 | 0.5)                              | 1 1                               | 0.1)                              |                                  1 | 0.3)                               | 2 (                               | 2.2)                              |                                  6 | 0.3)                               |
| Migraine                                        |                       6 | 0.9)                    |                                  0 | 0.0)                               |                                 1 | 0.2)                              | 2                                 | 0.3)                              |                                  0 | 0.0)                               | 0                                 | 0.0)                              |                                  3 | 0.2)                               |
| Pruritus                                        |                       0 | 0.0)                    |                                  0 | 0.0)                               |                                 0 | 0.0)                              | 2                                 | 0.3)                              |                                  0 | 0.0)                               | 0                                 | 0.0)                              |                                  2 | 0.1)                               |
| Rash                                            |                       0 | 0.0)                    |                                  0 | 0.0)                               |                                 0 | 0.0)                              | 2                                 | 0.3)                              |                                  0 | 0.0)                               | 0                                 | 0.0)                              |                                  2 | 0.1)                               |

<!-- image -->

## · Post marketing experience

Atogepant  10,  30,  and  60  mg  QD  was  approved  in  the  United  States  on  28  September  2021 (International Birth Date) for the preventive treatment of EM in adults. The cumulative patient exposure to Qulipta from 28 September 2021 is 35,827 patient treatment years, based on available sales data through 31 October 2022.

A summary of post-marketing reports from 28 September 2021 to 27 March 2022 showed no safety signals.

One spontaneous post-marketing report of acute liver failure with atogepant 60 mg QD that led to liver transplantation was retrieved from the search through 27 March 2022 (described in detail Mod. 2.7.4). AbbVie has performed additional follow-up with due diligence to acquire further information on the case (included in the CIOMS report). The expert opinion was sought to provide causality assessment for the acute liver failure event.

## Introduction

On 07 March 2022, AbbVie received follow-up information on a serious spontaneous report of acute liver failure with atogepant that was initially reported as non-serious acute hepatitis.

<div style=\"page-break-after: always\"></div>

AbbVie reviewed this case and sought the expert opinion. It was concluded there was insufficient data to assign causality. Additional follow-up with due diligence was performed to acquire further information on the case.

## Case Narrative

A female patient experienced acute liver failure on Day 127 after atogepant initiation, that led to liver transplantation. Atogepant 60 mg QD was started for \"headache\".

The patient's medical history included attention deficit and hyperactivity disorder (ADHD), depression, anxiety, migraine, constipation, and social occasional drinker. No history of obesity (unknown BMI), liver diseases, or alcohol abuse was noted.

The  patient's  concomitant  medications  and  herbal  dietary  supplements  included  paroxetine  for depression,  clonazepam  as  needed  for  anxiety,  amphetamine  and  dextroamphetamine  for  ADHD, trazodone as needed for anxiety, and linaclotide for constipation. No start date was reported for any of these medications; however, all were discontinued on Day 127. Botulinum toxin type A for migraine prevention was injected on an unknown day approximately 2 months after atogepant initiation.

On Day 76 after atogepant initiation, the patient underwent an outpatient surgical procedure. Cefazoline 2  grams  was  administered  pre-operatively.  Fentanyl,  rocuronium,  succinylcholine,  and  unspecified steroids (8 mg) were administered intra-operatively. It is unknown whether any inhaled anaesthetics were used or if the patient received inhaled anaesthetics in prior surgeries. A 7-day course of cephalexin was prescribed post-operatively. Acetaminophen and oxycodone were also prescribed as needed; no details on their use after surgery were reported.

Approximately 1 week before the surgery, on Day 68, mild elevations on ALT (86 U/L [ULN not stated]) were noticed with a decreasing trend (ALT 71 U/L on Day 71).

The patient received linaclotide and polyethylene glycol 3350 on unknown days due to aggravation of constipation. On Day 93, the patient received a single dose of fluconazole 150 mg orally due to vaginal yeast infection.

After the surgery, up to Day 127, the patient was observed 6 times by the surgeon, but no details on the clinic visits were provided. No laboratory tests were performed during this period. On Day 127, the surgeon  noticed  that  the  patient  had  jaundice  and  referred  the  patient  to  an  internal  medicine consultation. Fatigue was also reported on that day and laboratory tests revealed ALT of 1943 IU/L, AST &gt; 2000 IU/L, gamma-glutamyl transferase (GGT) of 174 IU/L, total bilirubin of 12 mg/dL (direct bilirubin not tested), albumin of 4.4 g/dL, creatinine of 1.1 mg/dL (baseline around 0.7 mg/dL), international normalised ratio (INR) of 1.8, prothrombin time (PT) of 19 seconds, and platelet count of 130,000/mm3 (was 220,000/mm3 on Day 71).

The patient discontinued all concomitant medications on Day 127 and went back to the clinic for retesting and supplementary testing on Day 131. Results showed ALT of 1798 IU/L, AST of 1163 IU/L, total bilirubin  of  23.9  mg/dL,  PT  of  21.7  and  25.4  later,  INR  of  2.1,  albumin  of  3.6  g/dL,  and  alkaline phosphatase (ALP) of 255 IU/L. Hepatitis A (HAV IgM), B (HBsAg, anti-HBc), and C (HCV RNA), HIV 1 and 2, and COVID serologies were negative. Reportedly, Epstein-Barr virus (EBV) and hepatitis E virus (HEV) serologies and autoimmune markers were negative. Acetaminophen levels were negative.

An abdominal ultrasound was performed on that day and revealed mild fatty liver and ascites. The patient was hospitalised on the same day in a liver transplant centre. During hospitalisation, a liver biopsy was performed  on  an  unknown  day  and  showed  \"80%  liver  necrosis  and  no  evidence  of  autoimmune hepatitis.\" The patient developed hepatic encephalopathy and multi-organ failure during hospitalisation and a liver transplantation was performed on Day 141.

<div style=\"page-break-after: always\"></div>

No further details on the hospitalisation, tests, treatments, or liver explant results were provided. The patient was discharged on Day 155. Liver test results during the events and evaluation testing results are presented in the table below.

Table 55: Liver test results during the events

| Date         | Davs After Starting Atogepant   | ALT (IU/L)   | AST (IU/L)   | ALP (U/L)   | GGT (U/L)   | TB (mg/dL)   | INR.   |
|--------------|---------------------------------|--------------|--------------|-------------|-------------|--------------|--------|
| Normal Range |                                 | NR           | NR.          | NR.         | NR          | NR.          | NR     |
|              | 68                              | 86           | 36           | 68          | NR.         | 0.4          | NR     |
|              | 71                              | 71           | 49           | NR          | NR          | 1            | NR     |
|              | 127                             | 1943         | >2000        | NR          | 174         | 12           | 1.8    |
|              | 131                             | 1798         | 1163         | 255         | NR          | 23.9         | 2.1    |

ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; GGT = gamma-ghutamyl transferase; INR = intemational normalized ratio; NR = not reported; TB = total bilirubin

Table 56: Evaluation testing and results

| Test                             | Test Done After Injuy Onset?   | Date(DayofOnset)andResult                                     |
|----------------------------------|--------------------------------|---------------------------------------------------------------|
| Hepatitis A IgM antibody         | Yes                            | (Day131),reportedlynegative                                   |
| HepatitisB suface antigen        | Yes                            | (Day131),reportedlynegative                                   |
| HepatitisBanti-HBcoreIgM antbody | s                              | (Day 131),reportedly negative                                 |
| Hepatitis C RNA                  | Yes                            | (Day131),reportedly negative                                  |
| HIV 1and2                        | Yes                            | (Day131),reportedlynegative                                   |
| SARS-CoV-2                       | Yes                            | (Day131),reportedlynegative                                   |
| HepatitisE IgM antibody          | Yes                            | Unknown date,reportedlly negative                             |
| EBV capsid antibody IgM          | Yes                            | Unknown date,reportedlynegative                               |
| Abdominalorliverultrasoumd       | Yes                            | (Day131),mild fatty liver,ascites                             |
| Liver histology                  | s                              | Unknowndate,\"80%necrosis andnoevidence of autoimmunehepatitis |

## Independent DILI Expert Causality Assessment

\" There is insufficient data to assign causality in this case. The event is compatible with DILI and the timing is consistent with a role for Atogepant. However, there was a balance in the incidence of liver chemistry elevations between Atogepant and placebo in the Atogepant clinical trials which is not expected for a drug that can cause liver failure (that is, Atogepant does not fulfill \"Temple's Corollary\"). In addition, this case is confounded by the surgical procedure this patient underwent that included treatment with potentially hepatotoxic drugs and all relevant data is not available. All efforts should be made to obtain the operative report (to check for inhaled anesthetic administration), the liver biopsy report, serial liver chemistries while hospitalized, and documentation of the full evaluation for alternate. Potential causes should also be sought for the mild elevation in serum ALT observed prior to surgery, including use of over-the-counter medications and herbal/dietary supplements .\"

<div style=\"page-break-after: always\"></div>

## 2.7. Discussion on clinical safety

## Safety database pools

The overall safety dataset was grouped into 4 distinct Analysis Sets. Of these, the Placebo-controlled Analysis Set (PCS, dose-finding study MD-01, EM study 301, CM study 303 [12-week DBT plus 4-week FU]; N=2500, n=1837 atogepant, n=663 placebo) and the Long-term Safety Analysis Set (LTS, N=1861, n=1665 atogepant, n=196 SOC) are of primary interest. The Long-term Safety Set comprises open label safety data obtained from EM patients (studies 302 and 309) and from CM patients (studies 306 and 312). Safety data from ongoing CM studies 306 and 312 were included as per ISS cutoff date 10 January 2022. Interim Summaries of Efficacy and Safety (Agency Response - EU - Oct 2022) were provided for studies 306 and 312. Study 306 is an open-label, long-term safety extension, conducted in Japanese adults who either completed Study 303 or who were recruited de novo. Per ISS cutoff date, N=155 CM patients were included from study 306 in the Long-term Safety Set. In open-label, long-term safety extension study 312, CM patients were included who completed either Study 303 or Study 304.

Overall exposure to atogepant is sufficiently large. A total of N=3230 unique participants (including 604 healthy volunteers, 656 participants with CM, and 1970 EM patients) were exposed to at least 1 dose of atogepant  during  clinical  development.  With  regard  to  the  duration  of  exposure,  the  minimum requirements as specified per ICH E1 Guidance are fulfilled.

## Demographics

In severely affected migraine patients of the PCS set, comorbidity with conditions like anxiety (16.7%), depression  (15.9%),  or  insomnia  (13.0%)  is  considered  representative  for  the  target  population  in clinical practice. Notably, a portion of 14.1% of patients presented with obesity. The mean BMI in the PCS set (N=2500) was 28.86 kg/m 2 .

Clinically significant cardiovascular or cerebrovascular disease were excluded, like e.g. ischaemic heart disease  (e.g.  unstable  angina  pectoris),  cardiac  rhythm  or  conduction  abnormalities  (e.g.  atrial fibrillation, second- or third-degree heart block), myocardial infarction, transient ischaemic attack, or stroke within 6 months prior to Visit 1, Hypertension [systolic blood pressure &gt; 160 mm Hg or sitting diastolic blood pressure &gt; 100 mm Hg]. Subjects with less significant cardiac or vascular conditions were not excluded. About 5% of included subjects presented with cardiac disorders at baseline in studies 301/303. Further 8-10% of subjects presented with less severe forms of hypertension. More than 70% of  PCS  subjects  took  concomitant  cardiovascular  medication.  The  rates  of  newly  initiated  or  CV medication dose increases were about equal between placebo (7.2%) and atogepant patients (8.0%).

## Most common adverse events

Atogepant preventive migraine treatment was well tolerated. The overall rate of subjects discontinuing due to AE was about equal in the PCS set between participants receiving atogepant 60 mg QD (3.1%) and placebo subjects (3.2%). In the Long-term Safety set, however, more patients discontinued for tolerability reasons in the atogepant arm (4.5%) as compared to SOC (2.6%).

The most common AEs in any atogepant group (≥ 5% of participants) were nausea, constipation, fatigue, and upper respiratory tract infection. Of these, constipation, nausea, and fatigue were considered as related to study drug in the majority of cases. In particular, for nausea (atogepant: 7.5%, placebo 3.3%) and constipation (atogepant: 7.2%, placebo: 2.0%) reporting rates in atogepant patients were higher as compared to placebo. Constipation is also labelled as common adverse reaction to biological CGRP antagonists erenumab and galzanezumab. Of note, the AE of decreased appetite was reported about ten times more often in atogepant patients (2.1%) as compared to placebo (0.2%). There was no clear dose response relation for the rate of TEAEs across the atogepant doses, ranging from atogepant 10 mg QD to supra-therapeutic atogepant 60 mg BID in the PCS set.

<div style=\"page-break-after: always\"></div>

In long-term safety study 302, a SOC arm was included to contextualise safety. The rate of patients showing TEAEs was lower for atogepant 60 mg QD (N=1662, 63.5%) as compared to SOC (N=196, 78.6%). However, interpretation is cautioned given the disparity of underlying datasets.

The number and percentage of participants with common AE in the LTS set reveals good tolerability of long-term atogepant 60 mg QD use as compared to the standard of care control arm. Of those AEs observed in the PCS set which were considered related to study drug, only constipation was reported more often for atogepant 60 mg QD (6.0%) as compared to SOC (3.1%). The remaining two 'related' AEs were observed more often in the SOC arm (nausea: atogepant 60 mg QD: 4.3%, SOC 6.1%; fatigue: atogepant 60 mg QD: 1.7%, SOC: 6.1%).

There was no indication atogepant would be liable to induce CNS-related AEs. Typical CNS-related AEs like dizziness (atogepant: 2.2%, SOC: 11.2%), anxiety (atogepant: 2.0%, SOC: 5.6%), somnolence (atogepant: 0.8%, SOC: 4.1%), or sedation (atogepant: 0.0%, SOC: 2.0%) were observed more often in patients receiving SOC preventive migraine treatment as compared to atogepant.

In line with reported AE of appetite decreased in the PCS set, after long term treatment with atogepant 60 mg QD more patients were seen with weight decreased (n=37, 2.2%) as compared to SOC (n=3, 1.5%). The inverse effect, i.e. weight increased, were observed more often across SOC patients (5.6%) as  compared  to  atogepant  (0.9%).  Among  commonly  used  standard  of  care  migraine  prevention therapeutics,  there  are  agents  for  which  a  potential  influence  on  body  weight  is  established  (e.g. topiramate, ß-blockers).

Adverse drug reactions (ADRs) were determined by evaluating TEAEs in the placebo-controlled migraine studies (Studies MD01, 301, and 303) that occurred with a ≥ 2% overall incidence rate in any of the atogepant groups and at a rate at least 2% greater than placebo. Constipation, decreased appetite, nausea, and fatigue/somnolence were identified as ADRs.

The overall incidence of SAE in the PSC set was low across atogepant treatment arms (&lt; 1.3%) and similar to placebo (1.1%). None of the observed SAE was reported in more than 1 participant.

There was one SAE of presumed optic neuritis, which was considered as related to study drug by the Investigator,  but  was  considered  not  related  by  the  Sponsor.  Irrespective  of  any  attempt  to retrospectively  decide  upon  potential  relatedness  of  the  single  SAE  of  presumed  optic  neuritis,  it  is suggested to examine future PSUR reports for potential signals in this regard.

In  the  LTS  set,  the  overall  rate  of  TESAE  was  higher  in  patients  receiving  SOC  (N=196,  3.6%)  as compared  to  patients  receiving  atogepant  60  mg  QD  (N=1662,  3.4%).  Importantly,  there  is  no accumulation of any SAE. For the vast majority of SAE per preferred term the frequency in atogepant subjects is 0.1%. This includes Hepatobiliary disorders (cholelithiasis, cholecystitis) and Investigations (ALT  increased,  AST  increased).  There  wasn't  any  cardiovascular  SAE  under  long-term  atogepant treatment.

## AEs of special interest

Cardiovascular  events  (cardiac  arrythmias,  central  nervous  system  vascular  disorders,  embolic  and thrombotic, hypertension, and ischaemic heart disease), hepatic AEs, suicide-related events, and abuserelated AEs were identified as AESIs for the placebo-controlled, long-term safety, and Phase 1 analysis sets.

## Cardiovascular Events

A comprehensive evaluation of cardiovascular safety of atogepant as TEAESI was provided for both the use  of  atogepant  under  placebo-controlled  conditions  and  long-term  over  52-weeks.  There  was  no incident of ischaemic heart disease. The incidence of arrhythmia-related AEs was low and similar between atogepant (0.3%) and placebo (0.2%). Across the PCS and LTS set, only two cases of hypertension as

<div style=\"page-break-after: always\"></div>

reported AE were considered by the Investigator as related to study medication. Based on the narratives, however,  there  is  no  clear  suspect  of  atogepant  having  a  causative  role  given  the  overall  medical conditions of concerned subjects and timing of reporting (resp. persistence of the event) in relation to atogepant treatment.

## Hepatic Safety

Historical clinical development programs for other members of the gepant family (telcagepant) were halted when liver toxicity was detected during migraine prophylaxis trials (Ho TW. Neurology 2014). Therefore,  AEs  related  to  hepatic  toxicity  were  systematically  evaluated  as  AEs  of  special  interest, including blinded adjudication of postbaseline elevations of ALT and/or AST ≥ 3 × ULN for participants who received either atogepant or placebo by an external expert committee. In the Placebo-controlled Analysis  Set,  hepatic  injury  TEAE  overall  (atogepant:  1.5%,  placebo:  1.8%),  and  hepatic  enzyme elevations (ALT increased: atogepant: 1.1%, placebo: 1.5%; AST increased: atogepant: 1.0%, placebo: 1.4%)  were  observed  more  often  in  placebo  patients  than  in  participants  receiving  atogepant.  The incidence of ALT or AST increase was independent of the atogepant dose.

A categorised overview was provided of participants in the PCS set with liver enzyme elevations per degree of enzyme elevation (&gt; 2 x ULN, &gt; 3 x ULN, &gt; 5 x ULN, &gt; 10 x ULN, &gt; 20 x ULN). In the PCS set, no subject was observed with elevations of &gt; 20 x ULN. In one patient receiving atogepant 10 mg QD, ALT and / or AST were elevated by &gt; 10 x ULN during safety FU. The respective subject never stopped atogepant and completed study 301. Liver enzymes were elevated on Day 1 prior to the first dose  of  atogepant  (ALT:  3.3  x  ULN;  AST:  4.3  x  ULN).  The  blinded  adjudication  experts  rated  the relationship to treatment as unlikely. However, there is concern about the potential role of continued atogepant treatment over 12 weeks in raising liver enzymes from 3.3-4.3 x ULN at study entry to &gt; 10 x ULN during follow-up.

A total of n=24 cases with aminotransferase elevations &gt; 3 x ULN were adjudicated by the external blinded Expert Committee in the PCS set. Of these, n=17 subjects received atogepant (n=7 received placebo).  Among the atogepant patients, n=4 subjects (out of N=1837) were adjudicated as either possible (n=2) or probably related (n=2) to atogepant treatment. Narratives were provided. In 3 of these  cases,  there  were  confounding  factors  like  intensive  weightlifting  in  the  gym,  extensive concomitant  acetaminophen  use  for  acute  headache,  or  Class  III  obesity  (BMI  39.6  kg/m 2 ).  All  4 atogepant-treated  cases  that  were  adjudicated  as  probably  or  possibly  related  to  study  drug  were asymptomatic, non-serious, mild or moderate in severity, without concurrent bilirubin elevations, and resolved with or without atogepant discontinuation.

There was one single case of temporary TBL elevation of 2.08 x ULN. It concerns a 29-year old male participant of study 301 receiving atogepant 60 mg QD. It was reported that his father had Gilbert Syndrome. Prior to receiving the first dose of atogepant on Day 1, total bilirubin was 2.1 mg/dL (1.75 x ULN). Aminotransferases were not relevantly elevated at any stage. Fluctuating bilirubin values were recorded  throughout  12-week  study  301  and  roll-over  to  open-label  extension  study  309.  Bilirubin elevations are considered not related to atogepant treatment.

Under long term treatment (LTS set), the incidence of hepatic injury overall (atogepant 2.5%, SOC 3.1%), and aminotransferase elevations as TEAE (AST increased: atogepant 1.7%, SOC 2.6%; ALT increased:  atogepant  1.6%,  SOC:  2.0%)  was  higher  in  participants  receiving  standard-of-care  as compared to atogepant.

Analysis of enzyme elevation categories in the long-term analysis set reveals that any aminotransferase elevation (AST or ALT &gt; 1 x ULN) was observed more frequently across SOC patients under long term treatment (28.9%) as compared to atogepant 60 mg QD patients (14.4%). Single cases of very high aminotransferase  increases,  however,  were  not  reported  in  SOC  patients  but  only  in  participants receiving atogepant (ALT or AST &gt; 10 x ULN: n=4 [0.2%], ALT or AST &gt; 20 x ULN: n=1 [0.1%]).

<div style=\"page-break-after: always\"></div>

Patients with hepatic enzyme elevations &gt; 3 x ULN under long-term atogepant treatment (n=24/1662) were also adjudicated by  the external blinded expert committee. In eight cases, the relationship of aminotransferase elevations to study drug was rated as possible or probable. Narratives were provided. In subjects recruited for long-term studies 302 and 309, confounding factors like weightlifting, obesity, history of binge drinking, or transient periods of increased alcohol consumption are reported and subjects completed the study. The remaining cases are reported for long-term study 306 conducted in Japan. Atogepant treatment was discontinued in n=4 subjects from study 306, for which the relationship to study  drug  was  rated  possible  or  probable.  In  these  cases,  confounding  factors  (e.g.  concomitant betahistine, cephalosporin, azithromycin) are less clear. There was an increase in any aminotransferase elevations for long-term use of atogepant (LTS: ALT or AST &gt; 1 x ULN: 236/1644 [14.4%]) as compared to the 12-week treatment period of the placebo-controlled analysis set (PCS: ALT or AST &gt; 1.0 x ULN: 198/1810  [10.9%]).  However,  the  frequency  of  any  aminotransferase  increase  under  long-term atogepant use (14.4%) was lower as compared to participants receiving long-term SOC (28.9%).

Of note, among the 8 cases that were adjudicated as probably or possibly related to study drug all were non-serious, mild to moderate in severity, without concurrent bilirubin elevation, and resolved with or without atogepant discontinuation.

In the clinical trial dataset (placebo-controlled and long-term), there was no case fulfilling criteria for potential Hy's Law (ALT or AST &gt; 3 x ULN and TBL &gt; 2 x ULN and ALP &lt; 2 x ULN).

Hence, the overall hepatic safety profile of atogepant, as obtained from clinical trials, appears rather favourable. Furthermore, a comprehensive re-evaluation of atogepant's hepatic safety was provided after receipt of one spontaneous post-marketing report of acute liver failure with atogepant 60 mg QD that led to liver transplantation.

The post-marketing case of drug-induced liver injury (DILI) was observed in a female who developed acute liver failure leading to liver transplant on Day 127 of atogepant 60 mg treatment for migraine prophylaxis.  An  independent  Expert  confirmed  the  event  to  be  compatible  with  DILI  and  timing  as consistent  with  a  role  for  atogepant.  However,  the  Expert  outlines  that  there  was  a  balance  in  the incidence of liver chemistry elevations between atogepant and placebo, which is not expected for a drug that can cause liver failure.

A thorough and comprehensive overall evaluation of atogepant's hepatic safety profile was submitted incl. updates of ongoing long-term safety studies 306 /312 and growing post-marketing experience.

The fact that the overall frequency of liver enzyme elevations was not increased in atogepant patients as compared to patients receiving placebo in the PCS dataset, or to subjects receiving SOC in LT study 302 is providing reassurance. In line with results obtained from the DILIsym model (including in vitro tests of mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis) atogepant is not considered to intrinsically induce hepatotoxicity.

A potential idiosyncratic liability, however, may only manifest with temporal latency, and due to its rarity, in larger populations. Across the placebo-controlled (PCS), long-term (LTS) and post-marketing datasets, clinically relevant enzyme elevations were observed in patients receiving atogepant (although mostly asymptomatic across clinical trials). In some of these cases, AST/ALT elevations were adjudicated as possibly or probably related to atogepant treatment based on positive dechallenge and / or absence of clear confounders.

The applicant's proposal is endorsed to address the issue in SmPC section 4.8. Also, the applicant's proposal to extend active surveillance by another year within the scope of ongoing long-term safety study 312 (to a total duration of 3 years) is endorsed.

<div style=\"page-break-after: always\"></div>

## Suicidal ideation

Atogepant was not associated with an increased risk of suicidal ideation or suicidal behaviour compared with placebo in the placebo-controlled analysis set or compared with the standard-of-care group in the long-term safety analysis set.

## Abuse liability

Potential  abuse  liability  of  atogepant  was  systematically  evaluated  by  screening  for  PTs  potentially predictive of abuse potential. It is to be noted that symptoms like dizziness, somnolence, or disturbance in attention may also well occur in the context of migraine attacks, and do not necessarily have to be associated to treatment. Over long-term treatment, all these AEs (dizziness, somnolence, disturbance in attention) were reported more often in SOC patients as compared to participants receiving atogepant 60 mg QD. It is reminded that single standard-of-care migraine preventive agents like e.g. amitriptyline or topiramate may account for respective AEs. No events of euphoria were reported. Overall, examination of  abuse-related  AEs  across  all  the  ISS  analysis  sets  showed  no  evidence  of  abuse  potential  with atogepant.

## Vital signs: Blood pressure

Throughout the 12-week DBT period, blood pressure was measured at baseline, scheduled Visits at Week 2, 4, 6, 8, 10, EoT, and Follow-up. Both for placebo and atogepant dose arms, mean systolic BP and diastolic BP remain virtually unaffected. Incidences of BP changes of clinical interest (e.g. systolic BP &gt; 180 mmHG or increases by &gt; 20 mmHg, or any &gt; 10 mmHg increase from baseline in systolic or diastolic BP) were rare and equally distributed across atogepant dose arms and placebo. It is noted that during study Visits BP was measured independent of the time of study medication intake. However, based on phase I population data summarizing vital sign (BP, heart rate) measurements taken per dose (incl. supra-therapeutic  doses  up  to  atogepant  300  mg  QD)  in  close  timely  relation  to  study  medication administration, it could be shown that no clear dose-related effect on BP / heart rate was observed for atogepant in healthy volunteers. This finding goes along with the favourable cardiovascular safety profile, which was monitored throughout the phase II/III trial programme as AE of special interest.

## Body weight

Decreases in  body  weight  by  &gt;  7%  from  baseline  were  observed  in  atogepant  patients  both  under placebo-controlled  conditions  and  under  long-term  open-label  conditions.  In  both  scenarios,  the incidence was higher in participants receiving atogepant as compared to the comparator (Body weight decrease by &gt; 7% from baseline: Placebo-controlled Set: atogepant overall: 4.6%, placebo: 2.5%; Longterm  Set:  atogepant  60  mg  QD:  23.4%,  SOC:  14.7%).  Throughout  the  12-week  DBT  period,  the incidence of weight decrease increased with atogepant dose (body weight decrease by &gt; 7%: atogepant 10 mg QD: 3.8%, atogepant 60 mg QD: 5.3%, atogepant 60 mg BID: 6.8%). The tendency for dosedependent decrease in body weight is adequately reflected in SmPC section 4.8.

It has to be considered that about 14% of participants in the placebo-controlled analysis set had a history of obesity at baseline. Mean weight at baseline for all participants was 79.3 kg, and mean BMI was 28.86 kg/m 2 , with 25% of participants weighing between 92.0 and 226 kg and 25% of participants with a BMI between 33.18 and 82.0 kg/m 2 . Analysis of a potential relationship between clinically significant weight decrease and obesity (BMI ≥ 30 kg/m 2 ) at baseline revealed that obese patients were not more likely to significantly lose weight under atogepant treatment as compared to normal-weight subjects. Conversely, normal weight subjects (BMI &lt; 30 kg/m 2 ) appeared to be more liable to significantly lose weight based on comparison with the matched placebo group (atogepant overall [N=1133]: 5.6%, placebo [N=426]: 1.6%).

## Transferability between EM and CM population

There were no relevant differences between the EM and CM populations in the PCS set both by the nature and frequency of most common observed AEs. This is considered to provide further assurance regarding

<div style=\"page-break-after: always\"></div>

transferability of safety data across populations. Long-term studies in the EM population (302 and 309) were completed and full CSRs were submitted. For the CM population, however, respective long-term studies (306 and 312) are still ongoing and only interim safety data per cutoff date 11 October 2022 could be filed.

## 2.7.1. Conclusions on the clinical safety

Based on data obtained from the clinical trials, the safety profile of atogepant in preventive migraine treatment  appears  favourable.  Most  common  ADRs  were  nausea  (7%),  constipation  (7%),  and fatigue/somnolence (5%). No safety concerns for hypertension AEs or other cardiovascular events were identified. Decreases in body weight by &gt; 7% from baseline were observed in atogepant patients in a dose-dependent way both under placebo-controlled and long-term treatment conditions.

A thorough and comprehensive overall evaluation of atogepant's hepatic safety profile was submitted incl. updates of ongoing long-term safety studies 306 /312 and growing post-marketing experience.

The proposals to address hepatic safety (inclusion of ALT / AST elevations in SmPC section 4.8, and prolongation of ongoing LT study 312 for another 12 months to an overall duration of 3 years) are endorsed.

## 2.8. Risk Management Plan

## 2.8.1. Safety concerns

Table 57: Summary of safety concerns

| Important identified risks   | None                                                                                                                              |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | None                                                                                                                              |
| Missing information          | Use in patients with significant cardiovascular and cerebrovascular diseases Use in pregnant women Long-term safety beyond 1 year |

## 2.8.2. Pharmacovigilance plan

Table 58: On-going and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| N/A                                                                                                                                                                                                                        | N/A                                                                                                                                                                                                                        | N/A                                                                                                                                                                                                                        | N/A                                                                                                                                                                                                                        | N/A                                                                                                                                                                                                                        |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| N/A                                                                                                                                                                                                                        | N/A                                                                                                                                                                                                                        | N/A                                                                                                                                                                                                                        | N/A                                                                                                                                                                                                                        | N/A                                                                                                                                                                                                                        |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| A Phase 3, multicentre, open label 104-week                                                                                                                                                                                | To evaluate the long- term safety and                                                                                                                                                                                      |                                                                                                                                                                                                                            | Draft Protocol Submission                                                                                                                                                                                                  | 10/2020                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                                         | Summary of objectives                                                                                                                                                   | Safety concerns addressed                           | Milestones                                            | Due dates                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine: Study 3101- 312-002 (ongoing, will be extended by an additional 1 year for a total of 3 years) | tolerability of atogepant 60 mg once daily in participants when taken for 104 weeks for the prevention of chronic migraine (CM) or episodic migraine (EM).              | Long-term safety beyond 1 year                      | Final Protocol Submission                             | 12/2020                                               |
| extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine: Study 3101- 312-002 (ongoing, will be extended by an additional 1 year for a total of 3 years) | tolerability of atogepant 60 mg once daily in participants when taken for 104 weeks for the prevention of chronic migraine (CM) or episodic migraine (EM).              | Long-term safety beyond 1 year                      | Study Completion                                      | 10/2024                                               |
| extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine: Study 3101- 312-002 (ongoing, will be extended by an additional 1 year for a total of 3 years) | tolerability of atogepant 60 mg once daily in participants when taken for 104 weeks for the prevention of chronic migraine (CM) or episodic migraine (EM).              | Long-term safety beyond 1 year                      | Final Report Submission                               | 02/2025                                               |
| Observational Study to Assess Pregnancy Outcomes Following Exposure to Atogepant: PMR 4152-7; Study P22- 419 (planned)                                                                                                                                               | To describe and compare the incidence of pregnancy outcomes in women with migraine who are exposed to atogepant during pregnancy                                        | Use in pregnant women                               | Draft Protocol Submission                             | 07/2022                                               |
| Observational Study to Assess Pregnancy Outcomes Following Exposure to Atogepant: PMR 4152-7; Study P22- 419 (planned)                                                                                                                                               | To describe and compare the incidence of pregnancy outcomes in women with migraine who are exposed to atogepant during pregnancy                                        | Use in pregnant women                               | Final Protocol Submission                             | 05/2023                                               |
| Observational Study to Assess Pregnancy Outcomes Following Exposure to Atogepant: PMR 4152-7; Study P22- 419 (planned)                                                                                                                                               | To describe and compare the incidence of pregnancy outcomes in women with migraine who are exposed to atogepant during pregnancy                                        | Use in pregnant women                               | Annual Interim Report Submissions                     | From 02/2024 to 02/2029                               |
| Observational Study to Assess Pregnancy Outcomes Following Exposure to Atogepant: PMR 4152-7; Study P22- 419 (planned)                                                                                                                                               | To describe and compare the incidence of pregnancy outcomes in women with migraine who are exposed to atogepant during pregnancy                                        | Use in pregnant women                               | Study Completion                                      | 02/2030                                               |
| Observational Study to Assess Pregnancy Outcomes Following Exposure to Atogepant: PMR 4152-7; Study P22- 419 (planned)                                                                                                                                               | To describe and compare the incidence of pregnancy outcomes in women with migraine who are exposed to atogepant during pregnancy                                        | Use in pregnant women                               | Final Report Submission                               | 04/2031                                               |
| Atogepant Pregnancy Exposure Registry: PMR 4152-6; Study P22-392 (planned)                                                                                                                                                                                           | To prospectively evaluate maternal, fetal, and infant outcomes through 12 months of age among women exposed to atogepant during pregnancy compared to comparator groups | Use in pregnant women                               | Draft Protocol Submission                             | 07/2022                                               |
| Atogepant Pregnancy Exposure Registry: PMR 4152-6; Study P22-392 (planned)                                                                                                                                                                                           | To prospectively evaluate maternal, fetal, and infant outcomes through 12 months of age among women exposed to atogepant during pregnancy compared to comparator groups | Use in pregnant women                               | Final Protocol Submission                             | 05/2023                                               |
| Atogepant Pregnancy Exposure Registry: PMR 4152-6; Study P22-392 (planned)                                                                                                                                                                                           | To prospectively evaluate maternal, fetal, and infant outcomes through 12 months of age among women exposed to atogepant during pregnancy compared to comparator groups | Use in pregnant women                               | Annual Interim Report Submissions                     | From 02/2024 to 02/2035                               |
| Atogepant Pregnancy Exposure Registry: PMR 4152-6; Study P22-392 (planned)                                                                                                                                                                                           | To prospectively evaluate maternal, fetal, and infant outcomes through 12 months of age among women exposed to atogepant during pregnancy compared to comparator groups | Use in pregnant women                               | Study Completion                                      | 02/2036                                               |
| Atogepant Pregnancy Exposure Registry: PMR 4152-6; Study P22-392 (planned)                                                                                                                                                                                           | To prospectively evaluate maternal, fetal, and infant outcomes through 12 months of age among women exposed to atogepant during pregnancy compared to comparator groups | Use in pregnant women                               | Final Report Submission                               | 04/2037                                               |
| PASS of atogepant in patients with significant cardiovascular and cerebrovascular diseases                                                                                                                                                                           | To characterise the safety of atogepant in patients with significant                                                                                                    | Use in patients with significant cardiovascular and | Study details will be provided to PRAC post- approval | Study details will be provided to PRAC post- approval |

<div style=\"page-break-after: always\"></div>

| Study Status   | Summary of objectives                        | Safety concerns addressed   | Milestones   | Due dates   |
|----------------|----------------------------------------------|-----------------------------|--------------|-------------|
| (planned)      | cardiovascular and cerebrovascular diseases. | cerebrovascular diseases    |              |             |

## Overall conclusions on the PhV Plan

The PRAC, having considered the data submitted, is of the opinion that the proposed post-authorisation PhV development plan is sufficient to identify and characterise the risks of the product.

## 2.8.3. Risk minimisation measures

Table 59: Description of routine risk minimisation measures by safety concern

| Safety concern                                                               | Routine risk minimisation activities                                                                                                                                                    |
|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in patients with significant cardiovascular and cerebrovascular diseases | Other routine RMMs beyond the Product Information: Legal status: Prescription only medicine                                                                                             |
| Use in pregnant women                                                        | Routine risk communication: The risk is communicated through the label in SmPC Section 4.6. Other routine RMMs beyond the Product Information: Legal status: Prescription only medicine |
| Long-term safety beyond 1 year                                               | Other routine RMMs beyond the Product Information: Legal status: Prescription only medicine                                                                                             |

## 2.8.4. Conclusion

The CHMP considers that the risk management plan version 1.0 is acceptable.

## 2.9. Pharmacovigilance

## 2.9.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.9.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 28 September 2021. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

<div style=\"page-break-after: always\"></div>

## 2.10. Product information

## 2.10.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.10.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Aquipta (atogepant) is included in the additional monitoring list as it includes new active substance.

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.2. Disease or condition

Migraine is a serious, chronic, disabling neurological disease characterised by attacks of moderate to severe headache (HA) pain associated with other symptoms such as nausea, vomiting, photophobia, and phonophobia. Migraine attacks typically last from 4 to 72 hours if untreated or unsuccessfully treated. People with migraine may experience an aura prior to the onset of their headache.

The indication proposed for Aquipta aligns with standard wordings approved for prophylactic treatment of migraine so far.

## 3.2.1. Available therapies and unmet medical need

The  range  of  established oral migraine  preventive  treatment  options  (ß-blockers,  topiramate, antidepressants etc.) most recently was complemented by CGRP antagonist antibodies (ABs, so-called biologicals) targeting circulating CGRP or its receptor (erenumab, fremanezumab, galcanezumab). All three ABs are indicated in the EU for prophylaxis of migraine in adults who have at least 4 migraine days per month. These ABs are injected following 4-week, resp. 12-week dosing intervals. Compliance is a well-documented  problem  in  migraine  preventive  therapy.  The  extended  dosing  intervals  of  the biologicals  may  therefore  be  interpreted  as  beneficial  by  increasing  compliance  of  the  patients. Irrespective of the compliance aspect, potential advantages for atogepant as a needle-free treatment option may be that it allows flexible treatment if immediate cessation of therapy is required, e.g. in case a serious AE or pregnancy.

Among currently approved preventive treatment options, anticonvulsant topiramate (e.g., Topamax) is indicated in the EU in adults for the prophylaxis of migraine headache after careful evaluation of possible alternative treatment options. Botox (botulinum toxin type A from Clostridium botulinum) is indicated in

<div style=\"page-break-after: always\"></div>

the EU for prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). Preventive treatment of CM with Botox requires multiple bilateral intramuscular injections divided across 7 specific head and neck muscle areas, with a recommended retreatment schedule of every 12 weeks.

These  options  are  not  optimal  for  many  patients  due  to  limited  effectiveness,  poor  tolerability, contraindications,  and  the  need  for  dose  titration  over  multiple  visits  for  some  medications.  The limitations in conventional oral migraine prevention treatments lead to poor adherence (Berger et al. 2012, Hepp et al. 2017) and reluctance to initiate prophylactic treatment (Silberstein 2015).

Indeed,  several  epidemiological  surveys  indicate  that  available  migraine  preventive  treatments  are significantly underutilised in clinical practice (D'Amico et al. 2006), which supports the need for greater dialogue concerning migraine prevention between patients and physicians. Compliance with preventive treatment remains a challenge. Based on a retrospective US claims analysis of N=8707 CM patients, persistence to initial oral preventive medication was only 25% at 6 months and 14% at 12 months followup  (Hepp  et  al.  2017).  Low  adherence  to  migraine  prophylaxis  treatment  with  antidepressants, antiepileptics, or beta blockers at 6 month follow-up was also previously reported (Berger et al. 2012).

## 3.2.2. Main clinical studies

The clinical data package in support of atogepant comprises phase II/III dose finding, pivotal efficacy/ safety studies in both the EM and CM population, and additional long-term tolerability studies, which also provide data to support maintenance of effect.

Primary evidence for efficacy is derived from 2 pivotal studies, Study 301 ('Advance' study, conducted in the US) for EM prevention and Study 303 ('Progress' study, conducted at 142 sites in the US, Europe, Russia, Japan, Korea and others) for the preventive treatment of CM. Additional supportive data are provided by dose-finding Study CGP-MD-01 for EM prophylaxis.

Furthermore, two long-term open-label studies in EM (Study 3101-302-002) [52-week duration] and Study  3101-309-002  [40-week  duration])  were  conducted.  Persistence  of  efficacy  data  in  EM  were obtained from long term study 302 including de novo participants and patients who completed dose finding Study CGP-MD-01. In long-term study 309, including rollover patients, who completed EM study 301, maintenance of effect was not recorded.

Studies 301 and 303 were 12-week, Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group studies comparing atogepant with placebo for the preventive treatment of migraine in participants with EM (Study 301; atogepant 10 mg, 30 mg, and 60 mg QD) and in participants with CM (Study 303; atogepant 30 mg BID and 60 mg QD).

Essential  features  of  prevention  studies  301  and  303  are  accordant  with  EU  Guideline  provisions (CPMP/EWP/788/01  Rev.1).  The  designs  of  studies  301  and  303  are  similar.  The  major  difference between the two studies lies in the target population (EM vs CM) and the atogepant dose range that was tested. While all once daily dose arms examined in dose finding study CGP-MD-01 (10 mg QD, 30 mg QD, 60 mg QD) were taken over into pivotal EM study 301, only the highest total daily dose of 60 mg atogepant (tested for the QD and BID dosing interval) was carried forward to the pivotal CM study 303.

Inclusion criteria applied throughout pivotal studies align with the standard ICHD-3 diagnostic criteria (ICHD-3,  2018).  Any  medication  to  be  taken  for  acute  migraine  attacks  (incl.  triptans,  NSAIDS, acetaminophen etc.) was permissible. As concerns concomitant preventive migraine medication, there were differences between the EM and the CM study. While any medication with demonstrated efficacy for the prevention of migraine (e.g. amitriptyline, topiramate, propranolol etc.) was prohibited in EM study  301,  participants  of  CM  study  303  could  take  one  preventive  medication  with  demonstrated

<div style=\"page-break-after: always\"></div>

efficacy. At study entry, about 83% of CM subjects reported the use of preventive medication in the past. This is considered to reflect clinical practice in the more severely affected CM population.

Standard and clinically meaningful efficacy endpoints were tested. The primary efficacy endpoint in both pivotal  studies  was  the  change  from  baseline  in  mean  monthly  migraine  days  across  the  12-week treatment  period  (DBT).  Further  secondary  endpoints  were  tested  for  superiority  of  atogepant  over placebo while controlling for multiplicity in studies 301/303. The three most relevant was the change from baseline in mean monthly headache days across the 12-week DBT [S1], change from baseline in mean monthly acute medication use days across the 12-week [S2 ], and ≥ 50% reduction in 3 -month average of monthly MDs as responder analysis [S3].

## 3.3. Favourable effects

Efficacy  of  atogepant  in  prevention  of  episodic  and  chronic  migraine  was  demonstrated  based  on statistically significant and clinically relevant results obtained across primary and secondary endpoints in both pivotal trials. The favourable outcome further translates into early onset of effect within the first month  of  treatment  and  persistence  of  effect  over  52-week  duration.  Robustness  of  data  was demonstrated  across  relevant  subgroups  per  baseline  disease  burden  (mean  monthly  MDs),  and prevalent medication overuse, resp. concomitant prophylactic treatment in CM participants.

## Primary: Reduction in MDs

Like it could be observed in previous migraine prevention trials, a considerable placebo response was observed in both populations. Both EM and CM placebo patients reduced the number of mean monthly MDs by up to one third (EM: -2.5 MD [-32.8%], CM: -5.1 MD [-26.9%]). Superiority over placebo was shown for all atogepant treatment arms across the two trials. A numerical dose-response relationship was evident for the change from baseline in mean monthly MDs across the 12-week treatment period in Study 301, with greater reductions seen with increasing atogepant dose from 10 to 60 mg QD (LSMD over placebo: 10 mg QD: -1.22, 30 mg QD: -1.38, 60 mg QD: -1.66). The placebo-corrected mean reduction from baseline in mean monthly migraine days observed with the atogepant 60 mg QD dose was the same in the EM and CM studies (LSMD of -1.66 in both Study 301 and Study 303).

## Secondary endpoints

A Headache Day (HD) is defined as any calendar day on which headache pain lasting 2 hours or longer occurs unless an acute headache medication (e.g. ibuprofen, triptan) was used after the start of the headache.  As  such,  a  HD  captures  days  with  headache  irrespective  of  any  other  migraine-specific symptoms. In particular in CM patients, where tension type headache and migraine headache often overlap, and who complain about highly frequent or almost continuous headache, measurement of HD is an important parameter for disease burden. Accordingly, reduction of HD from baseline during the 12week DBT was placed highest in hierarchical multiplicity testing [S1] of secondary endpoints. The results obtained for  the  S1  secondary  endpoint  are  similar  to  those  obtained  for  the  primary  MD  reduction endpoint. Statistically significant superiority over placebo after multiplicity adjustment was achieved for each of the atogepant dosages tested in studies 301 and 303. Numerically more favourable results were obtained with increasing doses across the QD (10 mg, 30 mg, 60 mg) dose arms in EM study 301. The net treatment effect over placebo was more favourable for the 30 mg BID dose arm as compared to the 60 mg QD dose arm in study 303 (LSMD for HD reduction from baseline: 30 mg BID: -2.14, 60 mg QD: -1.72).

At baseline, acute medication (incl. both unspecific analgesics and triptans) was used on a mean of 6-7 days among EM patients and on about 15 days per month in the CM population. The change from baseline in  mean  monthly  acute  medication  use  days  [S2]  was  second  in  hierarchical  testing  of  secondary

<div style=\"page-break-after: always\"></div>

endpoints. For both the Acute Medication Use Day and the Triptan Use Day (which was singled out) secondary endpoint significant superiority over placebo could be demonstrated for each atogepant dose arm.

In  terms  of  the  &gt;  50%  reduction  in  3-month  average  of  monthly  MDs  [S3],  statistically  significant superiority over placebo was achieved for each atogepant dose arm tested across studies 301 / 303. In study 301, more than 50% of subjects allocated to one of the atogepant dose arms achieved a reduction by &gt; 50% in the 3-month average of monthly MDs (atogepant: 10 mg QD: 54.6%, 30 mg QD: 58.5%, 60 mg QD: 59.3%; placebo 29.2%). This underlines the clinical relevance of the improvement achieved in terms of the primary MD reduction from baseline across all atogepant dose arms. Among the more severely affected CM population of study 303, response rates were slightly lower (30 mg BID: 42.1%, 60 mg QD: 40.1%). Nonetheless, the probability of achieving a &gt; 50% reduction in the 3-month average of monthly MDs was still about twice as high for atogepant as compared to placebo (OR: 30 mg BID: 2.03, 60 mg QD: 1.90).

## Time course

The major part of the overall treatment effect is achieved within the first 4-week dosing interval of the 12-week DBT in both the EM and CM population. Thereafter, the reduction of mean monthly MDs is maintained or even slightly increases. The dose response relation across the three QD dose arms of study 301 is consistently observed across the three 28-day intervals of the 12-week DBT. In CM study 303, the more favourable effect of the 30 mg BID dosing regimen as compared to the 60 mg QD dosing scheme gets more pronounced with ongoing treatment duration.

The course of treatment effect was further analysed per week for the first 28-day period of the DBT of studies 301 and 303. In both EM and CM patients, the treatment effect starts within the first week of treatment. There was no clear tendency of increasing or decreasing effect of atogepant over the four 1week intervals of the first 28-day treatment interval. This is considered to provide valuable information to  the  prescriber  when  the  treatment  effect  of  atogepant  is  evaluated  within  the  context  of  clinical monitoring.

## Persistence of effect

In open-label, long-term study 302, the daily use of 60 mg atogepant QD (N=546) was compared to SOC (N=198) over a 52-week treatment period in EM patients, either recruited de novo (85.6%) or taken  over  from  dose  finding  study  MD-01  (14.4%).  Participants  randomised  to  oral  SOC  migraine preventive medication (topiramate: 35.7%, beta-blockers 26.0%, tricyclic antidepressants 25.5%) were included to contextualise safety results.

It was primarily designed to examine safety of long term atogepant use in EM patients. However, efficacy was  also  monitored  in  those  subjects  randomised  to  atogepant.  In  atogepant  patients,  a  clinically relevant reduction in mean monthly MDs was achieved within the 1st month and was sustained over the 1-year treatment period. Atogepant treatment led to a reduction in the LS mean number of monthly MDs in the first month (Weeks 1-4) of 3.84 days with continued improvement during the remainder of the 52-week treatment period to a LS mean reduction of -5.19 days in the last month (Weeks 49 to 52).

Overall, it is noted that no efficacy assessment was performed in long-term extension study 309 (in completers of study 301). Nevertheless, the overall number of patients included in the other long-term study 302 in EM patients can be considered sufficient for the evaluation of a long-term efficacy.

## 3.4. Uncertainties and limitations about favourable effects

Given  the  overall  positive  efficacy  results,  there  is  little  uncertainty  about  the  favourable  effects  of atogepant in the targeted population. However, there is some concern related to the choice of the dosing

<div style=\"page-break-after: always\"></div>

interval proposed for the atogepant 60 mg standard daily dose that is to be taken as a single dose (QD), while numerically more favourable results were obtained for the atogepant 30 mg BID dose arm.

## Proposed atogepant 60 mg QD dosing interval

Apart from testing dose response in EM study 301 across the once daily 10, 30, 60 mg dose range, the effect of changing the dosing interval from once daily to twice daily was examined for the highest 60 mg daily dose in the CM population. A noticeable difference was observed in favour of the twice daily dosing schedule in terms of the net difference over placebo for the reduction of mean monthly MDs (Study 303: LSMD over placebo: 30 mg BID: -2.24, 60 mg QD: -1.66). The favourable treatment effect of the 30 mg BID regime (as compared to 60 mg QD) was analogously observed in phase II/III dose finding study MD-01 (reduction in mean monthly MDs from baseline: 30 mg BID: -4.0, 60 mg QD: -3.56). It also translates into most relevant secondary endpoints, like reduction of HDs, reduction of acute medication use, and 50% response rates. Further plausibility for the favourable outcome in the 30 mg BID treatment arm is provided by PK study P002. In study P002, plasma levels were compared for different atogepant doses  after  repetitive  dosing  over  10  days.  C24  hrs  trough  values  after  30  mg  BID  dosing  were remarkably high, higher than after 100 mg once daily dosing and almost reaching the level of the 170 mg once daily regime. Despite numerically more favourable results for the 30 mg BID dose arm across primary and secondary endpoints, the applicant's posology strategy is to confine to the uniform 60 mg once daily dosing schedule in order to provide a simple and convenient posology scheme. This is assumed to best promote patient compliance, which is an established challenge in migraine prevention.

## Potential rebound after treatment cessation.

Both in EM study 301 and CM study 303, subjects were followed up for another 4-week period after termination of the 12-week DBT or early discontinuation. According to the Schedule of Procedures of Study 301, participants' eDiary entries regarding headache were evaluated only in those patients who terminated early, but not in patients who completed the entire 12-week DBT. Hence, no data were provided on potential rebound of migraine after cessation of study medication in (all) participants of studies  301/303.  Instead,  efficacy  endpoint  MSQ  v2.1  Role  function-Restrictive  domain  scores  were collected at the safety follow-up visit (4 weeks after the treatment period). As indicated by smaller Change from Baseline values for MSQ RFR domain scores at 4 weeks Follow-up, the beneficial effect of atogepant treatment weans off after treatment cessation. However, the scores at the 4 week follow-up interview were still higher than baseline values, thereby showing that rebound effects in mean scores were not observed.

## 3.5. Unfavourable effects

Overall  safety  data  as  obtained  from  RCTs  point  to  a  rather  favourable  safety  profile  of  atogepant. Concerns about hepatic safety of atogepant, however, have arisen after receipt of a post-marketing report of possible DILI that was observed in a female patient during the first months of marketing in the US.

Overall exposure to atogepant is sufficiently large. A total of N=3230 unique participants (including 604 healthy volunteers, 656 participants with CM, and 1970 EM patients) were exposed to at least 1 dose of atogepant  during  clinical  development.  With  regard  to  the  duration  of  exposure,  the  minimum requirements as specified per ICH E1 Guidance are fulfilled.

## Most common adverse events

Atogepant preventive migraine treatment was well tolerated. The most common AEs in any atogepant group (≥ 5% of participants) were nausea, constipation, fatigue, and upper respiratory tract infection. Of these, constipation, nausea, and fatigue were considered as related to study drug in the majority of

<div style=\"page-break-after: always\"></div>

cases. In particular, for nausea (atogepant: 7.5%, placebo 3.3%) and constipation (atogepant: 7.2%, placebo: 2.0%) reporting rates in atogepant patients were higher as compared to placebo. Constipation is also labelled as common adverse reaction to biological CGRP antagonists erenumab and galzanezumab. Of note, the AE of decreased appetite was reported about ten times more often in atogepant patients (2.1%) as compared to placebo (0.2%). There was no clear dose response relation for the rate of TEAEs across the atogepant doses, ranging from atogepant 10 mg QD to supra-therapeutic atogepant 60 mg BID in the PCS set.

In long-term safety study 302, a SOC arm was included to contextualise safety. The rate of patients showing TEAEs was lower for atogepant 60 mg QD (N=1662, 63.5%) as compared to SOC (N=196, 78.6%). However, interpretation is cautioned given the disparity of underlying datasets.

The number and percentage of participants with common AE in the LTS set reveals good tolerability of long-term atogepant 60 mg QD use as compared to the standard of care control arm. Of those AEs observed in the PCS set which were considered related to study drug, only constipation was reported more often for atogepant 60 mg QD (6.0%) as compared to SOC (3.1%).

Adverse drug reactions (ADRs) were determined by evaluating TEAEs in the placebo-controlled migraine studies (Studies MD01, 301, and 303) that occurred with a ≥ 2% overall incidence rate in any of the atogepant groups and at a rate at least 2% greater than placebo. Constipation, decreased appetite, nausea, and fatigue/somnolence were identified as ADRs.

## Serious Adverse events (SAE)

The overall incidence of SAE in the PSC set was low across atogepant treatment arms (&lt; 1.3%) and similar to placebo (1.1%). None of the observed SAE was reported in more than 1 participant.

In  the  LTS  set,  the  overall  rate  of  TESAE  was  higher  in  patients  receiving  SOC  (N=196,  3.6%)  as compared  to  patients  receiving  atogepant  60  mg  QD  (N=1662,  3.4%).  Importantly,  there  is  no accumulation of any SAE. For the vast majority of SAE per preferred term the frequency in atogepant subjects is 0.1%. This includes Hepatobiliary disorders (cholelithiasis, cholecystitis) and Investigations (ALT  increased,  AST  increased).  There  wasn't  any  cardiovascular  SAE  under  long-term  atogepant treatment.

## Adverse Events of special interest (AESI)

Cardiovascular  events  (cardiac  arrythmias,  central  nervous  system  vascular  disorders,  embolic  and thrombotic, hypertension, and ischaemic heart disease), hepatic AEs, suicide-related events, and abuserelated AEs were identified as AESIs for the placebo-controlled, long-term safety, and Phase 1 analysis sets.

## Cardiovascular Events

A comprehensive evaluation of cardiovascular safety of atogepant as TEAESI was provided for both the use  of  atogepant  under  placebo-controlled  conditions  and  long-term  over  52-weeks.  There  was  no incident of ischaemic heart disease. The incidence of arrhythmia-related AEs was low and similar between atogepant (0.3%) and placebo (0.2%). Across the PCS and LTS set, only two cases of hypertension as reported AE were considered by the Investigator as related to study medication. Based on the narratives, however,  there  is  no  clear  suspect  of  atogepant  having  a  causative  role  given  the  overall  medical conditions of concerned subjects and timing of reporting (resp. persistence of the event) in relation to atogepant treatment.

## Hepatic Safety

Historical clinical development programs for other members of the gepant family (telcagepant) were halted when liver toxicity was detected during migraine prophylaxis trials (Ho TW. Neurology 2014).

<div style=\"page-break-after: always\"></div>

Therefore,  AEs  related  to  hepatic  toxicity  were  systematically  evaluated  as  AEs  of  special  interest, including blinded adjudication of postbaseline elevations of ALT and/or AST ≥ 3 × U LN for participants who received either atogepant or placebo by an external expert committee.

## Incidence of hepatic injury, AST/ALT elevations

Absolute figures for the incidence of hepatic injury and/or any liver enzyme elevation (&gt; 1 x ULN) in atogepant patients as compared to placebo appear favourable.

- In  the  Placebo-controlled  Analysis  Set,  hepatic  injury  TEAE  overall  (atogepant:  1.5%,  placebo: 1.8%),  and  hepatic  enzyme  elevations  (ALT  increased:  atogepant:  1.1%,  placebo:  1.5%;  AST increased: atogepant: 1.0%, placebo: 1.4%) were observed more often in placebo patients than in participants receiving atogepant. The incidence of ALT or AST increase as TEAE was independent of the atogepant dose.
- Categorical analysis of liver enzyme elevations shows that any aminotransferase elevation (AST or ALT &gt; 1 x ULN) was observed more frequently under placebo (14.2%) as compared to all atogepant patients (10.9%) in the PCS set.
- Likewise, under long term treatment (LTS set), the incidence of hepatic injury overall (atogepant 2.5%, SOC 3.1%), and aminotransferase elevations as TEAE (AST increased: atogepant 1.7%, SOC 2.6%; ALT increased: atogepant 1.6%, SOC: 2.0%) was higher in participants receiving standardof-care as compared to atogepant.
- Analysis of enzyme  elevation categories in the long-term analysis set reveals that any aminotransferase elevation  (AST  or  ALT  &gt;  1  x  ULN)  was  observed  more  frequently  across  SOC patients under long term treatment (28.9%) as compared to atogepant 60 mg QD patients (14.4%).

## Adjudication of relationship to treatment

- In  the  PCS  set,  a  total  of  n=24/2500  cases  with  aminotransferase  elevations  &gt;  3  x  ULN  were adjudicated by the external blinded Expert Committee. Of these, n=17 subjects received atogepant (n=7  received  placebo).  Among  the  atogepant  patients,  n=4  subjects  (out  of  N=1837)  were adjudicated as either possible (n=2) or probably related (n=2) to atogepant treatment. Narratives were provided. In 3 of these cases, there were confounding factors like intensive weightlifting in the gym, extensive concomitant acetaminophen use for acute headache, or Class III obesity (BMI 39.6 kg/m 2 ). All 4 atogepant-treated cases that were adjudicated as probably or possibly related to study drug were asymptomatic, non-serious, mild or moderate in severity, without concurrent bilirubin elevations, and resolved with or without atogepant discontinuation.
- In the LTS set, a total of n=24/1662 patients with hepatic enzyme elevations &gt; 3 x ULN under longterm atogepant treatment were adjudicated. In eight cases, the relationship of aminotransferase elevations to study drug was rated as possible or probable. Narratives were provided. In subjects recruited for long-term studies 302 and 309, confounding factors like weightlifting, obesity, history of binge drinking, or transient periods of increased alcohol consumption are reported and subjects completed the study. The remaining cases are reported for long-term study 306 conducted in Japan. Atogepant treatment was discontinued in n=4 subjects from study 306, for which the relationship to study drug was rated possible or probable. In these cases, confounding factors (e.g. concomitant betahistine,  cephalosporin,  azithromycin)  are  less  clear.  Of  note,  among  the  8  cases  that  were adjudicated as probably or possibly related to study drug all were non-serious, mild to moderate in severity, without concurrent bilirubin elevation, and resolved with or without atogepant discontinuation.

In the clinical trial dataset (placebo-controlled and long-term), there was no case fulfilling criteria for potential Hy's Law (ALT or AST &gt; 3 x ULN and TBL &gt; 2 x ULN and ALP &lt; 2 x ULN).

<div style=\"page-break-after: always\"></div>

Hence, the overall hepatic safety profile of atogepant, as obtained from clinical trials, appears rather favourable. However, a re-evaluation of atogepant's hepatic safety was required after receipt of one spontaneous post-marketing report of acute liver failure with atogepant 60 mg QD that led to liver transplantation.

## 3.6. Uncertainties and limitations about unfavourable effects

## Hepatic safety

Across the placebo-controlled (PCS), long-term (LTS) and post-marketing datasets, clinically relevant enzyme elevations were observed in patients receiving atogepant (although mostly asymptomatic across clinical trials). In some of these cases, AST/ALT elevations were adjudicated as possibly or probably related to atogepant treatment based on positive dechallenge and / or absence of clear confounders.

For the clinical trial dataset, it is confirmed that the elevations of aminotransferases that are probably or possibly related to atogepant were mostly asymptomatic, all were non-serious, mild to moderate in severity, without concurrent bilirubin elevations and transient in nature. There were no Hy's law cases, coagulopathy, encephalopathy or other organ dysfunction, hospitalisation, liver transplant, acute liver failure, or death due to liver injury in the clinical development programme of atogepant.

Conversely, in the post marketing setting, two cases of serious liver-related events have been reported. The first relates to the female experiencing acute liver failure (on Day 127 after atogepant initiation) leading to liver transplant. With extended post-marketing surveillance (data lock-off 11 October 2022) another suspected case of serious liver-related events (liver cirrhosis) was reported (at the time of first reporting without any further background information). The case of the female patient concerns nonalcoholic fatty liver disease (NAFLD) diagnosed in 2016, i.e. about six years before 30 mg atogepant was initiated  (Oct  2022).  Hence,  the  suspected  second  case  of  serious  post-marketing  hepatotoxicity  is unlikely to be related to atogepant therapy.

The fact that the overall frequency of liver enzyme elevations was not increased in atogepant patients as compared to patients receiving placebo in the PCS dataset, or to subjects receiving SOC in LT study 302 is providing reassurance. In line with results obtained from the DILIsym model (including in vitro tests of mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis) atogepant is not considered to intrinsically induce hepatotoxicity.

Graphical presentations of Time to onset (TTO) were provided on the cumulative number of atogepant participants with ALT /AST elevations &gt; 3 x ULN across the PCS and LTS set to further elucidate the relation between atogepant exposure and liver enzyme elevations. Overall, the TTO of all atogepanttreated cases of aminotransferase elevation ≥ 3 × ULN was wide both in the PCS and LTS studies, ranging from the first week after treatment initiation to the end of the observation period (12+4 weeks for  PCS,  &gt;  1  year  for  LTS).  Hence,  no  temporal  relation  between  atogepant  exposure  and  enzyme elevations could be established.

## Further issues of uncertainty

There was one SAE of presumed optic neuritis, which was considered as related to study drug by the Investigator,  but  was  considered  not  related  by  the  Sponsor.  Irrespective  of  any  attempt  to retrospectively  decide  upon  potential  relatedness  of  the  single  SAE  of  presumed  optic  neuritis,  it  is suggested to examine future PSUR reports for potential signals in this regard.

<div style=\"page-break-after: always\"></div>

## 3.7. Effects Table

Table 60: Effects Table of Aquipta for prophylaxis of migraine in adults who at least 4 migraine days per month, (data cut-off: Day 80).

| Effect                                                          | Short Description                                                            | Placebo N=216                                                                | Atogepant 10 mg QD N=216                                                     | Atogepant 30 mg QD N=224                                                     | Atogepant 60 mg QD N=226                                                     | Strengths / Uncertainties / Limitations                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                 | Favourable Effects: Prevention of episodic migraine (EM), Study 3101-301-002 | Favourable Effects: Prevention of episodic migraine (EM), Study 3101-301-002 | Favourable Effects: Prevention of episodic migraine (EM), Study 3101-301-002 | Favourable Effects: Prevention of episodic migraine (EM), Study 3101-301-002 | Favourable Effects: Prevention of episodic migraine (EM), Study 3101-301-002 | Favourable Effects: Prevention of episodic migraine (EM), Study 3101-301-002                                                                                                                                                                                                                                                                                                                  |
| Change Baseline in Mean                                         | Baseline No. of monthly MDs, Mean (SD)                                       | 7.53 (2.394)                                                                 | 7.46 (2.466)                                                                 | 7.86 (2.311)                                                                 | 7.75 (2.334)                                                                 | • Study population representative for clinical practice in preventive therapy of EM                                                                                                                                                                                                                                                                                                           |
| Change Baseline in Mean                                         | LS Mean (SE) change from baseline                                            | -2.47 (0.210)                                                                | -3.69 (0.209)                                                                | -3.85 (0.206)                                                                | -4.14 (0.205)                                                                | • Primary and secondary endpoints [S1-S3] met after multiplicity control                                                                                                                                                                                                                                                                                                                      |
| from Monthly Migraine Days (MD) across the 12-week DBT, Primary | LSMD (95% CI) Atogepant vs PBO, adjusted p-value                             |                                                                              | -1.22 (-1.79, -0.65) <0.0001                                                 | -1.38 (-1.94, -0.81) <0.0001                                                 | -1.66 (-2.23, -1.10) <0.0001                                                 | • Magnitude of effect clinically relevant • Early onset of effect within the first four weeks • Robust effect across subgroups, e.g. per baseline MDs (< 8 and > 8 monthly MDs) • Maintenance of effect in the EM population shown under long-term open-label conditions over 52 weeks • Most effective dose in dose finding study MD-01 (30 mg BID) not taken over into pivotal EM study 301 |

<div style=\"page-break-after: always\"></div>

| Effect                                                | Short Description                                       | Placebo N=216   | Atogepant 10 mg QD N=216     | Atogepant 30 mg QD N=224     | Atogepant 60 mg QD N=226     | Strengths / Uncertainties / Limitations   |
|-------------------------------------------------------|---------------------------------------------------------|-----------------|------------------------------|------------------------------|------------------------------|-------------------------------------------|
| Change from Baseline in mean                          | Baseline No. of monthly HDs, Mean (SD)                  | 8.45 (2.550)    | 8.43 (2.754)                 | 8.78 (2.615)                 | 8.99 (2.577)                 |                                           |
| monthly Headache Days (HD) across the 12-week         | LS Mean (SE) change from baseline                       | -2.52 (0.225)   | -3.94 (0.224)                | -4.03 (0.220)                | -4.17 (0.219)                |                                           |
| DBT, Secondary [S1]                                   | LSMD (95% CI) Atogepant vs PBO, adjusted p-value        |                 | -1.42 (-2.03, -0.81) <0.0001 | -1.51 (-2.11, -0.91) <0.0001 | -1.65 (-2.25, -1.04) <0.0001 |                                           |
| Change from Baseline in mean monthly Acute Medication | Baseline No. of monthly Acute Mx Use Days, Mean (SD)    | 6.50 (3.152)    | 6.58 (2.989)                 | 6.66 (3.050)                 | 6.88 (3.151)                 |                                           |
| Use Days across the 12-week DBT,                      | LS Mean (SE) change from baseline                       | -2.34 (0.184)   | -3.68 (0.183)                | -3.65 (0.181)                | -3.78 (0.180)                |                                           |
| Secondary [S2]                                        | LSMD (95% CI) Atogepant vs PBO, adjusted p-value        |                 | -1.34 (-1.84, -0.84) <0.0001 | -1.31 (-1.81, -0.82) <0.0001 | -1.44 (-1.93, -0.94) <0.0001 |                                           |
| Portion with > 50% reduction in 3-month average of    | Responders, n (%)                                       | 63 (29.2)       | 118 (54.6)                   | 131 (58.5)                   | 134 (59.3)                   |                                           |
| monthly MDs, Secondary [S3]                           | Odds ratio (95% CI), Atogepant vs PBO, adjusted p-value |                 | 2.91 (1.95, 4.33) <0.0001    | 3.46 (2.32, 5.14) <0.0001    | 3.55 (2.39, 5.28) <0.0001    |                                           |

<div style=\"page-break-after: always\"></div>

| Effect   | Short Description                                                                                                                                                       | Placebo N=216                                                                                                                                                           | Atogepant 10 mg QD N=216                                                                                                                                                | Atogepant 30 mg QD N=224                                                                                                                                                | Atogepant 60 mg QD N=226                                                                                                                                                | Strengths / Uncertainties / Limitations   |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Notes    | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error rate for multiple comparisons | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error rate for multiple comparisons | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error rate for multiple comparisons | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error rate for multiple comparisons | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error rate for multiple comparisons |                                           |

| Effect                  | Short Description                                                           | Placebo N=249                                                               | Atogepant 30 mg BID N=254                                                   | Atogepant 60 mg QDo N=257                                                   | Strengths / Uncertainties / Limitations                                     |
|-------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
|                         | Favourable Effects: Prevention of chronic migraine (CM), Study 3101-303-002 | Favourable Effects: Prevention of chronic migraine (CM), Study 3101-303-002 | Favourable Effects: Prevention of chronic migraine (CM), Study 3101-303-002 | Favourable Effects: Prevention of chronic migraine (CM), Study 3101-303-002 | Favourable Effects: Prevention of chronic migraine (CM), Study 3101-303-002 |
| Change from Baseline in | Baseline No. of monthly MDs, Mean (SD)                                      | 19.0 (4.80)                                                                 | 18.6 (5.09)                                                                 | 19.2 (5.29)                                                                 | • Study population representative for clinical                              |

<div style=\"page-break-after: always\"></div>

| Effect                                                          | Short Description                                | Placebo N=249   | Atogepant 30 mg BID N=254    | Atogepant 60 mg QDo N=257   | Strengths / Uncertainties / Limitations                                                                                                                                                                                                                                                                                                                               |
|-----------------------------------------------------------------|--------------------------------------------------|-----------------|------------------------------|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mean Monthly Migraine Days (MD) across the 12-week DBT, Primary |                                                  |                 |                              |                             | practice in preventive therapy of CM • Primary and secondary endpoints [S1-S3] met after multiplicity control • Magnitude of effect clinically relevant • Early onset of effect within the first four weeks                                                                                                                                                           |
|                                                                 | LS Mean (SE) change from baseline                | -5.09 (0.409)   | -7.33 (0.406)                | -6.75 (0.406)               | • Robust effect across subgroups, e.g. per baseline MDs (< 18 and > 18 monthly MDs), per concomitant preventive treatment, and per Medication Overuse • Long-term studies in CM are ongoing. No maintenance of effect data in CM available yet • Numerically most favourable results for the 30 mg BID regimen. However, atogepant 60 mg QD proposed as standard dose |
|                                                                 | LSMD (95% CI) Atogepant vs PBO, adjusted p-value |                 | -2.24 (-3.31, -1.16) <0.0001 | -1.66 (-2.72, -0.59) 0.0024 |                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Effect                                  | Short Description                                                                                                                                                       | Placebo N=249                                                                                                                                                           | Atogepant 30 mg BID N=254                                                                                                                                               | Atogepant 60 mg QDo N=257                                                                                                                                               | Strengths / Uncertainties / Limitations   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Change from Baseline in mean monthly    | Baseline No. of monthly HDs, Mean (SD)                                                                                                                                  | 21.4 (4.11)                                                                                                                                                             | 21.2 (4.15)                                                                                                                                                             | 21.5 (4.32)                                                                                                                                                             |                                           |
| Headache Days (HD) across the           | LS Mean (SE) change from baseline                                                                                                                                       | -5.17 (0.403)                                                                                                                                                           | -7.32 (0.399)                                                                                                                                                           | -6.90 (0.399)                                                                                                                                                           |                                           |
| 12-week DBT, Secondary [S1]             | LSMD (95% CI) Atogepant vs PBO, adjusted p-value                                                                                                                        |                                                                                                                                                                         | -2.14 (-3.20, -1.09) 0.0002                                                                                                                                             | -1.72 (-2.78, -0.67) 0.0024                                                                                                                                             |                                           |
| Change from Baseline in mean monthly    | Baseline No. of monthly Acute Mx Use Days, Mean (SD)                                                                                                                    | 15.3 (7.05)                                                                                                                                                             | 14.5 (7.22)                                                                                                                                                             | 15.5 (7.36)                                                                                                                                                             |                                           |
| Acute Medication Use Days across the    | LS Mean (SE) change from baseline                                                                                                                                       | -4.09 (0.389)                                                                                                                                                           | -6.61 (0.388)                                                                                                                                                           | -6.19 (0.383)                                                                                                                                                           |                                           |
| 12-week DBT, Secondary [S2]             | LSMD (95% CI) Atogepant vs PBO, adjusted p-value                                                                                                                        |                                                                                                                                                                         | -2.52 (-3.52, -1.53) 0.0002                                                                                                                                             | -2.09 (-3.09, -1.10) 0.0024                                                                                                                                             |                                           |
| Portion with > 50% reduction in 3-month | Responders, n (%)                                                                                                                                                       | 66 (26.5)                                                                                                                                                               | 107 (42.1)                                                                                                                                                              | 103 (40.1))                                                                                                                                                             |                                           |
| average of monthly MDs, Secondary [S3]  | Odds ratio (95% CI), Atogepant vs PBO, adjusted p-value                                                                                                                 |                                                                                                                                                                         | 2.03 (1.38, 2.98) 0.0006                                                                                                                                                | 1.90 (1.29, 2.79) 0.0024                                                                                                                                                |                                           |
| Notes                                   | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error rate for multiple comparisons | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error rate for multiple comparisons | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error rate for multiple comparisons | LS = least squares; LSMD = least squares mean difference; Adjusted p-values: using graphical approach to control the overall type I error rate for multiple comparisons |                                           |

<div style=\"page-break-after: always\"></div>

## Effect Short Description

## Unfavourable Effects

- Comprehensive safety evaluation was provided, incl. focus on relevant AEs of Special Interest (AESI)
- Most common ADRs were nausea (7%), constipation (7%), and fatigue/somnolence (5%).
- No liability for abuse, no signal for suicidality
- No safety concerns for hypertension AEs or other cardiovascular events were identified.
- Decreases in body weight by &gt; 7% from baseline were observed in atogepant patients in a dose-dependent way both under placebo-controlled and long-term treatment conditions.
- Further elucidation of atogepant's liability to induce liver enzyme elevations is required, based on
- One case of possible DILI reported post-marketing
- Single cases of particularly high liver enzyme elevations in the PSC and LTS set
- Uncertainty about the role of atogepant treatment duration in relation to aminotransferase elevations
- Need for updated post-marketing data and long-term treatment data from ongoing studies

## Atogepant Safety Dataset, of primary interest:

-  Placebo-controlled Safety (PCS) Pool, N = 2500 incl. n = 663 placebo;
-  Long-term Safety (LTS) Pool, N = 1665 atogepant, plus N = 196 SOC

Strengths / Uncertainties / Limitations

<div style=\"page-break-after: always\"></div>

## 3.8. Benefit-risk assessment and discussion

## 3.9. Importance of favourable and unfavourable effects

## Efficacy

Dose-finding  study  MD-01  and  pivotal  studies  301  (EM  population)  and  303  (CM  population)  were designed concordant with IHS and EMA guidance and provide a sound database demonstrating evidence for the benefit of atogepant in preventive migraine treatment across the full spectrum of episodic and chronic forms of the disease.

Atogepant in dosages of 10, 30, and 60 mg QD in EM and 60 mg QD and 30 mg BID in CM demonstrated superiority over placebo in reducing the frequency of both migraine days [primary P1], as well as the frequency of headache days [secondary S1] and the associated use of medication for the acute treatment of migraine [S2]. Higher response rates were seen with each atogepant dosage compared with placebo for participants with ≥ 50% reduction in the 3 -month average of monthly migraine days [S3].

A numerical dose-response relationship was evident for the change from baseline in mean monthly MDs across the 12-week DBT in EM Study 301, with greater reductions seen with increasing atogepant dose from 10 to 60 mg QD. Only the highest maximum daily dose of 60 mg tested in EM study 301 was taken over in CM Study 303. To explore the potential impact of the once daily vs twice daily dosing regimen, the 60 mg daily dose was examined across a 60 mg QD and a 30 mg BID treatment arm in CM Study 303. The placebo-corrected mean reduction from baseline in mean monthly migraine days observed with the atogepant 60 mg QD dose was the same in the EM and CM studies (LSMD of -1.66 in both Study 301 and 303).

The robustness of the primary and secondary endpoint results [S1-3] after multiplicity adjustment for each  of  the  atogepant  dosages  tested  in  studies  301/303  was  confirmed  across  several  subgroup analyses,  like  e.g.  prior  use  of  prevention  medication,  concomitant  use  of  another  prophylactic medication (study 303), or prevalent medication overuse (study 303).

The onset of the clinical effect of atogepant is early. In both the EM and CM population, the overall treatment effect in terms of MD reduction is achieved mainly within the first 28-day period of the 12week DBT of studies 301 and 303.

In terms of persistence of effect, supportive efficacy data are obtained from open-label, long-term study 302 in EM patients for treatment with atogepant 60 QD over 52 weeks. A clinically relevant reduction in mean monthly MDs was achieved within the 1st month and was sustained over the 1-year treatment period.

Overall, efficacy was adequately demonstrated for the proposed use of atogepant in migraine prevention.

## Posology

With  regard  to  proposed  posology,  the  numerically  most  favourable  outcome  across  primary  and secondary endpoints in studies MD-01 (EM) and pivotal study 303 (CM) was observed for the 30 mg BID dosing regimen. However, the applicant applies for the 60 mg QD once daily as regular dosing scheme only.  It  is  established  that  compliance  with  migraine  preventive  treatment  remains  a  challenge. Therefore, the potential advantage of a once daily dosing regimen is evident in terms of compliance. On the other hand, administration of the most effective treatment is equally expected to positively impact on patient compliance. A 30 mg tablet formulation was tested in Study 301, i.e. is available. Despite numerically  more  favourable  results  for  the  30  mg  BID  dose  arm  across  primary  and  secondary

<div style=\"page-break-after: always\"></div>

endpoints, the applicant's posology strategy is to confine to the uniform 60 mg once daily dosing schedule in order to provide a simple and convenient posology scheme.

## Safety

Based on data obtained from the clinical trials, the safety profile of atogepant in preventive migraine treatment  appears  favourable.  Most  common  ADRs  were  nausea  (7%),  constipation  (7%),  and fatigue/somnolence (5%). No safety concerns for hypertension AEs or other cardiovascular events were identified. Decreases in body weight by &gt; 7% from baseline were observed in atogepant patients in a dose-dependent way both under placebo-controlled and long-term treatment conditions.

Concerns about atogepant's hepatic safety profile were raised after receipt of a post-marketing report of a female who developed acute liver failure leading to liver transplant on Day 127 of atogepant 60 mg treatment for migraine prophylaxis. An independent expert confirmed the event to be compatible with DILI and timing as consistent with a role for atogepant.

In-depth  evaluation  of  atogepant's  hepatic  safety  profile  was  provided  based  on  modelled  DILIsym results, the PCS dataset, extended long-term data (from ongoing studies 306 and 312), and further post-marketing experience (cumulative patient exposure / sales data from 28 Sep 2021 to 31 Oct 2022).

The fact that the overall frequency of liver enzyme elevations was not increased in atogepant patients as compared to patients receiving placebo in the PCS dataset, or to subjects receiving SOC in LT study 302 is providing reassurance. In line with results obtained from the DILIsym model (including in vitro tests of mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis) atogepant is not considered to intrinsically induce hepatotoxicity.

A potential idiosyncratic liability, however, may only manifest with temporal latency, and due to its rarity, in larger populations. Across the placebo-controlled (PCS), long-term (LTS) and post-marketing datasets, clinically relevant enzyme elevations were observed in patients receiving atogepant (although mostly asymptomatic across clinical trials). In some of these cases, AST/ALT elevations were adjudicated as possibly or probably related to atogepant treatment based on positive dechallenge and / or absence of clear confounders.

## 3.9.1. Balance of benefits and risks

Efficacy was adequately shown for the proposed use of atogepant for prophylaxis of migraine in adults who have at least 4 migraine days per month. In-depth evaluation of atogepant's hepatic safety profile provided reassurance.

## 3.9.2. Additional considerations on the benefit-risk balance

NA

## 3.10. Conclusions

The overall benefit/risk balance of Aquipta is positive, subject to the conditions stated in section Recommendations.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Aquipta is favourable in the following indication(s):

Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product on medical prescription for renewable delivery.

## Other conditions and requirements of the marketing authorisation

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

- Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that atogepant is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.